AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
AZ_NN
AR_NN
OuterCovs_NN
._.
com_NN
Annual_JJ
R_NN
Form_NN
20_CD
2003_CD
Contact_NN
information_NOMZ
Registered_NN
office_NN
and_CC
corporate_JJ
headquarters_NN
address_NN
:_:
Registrar_NN
and_CC
transfer_VB
office_NN
:_:
AstraZeneca_NN
PLC_NN
Lloyds_NN
TSB_NN
Registrars_NN
15_CD
Stanhope_NN
Gate_NN
The_NN
Causeway_NN
London_NN
W1K_NN
1LN_NN
Worthing_GER
UK_NN
West_NN
Sussex_NN
Tel_NN
:_:
44_CD
0_CD
20 7304 5000_CD
BN99_NN
6DA_NN
Fax_NN
:_:
44_CD
0_CD
20 7304 5183_CD
UK_NN
Tel_NN
in_PIN
the_DT
UK_NN
:_:
0870 600 3956_CD
R&D_NN
headquarters_NN
address_NN
:_:
Tel_NN
outside_PLACE
the_DT
UK_NN
:_:
44_CD
0_CD
121 415 7033_CD
AstraZeneca_NN
AB_NN
R&D_NN
Headquarters_NN
Swedish_NN
securities_NOMZ
registration_NOMZ
center_NN
:_:
SE-151_CD
85_CD
Sdertlje_NN
VPC_NN
AB_NN
Sweden_NN
PO_NN
Box_NN
7822_CD
Tel_NN
:_:
46_CD
0_CD
8_CD
553_CD
260_CD
00_CD
SE-103_NN
97_CD
Stockholm_NN
Fax_NN
:_:
46_CD
0_CD
8_CD
553_CD
290_CD
00_CD
Sweden_NN
Tel_NN
:_:
46_CD
0_CD
8_CD
402_CD
9000_CD
Investor_NN
relations_NOMZ
contacts_NN
:_:
UK_NN
and_PHC
Sweden_NN
:_:
As_IN
above_PLACE
or_CC
e-mail_VB
:_:
US_FPP1
depositary_NN
:_:
IR@astrazeneca_NN
._.
com_NN
JPMorgan_NN
Chase_NN
Bank_NN
US_FPP1
:_:
PO_NN
Box_NN
43013_CD
Investor_NN
Relations_NOMZ
Providence_NN
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
RI_NN
02940-3013_CD
1800_CD
Concord_NN
Pike_NN
US_FPP1
PO_NN
Box_NN
15438_CD
Tel_NN
toll_NN
free_JJ
in_PIN
the_DT
US_FPP1
:_:
888 697 8018_CD
Wilmington_NN
Tel_NN
:_:
1_CD
781 575 4328_CD
fide_NN
19850-5438_CD
US_FPP1
Tel_NN
:_:
1_CD
302 886 3000_CD
Fax_NN
:_:
1_CD
302 886 2972_CD
On_PIN
the_DT
path_NN
to_PIN
growth_NN
Annual_JJ
Review_NN
2003_CD
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
Commitment_NOMZ
The_NN
path_NN
to_PIN
a_DT
new_JJ
medicine_NN
is_VPRT [BEMA]
long_PRED
and_PHC
complex_PRED
._.
Success_NN
requires_VPRT [SUAV]
a_DT
major_JJ
commitment_NOMZ
of_PIN
time_NN
,_,
money_NN
and_PHC
resource_NN
,_,
backed_VBN [PASTP]
by_PIN
clear_JJ
strategic_JJ
objectives_NN
._.
Here_RB
we_FPP1
describe_VPRT
what_WP
it_PIT
takes_VPRT
to_TO
deliver_VB
and_PHC
realize_VB [PRIV]
the_DT
full_JJ
potential_NN
of_PIN
the_DT
innovation_NOMZ
that_TSUB
supports_VPRT
our_FPP1
continued_JJ
growth_NN
._.
Discovery_NN
Development_NOMZ
Supply_NN
Marketing_GER
Inspiration_NOMZ
Identification_NOMZ
of_PIN
Progressing_GER
Fast_NN
,_,
flexible_JJ
and_CC
Building_GER
strong_JJ
Driving_VBG
continued_VBN
compounds_NN
with_PIN
high_JJ
potential_JJ
cost-effective_JJ
relationships_NN
in_PIN
success_NN
and_CC
added_VBD [PUBV]
the_DT
highest_JJ
potential_JJ
compounds_NN
along_IN
supply_NN
of_PIN
our_FPP1
local_JJ
markets_NN
,_,
value_NN
for_PIN
all_QUAN
our_FPP1
to_TO
become_VB
new_JJ
the_DT
full_JJ
length_NN
of_PIN
the_DT
products_NN
wherever_RB
backed_VBN
by_PIN
our_FPP1
stakeholders_NN
._.
Page_NN
12_CD
Page_NN
4_CD
Page_NN
6_CD
Page_NN
8_CD
Page_NN
10_CD
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
01_CD
Key_NN
achievements_NOMZ
Sales_NN
for_PIN
the_DT
year_NN
were_VBD
$_$
18.8_CD
billion_CD
._.
Arimidex_NN
is_VPRT
moving_VBG [SUAV]
rapidly_RB
towards_PIN
At_PIN
constant_JJ
exchange_NN
rates_NN
,_,
replacing_VBG
tamoxifen_NN
as_IN
the_DT
standard_JJ
sales_NN
were_VBD [BEMA]
unchanged_JJ
whilst_OSUB
of_PIN
care_NN
in_PIN
breast_NN
cancer_NN
._.
Sales_NN
up_IN
absorbing_VBG
the_DT
loss_NN
of_PIN
$_$
2.6_CD
billion_CD
46_CD
%_NN
to_TO
$_$
519_CD
million_CD
._.
in_PIN
US_FPP1
sales_NN
of_PIN
Losec_NN
Prilosec_NN
,_,
Zestril_NN
and_PHC
Nolvadex_NN
following_VBG [WZPRES]
Rapid_NN
uptake_NN
of_PIN
Iressa_NN
since_OSUB
first_JJ
anticipated_VBN [PRIV]
patent_NN
expiries_NN
._.
launch_NN
in_PIN
Japan_NN
in_PIN
2002_CD
and_CC
in_PIN
the_DT
US_FPP1
in_PIN
2003_CD
,_,
with_PIN
over_IN
100,000_CD
Operating_GER
profit_NN
was_VBD [BEMA]
down_RB
11_CD
%_NN
patients_NN
treated_VBD
since_OSUB
launch_NN
._.
at_PIN
$_$
4.1_CD
billion_CD
,_,
due_JJ
to_TO
planned_VBN
2003_CD
sales_NN
reached_VBD
$_$
228_CD
million_CD
._.
investments_NOMZ
in_PIN
R&D_NN
and_CC
other_JJ
areas_NN
required_VBN [SUAV]
to_TO
launch_VB
new_JJ
products_NN
and_PHC
Crestor_NN
sales_NN
reached_VBD
$_$
129_CD
million_CD
._.
complete_JJ
the_DT
product_NN
portfolio_NN
We_FPP1
estimate_VPRT [PRIV]
that_THVC
more_EMPH
than_PIN
1.5_CD
transformation_NOMZ
._.
million_CD
prescriptions_NOMZ
had_VBD [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
for_PIN [STPR]
,_,
and_ANDC
over_IN
750,000_CD
Dividend_NN
increased_VBN [WZPAST]
by_PIN
13.6_CD
%_NN
to_PIN
patients_NN
had_VBD [PEAS]
been_VBN [PASS]
treated_VBN
with_PIN
79.5_CD
cents_NN
for_PIN
the_DT
full_JJ
year_NN
._.
Crestor_NN
by_PIN
the_DT
end_NN
of_PIN
January_NN
2004_CD
._.
Sales_NN
for_PIN
key_JJ
growth_NN
and_PHC
launch_NN
Exanta_NN
received_VBD
its_PIT
first_JJ
regulatory_JJ
products_NN
increased_VBN [WZPAST]
by_PIN
45_CD
%_NN
to_PIN
approval_NN
in_PIN
France_NN
in_PIN
December_NN
$_$
8.2_CD
billion_CD
and_CC
now_TIME
represent_VPRT
2003_CD
._.
Regulatory_NN
submissions_VPRT
44_CD
%_NN
of_PIN
total_JJ
sales_NN
._.
were_VBD [PASS]
made_VBN
in_PIN
the_DT
US_FPP1
and_PHC
Europe_NN
for_PIN
key_JJ
chronic_NN
indications_NOMZ
,_,
including_VBG
Nexium_NN
sales_NN
reached_VBD
$_$
3.3_CD
billion_CD
,_,
prevention_NOMZ
of_PIN
stroke_NN
associated_VBN [WZPAST]
with_PIN
up_RB
62_CD
%_NN
atrial_JJ
fibrillation_NOMZ
._.
Seroquel_NN
sales_NN
reached_VBD
$_$
1.5_CD
billion_CD
,_,
R&D_NN
investment_NOMZ
totalled_VBD
$_$
3.5_CD
billion_CD
._.
Approvals_NN
for_PIN
use_NN
of_PIN
We_FPP1
now_TIME
have_VPRT
12_CD
projects_NN
in_PIN
phase_NN
2_CD
Seroquel_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
acute_JJ
development_NOMZ
and_CC
28_CD
projects_NN
in_PIN
bipolar_NN
mania_NN
were_VBD [PASS]
received_VBN
in_PIN
the_DT
phase_NN
3_CD
._.
Continued_VBN
enhancement_NOMZ
of_PIN
supply_NN
Symbicort_NN
sales_NN
reached_VBD
$_$
549_CD
million_CD
,_,
and_ANDC
manufacturing_VBG
processes_NN
led_VBD
to_TO
up_RP
61_CD
%_NN
._.
Symbicort_NN
also_RB
gained_VBD
first_RB
improved_VBN
customer_NN
service_NN
levels_NN
approval_NN
in_PIN
Europe_NN
for_PIN
use_NN
in_PIN
the_DT
and_CC
reduced_VBN
manufacturing_GER
lead_NN
treatment_NOMZ
of_PIN
chronic_JJ
obstructive_JJ
times_NN
which_WDT [WHSUB]
consequently_CONJ
reduced_VBD
pulmonary_JJ
disease_NN
._.
the_DT
requirement_NOMZ
for_PIN
stock_NN
build-up_NN
._.
AstraZeneca_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
worlds_NN
leading_VBG [WZPRES]
Contents_NN
Remuneration_NOMZ
policy_NN
19_CD
Chairmans_NN
statement_NOMZ
02_CD
Summary_NN
financial_JJ
review_NN
21_CD
pharmaceutical_JJ
companies_NN
._.
Our_FPP1
strong_JJ
Strategy_NN
02_CD
Summary_NN
financial_JJ
statements_NOMZ
23_CD
research_NN
base_NN
,_,
backed_VBN [PASTP]
by_PIN
our_FPP1
extensive_JJ
Chief_NN
Executives_NN
review_NN
03_CD
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
24_CD
manufacturing_GER
and_CC
commercial_JJ
skills_NN
,_,
Discovery_NN
04_CD
Group_NN
balance_NN
sheet_NN
26_CD
focuses_VPRT
on_PIN
turning_VBG
ideas_NN
into_PIN
effective_JJ
Development_NOMZ
pipeline_NN
07_CD
Statement_NOMZ
of_PIN
Group_NN
cash_NN
flow_NN
27_CD
medicines_NN
that_TSUB
meet_VPRT
patient_JJ
needs_NN
in_PIN
Supply_NN
08_CD
Dividends_NN
28_CD
important_JJ
areas_NN
of_PIN
healthcare_NN
._.
We_FPP1
Marketing_GER
10_CD
Earnings_GER
per_PIN
share_NN
28_CD
encourage_VPRT
innovation_NOMZ
in_PIN
all_QUAN
areas_NN
of_PIN
our_FPP1
Inspiration_NOMZ
12_CD
Emoluments_NOMZ
of_PIN
Directors_NN
29_CD
business_NOMZ
because_CAUS
the_DT
more_EMPH
good_JJ
ideas_NN
Therapy_NN
area_NN
review_NN
14_CD
Group_NN
financial_JJ
record_NN
30_CD
we_FPP1
have_VPRT
,_,
the_DT
more_EMPH
we_FPP1
can_POMD
add_VB [PUBV]
value_NN
for_PIN
Board_NN
of_PIN
Directors_NN
16_CD
Share_NN
information_NOMZ
31_CD
our_FPP1
shareholders_NN
,_,
customers_NN
,_,
employees_NN
Summary_NN
Directors_NN
report_VPRT [PUBV]
18_CD
Shareholder_NN
information_NOMZ
32_CD
and_CC
the_DT
wider_JJ
community_NOMZ
._.
com_NN
02_CD
Accountability_NOMZ
Five_CD
years_NN
ago_RB
,_,
on_PIN
the_DT
completion_NOMZ
of_PIN
the_DT
Property_NN
Rights_NN
TRIPs_NN
and_CC
the_DT
public_JJ
health_NN
have_VPRT [SPAU] [PEAS]
also_RB
reviewed_VBN
and_PHC
strengthened_VBD
the_DT
merger_NN
of_PIN
the_DT
Astra_NN
and_PHC
Zeneca_NN
businesses_NOMZ
,_,
benefits_NN
that_TSUB
will_PRMD
flow_VB
from_PIN
this_DEMO
resolution_NOMZ
._.
In_PIN
the_DT
US_FPP1
we_FPP1
the_DT
new_JJ
Board_NN
had_VBD
a_DT
clear_JJ
vision_NN
._.
have_VB [PEAS]
undertaken_VBN
significant_JJ
compliance_NN
In_PIN
the_DT
context_NN
of_PIN
this_DEMO
business_NOMZ
environment_NOMZ
training_GER
with_PIN
our_FPP1
sales_NN
and_CC
other_JJ
relevant_JJ
AstraZeneca_NN
was_VBD
to_TO
be_VB [BEMA]
a_DT
creative_JJ
,_,
fast_JJ
and_CC
and_CC
recognizing_VBG [PRIV]
the_DT
specific_JJ
challenges_NN
personnel_NN
pursuant_JJ
to_PIN
the_DT
Corporate_JJ
Integrity_NOMZ
effective_JJ
,_,
research-based_JJ
pharmaceutical_JJ
faced_VBN
by_PIN
the_DT
Company_NN
,_,
AstraZenecas_NN
Agreement_NOMZ
with_PIN
the_DT
Office_NN
of_PIN
Inspector_NN
company_NN
._.
Its_PIT
increased_VBN
global_JJ
marketing_GER
financial_JJ
performance_NN
in_PIN
2003_CD
has_VPRT [PEAS]
been_VBN
General_NN
of_PIN
the_DT
Department_NOMZ
of_PIN
Health_NN
and_PHC
strength_NN
provided_VBD
the_DT
platform_NN
to_TO
realize_VB [PRIV]
the_DT
excellent_JJ
and_CC
the_DT
Board_NN
has_VPRT [PEAS]
recommended_VBN [SUAV]
a_DT
Human_NN
Services_NN
._.
full_JJ
potential_NN
of_PIN
its_PIT
productive_JJ
R&D_NN
and_CC
deliver_VB
second_JJ
interim_JJ
dividend_NN
of_PIN
$_$
0.54_CD
:_:
29.4_CD
sustainable_JJ
value_NN
to_PIN
all_QUAN
its_PIT
stakeholders_NN
._.
pence_NN
:_:
SEK3_CD
.91_CD
per_PIN
Ordinary_NN
Share_NN
bringing_VBG [WZPRES]
We_FPP1
welcome_JJ
Michele_NN
Hooper_NN
and_PHC
Joe_NN
the_DT
total_JJ
dividend_NN
for_PIN
the_DT
year_NN
to_TO
$_$
0.795_CD
:_:
45.3_CD
Jimenez_NN
,_,
who_WP
joined_VBD
the_DT
Board_NN
in_PIN
July_NN
as_IN
Back_NN
in_PIN
1999_CD
,_,
there_EX
were_VBD
some_QUAN
substantial_JJ
pence_NN
:_:
SEK5_CD
.98_CD
,_,
an_DT
increase_NN
of_PIN
13.6_CD
%_NN
in_PIN
Non-Executive_JJ
Directors_NN
._.
Micheles_NN
hurdles_NN
to_TO
overcome_VB
before_IN
this_DEMO
vision_NN
could_POMD
dollar_NN
terms_NN
._.
The_DT
share_NN
re-purchase_JJ
experience_NN
at_PIN
Caremark_NN
International_NN
and_CC
be_VB [PASS]
turned_VBN
into_PIN
reality_NOMZ
._.
The_DT
first_JJ
of_PIN
these_DEMP
was_VBD
to_TO
program_VB
continued_VBN
in_PIN
2003_CD
with_PIN
27.2_CD
Baxter_NN
Healthcare_NN
in_PIN
the_DT
US_FPP1
and_PHC
Joes_NN
rapidly_RB
complete_VB
the_DT
merger_NN
,_,
build_VB
on_PIN
the_DT
million_CD
shares_NN
re-purchased_JJ
for_PIN
cancellation_NOMZ
background_NN
as_IN
President_NN
and_PHC
CEO_NN
of_PIN
Heinz_NN
strengths_NN
of_PIN
the_DT
two_CD
partners_NN
to_TO
create_VB
a_DT
at_PIN
a_DT
total_JJ
cost_NN
of_PIN
$_$
1,154_CD
million_CD
._.
The_DT
Board_NN
is_VPRT
Europe_NN
and_CC
earlier_TIME
positions_NOMZ
in_PIN
the_DT
US_FPP1
bring_VB
single_JJ
unified_JJ
culture_NN
and_CC
realize_VB [PRIV] [THATD]
the_DT
merger_NN
proposing_VBG [SUAV] [WZPRES]
a_DT
further_JJ
share_NN
re-purchase_JJ
additional_JJ
strengths_NN
to_PIN
the_DT
Board_NN
._.
Hkan_JJ
cost_NN
benefits_NN
without_PIN
significantly_RB
disturbing_JJ
program_NN
of_PIN
$_$
4_CD
billion_CD
to_TO
be_VB [BYPA]
completed_VBN
by_PIN
Mogren_NN
stepped_VBD
down_RP
as_IN
Executive_NN
Deputy_NN
our_FPP1
day-to-day_TIME
operations_NOMZ
._.
This_DEMP
was_VBD [BEMA]
the_DT
end_NN
of_PIN
2005_CD
,_,
subject_JJ
to_PIN
shareholders_NN
Chairman_NN
in_PIN
August_NN
2003_CD
and_CC
continues_VPRT
as_RB
achieved_VBN
in_PIN
the_DT
first_JJ
two_CD
years_NN
._.
renewing_VBG [PRESP]
the_DT
Companys_NN
authority_NOMZ
to_PIN
Non-Executive_JJ
Deputy_NN
Chairman_NN
._.
In_PIN
his_TPP3
re-purchase_NN
its_PIT
own_JJ
shares_NN
at_PIN
the_DT
Annual_JJ
executive_NN
capacity_NOMZ
,_,
Hkan_NN
Mogren_NN
served_VBD
Our_FPP1
focus_NN
was_VBD [BEMA]
then_RB
on_PIN
another_DT
major_JJ
General_NN
Meeting_VBG [WZPRES]
in_PIN
April_NN
._.
both_DT
Astra_NN
AB_NN
and_PHC
AstraZeneca_NN
PLC_NN
with_PIN
challenge_NN
:_:
the_DT
transformation_NOMZ
of_PIN
our_FPP1
product_NN
distinction_NOMZ
and_CC
I_FPP1
am_VPRT [BEMA]
delighted_PRED
that_THAC
the_DT
Board_NN
portfolio_NN
from_PIN
its_PIT
historic_JJ
reliance_NN
on_PIN
The_DT
AstraZeneca_NN
share_NN
price_NN
performed_VBD
well_RB
will_PRMD
continue_VB
to_TO
benefit_VB
from_PIN
his_TPP3
wise_JJ
counsel_NN
._.
successful_JJ
but_CC
maturing_VBG
products_NN
,_,
such_JJ
as_IN
in_PIN
2003_CD
in_PIN
both_DT
absolute_JJ
terms_NN
and_ANDC
when_RB
Losec_NN
Prilosec_NN
and_PHC
Zestril_NN
,_,
into_PIN
a_DT
range_NN
of_PIN
compared_VBN
with_PIN
an_DT
international_JJ
group_NN
of_PIN
I_FPP1
am_VPRT [BEMA]
grateful_PRED
to_PIN
my_FPP1
colleagues_NN
on_PIN
the_DT
Board_NN
newer_JJ
high_JJ
potential_NN
medicines_NN
._.
Many_QUAN
leading_VBG
pharmaceutical_JJ
companies_NN
,_,
for_PIN
their_TPP3
support_NN
,_,
to_PIN
the_DT
Senior_NN
Executive_NN
commentators_NN
predicted_VBD [PUBV]
a_DT
steep_JJ
decline_NN
in_PIN
reflecting_VBG [PRIV]
the_DT
markets_NN
positive_JJ
view_NN
of_PIN
the_DT
Team_NN
and_CC
to_PIN
all_QUAN
our_FPP1
employees_NN
worldwide_JJ
sales_NN
and_PHC
profit_NN
during_PIN
this_DEMO
period_NN
._.
By_PIN
the_DT
end_NN
Companys_NN
future_JJ
growth_NN
prospects_NN
._.
for_PIN
their_TPP3
impressive_JJ
contributions_NOMZ
to_PIN
the_DT
of_PIN
2003_CD
,_,
this_DEMO
transformation_NOMZ
had_VBD [SPAU] [PEAS]
largely_RB
been_VBN
Companys_NN
success_NN
._.
On_PIN
behalf_NN
of_PIN
the_DT
Board_NN
,_,
achieved_VBD
._.
There_EX
have_VPRT [PEAS]
been_VBN
some_QUAN
delays_NN
in_PIN
During_PIN
a_DT
busy_JJ
year_NN
,_,
the_DT
Board_NN
analyzed_VBD
I_FPP1
would_PRMD
like_VB
to_TO
thank_VB
them_TPP3
most_EMPH
warmly_RB
._.
new_JJ
product_NN
launches_NN
but_CC
also_RB
some_QUAN
of_PIN
the_DT
trends_NN
in_PIN
the_DT
pharmaceutical_JJ
environment_NOMZ
more_EMPH
mature_JJ
brands_NN
have_VPRT [PEAS]
not_XX0
declined_VBN
as_IN
and_CC
reviewed_VBN
the_DT
Companys_NN
overall_JJ
strategy_NN
In_PIN
2004_CD
,_,
we_FPP1
aim_VPRT
to_TO
deliver_VB
strong_JJ
sales_NN
fast_RB
as_IN
expected_VBN [PRIV]
._.
AstraZeneca_NN
is_VPRT [SPAU]
now_TIME
facing_VBG
and_CC
performance_NN
._.
I_FPP1
am_VPRT [BEMA]
happy_PRED
to_TO
report_VB [PUBV]
good_JJ
growth_NN
from_PIN
our_FPP1
portfolio_NN
of_PIN
important_JJ
an_DT
exciting_JJ
period_NN
of_PIN
expansion_NN
with_PIN
few_QUAN
progress_NN
in_PIN
the_DT
productivity_NOMZ
increase_NN
medicines_NN
while_OSUB
,_,
at_PIN
the_DT
same_JJ
time_NN
,_,
patent_NN
expiries_NN
and_PHC
growth_NN
driven_VBN [WZPAST]
by_PIN
the_DT
programs_NN
that_TSUB
cover_VPRT
all_QUAN
parts_NN
of_PIN
the_DT
progressing_VBG
the_DT
next_JJ
wave_NN
of_PIN
novel_NN
products_NN
._.
recently_TIME
introduced_VBN
products_NN
and_CC
by_PIN
further_JJ
Company_NN
._.
In_PIN
line_NN
with_PIN
this_DEMO
culture_NN
of_PIN
We_FPP1
will_PRMD
continue_VB
our_FPP1
investment_NOMZ
strategy_NN
in_PIN
new_JJ
product_NN
launches_NN
._.
Recent_JJ
investments_NOMZ
continuous_JJ
improvement_NOMZ
,_,
the_DT
performance_NN
of_PIN
developing_VBG
regions_NN
to_TO
complement_VB
our_FPP1
in_PIN
developing_VBG
countries_NN
also_RB
add_VPRT [PUBV]
to_PIN
the_DT
the_DT
Board_NN
,_,
its_PIT
committees_NN
and_CC
all_QUAN
individual_JJ
strong_JJ
presence_NN
in_PIN
the_DT
major_JJ
established_VBN [PRIV]
potential_NN
for_PIN
growth_NN
._.
members_NN
were_VBD [PASS]
reviewed_VBN
in_PIN
a_DT
constructive_JJ
markets_NN
._.
Through_PIN
strong_JJ
sales_NN
growth_NN
discussion_NN
that_TSUB
identified_VBD
areas_NN
for_PIN
further_JJ
coupled_VBN
with_PIN
productivity_NOMZ
improvements_NOMZ
Taking_VBG [WZPRES]
a_DT
wider_JJ
perspective_NN
,_,
the_DT
improvement_NOMZ
._.
across_PLACE
all_QUAN
our_FPP1
activities_NOMZ
,_,
we_FPP1
expect_VPRT [PRIV]
to_TO
deliver_VB
pharmaceutical_JJ
sector_NN
continued_VBD
to_TO
top_VB
tier_JJ
financial_JJ
performance_NN
in_PIN
the_DT
years_NN
experience_NN
pricing_GER
pressures_NN
in_PIN
major_JJ
During_PIN
the_DT
year_NN
the_DT
Board_NN
has_VPRT [PEAS]
reviewed_VBN
its_PIT
ahead_PLACE
._.
markets_NN
during_PIN
2003_CD
and_CC
the_DT
AstraZeneca_NN
already_RB
demanding_VBG [SUAV]
compliance_NN
procedures_NN
Board_NN
reviewed_VBD
the_DT
Companys_NN
approach_NN
to_TO
to_TO
respond_VB
to_PIN
new_JJ
laws_NN
and_PHC
regulations_NOMZ
in_PIN
the_DT
product_NN
pricing_GER
and_PHC
market_NN
access_NN
for_PIN
our_FPP1
US_FPP1
,_,
Sweden_NN
and_CC
the_DT
UK_NN
._.
We_FPP1
support_VPRT
the_DT
World_NN
Trade_NN
Review_NN
,_,
our_FPP1
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
Organisation_NOMZ
WTO_NN
resolution_NOMZ
of_PIN
outstanding_JJ
Information_NOMZ
and_CC
Corporate_JJ
Responsibility_NOMZ
issues_NN
relating_VBG [WZPRES]
to_PIN
the_DT
Doha_NN
Agreement_NOMZ
on_PIN
Summary_NN
Report_NN
have_VPRT
all_QUAN
been_VBN [PASS]
prepared_VBN
in_PIN
Percy_NN
Barnevik_NN
Trade_NN
Related_NN
Aspects_NN
of_PIN
Intellectual_NN
accordance_NN
with_PIN
the_DT
new_JJ
requirements_NOMZ
._.
We_FPP1
Chairman_NN
We_FPP1
aspire_VPRT
to_TO
be_VB [BEMA]
the_DT
best_JJ
in_PIN
all_QUAN
areas_NN
of_PIN
our_FPP1
Expansion_NN
of_PIN
the_DT
Successful_JJ
delivery_NN
AstraZeneca_NN
relative_JJ
share_NN
performance_NN
business_NOMZ
within_PIN
a_DT
culture_NN
based_VBN [WZPAST]
on_PIN
innovation_NOMZ
development_NOMZ
to_PIN
market_NN
of_PIN
the_DT
31_CD
December_NN
1998_CD
31_CD
December_NN
2003_CD
combined_VBN
with_PIN
the_DT
disciplined_JJ
and_CC
pipeline_NN
through_PIN
next_JJ
wave_NN
of_PIN
AstraZeneca_NN
responsible_JJ
approach_NN
required_VBN [SUAV]
to_TO
achieve_VB
improved_VBN
differentiated_JJ
Major_JJ
international_JJ
pharmaceutical_JJ
companies_NN
industry_NN
leading_VBG [WZPRES]
productivity_NOMZ
._.
By_PIN
discovering_VBG [PRIV]
,_,
in-house_JJ
discovery_NN
products_NN
currently_RB
160_CD
developing_VBG
,_,
manufacturing_VBG
and_PHC
marketing_VBG
processes_NN
coupled_VBN [WZPAST]
in_PIN
late_TIME
stage_NN
differentiated_VBD
medicines_NN
that_TSUB
make_VPRT
a_DT
real_JJ
with_PIN
complementary_JJ
development_NOMZ
._.
130_CD
contribution_NOMZ
to_PIN
human_JJ
health_NN
,_,
AstraZeneca_NN
external_JJ
aims_NN
to_TO
create_VB
enduring_VBG
value_NN
for_PIN
collaborations_NOMZ
100_CD
shareholders_NN
and_PHC
society_NN
and_CC
deliver_VB
a_DT
and_CC
partnerships_NN
._.
70_CD
sustained_VBD
financial_JJ
performance_NN
that_TSUB
will_PRMD
Dec_NN
Jun_NN
Dec_NN
Jun_NN
Dec_NN
Jun_NN
Dec_NN
Jun_NN
Dec_NN
Jun_NN
Dec_NN
match_VPRT
the_DT
best_JJ
in_PIN
the_DT
industry_NN
._.
Our_FPP1
strategy_NN
98_CD
99_CD
99_CD
00_CD
00_CD
01_CD
01_CD
02_CD
02_CD
03_CD
03_CD
for_PIN
sustainable_JJ
growth_NN
is_VPRT
:_:
Abbott_NN
Labs_NN
,_,
AHP_NN
,_,
Aventis_NN
,_,
BMS_NN
,_,
Eli_NN
Lilly_NN
,_,
GSK_NN
,_,
JNJ_NN
,_,
Merck_NN
,_,
Novartis_NN
,_,
Pfizer_NN
,_,
Pharmacia_NN
,_,
Roche_NN
,_,
Sanofi-Synthelabo_NN
,_,
Schering_GER
and_PHC
Schering-Plough_NN
Source_NN
:_:
Thomson_NN
Financial_NN
Datastream_NN
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
03_CD
Performance_NN
In_PIN
2003_CD
,_,
AstraZeneca_NN
made_VBD
excellent_JJ
after_IN
its_PIT
first_JJ
introduction_NOMZ
in_PIN
the_DT
US_FPP1
,_,
making_VBG [PRESP]
it_PIT
Exanta_NN
met_VBD
important_JJ
milestones_NN
at_PIN
the_DT
progress_NN
establishing_VBG [PRIV] [WZPRES]
itself_PIT
as_IN
a_DT
world_NN
leading_VBG [WZPRES]
one_CD
of_PIN
the_DT
most_EMPH
successful_JJ
launches_NN
ever_RB
of_PIN
a_DT
end_NN
of_PIN
2003_CD
._.
In_PIN
December_NN
we_FPP1
gained_VBD
our_FPP1
pharmaceutical_JJ
company_NN
focused_VBD
on_PIN
the_DT
new_JJ
medicine_NN
._.
first_RB
approval_NN
in_PIN
France_NN
for_PIN
this_DEMO
breakthrough_NN
research_NN
,_,
development_NOMZ
,_,
manufacture_NN
and_PHC
medicine_NN
in_PIN
the_DT
prevention_NOMZ
of_PIN
blood_NN
clots_NN
marketing_GER
of_PIN
valuable_JJ
prescription_NOMZ
medicines_NN
Seroquel_NN
continues_VPRT
to_TO
grow_VB
strongly_AMP
in_PIN
the_DT
following_VBG
orthopaedic_NN
surgery_NN
._.
As_IN
scheduled_VBN
,_,
and_ANDC
creating_VBG
the_DT
platform_NN
for_PIN
top_JJ
tier_NN
financial_JJ
anti-psychotic_JJ
market_NN
where_RB
its_PIT
attractive_JJ
in_PIN
December_NN
we_FPP1
also_RB
filed_VBD
in_PIN
the_DT
US_FPP1
,_,
Canada_NN
performance_NN
in_PIN
the_DT
coming_VBG
years_NN
._.
profile_NN
makes_VPRT
it_PIT
the_DT
agent_NN
of_PIN
choice_NN
for_PIN
and_CC
Europe_NN
our_FPP1
largest_JJ
ever_RB
regulatory_JJ
increasing_VBG
numbers_NN
of_PIN
physicians_NN
and_PHC
submission_NN
,_,
this_DEMO
time_NN
for_PIN
long_JJ
term_NN
uses_NN
of_PIN
First_NN
launches_NN
of_PIN
Crestor_NN
,_,
the_DT
further_JJ
patients_NN
._.
Sales_NN
in_PIN
2003_CD
were_VBD
$_$
1.5_CD
billion_CD
and_CC
Exanta_NN
in_PIN
conditions_NOMZ
such_JJ
as_IN
the_DT
prevention_NOMZ
development_NOMZ
of_PIN
marketed_VBN
products_NN
such_JJ
as_IN
now_TIME
,_,
with_PIN
the_DT
approval_NN
of_PIN
a_DT
major_JJ
new_JJ
of_PIN
stroke_NN
in_PIN
patients_NN
with_PIN
atrial_JJ
fibrillation_NOMZ
._.
Iressa_NN
,_,
Nexium_NN
and_PHC
Seroquel_NN
,_,
and_ANDC
the_DT
first_JJ
indication_NOMZ
,_,
the_DT
treatment_NOMZ
of_PIN
mania_NN
associated_VBN
approval_NN
for_PIN
the_DT
revolutionary_JJ
anti-coagulant_JJ
,_,
with_PIN
bipolar_JJ
disease_NN
,_,
Seroquel_NN
looks_VPRT
set_VBN
to_PIN
In_CONJ
summary_NULL
,_,
2003_CD
has_VPRT [PEAS]
been_VBN [BEMA]
an_DT
exciting_JJ
Exanta_NN
,_,
herald_VPRT
the_DT
passage_NN
into_PIN
an_DT
exciting_JJ
play_NN
a_DT
key_JJ
part_NN
in_PIN
our_FPP1
future_JJ
growth_NN
._.
I_FPP1
would_PRMD
like_VB
to_PIN
new_JJ
era_NN
for_PIN
the_DT
Company_NN
._.
acknowledge_VPRT [PUBV]
the_DT
tremendous_JJ
support_NN
I_FPP1
AstraZenecas_NN
cancer_NN
portfolio_NN
also_RB
made_VBD
have_VPRT [PEAS]
received_VBN
from_PIN
my_FPP1
executive_NN
team_NN
Our_FPP1
sales_NN
and_PHC
marketing_GER
teams_NN
around_PLACE
the_DT
strong_JJ
progress_NN
during_PIN
the_DT
year_NN
with_PIN
and_CC
to_TO
recognize_VB [PRIV]
the_DT
immense_JJ
contribution_NOMZ
world_NN
now_TIME
have_VPRT
the_DT
opportunity_NOMZ
to_TO
realize_VB [PRIV] [THATD]
the_DT
excellent_JJ
data_NN
supporting_VBG [WZPRES]
the_DT
use_NN
of_PIN
Arimidex_NN
made_VBN [WZPAST]
by_PIN
our_FPP1
creative_JJ
,_,
hardworking_VBG
and_CC
full_JJ
potential_NN
of_PIN
our_FPP1
successful_JJ
research_NN
and_CC
2003_CD
sales_NN
$_$
519_CD
million_CD
in_PIN
the_DT
adjuvant_JJ
committed_JJ
employees_NN
around_PLACE
the_DT
world_NN
._.
development_NOMZ
and_CC
,_,
through_PIN
wise_JJ
investment_NOMZ
treatment_NOMZ
of_PIN
breast_NN
cancer_NN
,_,
strong_JJ
sales_NN
for_PIN
Their_TPP3
combined_VBN
efforts_NN
have_VPRT
already_RB
and_CC
a_DT
continuing_VBG
drive_NN
for_PIN
improved_VBN
Faslodex_NN
$_$
77_CD
million_CD
which_WDT
was_VBD [PASS]
launched_VBN
achieved_VBD
a_DT
great_JJ
deal_NN
._.
There_EX
is_VPRT
now_TIME
much_QUAN
productivity_NOMZ
,_,
deliver_VPRT
enduring_VBG
growth_NN
of_PIN
in_PIN
2002_CD
in_PIN
the_DT
US_FPP1
,_,
and_ANDC
the_DT
successful_JJ
US_FPP1
to_TO
do_VB
to_TO
realize_VB [PRIV]
the_DT
potential_NN
for_PIN
outstanding_JJ
shareholder_NN
value_NN
._.
launch_NN
of_PIN
Iressa_NN
2003_CD
global_JJ
sales_NN
$_$
228_CD
growth_NN
and_CC
financial_JJ
performance_NN
from_PIN
this_DEMO
million_CD
for_PIN
the_DT
treatment_NOMZ
of_PIN
late_TIME
stage_NN
strong_JJ
base_NN
._.
In_CONJ
addition_NULL
to_PIN
good_JJ
progress_NN
with_PIN
the_DT
new_JJ
non-small_JJ
cell_NN
lung_NN
cancer_NN
._.
products_NN
,_,
we_FPP1
have_VPRT [SPAU] [PEAS]
also_RB
expanded_VBN
our_FPP1
global_JJ
The_DT
external_JJ
environment_NOMZ
is_VPRT
changing_VBG
presence_NN
with_PIN
investments_NOMZ
in_PIN
research_NN
,_,
The_DT
year_NN
also_RB
saw_VBD [PRIV]
significant_JJ
developments_NOMZ
and_CC
our_FPP1
industry_NN
has_VPRT
to_TO
change_VB
with_PIN
it_PIT
._.
development_NOMZ
,_,
manufacturing_GER
and_PHC
marketing_GER
in_PIN
AstraZenecas_NN
cardiovascular_JJ
business_NOMZ
Demographics_NN
and_PHC
technology_NN
continue_VPRT
in_PIN
important_JJ
emerging_VBG
markets_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
including_VBG
the_DT
launch_NN
in_PIN
the_DT
US_FPP1
and_CC
20_CD
other_JJ
to_TO
drive_VB
demand_NN
for_PIN
healthcare_NN
and_CC
for_PIN
our_FPP1
these_DEMP
and_CC
other_JJ
initiatives_NN
,_,
AstraZeneca_NN
has_VPRT
markets_NN
of_PIN
the_DT
lipid-lowering_JJ
drug_NN
Crestor_NN
products_NN
with_PIN
the_DT
result_NN
that_TOBJ
governments_NOMZ
become_VPRT
one_CD
of_PIN
the_DT
fastest_JJ
growing_VBG
2003_CD
sales_NN
$_$
129_CD
million_CD
._.
The_DT
treatment_NOMZ
of_PIN
and_CC
payers_NN
face_VPRT
increasing_VBG
pressure_NN
to_PIN
pharmaceutical_JJ
companies_NN
in_PIN [STPR]
,_,
among_PIN
others_NN
,_,
lipid_JJ
disorders_NN
is_VPRT [BEMA]
a_DT
major_JJ
priority_NOMZ
for_PIN
control_NN
costs_NN
._.
At_PIN
the_DT
same_JJ
time_NN
the_DT
disparity_NOMZ
Japan_NN
,_,
China_NN
and_PHC
Mexico_NN
._.
healthcare_NN
systems_NN
around_PLACE
the_DT
world_NN
and_CC
the_DT
of_PIN
healthcare_NN
between_PIN
the_DT
developed_VBN
and_CC
the_DT
profile_NN
of_PIN
Crestor_NN
,_,
which_WDT [SERE]
allows_VPRT [SUAV]
physicians_NN
least_JJ
developed_JJ
nations_NOMZ
continues_VPRT
to_TO
grow_VB
During_PIN
2003_CD
the_DT
performance_NN
of_PIN
the_DT
new_JJ
and_CC
and_CC
patients_NN
to_TO
achieve_VB
guideline_NN
lipid_NN
levels_NN
and_CC
the_DT
industry_NN
finds_VPRT [PRIV]
itself_PIT
at_PIN
the_DT
center_NN
of_PIN
growth_NN
products_NN
in_PIN
the_DT
Companys_NN
revitalised_VBD
quickly_RB
and_PHC
easily_RB
,_,
gives_VPRT
us_FPP1
an_DT
opportunity_NOMZ
to_PIN
much_QUAN
of_PIN
this_DEMO
debate_NN
._.
It_PIT
is_VPRT [BEMA]
in_PIN
this_DEMO
environment_NOMZ
portfolio_NN
$_$
8.2_CD
billion_CD
largely_RB
offset_VPRT
the_DT
decline_NN
build_VB
a_DT
major_JJ
new_JJ
franchise_NN
in_PIN
one_CD
of_PIN
the_DT
that_DEMO
AstraZeneca_NN
has_VPRT
to_TO
succeed_VB
if_COND
it_PIT
is_VPRT [BEMA]
to_PIN
in_PIN
global_JJ
sales_NN
of_PIN
Losec_NN
Prilosec_NN
,_,
Zestril_NN
and_CC
largest_JJ
sectors_NN
of_PIN
medicine_NN
._.
Following_VBG
create_VB
value_NN
for_PIN
all_QUAN
its_PIT
stakeholders_NN
._.
This_DEMO
transformation_NOMZ
,_,
successful_JJ
introduction_NOMZ
into_PIN
a_DT
number_NN
of_PIN
work_NN
of_PIN
the_DT
last_JJ
five_CD
years_NN
has_VPRT [PEAS]
positioned_VBN
us_FPP1
achieved_VBD
without_PIN
a_DT
decline_NN
in_PIN
top-line_JJ
sales_NN
,_,
other_JJ
markets_NN
,_,
launch_NN
in_PIN
the_DT
very_AMP
important_JJ
well_RB
._.
We_FPP1
recognize_VPRT [PRIV]
and_PHC
understand_VPRT [PRIV]
the_DT
from_PIN
a_DT
company_NN
that_TSUB
faced_VBD
the_DT
biggest_JJ
threat_NN
US_FPP1
market_NN
has_VPRT [PEAS]
gone_VBN
well_RB
and_PHC
early_TIME
sales_NN
challenges_VPRT
the_DT
future_JJ
holds_VPRT [PRIV]
and_CC
we_FPP1
look_VPRT
from_PIN
patent_NN
expiries_NN
in_PIN
the_DT
industrys_NN
history_NN
,_,
progress_NN
is_VPRT
encouraging_VBG
._.
An_DT
important_JJ
new_JJ
forward_RB
to_TO
meeting_VBG
those_DEMO
challenges_NN
in_PIN
into_PIN
the_DT
one_CD
with_PIN
perhaps_RB
the_DT
best_JJ
growth_NN
study_NN
CHARM_NN
supporting_VBG [WZPRES]
the_DT
use_NN
of_PIN
2004_CD
and_CC
beyond_IN
._.
portfolio_NN
,_,
is_VPRT
something_QUPR
of_PIN
which_WDT [PIRE]
our_FPP1
Atacand_NN
2003_CD
sales_NN
$_$
750_CD
million_CD
in_PIN
heart_NN
employees_NN
are_VPRT [BEMA]
justifiably_RB
proud_PRED
._.
failure_NN
and_CC
the_DT
continued_JJ
growth_NN
of_PIN
Seloken_NN
Toprol-XL_NN
2003_CD
sales_NN
$_$
1.3_CD
billion_CD
Nexium_NN
,_,
for_PIN
gastrointestinal_JJ
disorders_NN
,_,
has_VPRT
have_VPRT [SPAU] [PEAS]
also_RB
helped_VBN
to_TO
reinforce_VB
a_DT
leading_VBG
maintained_VBN [PUBV]
strong_JJ
momentum_NN
despite_PIN
an_DT
position_NOMZ
in_PIN
cardiovascular_JJ
medicine_NN
._.
In_PIN
the_DT
US_FPP1
alone_RB
,_,
Nexium_NN
achieved_VBD
sales_NN
of_PIN
After_IN
a_DT
lengthy_JJ
development_NOMZ
program_NN
$_$
2.5_CD
billion_CD
in_PIN
the_DT
year_NN
._.
Globally_RB
annual_JJ
sales_NN
involving_VBG [WZPRES]
more_EMPH
than_PIN
30,000_CD
patients_NN
,_,
I_FPP1
am_VPRT
Sir_NN
Tom_NN
McKillop_NN
reached_VBD
$_$
3.3_CD
billion_CD
,_,
less_JJ
than_PIN
three_CD
years_NN
pleased_JJ
to_TO
report_VB [PUBV]
that_THVC
the_DT
oral_JJ
anti-coagulant_JJ
Chief_NN
Executive_NN
Realising_VBG [PRIV] [WZPRES]
the_DT
full_JJ
Further_JJ
Enhancing_VBG
our_FPP1
Pursuing_GER
Continuing_GER
Delivering_GER
our_FPP1
potential_NN
of_PIN
our_FPP1
strengthening_VBG
our_FPP1
presence_NN
in_PIN
value_NN
creating_VBG [WZPRES]
to_TO
improve_VB
core_NN
values_NN
therapies_NN
through_PIN
commercial_JJ
skills_NN
important_JJ
new_JJ
,_,
investment_NOMZ
in_PIN
productivity_NOMZ
through_PIN
a_DT
investment_NOMZ
in_PIN
to_TO
drive_VB
success_NN
emerging_VBG [WZPRES]
markets_NN
significant_JJ
targeted_VBN
in_PIN
pursuit_NN
of_PIN
responsible_JJ
projects_NN
that_TSUB
will_PRMD
in_PIN
our_FPP1
key_JJ
markets_NN
._.
through_PIN
organic_JJ
licensing_GER
and_CC
operational_JJ
approach_NN
extend_VPRT
their_TPP3
use_NN
growth_NN
and_PHC
acquisition_NOMZ
excellence_NN
to_PIN
business_NOMZ
._.
and_ANDC
bring_VB
benefits_NN
strategic_JJ
regional_JJ
opportunities_NOMZ
._.
in_PIN
all_QUAN
our_FPP1
to_PIN
new_JJ
patient_JJ
investments_NOMZ
._.
com_NN
04_CD
Discovery_NN
We_FPP1
use_VPRT
leading_VBG
edge_NN
science_NN
and_PHC
technology_NN
to_TO
identify_VB
the_DT
compounds_NN
with_PIN
the_DT
highest_JJ
potential_NN
to_TO
become_VB
new_JJ
medicines_NN
._.
In_PIN
2003_CD
,_,
our_FPP1
We_FPP1
have_VPRT
over_IN
During_PIN
2003_CD
,_,
We_FPP1
continue_VPRT
During_PIN
the_DT
year_NN
,_,
we_FPP1
entered_VBD
into_PIN
more_EMPH
than_PIN
research_NN
and_CC
11,500_CD
people_NN
a_DT
further_JJ
15_CD
to_TO
invest_VB
in_PIN
our_FPP1
200_CD
new_JJ
collaborations_NOMZ
including_VBG [WZPRES]
with_PIN
the_DT
development_NOMZ
dedicated_VBN [WZPAST]
to_PIN
the_DT
candidate_NN
drugs_NN
facilities_NOMZ
and_PHC
University_NOMZ
of_PIN
Dundee_NN
,_,
the_DT
University_NOMZ
of_PIN
investment_NOMZ
discovery_NN
and_CC
were_VBD [PASS]
selected_VBN
and_CC
,_,
in_PIN
2003_CD
,_,
new_JJ
Gratz_NN
,_,
Sumitomo_NN
Pharmaceutical_NN
Co._NN
._.
Ltd._NN
totalled_VBD
$_$
3.5_CD
billion_CD
development_NOMZ
of_PIN
in_CONJ
addition_NULL
,_,
10_CD
or_CC
upgraded_VBN
NeoGenesis_NN
Pharmaceuticals_NN
,_,
Inc._NN
up_IN
from_PIN
$_$
3.1_CD
new_JJ
medicines_NN
at_PIN
early_TIME
development_NOMZ
laboratories_NN
Cytokinetics_NN
,_,
Inc._NN
._.
Biosignal_NN
Inc._NN
._.
11_CD
R&D_NN
centres_NN
in_PIN
projects_NN
reached_VBN [WZPAST]
were_VBD [PASS]
opened_VBN
in_PIN
Biopharma_NN
and_PHC
Abgenix_NN
Inc._NN
seven_CD
countries_NN
the_DT
stage_NN
of_PIN
Sweden_NN
,_,
the_DT
UK_NN
,_,
the_DT
UK_NN
,_,
the_DT
US_FPP1
,_,
human_JJ
testing_GER
._.
Sweden_NN
,_,
France_NN
,_,
Canada_NN
,_,
India_NN
and_PHC
Japan_NN
._.
com_NN
05_CD
AstraZeneca_NN
focuses_VPRT
its_PIT
skills_NN
,_,
experience_NN
We_FPP1
are_VPRT [SPAU]
continuously_RB
improving_VBG
the_DT
and_CC
resources_NN
on_PIN
six_CD
therapy_NN
areas_NN
:_:
productivity_NOMZ
and_PHC
efficiency_NN
of_PIN
our_FPP1
Cardiovascular_NN
,_,
Gastrointestinal_NN
,_,
discovery_NN
and_PHC
development_NOMZ
by_PIN
Infection_NOMZ
,_,
Neuroscience_NN
,_,
Oncology_NN
,_,
simplifying_VBG [PRESP]
our_FPP1
processes_NN
,_,
speeding_VBG
and_CC
Respiratory_NN
and_PHC
Inflammation_NOMZ
up_IN
decision_NN
making_VBG [WZPRES]
and_PHC
investing_VBG
in_PIN
important_JJ
areas_NN
of_PIN
healthcare_NN
which_WDT [WHOBJ]
areas_NN
directly_RB
linked_VBN
to_TO
increasing_VBG
the_DT
represent_VPRT
the_DT
majority_NOMZ
of_PIN
the_DT
worldwide_JJ
quality_NOMZ
and_PHC
number_NN
of_PIN
new_JJ
products_NN
._.
We_FPP1
have_VPRT
a_DT
powerful_JJ
During_PIN
2003_CD
we_FPP1
significantly_RB
increased_VBD
range_NN
of_PIN
products_NN
that_TSUB
meet_VPRT
patient_JJ
the_DT
number_NN
of_PIN
new_JJ
discovery_NN
projects_NN
,_,
needs_VPRT
in_PIN
these_DEMO
areas_NN
and_CC
a_DT
commitment_NOMZ
delivered_VBD
a_DT
more_EMPH
consistent_JJ
flow_NN
of_PIN
to_TO
delivering_VBG
more_EMPH
new_JJ
,_,
medically_RB
quality_JJ
candidate_NN
drugs_NN
throughout_PIN
the_DT
important_JJ
and_CC
commercially_RB
successful_JJ
year_NN
,_,
increased_VBD
the_DT
number_NN
of_PIN
drugs_NN
products_NN
to_PIN
the_DT
market_NN
every_QUAN
year_NN
._.
reaching_VBG
clinical_JJ
testing_GER
and_CC
progressed_VBD
a_DT
greater_JJ
number_NN
of_PIN
products_NN
that_TOBJ
Medical_NN
research_NN
is_VPRT [BEMA]
more_EMPH
exciting_PRED
than_PIN
showed_VBD [PRIV]
therapeutic_JJ
potential_NN
._.
ever_RB
as_IN
new_JJ
technology_NN
is_VPRT [PASS]
applied_VBN
to_TO
understanding_VBG [PRIV]
what_WP [WHCL]
causes_VPRT
disease_NN
On_PIN
average_NN
,_,
at_PIN
least_JJ
one_CD
quality_NOMZ
CD_NN
now_TIME
and_ANDC
how_RB
it_PIT
may_POMD
be_VB [PASS]
prevented_VBN
or_CC
treated_VBN
._.
enters_VPRT
pre-clinical_JJ
development_NOMZ
each_QUAN
month_NN
._.
During_PIN
2003_CD
,_,
a_DT
further_JJ
15_CD
CDs_NN
We_FPP1
have_VPRT
six_CD
major_JJ
joint_JJ
discovery_NN
and_CC
were_VBD [PASS]
selected_VBN
and_CC
,_,
in_CONJ
addition_NULL
,_,
10_CD
early_TIME
development_NOMZ
facilities_NOMZ
in_PIN
the_DT
UK_NN
,_,
the_DT
US_FPP1
development_NOMZ
projects_NN
reached_VBD
the_DT
stage_NN
and_PHC
Sweden_NN
:_:
a_DT
further_JJ
four_CD
sites_NN
in_PIN
the_DT
of_PIN
human_JJ
testing_GER
._.
US_FPP1
,_,
Canada_NN
,_,
India_NN
and_PHC
France_NN
which_WDT [WHSUB]
focus_VPRT
only_DWNT
on_PIN
discovery_NN
,_,
and_ANDC
a_DT
facility_NOMZ
Our_FPP1
global_JJ
Enabling_GER
Science_NN
and_CC
in_PIN
Japan_NN
for_PIN
development_NOMZ
only_DWNT
._.
These_DEMO
Technology_NN
group_NN
supports_VPRT
all_QUAN
research_NN
resources_NN
are_VPRT [BYPA]
complemented_VBN
by_PIN
clinical_JJ
areas_NN
with_PIN
skills_NN
in_PIN
compound_NN
managedevelopment_NOMZ
at_PIN
43_CD
sites_NN
around_PLACE
the_DT
ment_NOMZ
,_,
natural_JJ
product_NN
screening_GER
,_,
world_NN
._.
structural_JJ
chemistry_NN
,_,
bio-imaging_GER
,_,
genetics_NN
,_,
transgenics_NN
,_,
protein_NN
science_NN
In_PIN
AstraZeneca_NN
Discovery_NN
,_,
our_FPP1
scientists_NN
and_PHC
informatics_NN
._.
New_NN
enabling_VBG [WZPRES]
techfocus_NN
on_PIN
finding_VBG [PRIV]
new_JJ
compounds_NN
with_PIN
nologies_NN
for_PIN
drug_NN
searching_VBG [WZPRES]
have_VPRT [PEAS]
been_VBN [BEMA]
high_JJ
potential_NN
as_IN
new_JJ
medicines_NN
in_PIN
our_FPP1
introduced_VBN
and_CC
a_DT
global_JJ
compound_NN
chosen_VBN
areas_NN
of_PIN
activity_NOMZ
,_,
working_VBG
across_PLACE
collection_NOMZ
enhancement_NOMZ
project_NN
is_VPRT
boundaries_NN
to_TO
exchange_VB
ideas_NN
,_,
to_TO
share_VB
ongoing_JJ
._.
best_RB
practice_NN
and_CC
to_TO
make_VB
the_DT
most_EMPH
of_PIN
the_DT
efficiencies_NN
that_TOBJ
global_JJ
working_VBG
offers_NN
._.
Broadening_VBG [PRESP]
the_DT
approach_NN
In_PIN
todays_NN
world_NN
of_PIN
rapid_JJ
scientific_JJ
and_CC
Our_FPP1
efforts_NN
to_TO
improve_VB
the_DT
links_NN
between_PIN
technological_JJ
advance_NN
,_,
no_SYNE
company_NN
can_POMD
basic_JJ
science_NN
and_CC
clinical_JJ
medicine_NN
are_VPRT
rely_VPRT
exclusively_RB
on_PIN
its_PIT
own_JJ
discovery_NN
and_CC
already_RB
proving_VBG [PRIV]
valuable_JJ
to_PIN
the_DT
drug_NN
development_NOMZ
._.
We_FPP1
also_RB
work_VPRT
with_PIN
leading_VBG
discovery_NN
process_NN
,_,
as_IN
we_FPP1
gain_VPRT
a_DT
better_JJ
academic_JJ
centres_NN
and_PHC
biotechnology_NN
understanding_GER
of_PIN
human_JJ
diseases_NN
companies_NN
with_PIN
skills_NN
that_TSUB
complement_VPRT
and_ANDC
how_RB
future_JJ
medicines_NN
will_PRMD
work_VB
our_FPP1
own_JJ
capabilities_NOMZ
and_CC
broaden_VB
the_DT
to_TO
prevent_VB
and_PHC
treat_VB
them_TPP3
._.
We_FPP1
also_RB
base_NN
for_PIN
disease_NN
research_NN
._.
continue_VB
to_TO
introduce_VB
earlier_TIME
in_PIN
the_DT
process_NN
more_EMPH
stringent_JJ
testing_GER
of_PIN
drug_NN
safety_NN
and_ANDC
how_RB
a_DT
medicine_NN
gets_VPRT
distributed_VBN
around_PLACE
,_,
and_ANDC
out_PIN [STPR]
,_,
of_PIN
the_DT
human_JJ
body_NN
._.
This_DEMP
helps_VPRT
us_FPP1
to_TO
eliminate_VB
the_DT
candidate_NN
drugs_NN
CDs_NN
that_TSUB
are_VPRT [BEMA]
less_RB
likely_PRED
to_TO
succeed_VB
earlier_TIME
in_PIN
the_DT
process_NN
._.
com_NN
06_CD
Development_NOMZ
We_FPP1
are_VPRT [SPAU]
continuously_RB
improving_VBG
our_FPP1
development_NOMZ
processes_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
we_FPP1
get_VPRT
life_NN
changing_VBG [WZPRES]
medicines_NN
to_PIN
patients_NN
as_RB
quickly_RB
as_IN
possible_JJ
._.
AstraZeneca_NN
Our_FPP1
high_JJ
quality_NOMZ
As_IN
part_NN
of_PIN
our_FPP1
drive_NN
to_TO
speed_VB
development_NOMZ
,_,
currently_RB
has_VPRT
12_CD
pipeline_NN
is_VPRT [PASS]
geared_VBN
we_FPP1
introduced_VBD
a_DT
number_NN
of_PIN
e-based_JJ
clinical_JJ
projects_NN
in_PIN
phase_NN
2_CD
to_TO
continued_VBN
and_CC
and_CC
regulatory_JJ
systems_NN
during_PIN
the_DT
year_NN
development_NOMZ
and_CC
long_JJ
term_NN
innovation_NOMZ
which_WDT [WHSUB]
make_VPRT
data_NN
more_EMPH
quickly_RB
and_PHC
easily_RB
28_CD
in_PIN
phase_NN
3_CD
._.
that_DEMP
meets_VPRT
the_DT
accessible_JJ
worldwide_NN
._.
needs_NN
of_PIN
patients_NN
and_CC
the_DT
healthcare_NN
professionals_NN
who_WP [WHSUB]
treat_VPRT
them_TPP3
._.
com_NN
07_CD
Our_FPP1
aim_NN
is_VPRT
to_TO
develop_VB
better_JJ
drugs_NN
Compound_NN
Areas_NN
under_IN
investigation_NOMZ
Estimated_VBN [PRIV]
filing_NN
date_NN
Stage_NN
of_PIN
development_NOMZ
MAA_NN
NDA_NN
PC_NN
1_CD
2_CD
3_CD
faster_JJ
._.
People_NN
in_PIN
our_FPP1
Development_NOMZ
Cardiovascular_NN
organization_NOMZ
work_NN
globally_RB
in_PIN
therapy_NN
Exanta_NN
prevention_NOMZ
of_PIN
VTE_NN
Approved_NN
Filed_NN
area_NN
led_VBD
product_NN
teams_NN
that_TSUB
bring_VPRT
Exanta_JJ
together_RB
all_QUAN
the_DT
relevant_JJ
functional_JJ
skills_NN
SC_NN
formulation_NOMZ
prevention_NOMZ
of_PIN
VTE_NN
Approved_NN
2006_CD
Galida_NN
diabetes_NN
metabolic_JJ
syndrome_NN
2006_CD
2006_CD
and_CC
experience_VB
needed_VBN
for_PIN
the_DT
robust_JJ
,_,
AZD6140_JJ
arterial_JJ
thrombosis_NN
2006_CD
2006_CD
rapid_JJ
progress_NN
of_PIN
new_JJ
medicines_NN
._.
AZD7009_CD
atrial_JJ
fibrillation_NOMZ
2006_CD
2006_CD
AZD9684_NN
thrombosis_NN
2006_CD
2006_CD
In_PIN
2003_CD
,_,
we_FPP1
successfully_RB
completed_VBD
AZD0837_NN
thrombosis_NN
2006_CD
2006_CD
the_DT
development_NOMZ
programs_NN
,_,
and_ANDC
AZD7806_NN
dyslipidemia_NN
2006_CD
2006_CD
AZD6610_NN
dyslipidemia_NN
2006_CD
2006_CD
provided_VBD
the_DT
regulatory_JJ
support_NN
required_VBN [SUAV]
AZD4619_NN
dyslipidemia_NN
2006_CD
2006_CD
for_PIN
the_DT
approval_NN
of_PIN
Exanta_NN
and_CC
for_PIN
the_DT
AZD0303_NN
thrombosis_NN
2006_CD
2006_CD
approval_NN
and_PHC
launch_NN
of_PIN
Crestor_NN
and_PHC
Iressa_NN
._.
AZD8294_CD
dyslipidemia_NN
2006_CD
2006_CD
France_NN
,_,
Reference_NN
Member_NN
State_NN
for_PIN
the_DT
EU_NN
Mutual_NN
Recognition_NOMZ
Procedure_NN
._.
We_FPP1
also_RB
explore_VPRT
all_QUAN
the_DT
ways_NN
our_FPP1
Gastrointestinal_NN
launched_VBD
products_NN
can_POMD
be_VB [PASS]
used_VBN
AZD0865_CD
acid_NN
related_VBN
GI_NN
disease_NN
2006_CD
2006_CD
or_CC
improved_VBN
to_TO
get_VB
the_DT
most_EMPH
benefit_VB
for_PIN
AZD3355_NN
GERD_NN
2006_CD
2006_CD
patients_NN
._.
During_PIN
the_DT
year_NN
,_,
we_FPP1
delivered_VBD
AZD7371_NN
functional_JJ
GI_NN
disorders_NN
2006_CD
2006_CD
further_JJ
product_NN
development_NOMZ
designed_VBN
AZD9343_NN
GERD_NN
2006_CD
2006_CD
to_TO
maximize_VB
the_DT
potential_NN
of_PIN
key_JJ
Neuroscience_NN
marketed_VBD
brands_NN
,_,
including_VBG
Nexium_NN
,_,
Cerovive_NN
Seroquel_NN
and_PHC
Symbicort_NN
._.
previously_TIME
NXY059_CD
stroke_NN
2006_CD
2006_CD
The_DT
table_NN
on_PIN
the_DT
right_JJ
summarises_NN
ZD0947_NN
overactive_JJ
bladder_NN
2006_CD
2006_CD
AR-A2_NN
anxiety_NN
depression_NN
2006_CD
2006_CD
the_DT
new_JJ
chemical_NN
entities_NOMZ
currently_RB
AZD4282_CD
neuropathic_JJ
pain_NN
2006_CD
2006_CD
in_PIN
development_NOMZ
._.
A_DT
fuller_JJ
description_NOMZ
AZD4750_NN
multiple_JJ
sclerosis_NN
2006_CD
2006_CD
of_PIN
our_FPP1
development_NOMZ
pipeline_NN
,_,
including_VBG
AZD5455_NN
anxiety_NN
disorders_NN
2006_CD
2006_CD
line_NN
extensions_NN
,_,
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
AZD0328_NN
Alzheimers_NN
disease_NN
2006_CD
2006_CD
AZD2858_NN
Alzheimers_NN
disease_NN
2006_CD
2006_CD
separate_JJ
AstraZeneca_NN
2003_CD
Annual_JJ
AZD3102_NN
Alzheimers_NN
disease_NN
2006_CD
2006_CD
Report_NN
and_PHC
Form_NN
20-F_JJ
Information_NOMZ
or_CC
on_PIN
our_FPP1
website_NN
._.
Oncology_NN
Faslodex_NN
2nd_JJ
line_NN
advanced_VBD
breast_NN
cancer_NN
Filed_NN
Launched_NN
IressaNSCLC_NN
FiledLaunched_NN
ZD6474_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
ZD4054_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
ZD6126_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
AZD2171_NN
solid_JJ
tumors_NN
and_CC
hematological_JJ
malignancies_NN
2006_CD
2006_CD
AZD3409_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
AZD0530_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
AZD5438_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
AZD4440_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
AZD9935_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
AZD0424_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
AZD1152_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
AZD6244_NN
solid_JJ
tumors_NN
2006_CD
2006_CD
Respiratory_NN
and_PHC
Inflammation_NOMZ
AZD9056_NN
rheumatoid_VBD
arthritis_NN
2006_CD
2006_CD
AZD8309_NN
rheumatoid_JJ
arthritis_NN
2006_CD
2006_CD
Abbreviations_NOMZ
used_VBN [WZPAST]
in_PIN
pipeline_NN
table_NN
:_:
AZD8309_CD
COPD_NN
2006_CD
2006_CD
COPD_NN
chronic_NN
obstructive_JJ
pulmonary_JJ
disease_NN
AZD9056_NN
COPD_NN
2006_CD
2006_CD
GERD_NN
gastro-oesophageal_JJ
reflux_NN
disease_NN
AZD3342_NN
COPD_NN
2006_CD
2006_CD
GI_NN
gastrointestinal_JJ
MAA_NN
marketing_GER
authorisation_NOMZ
2006_CD
2006_CD
Europe_NN
AZD0902_NN
rheumatoid_VBD
arthritis_NN
2006_CD
2006_CD
NDA_NN
new_JJ
drug_NN
application_NOMZ
US_FPP1
AZD9056_NN
osteoarthritis_VPRT
2006_CD
2006_CD
NSCLC_NN
non-small_JJ
cell_NN
lung_NN
cancer_NN
AZD8955_NN
osteoarthritis_VPRT
2006_CD
2006_CD
PC_NN
pre-clinical_JJ
:_:
candidate_NN
drug_NN
accepted_VBN [PRIV] [WZPAST]
for_PIN
AZD3778_NN
asthma_NN
rhinitis_VPRT
2006_CD
2006_CD
development_NOMZ
but_CC
not_XX0
yet_RB
administered_VBN
to_TO
man_VB
AZD6067_NN
COPD_NN
2006_CD
2006_CD
SC_NN
subcutaneous_JJ
AZD2098_NN
asthma_NN
2006_CD
2006_CD
VTE_NN
venous_JJ
thromboembolism_NN
AZD1981_NN
asthma_NN
2006 2006 2006_CD
not_XX0
earlier_TIME
than_PIN
2007_CD
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
08_CD
Supply_NN
We_FPP1
aim_VPRT
to_TO
provide_VB
fast_JJ
,_,
flexible_JJ
and_PHC
reliable_JJ
manufacturing_GER
and_PHC
supply_NN
of_PIN
all_QUAN
the_DT
products_NN
in_PIN
our_FPP1
range_NN
,_,
wherever_RB
they_TPP3
are_VPRT [PASS]
needed_VBN
._.
We_FPP1
have_VPRT
31_CD
Around_PLACE
16,000_CD
We_FPP1
complement_VPRT
Our_FPP1
investment_NOMZ
In_PIN
the_DT
US_FPP1
,_,
supplies_VPRT
manufacturing_VBG
sites_NN
people_NN
worldwide_JJ
our_FPP1
in-house_NN
in_PIN
supply_NN
and_CC
of_PIN
our_FPP1
new_JJ
statin_NN
,_,
in_PIN
20_CD
countries_NN
._.
work_NN
in_PIN
supply_NN
and_PHC
manufacturing_GER
manufacturing_GER
Crestor_NN
,_,
were_VBD
manufacturing_VBG
,_,
capabilities_NOMZ
facilities_NOMZ
in_PIN
2003_CD
available_JJ
to_TO
including_VBG
some_QUAN
with_PIN
strategic_JJ
totalled_VBD
$_$
496_CD
million_CD
._.
wholesalers_NN
within_PIN
13,000_CD
people_NN
in_PIN
outsourcing_VBG
three_CD
days_NN
of_PIN
FDA_NN
formulation_NOMZ
and_CC
to_PIN
external_JJ
approval_NN
of_PIN
the_DT
packaging_GER
,_,
and_ANDC
contractors_NN
._.
therapy_NN
and_CC
the_DT
1,750_CD
in_PIN
active_JJ
majority_NOMZ
of_PIN
retail_JJ
pharmaceutical_JJ
stores_NN
were_VBD
ingredient_NN
supply_NN
._.
com_NN
09_CD
Cost_NN
management_NOMZ
Customer_NN
service_NN
Safety_NN
,_,
health_NN
and_PHC
environment_NOMZ
SHE_TPP3
Our_FPP1
supply_NN
chains_NN
are_VPRT [PASS]
designed_VBN
to_PIN
The_DT
continued_VBN
implementation_NOMZ
of_PIN
a_DT
operating_GER
standards_NN
are_VPRT [SPAU]
increasingly_RB
maximize_VB
our_FPP1
flexibility_NOMZ
and_CC
ensure_VB [SUAV] [PRIV]
the_DT
new_JJ
supply_NN
system_NN
across_PLACE
our_FPP1
global_JJ
stringent_JJ
with_PIN
regulators_NN
placing_VBG [WZPRES]
fast_RB
,_,
efficient_JJ
introduction_NOMZ
of_PIN
new_JJ
network_NN
achieved_VBD
positive_JJ
results_NN
in_CONJ
particular_NULL
emphasis_NN
on_PIN
environmental_JJ
medicines_NN
._.
Manufacturing_GER
lead_JJ
times_NN
have_VPRT
issues_NN
and_CC
the_DT
safety_NN
of_PIN
chemicals_NN
._.
product_NN
launches_NN
,_,
major_JJ
products_NN
and_CC
been_VBN [PASS]
shortened_VBN
,_,
which_WDT [SERE]
has_VPRT [PEAS]
reduced_VBN
the_DT
Our_FPP1
manufacturing_GER
sites_NN
operate_VPRT
under_IN
line_NN
extensions_NN
were_VBD [SPAU]
successfully_RB
need_VB
for_PIN
build_VB
up_IN
of_PIN
stock_NN
and_PHC
customer_NN
various_JJ
licensing_GER
regimes_NN
and_CC
we_FPP1
are_VPRT [PASS]
supported_VBN
with_PIN
supplies_NN
available_JJ
to_PIN
service_NN
levels_NN
have_VPRT [PEAS]
improved_VBN
._.
committed_VBN
to_TO
meeting_VBG
all_QUAN
regulatory_JJ
meet_VPRT
market_NN
demand_NN
._.
The_DT
new_JJ
supply_NN
system_NN
has_VPRT
also_RB
There_EX
are_VPRT
currently_RB
no_SYNE
environmental_JJ
As_IN
part_NN
of_PIN
our_FPP1
overall_JJ
risk_NN
management_NOMZ
,_,
enabled_VBD
more_EMPH
effective_JJ
management_NOMZ
issues_NN
that_TSUB
constrain_VPRT
AstraZeneca_NN
from_PIN
we_FPP1
carefully_RB
consider_VPRT [PRIV]
the_DT
timing_NN
of_PIN
of_PIN
the_DT
costs_NN
of_PIN
a_DT
product_NN
,_,
prior_RB
to_TO
making_VBG
full_JJ
use_NN
of_PIN
its_PIT
sites_NN
._.
investment_NOMZ
relating_VBG [WZPRES]
to_PIN
the_DT
launch_NN
of_PIN
new_JJ
launch_NN
and_CC
throughout_PIN
its_PIT
lifecycle_NN
._.
Secure_VB
supply_NN
chains_NN
are_VPRT [BEMA]
in_PIN
Developments_NOMZ
include_VPRT
the_DT
use_NN
of_PIN
We_FPP1
are_VPRT
making_VBG
steady_JJ
progress_NN
against_PIN
place_NN
for_PIN
all_QUAN
the_DT
products_NN
currently_RB
in_PIN
late_TIME
e-based_JJ
supply_NN
chain_NN
management_NOMZ
our_FPP1
targets_NN
for_PIN
the_DT
reduction_NOMZ
of_PIN
waste_NN
stage_NN
development_NOMZ
._.
systems_NN
to_TO
improve_VB
efficiencies_NN
with_PIN
and_CC
energy_NN
usage_NN
and_CC
the_DT
level_NN
of_PIN
suppliers_NN
and_CC
drive_VB
down_RP
costs_NN
._.
accidents_NN
with_PIN
injury_NN
has_VPRT [PEAS]
been_VBN [PASS]
reduced_VBN
._.
Supply_NN
capability_NOMZ
Within_PIN
AstraZeneca_NN
,_,
we_FPP1
have_VPRT
active_JJ
Cost_NN
efficiencies_NN
are_VPRT [SPAU] [BYPA]
also_RB
driven_VBN
by_PIN
our_FPP1
Our_FPP1
aim_NN
for_PIN
continuous_JJ
improvement_NOMZ
ingredient_NN
manufacturing_VBG [WZPRES]
sites_NN
in_PIN
the_DT
UK_NN
,_,
continuous_JJ
review_NN
of_PIN
manufacturing_GER
includes_VPRT
learning_VBG [PRIV]
from_PIN
incidences_NN
of_PIN
Sweden_NN
,_,
France_NN
and_PHC
Puerto_NN
Rico_NN
and_CC
a_DT
assets_NN
to_TO
make_VB
sure_JJ
that_THAC
they_TPP3
are_VPRT
being_VBG [BEMA]
non-compliance_PRED
and_CC
sharing_VBG
best_JJ
bulk_NN
drug_NN
purification_NOMZ
plant_NN
in_PIN
Germany_NN
._.
used_VBN [PASTP]
most_EMPH
effectively_RB
,_,
whilst_OSUB
preserving_VBG
practice_NN
to_PIN
further_JJ
promote_VB
high_JJ
We_FPP1
also_RB
make_VPRT
strategic_JJ
use_NN
of_PIN
outthe_NN
flexibility_NOMZ
we_FPP1
need_VPRT
to_TO
respond_VB
to_PIN
standards_NN
._.
We_FPP1
also_RB
work_VPRT
closely_RB
with_PIN
sourcing_VBG
to_PIN
external_JJ
specialty_NN
chemical_NN
fluctuations_NOMZ
in_PIN
demand_NN
._.
In_PIN
2003_CD
,_,
we_FPP1
our_FPP1
suppliers_NN
to_TO
encourage_VB
standards_NN
manufacturers_NN
to_TO
extend_VB
our_FPP1
in-house_NN
closed_VBD
a_DT
number_NN
of_PIN
obsolete_JJ
units_NN
and_CC
similar_JJ
to_PIN
our_FPP1
own_JJ
,_,
share_NN
best_JJ
practice_NN
capacity_NOMZ
._.
sold_VBN
our_FPP1
facility_NOMZ
in_PIN
Sanda_NN
,_,
Japan_NN
._.
We_FPP1
will_PRMD
and_ANDC
where_RB
needed_VBN
,_,
stimulate_VPRT
continue_VB
to_TO
make_VB
further_JJ
adjustments_NOMZ
to_PIN
improvements_NOMZ
._.
We_FPP1
make_VPRT
our_FPP1
various_JJ
product_NN
formuor_NN
manufacturing_GER
base_NN
to_TO
ensure_VB [SUAV] [PRIV]
best_JJ
lations_NOMZ
tablets_NN
,_,
capsules_NN
,_,
injectable_JJ
and_CC
use_NN
of_PIN
production_NOMZ
facilities_NOMZ
._.
More_EMPH
information_NOMZ
about_IN
our_FPP1
SHE_TPP3
inhalation_NOMZ
at_PIN
sites_NN
in_PIN
the_DT
US_FPP1
,_,
the_DT
UK_NN
,_,
performance_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
Sweden_NN
,_,
France_NN
,_,
Germany_NN
and_PHC
Puerto_NN
Licence_NN
to_TO
operate_VB
separate_JJ
2003_CD
Corporate_JJ
Responsibility_NOMZ
Rico_NN
._.
Ensuring_VBG [SUAV] [PRIV] [PRESP]
the_DT
quality_NOMZ
,_,
safety_NN
and_PHC
efficacy_NN
Summary_NN
Report_NN
or_CC
on_PIN
our_FPP1
website_NN
._.
of_PIN
our_FPP1
medicines_NN
is_VPRT [BEMA]
a_DT
core_NN
priority_NOMZ
._.
As_IN
Product_NN
packaging_GER
is_VPRT [PASS]
done_VBN [PROD]
at_PIN
a_DT
large_JJ
part_NN
of_PIN
this_DEMP
,_,
reports_NN
from_PIN
internal_JJ
routine_JJ
number_NN
of_PIN
sites_NN
worldwide_JJ
,_,
both_DT
inspections_NOMZ
as_RB
well_RB
as_IN
those_DEMO
by_PIN
AstraZenecas_NN
and_PHC
contractors_NN
regulatory_JJ
authorities_NOMZ
are_VPRT [BEMA]
rigorously_RB
all_QUAN
located_VBN
close_NN
to_PIN
our_FPP1
marketing_GER
reviewed_VBN
and_ANDC
if_COND
required_VBN [SUAV]
,_,
actions_NOMZ
taken_VBN
companies_NN
to_TO
support_VB
rapid_JJ
response_NN
to_TO [SPIN]
further_RB
enhance_VB
compliance_NN
._.
results_NN
of_PIN
all_QUAN
external_JJ
inspections_NOMZ
carried_VBD
out_PIN
during_PIN
2003_CD
were_VBD [BEMA]
satisfactory_PRED
and_PHC
New_PRED
facilities_NOMZ
opened_VBN [WZPAST]
during_PIN
2003_CD
we_FPP1
did_VBD
not_XX0
experience_VB
any_QUAN
delays_NN
in_PIN
included_VBN
additional_JJ
active_JJ
ingredient_NN
product_NN
approvals_NN
due_JJ
to_PIN
regulatory_JJ
capacity_NOMZ
for_PIN
Crestor_NN
in_PIN
the_DT
UK_NN
,_,
compliance_NN
issues_NN
at_PIN
our_FPP1
sites_NN
or_CC
those_DEMO
formulation_NOMZ
capacity_NOMZ
for_PIN
Crestor_NN
in_PIN
of_PIN
our_FPP1
contractors_NN
._.
Puerto_NN
Rico_NN
and_CC
additional_JJ
capacity_NOMZ
for_PIN
Pulmicort_NN
in_PIN
the_DT
US_FPP1
._.
Looking_VBG [PRESP]
ahead_PLACE
,_,
plans_NN
are_VPRT [BEMA]
in_PIN
place_NN
to_TO
expand_VB
capacity_NOMZ
in_PIN
the_DT
US_FPP1
,_,
France_NN
,_,
Sweden_NN
and_PHC
Puerto_NN
Rico_NN
to_TO
meet_VB
the_DT
growing_VBG
demands_NN
of_PIN
our_FPP1
product_NN
portfolio_NN
including_VBG [WZPRES]
Crestor_NN
,_,
Pulmicort_NN
Respules_NN
and_PHC
Symbicort_NN
._.
com_NN
10_CD
Marketing_GER
We_FPP1
combine_VPRT
our_FPP1
global_JJ
capabilities_NOMZ
with_PIN
high_JJ
quality_NOMZ
relationships_NN
in_PIN
local_JJ
markets_NN
and_CC
focus_VB
on_PIN
responding_VBG
quickly_RB
and_PHC
effectively_RB
to_PIN
our_FPP1
customers_NN
changing_VBG [WZPRES]
needs_NN
._.
Key_NN
products_NN
:_:
Cardiovascular_NN
Key_NN
products_NN
:_:
Gastrointestinal_NN
Key_NN
products_NN
:_:
Neuroscience_NN
1_CD
Atacand_NN
candesartan_NN
cilexetil_NN
angiotensin_NN
II_NN
Losec_NN
Prilosec_NN
omeprazole_NN
proton_NN
pump_NN
inhibitor_NN
Diprivan_NN
propofol_NN
intravenous_JJ
general_JJ
anesthetic_NN
for_PIN
antagonist_NN
for_PIN
hypertension_NN
for_PIN
acid_NN
related_VBN
diseases_NN
induction_JJ
maintenance_NN
of_PIN
anaesthesia_NN
and_PHC
sedation_NOMZ
of_PIN
intensive_JJ
care_NN
patients_NN
2_CD
Crestor_NN
rosuvastatin_NN
HMG-CoA_NN
reductase_NN
inhibitor_NN
Losec_NN
MUPS_NN
omeprazole_NN
in_PIN
tablet_NN
form_NN
statin_NN
for_PIN
dyslipidemia_NN
Naropin_NN
ropivacaine_NN
local_JJ
anesthetic_JJ
for_PIN
surgical_JJ
Nexium_NN
esomeprazole_NN
proton_NN
pump_NN
inhibitor_NN
for_PIN
anaesthesia_NN
and_CC
acute_JJ
pain_NN
management_NOMZ
Exanta_NN
ximelagatran_JJ
oral_JJ
direct_JJ
thrombin_NN
inhibitor_NN
for_PIN
acid_NN
related_VBN
diseases_NN
prevention_NOMZ
of_PIN
thrombosis_NN
in_PIN
association_NOMZ
with_PIN
major_JJ
Seroquel_NN
quetiapine_NN
atypical_JJ
anti-psychotic_JJ
for_PIN
orthopaedic_JJ
surgery_NN
schizophrenia_NN
and_CC
other_JJ
psychotic_JJ
disorders_NN
Key_NN
products_NN
:_:
Infection_NOMZ
Plendil_NN
felodipine_NN
calcium_NN
antagonist_NN
for_PIN
hypertension_NN
Xylocaine_NN
lidocaine_NN
local_JJ
anesthetic_JJ
for_PIN
use_NN
in_PIN
4_CD
Merrem_NN
Meronem_NN
meropenem_NN
ultra_NN
broad_JJ
and_CC
angina_NN
surgery_NN
and_PHC
dentistry_NN
spectrum_NN
injectable_JJ
antibiotic_JJ
for_PIN
serious_JJ
bacterial_JJ
Seloken_NN
Toprol-XL_NN
metoprolol_NN
beta_NN
blocker_NN
for_PIN
Zomig_NN
zolmitriptan_NN
for_PIN
the_DT
treatment_NOMZ
of_PIN
acute_JJ
infection_NOMZ
hypertension_NN
,_,
angina_NN
,_,
heart_NN
failure_NN
and_CC
other_JJ
uses_NN
migraine_VPRT
with_PIN
or_CC
without_PIN
aura_NN
3_CD
Zestril_NN
lisinopril_NN
angiotensin_NN
converting_VBG [WZPRES]
enzyme_NN
inhibitor_NN
for_PIN
hypertension_NN
,_,
heart_NN
failure_NN
and_CC
diabetic_JJ
nephropathy_NN
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
11_CD
Sales_NN
and_PHC
marketing_GER
Product_NN
strategy_NN
and_PHC
licensing_GER
We_FPP1
continued_VBD
to_TO
be_VB [BEMA]
the_DT
fastest_JJ
growing_VBG
To_TO
ensure_VB [SUAV] [PRIV]
the_DT
success_NN
of_PIN
our_FPP1
medicines_NN
,_,
We_FPP1
have_VPRT
an_DT
extensive_JJ
,_,
high_JJ
quality_NOMZ
pharmaceutical_JJ
company_NN
in_PIN
Japan_NN
we_FPP1
must_NEMD
address_VB
unmet_JJ
medical_JJ
needs_NN
,_,
sales_NN
and_PHC
marketing_GER
network_NN
worldduring_VBG [WZPRES]
2003_CD
,_,
with_PIN
sales_NN
of_PIN
$_$
1.2_CD
billion_CD
._.
find_VB [PRIV]
novel_JJ
solutions_NOMZ
,_,
minimize_VPRT
technical_JJ
wide_JJ
,_,
structured_VBN
to_TO
anticipate_VB [PRIV]
and_CC
We_FPP1
now_TIME
rank_VPRT
14th_JJ
by_PIN
sales_NN
in_PIN
this_DEMP
,_,
the_DT
risk_NN
and_CC
make_VB
the_DT
most_EMPH
of_PIN
our_FPP1
respond_NN
to_PIN
local_JJ
market_NN
needs_NN
._.
We_FPP1
sell_VPRT
worlds_NN
second_RB
largest_JJ
pharmaceutical_JJ
commercial_JJ
opportunities_NOMZ
._.
mostly_RB
through_PIN
our_FPP1
own_JJ
local_JJ
marketing_GER
market_NN
._.
companies_NN
and_CC
our_FPP1
products_NN
are_VPRT [BEMA]
Our_FPP1
product_NN
strategy_NN
and_PHC
licensing_GER
marketed_VBN [WZPAST]
mainly_RB
to_PIN
physicians_NN
and_CC
other_JJ
In_PIN
Europe_NN
,_,
pharmaceutical_JJ
cost_NN
control_NN
organization_NOMZ
,_,
working_VBG [PRESP]
closely_RB
with_PIN
healthcare_NN
professionals_NN
._.
We_FPP1
also_RB
pressure_NN
,_,
generic_JJ
substitution_NOMZ
and_CC
the_DT
our_FPP1
R&D_NN
community_NOMZ
and_CC
our_FPP1
major_JJ
explain_VPRT [PUBV]
the_DT
economic_JJ
as_RB
well_RB
as_IN
the_DT
movement_NOMZ
of_PIN
products_NN
from_PIN
lower_JJ
price_NN
marketing_GER
companies_NN
,_,
leads_VPRT
the_DT
therapeutic_JJ
advantages_NN
of_PIN
our_FPP1
products_NN
countries_NN
,_,
all_QUAN
contribute_VPRT
to_TO
creating_VBG
commercial_JJ
aspects_NN
of_PIN
drug_NN
developto_NN
governments_NOMZ
and_PHC
healthcare_NN
buying_NN
another_DT
challenging_JJ
environment_NOMZ
for_PIN
our_FPP1
ment_NOMZ
and_PHC
co-ordinates_NN
global_JJ
market_NN
groups_NN
,_,
such_JJ
as_IN
managed_VBN
care_NN
industry_NN
._.
This_DEMP
includes_VPRT
selecting_VBG
the_DT
right_JJ
organizations_NOMZ
in_PIN
the_DT
US_FPP1
._.
Crestor_NN
,_,
coupled_VBN [PASTP]
with_PIN
our_FPP1
strong_JJ
growth_NN
products_NN
and_PHC
projects_NN
for_PIN
investment_NOMZ
,_,
in_PIN
central_JJ
and_PHC
eastern_JJ
Europe_NN
,_,
give_VPRT
us_FPP1
a_DT
developing_VBG
effective_JJ
marketing_GER
platforms_NN
Success_NN
in_PIN
key_JJ
markets_NN
is_VPRT [BEMA]
a_DT
priority_NOMZ
solid_JJ
platform_NN
for_PIN
future_JJ
growth_NN
in_PIN
the_DT
in_PIN
time_NN
for_PIN
new_JJ
product_NN
launches_NN
and_PHC
objective_NN
._.
We_FPP1
aim_VPRT
to_TO
retain_VB
and_PHC
build_VB
on_PIN
region_NN
._.
Sales_NN
totalled_VBD
$_$
6.7_CD
billion_CD
in_PIN
2003_CD
directing_VBG
the_DT
creation_NOMZ
and_PHC
delivery_NN
of_PIN
our_FPP1
leading_VBG
positions_NOMZ
in_PIN
major_JJ
markets_NN
,_,
and_ANDC
AstraZeneca_NN
ranks_VPRT
fifth_JJ
in_PIN
Europe_NN
._.
product_NN
marketing_GER
strategies_NN
that_DEMO
especially_RB
the_DT
US_FPP1
,_,
Europe_NN
and_PHC
Japan_NN
successfully_RB
align_JJ
global_JJ
and_PHC
national_JJ
whilst_OSUB
increasing_VBG
our_FPP1
strength_NN
through_PIN
Elsewhere_RB
,_,
significant_JJ
growth_NN
in_PIN
China_NN
plans_NN
._.
strategic_JJ
investment_NOMZ
in_PIN
the_DT
small_JJ
but_CC
fast_JJ
37_CD
%_NN
,_,
South_NN
Korea_NN
and_PHC
India_NN
growing_VBG [WZPRES]
markets_NN
of_PIN
the_DT
future_NN
the_DT
strengthened_VBD
the_DT
platform_NN
for_PIN
regional_JJ
Our_FPP1
rigorous_JJ
lifecycle_NN
management_NOMZ
of_PIN
emerging_VBG
economies_NN
._.
expansion_NN
plans_NN
and_CC
future_JJ
growth_NN
._.
key_JJ
marketed_VBN
brands_NN
aims_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
we_FPP1
maximize_VPRT
the_DT
commercial_JJ
Continued_VBN
success_NN
in_PIN
the_DT
US_FPP1
,_,
the_DT
E-marketing_JJ
potential_NN
as_RB
well_RB
as_IN
the_DT
benefit_NN
that_TOBJ
new_JJ
worlds_NN
largest_JJ
pharmaceutical_JJ
market_NN
,_,
To_TO
boost_VB
our_FPP1
marketing_GER
effectiveness_NOMZ
,_,
uses_VPRT
for_PIN
our_FPP1
medicines_NN
bring_VPRT
to_PIN
patients_NN
depends_VPRT
on_PIN
effectively_RB
managing_VBG
the_DT
we_FPP1
have_VPRT [PEAS]
integrated_VBN
e-marketing_VBG
into_PIN
our_FPP1
lives_NN
._.
increasing_VBG
regulatory_JJ
and_CC
cost_NN
control_NN
commercial_JJ
activities_NOMZ
worldwide_JJ
and_CC
pressures_NN
whilst_OSUB
making_VBG
the_DT
most_EMPH
of_PIN
the_DT
have_VPRT
a_DT
broad_JJ
range_NN
of_PIN
internet-based_JJ
In_PIN
common_JJ
with_PIN
other_JJ
leading_VBG
opportunities_NOMZ
presented_VBN [WZPAST]
by_PIN
the_DT
growing_VBG
physician_NN
resources_NN
in_PIN
key_JJ
therapy_NN
pharmaceutical_JJ
companies_NN
,_,
we_FPP1
also_RB
demand_VPRT [SUAV]
for_PIN
innovative_JJ
medicines_NN
._.
In_PIN
the_DT
US_FPP1
,_,
we_FPP1
maximize_VPRT
the_DT
look_NN
to_TO
strengthen_VB
our_FPP1
portfolio_NN
with_PIN
Our_FPP1
sales_NN
of_PIN
$_$
8.7_CD
billion_CD
in_PIN
the_DT
US_FPP1
in_PIN
opportunities_NOMZ
for_PIN
direct_JJ
communication_NOMZ
attractive_JJ
products_NN
or_CC
technologies_NN
from_PIN
2003_CD
reflect_VPRT [PRIV]
our_FPP1
commitment_NOMZ
to_TO
driving_VBG
with_PIN
patients_NN
and_CC
their_TPP3
carers_NN
,_,
by_PIN
external_JJ
sources_NN
and_CC
we_FPP1
continuously_RB
growth_NN
in_PIN
this_DEMO
key_JJ
area_NN
._.
With_PIN
a_DT
5_CD
%_NN
providing_VBG [WZPRES]
online_JJ
information_NOMZ
about_IN
our_FPP1
monitor_NN
the_DT
opportunities_NOMZ
for_PIN
licensing_GER
market_NN
share_NN
,_,
AstraZeneca_NN
is_VPRT [BEMA]
the_DT
fifth_JJ
medicines_NN
and_CC
the_DT
conditions_NOMZ
for_PIN
which_WDT [PIRE]
partnerships_NN
._.
largest_JJ
pharmaceutical_JJ
company_NN
in_PIN
they_TPP3
are_VPRT [PASS]
prescribed_VBN
._.
Asia_NN
,_,
we_FPP1
have_VPRT
e-business_JJ
pilot_NN
studies_NN
underway_VPRT
to_TO
improve_VB
interaction_NOMZ
with_PIN
healthcare_NN
professionals_NN
._.
1_CD
Key_NN
products_NN
:_:
Oncology_NN
Key_NN
products_NN
:_:
Respiratory_NN
&_CC
Inflammation_NOMZ
Licensed_VBD
from_PIN
Takeda_NN
Chemical_NN
Industries_NN
Ltd._NN
2_CD
Licensed_VBN
from_PIN
Shionogi_NN
&_CC
Co._NN
._.
Ltd._NN
._.
Arimidex_NN
anastrozole_NN
aromatase_NN
inhibitor_NN
for_PIN
Accolate_NN
zafirlukast_NN
oral_JJ
leukotriene_NN
receptor_NN
3_CD
Licensed_VBN
from_PIN
Merck_NN
&_CC
Co._NN
._.
Inc._NN
breast_NN
cancer_NN
antagonist_NN
for_PIN
control_NN
of_PIN
asthma_NN
4_CD
Licensed_VBN
from_PIN
Sumitomo_NN
Pharmaceuticals_NN
Co._NN
._.
Ltd._NN
._.
Casodex_NN
bicalutamide_NN
anti-androgen_NN
for_PIN
prostate_NN
Oxis_NN
formoterol_NN
inhaled_VBD
fast_RB
onset_NN
long-acting_JJ
cancer_NN
bronchodilator_NN
for_PIN
relief_NN
of_PIN
asthma_NN
symptoms_NN
Faslodex_NN
fulvestrant_JJ
estrogen_NN
receptor_NN
antagonist_NN
Pulmicort_NN
budesonide_NN
inhaled_VBD
anti-inflammatory_JJ
with_PIN
no_SYNE
agonist_JJ
effects_NN
for_PIN
breast_NN
cancer_NN
for_PIN
asthma_NN
control_NN
Iressa_NN
gefitinib_NN
signal_NN
transduction_NOMZ
inhibitor_NN
for_PIN
nonRhinocort_NN
budesonide_NN
topical_JJ
nasal_JJ
small_JJ
cell_NN
lung_NN
cancer_NN
anti-inflammatory_JJ
for_PIN
control_NN
of_PIN
rhinitis_NN
Nolvadex_NN
tamoxifen_JJ
anti-oestrogen_NN
for_PIN
breast_NN
cancer_NN
Symbicort_NN
budesonide_NN
formoterol_NN
inhaled_VBD
combination_NOMZ
of_PIN
anti-inflammatory_JJ
and_PHC
fast_JJ
onset_NN
Zoladex_NN
goserelin_NN
LHRH_NN
agonist_NN
for_PIN
prostate_NN
and_CC
long-acting_JJ
bronchodilator_NN
in_PIN
a_DT
single_JJ
inhaler_NN
pre-menopausal_JJ
breast_NN
cancer_NN
,_,
certain_JJ
benign_JJ
gynaecological_JJ
disorders_NN
and_CC
assisted_VBN
reproduction_NOMZ
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
12_CD
Inspiration_NOMZ
The_DT
success_NN
of_PIN
our_FPP1
business_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
our_FPP1
commitment_NOMZ
to_PIN
new_JJ
ideas_NN
ideas_NN
that_TSUB
are_VPRT [BYPA]
inspired_VBN
by_PIN
life_NN
and_ANDC
which_WDT
in_PIN
turn_NN
help_NN
to_TO
inspire_VB
the_DT
lives_NN
of_PIN
our_FPP1
stakeholders_NN
._.
We_FPP1
turn_VPRT
good_JJ
We_FPP1
also_RB
focus_VB
We_FPP1
aim_VB
to_TO
stimulate_VB
We_FPP1
encourage_VPRT
Along_IN
with_PIN
our_FPP1
Our_FPP1
core_NN
values_NN
are_VPRT
:_:
ideas_NN
into_PIN
effective_JJ
on_PIN
getting_VBG
the_DT
continued_VBN
creativity_NOMZ
the_DT
sharing_GER
of_PIN
commitment_NOMZ
Integrity_NOMZ
and_CC
high_JJ
medicines_NN
most_EMPH
benefit_VB
for_PIN
by_PIN
maintaining_VBG [PUBV]
knowledge_NN
and_CC
to_PIN
competitiveness_NOMZ
ethical_JJ
standards_NN
designed_VBN [WZPAST]
to_PIN
patients_NN
from_PIN
every_QUAN
a_DT
culture_NN
in_PIN
which_WDT [PIRE]
ideas_NN
across_PLACE
and_CC
performance_NN
,_,
Respect_NN
for_PIN
the_DT
improve_VB
the_DT
health_NN
medicine_NN
we_FPP1
make_VPRT
our_FPP1
people_NN
feel_VPRT [PRIV]
functional_JJ
and_CC
we_FPP1
will_PRMD
continue_VB
to_PIN
individual_JJ
and_CC
diversity_NOMZ
and_PHC
quality_NOMZ
of_PIN
by_PIN
exploring_VBG
all_QUAN
valued_VBN
,_,
energised_VBN
territorial_JJ
boundaries_NN
be_VB [BYPA]
led_VBN
by_PIN
our_FPP1
core_NN
Openness_NOMZ
,_,
honesty_NN
,_,
life_NN
of_PIN
patients_NN
the_DT
ways_NN
it_PIT
can_POMD
be_VB
and_PHC
rewarded_VBD
for_PIN
to_TO [SPIN]
further_RB
stimulate_VB
values_NN
to_TO
achieve_VB
trust_NN
and_PHC
support_NN
around_PLACE
the_DT
world_NN
._.
their_TPP3
ideas_NN
and_PHC
creativity_NOMZ
and_CC
best_JJ
sustainable_JJ
for_PIN
each_QUAN
other_JJ
contribution_NOMZ
to_PIN
our_FPP1
practice_NN
across_PLACE
the_DT
success_NN
._.
Leadership_NN
by_PIN
success_NN
ideas_NN
Company_NN
._.
example_NN
at_PIN
all_QUAN
levels_NN
which_WDT [WHSUB]
can_POMD
make_VB
a_DT
difference_NN
in_PIN
all_QUAN
aspects_NN
of_PIN
our_FPP1
business_NOMZ
._.
com_NN
13_CD
designed_VBN
to_TO
take_VB
account_NN
of_PIN
individual_JJ
The_DT
path_NN
to_PIN
growth_NN
We_FPP1
are_VPRT [BEMA]
a_DT
creative_JJ
,_,
fast_JJ
and_PHC
effective_JJ
needs_NN
by_PIN
introducing_VBG
elements_NOMZ
of_PIN
company_NN
with_PIN
a_DT
powerful_JJ
range_NN
of_PIN
personal_JJ
choice_NN
and_PHC
flexibility_NOMZ
in_PIN
how_RB
high_JJ
quality_NOMZ
products_NN
that_TSUB
will_PRMD
drive_VB
benefits_NN
are_VPRT [PASS]
taken_VBN
._.
Inspiring_JJ
leadership_NN
is_VPRT [BEMA]
key_PRED
to_TO
stimulating_VBG
In_PIN
recent_JJ
years_NN
,_,
we_FPP1
have_VPRT [PEAS]
launched_VBN
a_DT
high_JJ
performance_NN
._.
We_FPP1
have_VPRT
global_JJ
range_NN
of_PIN
important_JJ
new_JJ
medicines_NN
,_,
programs_NN
designed_VBN
to_TO
strengthen_VB
including_VBG
high_JJ
potential_JJ
therapies_NN
for_PIN
leadership_NN
capabilities_NOMZ
,_,
enhance_VB
core_NN
treating_VBG [WZPRES]
cancer_NN
Casodex_NN
,_,
Arimidex_NN
,_,
management_NOMZ
skills_NN
and_PHC
help_NN
leaders_NN
Faslodex_NN
and_PHC
Iressa_NN
,_,
gastrointestinal_JJ
develop_VB
good_JJ
working_VBG
relationships_NN
disease_NN
Nexium_NN
,_,
asthma_NN
Symbicort_NN
,_,
across_PLACE
the_DT
organization_NOMZ
._.
These_DEMO
hypertension_NN
Atacand_NN
,_,
high_JJ
cholesterol_NN
programs_NN
are_VPRT [BEMA]
complemented_JJ
Crestor_NN
,_,
migraine_NN
Zomig_NN
and_CC
schizoby_JJ
local_JJ
initiatives_NN
,_,
which_WDT [SERE]
include_VPRT
phrenia_NN
Seroquel_NN
._.
These_DEMP
and_CC
the_DT
first_JJ
functional_JJ
or_CC
country_NN
specific_JJ
aspects_NN
approval_NN
of_PIN
Exanta_NN
in_PIN
France_NN
in_PIN
of_PIN
leadership_NN
development_NOMZ
._.
December_NN
2003_CD
mark_NN
the_DT
start_NN
of_PIN
an_DT
exciting_JJ
new_JJ
era_NN
for_PIN
the_DT
Company_NN
._.
The_DT
sharing_GER
of_PIN
information_NOMZ
is_VPRT [BEMA]
essential_PRED
to_TO
maintaining_VBG [PUBV]
employee_NN
confidence_NN
in_PIN
Making_VBG
it_PIT
happen_VB
AstraZeneca_NN
and_CC
its_PIT
objectives_NN
._.
We_FPP1
use_VPRT
a_DT
Without_PIN
the_DT
creativity_NOMZ
,_,
energy_NN
and_PHC
range_NN
of_PIN
communications_NOMZ
media_NN
,_,
as_RB
well_RB
commitment_NOMZ
of_PIN
our_FPP1
people_NN
,_,
our_FPP1
as_IN
face_NN
to_TO
face_VB
meetings_GER
,_,
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
our_FPP1
business_NOMZ
would_PRMD
not_XX0
succeed_VB
._.
We_FPP1
are_VPRT
people_NN
are_VPRT [PASS]
kept_VBN
up_RP
to_PIN
date_NN
with_PIN
business_NOMZ
very_AMP
proud_JJ
of_PIN
our_FPP1
60,000_CD
employees_NN
developments_NOMZ
and_CC
are_VPRT [BEMA]
clear_PRED
about_IN
their_TPP3
in_PIN
45_CD
countries_NN
and_PHC
value_NN
the_DT
diversity_NOMZ
individual_NN
and_PHC
team_NN
roles_NN
and_PHC
targets_NN
._.
of_PIN
skills_NN
and_PHC
abilities_NOMZ
that_TOBJ
they_TPP3
bring_VPRT
to_PIN
our_FPP1
business_NOMZ
._.
Feedback_NN
is_VPRT [BEMA]
very_AMP
important_PRED
to_PIN
us_FPP1
and_CC
opportunities_NOMZ
for_PIN
giving_VBG
feedback_NN
are_VPRT [BEMA]
We_FPP1
encourage_VB
and_PHC
support_VB
all_QUAN
our_FPP1
built_VBN
in_PIN
to_PIN
all_QUAN
levels_NN
of_PIN
communication_NOMZ
._.
people_NN
in_PIN
developing_VBG
their_TPP3
capabilities_NOMZ
We_FPP1
also_RB
use_VPRT
a_DT
two-yearly_JJ
global_JJ
to_PIN
the_DT
full_JJ
with_PIN
high_JJ
quality_NOMZ
learning_GER
and_PHC
employee_NN
survey_NN
to_TO
identify_VB
areas_NN
development_NOMZ
opportunities_NOMZ
,_,
backed_VBN [PASTP]
by_PIN
of_PIN
both_DT
satisfaction_NOMZ
and_PHC
concern_NN
._.
management_NOMZ
responsibility_NOMZ
for_PIN
ensuring_VBG [SUAV] [PRIV]
Priority_NOMZ
attention_NOMZ
is_VPRT [PASS]
given_VBN
to_PIN
areas_NN
that_TSUB
individually_RB
tailored_VBD
development_NOMZ
for_PIN
improvement_NOMZ
highlighted_VBN [WZPAST]
in_PIN
plans_NN
are_VPRT [BEMA]
in_PIN
place_NN
for_PIN
each_QUAN
member_NN
of_PIN
these_DEMO
surveys_NN
._.
their_TPP3
team_NN
,_,
throughout_PIN
their_TPP3
careers_NN
._.
Equal_NN
opportunity_NOMZ
for_PIN
all_QUAN
is_VPRT [BEMA]
a_DT
cornerstone_NN
A_DT
responsible_JJ
approach_NN
of_PIN
our_FPP1
culture_NN
in_PIN
which_WDT [PIRE]
personal_JJ
success_NN
With_PIN
a_DT
global_JJ
business_NOMZ
comes_VPRT
a_DT
global_JJ
is_VPRT [PASS]
based_VBN
solely_RB
on_PIN
individual_JJ
ability_NOMZ
and_PHC
responsibility_NOMZ
for_PIN
high_JJ
standards_NN
of_PIN
contribution_NOMZ
._.
We_FPP1
aim_VPRT
to_TO
manage_VB
that_DEMO
responsibility_NOMZ
effectively_RB
The_DT
wellbeing_GER
of_PIN
our_FPP1
people_NN
is_VPRT [BEMA]
a_DT
core_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
we_FPP1
continue_VPRT
to_TO
be_VB
priority_NOMZ
and_CC
we_FPP1
have_VPRT
a_DT
broad_JJ
range_NN
of_PIN
welcomed_VBN
as_IN
a_DT
trusted_VBN
and_PHC
valued_VBN
initiatives_NN
aimed_VBN [WZPAST]
at_PIN
promoting_VBG
the_DT
health_NN
,_,
member_NN
of_PIN
the_DT
global_JJ
community_NOMZ
._.
safety_NN
and_PHC
welfare_NN
of_PIN
all_QUAN
our_FPP1
employees_NN
worldwide_VPRT
._.
These_DEMP
include_VPRT
behaviourYou_NN
can_POMD
read_VB
more_EMPH
about_IN
our_FPP1
approach_NN
based_VBN
safety_NN
and_CC
occupational_JJ
health_NN
to_PIN
corporate_JJ
responsibility_NOMZ
,_,
and_ANDC
our_FPP1
2003_CD
programs_NN
as_RB
well_RB
as_IN
initiatives_NN
that_DEMO
performance_NN
,_,
in_PIN
the_DT
separate_JJ
2003_CD
encourage_VPRT
and_PHC
support_VPRT
work_NN
life_NN
Corporate_JJ
Responsibility_NOMZ
Summary_NN
balance_NN
through_PIN
flexible_JJ
working_VBG
hours_NN
Report_NN
or_CC
visit_VB
our_FPP1
website_NN
for_PIN
full_JJ
details_NN
._.
and_ANDC
opportunities_NOMZ
to_TO
work_VB
from_PIN
home_NN
._.
Looking_VBG [PRESP]
to_PIN
the_DT
future_JJ
Rewarding_GER
people_NN
for_PIN
their_TPP3
contribution_NOMZ
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
continued_VBN
isnt_NN
,_,
we_FPP1
believe_VPRT [PRIV]
,_,
just_EMPH
about_IN
offering_VBG
a_DT
achievement_NOMZ
in_PIN
all_QUAN
our_FPP1
activities_NOMZ
competitive_JJ
benefits_NN
package_NN
._.
Our_FPP1
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
healthy_JJ
future_NN
for_PIN
our_FPP1
integrated_VBN
reward_NN
schemes_NN
are_VPRT
business_NOMZ
and_CC
added_VBD [PUBV]
value_NN
for_PIN
all_QUAN
those_DEMP
who_WP
benefit_VPRT
from_PIN
it_PIT
._.
com_NN
14_CD
Therapy_NN
area_NN
review_NN
Gastrointestinal_NN
Cardiovascular_NN
Infection_NOMZ
Our_FPP1
world_NN
leading_VBG [WZPRES]
position_NOMZ
in_PIN
cardioWe_NN
are_VPRT [BEMA]
the_DT
world_NN
number_NN
one_CD
in_PIN
the_DT
World_NN
demand_NN
for_PIN
antibiotics_NN
remains_VPRT
vascular_JJ
CV_NN
is_VPRT [PASS]
based_VBN
on_PIN
over_IN
40_CD
years_NN
treatment_NOMZ
of_PIN
gastrointestinal_JJ
GI_NN
disease_NN
high_JJ
due_JJ
to_TO
escalating_VBG
resistance_NN
and_PHC
experience_NN
in_PIN
this_DEMO
field_NN
._.
Backed_NN
by_PIN
our_FPP1
and_CC
aim_NN
to_TO
maintain_VB [PUBV] [THATD]
that_DEMP
leading_VBG
position_NOMZ
the_DT
increased_VBN
risk_NN
of_PIN
serious_JJ
infections_NOMZ
._.
powerful_JJ
range_NN
of_PIN
products_NN
and_PHC
quality_NOMZ
through_PIN
continued_VBN
sales_NN
and_CC
further_JJ
research_NN
,_,
we_FPP1
aim_VPRT
to_TO
build_VB
on_PIN
our_FPP1
strong_JJ
development_NOMZ
of_PIN
Nexium_NN
,_,
the_DT
latest_JJ
Infectious_JJ
diseases_NN
cause_VPRT
more_EMPH
than_PIN
11_CD
position_NOMZ
,_,
focusing_VBG [PRESP]
on_PIN
important_JJ
areas_NN
of_PIN
addition_NOMZ
to_PIN
our_FPP1
GI_NN
range_NN
._.
need_NN
such_JJ
as_IN
hypertension_NN
and_PHC
thrombosis_NN
._.
40_CD
%_NN
of_PIN
adults_NN
in_PIN
the_DT
western_JJ
world_NN
2003_CD
saw_VBD [PRIV]
steady_JJ
sales_NN
growth_NN
globally_RB
regularly_RB
experience_VB
heartburn_NN
and_CC
10_CD
%_NN
for_PIN
Merrem_NN
,_,
our_FPP1
antibiotic_JJ
for_PIN
the_DT
CV_NN
diseases_NN
account_VPRT
for_PIN
17_CD
million_CD
have_VPRT
gastro-oesophageal_JJ
reflux_NN
disease_NN
._.
treatment_NOMZ
of_PIN
serious_JJ
hospital-acquired_JJ
deaths_NN
worldwide_JJ
each_QUAN
year_NN
,_,
making_VBG [PRESP]
it_PIT
infections_NOMZ
._.
Clinical_JJ
studies_NN
are_VPRT [BEMA]
in_PIN
place_NN
the_DT
greatest_JJ
risk_NN
to_PIN
life_NN
for_PIN
most_EMPH
adults_NN
._.
Nexium_NN
continues_VPRT
to_TO
establish_VB [PRIV]
a_DT
new_JJ
to_TO
support_VB
a_DT
supplementary_JJ
new_JJ
drug_NN
improved_VBN
treatment_NOMZ
standard_NN
and_CC
this_DEMO
application_NOMZ
in_PIN
the_DT
US_FPP1
in_PIN
2004_CD
aimed_VBN
at_PIN
During_PIN
the_DT
year_NN
,_,
Crestor_NN
,_,
our_FPP1
new_JJ
statin_NN
was_VBD [PASS]
reflected_VBN [PRIV]
in_PIN
its_PIT
global_JJ
sales_NN
,_,
which_WDT [SERE]
securing_VBG
an_DT
indication_NOMZ
for_PIN
skin_NN
and_PHC
skin_NN
for_PIN
controlling_VBG
high_JJ
cholesterol_NN
levels_NN
,_,
exceeded_VBD
$_$
3_CD
billion_CD
in_PIN
2003_CD
._.
structure_NN
infections_NOMZ
in_PIN
2005_CD
._.
gained_VBN
regulatory_JJ
approval_NN
in_PIN
more_EMPH
than_PIN
40_CD
countries_NN
._.
By_PIN
the_DT
end_NN
of_PIN
January_NN
First_NN
launched_VBD
in_PIN
Sweden_NN
in_PIN
August_NN
In_PIN
June_NN
2003_CD
,_,
we_FPP1
opened_VBD
our_FPP1
new_JJ
2004_CD
,_,
it_PIT
was_VBD [PASS]
launched_VBN
in_PIN
over_IN
25_CD
2000_CD
,_,
it_PIT
is_VPRT [BEMA]
now_TIME
available_PRED
in_PIN
100_CD
markets_NN
,_,
laboratories_NN
at_PIN
our_FPP1
research_NN
facility_NOMZ
countries_NN
including_VBG [WZPRES]
the_DT
US_FPP1
,_,
Canada_NN
,_,
including_VBG [PRESP]
the_DT
US_FPP1
,_,
Canada_NN
and_CC
all_QUAN
in_PIN
Bangalore_NN
,_,
India_NN
where_RB
work_NN
is_VPRT [BEMA]
the_DT
UK_NN
and_CC
the_DT
Netherlands_NN
,_,
and_ANDC
we_FPP1
European_JJ
countries_NN
._.
It_PIT
has_VPRT [PEAS]
been_VBN [SPAU] [PASS]
well_RB
focused_VBN
on_PIN
finding_VBG [PRIV]
a_DT
new_JJ
treatment_NOMZ
estimate_NN
that_TOBJ
more_EMPH
than_PIN
1.5_CD
million_CD
received_VBN
by_PIN
patients_NN
and_PHC
physicians_NN
alike_RB
for_PIN
tuberculosis_NN
,_,
the_DT
single_JJ
largest_JJ
prescriptions_NOMZ
had_VBD [PEAS]
been_VBN [PASS]
written_VBN [PUBV]
for_PIN [STPR]
,_,
and_ANDC
and_CC
over_IN
145_CD
million_CD
patient_JJ
treatments_NOMZ
cause_NN
of_PIN
adult_NN
death_NN
from_PIN
infectious_JJ
over_IN
750,000_CD
patients_NN
had_VBD [PEAS]
been_VBN [PASS]
treated_VBN
had_VBD [PEAS]
been_VBN [BYPA]
administered_VBN
by_PIN
the_DT
end_NN
of_PIN
disease_NN
in_PIN
the_DT
world_NN
._.
Its_PIT
strong_JJ
performance_NN
in_PIN
the_DT
US_FPP1
makes_VPRT
Nexium_NN
one_CD
of_PIN
the_DT
most_EMPH
We_FPP1
gained_VBD
first_JJ
approval_NN
in_PIN
France_NN
for_PIN
successful_JJ
pharmaceutical_JJ
launches_NN
Exanta_NN
,_,
the_DT
first_JJ
new_JJ
oral_JJ
anti-coagulant_JJ
ever_RB
._.
in_PIN
almost_DWNT
60_CD
years_NN
for_PIN
chronic_JJ
indications_NOMZ
._.
We_FPP1
also_RB
made_VBD
regulatory_JJ
An_DT
injectable_JJ
formulation_NOMZ
of_PIN
Nexium_NN
submissions_NN
in_PIN
the_DT
US_FPP1
,_,
Canada_NN
and_CC
was_VBD [PASS]
approved_VBN
in_PIN
Europe_NN
in_PIN
late_TIME
2003_CD
,_,
Europe_NN
towards_PIN
the_DT
end_NN
of_PIN
the_DT
year_NN
._.
for_PIN
use_NN
when_RB
an_DT
oral_JJ
treatment_NOMZ
of_PIN
gastro-oesophageal_JJ
reflux_NN
disease_NN
is_VPRT
Seloken_NN
Toprol-XL_NN
sales_NN
continued_VBD
to_TO
not_XX0
applicable_JJ
._.
grow_VB
strongly_AMP
and_CC
Atacand_NN
increased_VBD
its_PIT
market_NN
share_NN
._.
As_IN
anticipated_VBN [PRIV]
,_,
sales_NN
of_PIN
Zestril_NN
continued_VBD
to_TO
decline_VB
as_IN
patents_NN
expired_VBD
in_PIN
major_JJ
markets_NN
._.
com_NN
15_CD
Oncology_NN
Neuroscience_NN
Respiratory_NN
and_PHC
Inflammation_NOMZ
We_FPP1
aim_VPRT
to_TO
be_VB [BEMA]
a_DT
leader_NN
in_PIN
neuroscience_NN
We_FPP1
aim_VPRT
to_TO
maintain_VB [PUBV]
our_FPP1
position_NOMZ
as_IN
a_DT
Already_RB
a_DT
leader_NN
in_PIN
the_DT
treatment_NOMZ
of_PIN
by_PIN
continuing_VBG
to_TO
deliver_VB
a_DT
range_NN
of_PIN
life_NN
world_NN
leader_NN
in_PIN
cancer_NN
treatment_NOMZ
asthma_NN
,_,
we_FPP1
plan_VPRT
to_TO
expand_VB
our_FPP1
range_NN
changing_VBG [WZPRES]
medicines_NN
in_PIN
three_CD
key_JJ
areas_NN
through_PIN
continued_VBN
growth_NN
for_PIN
key_NN
through_PIN
the_DT
introduction_NOMZ
of_PIN
new_JJ
treatments_NOMZ
of_PIN
psychiatry_NN
,_,
analgesia_NN
and_PHC
neurology_NN
,_,
products_NN
in_PIN
our_FPP1
portfolio_NN
,_,
continued_VBD
and_CC
new_JJ
uses_NN
for_PIN
our_FPP1
key_JJ
products_NN
in_PIN
and_CC
by_PIN
maintaining_VBG [PUBV] [THATD]
our_FPP1
world_NN
leading_VBG [WZPRES]
launches_NN
for_PIN
our_FPP1
new_JJ
products_NN
and_CC
the_DT
other_JJ
areas_NN
of_PIN
inflammatory_JJ
disease_NN
,_,
position_NOMZ
in_PIN
anaesthesia_NN
._.
successful_JJ
introduction_NOMZ
of_PIN
novel_NN
such_JJ
as_IN
chronic_JJ
obstructive_JJ
pulmonary_JJ
approaches_NN
currently_RB
in_PIN
the_DT
pipeline_NN
._.
disease_NN
COPD_NN
and_CC
rheumatoid_JJ
Health_NN
problems_NN
related_VBN [WZPAST]
to_PIN
the_DT
function_NOMZ
arthritis_NN
._.
of_PIN
the_DT
central_JJ
nervous_JJ
system_NN
,_,
including_VBG
Over_IN
12_CD
million_CD
people_NN
are_VPRT [PASS]
diagnosed_VBN
the_DT
brain_NN
,_,
are_VPRT [BEMA]
a_DT
complex_JJ
area_NN
of_PIN
with_PIN
cancer_NN
each_QUAN
year_NN
._.
It_PIT
is_VPRT [PASS]
predicted_VBN [PUBV]
to_PIN
The_DT
World_NN
Health_NN
Organisation_NOMZ
significant_JJ
medical_JJ
need_NN
that_TOBJ
touches_NN
be_VB [BEMA]
the_DT
leading_VBG
cause_NN
of_PIN
death_NN
in_PIN
the_DT
US_FPP1
estimates_VPRT [PRIV]
that_THVC
100_CD
million_CD
people_NN
many_QUAN
peoples_NN
lives_NN
._.
by_PIN
2005_CD
._.
worldwide_JJ
suffer_VPRT
from_PIN
asthma_NN
and_CC
that_THVC
COPD_NN
is_VPRT [BEMA]
the_DT
fourth_JJ
greatest_JJ
cause_NN
of_PIN
Sales_NN
of_PIN
Seroquel_NN
,_,
our_FPP1
schizophrenia_NN
Sales_NN
of_PIN
Casodex_NN
and_PHC
Arimidex_NN
,_,
for_PIN
death_NN
worldwide_NN
._.
therapy_NN
,_,
have_VPRT [SPAU] [PEAS]
now_TIME
exceeded_VBN
$_$
4_CD
billion_CD
treating_VBG
prostate_NN
and_PHC
breast_NN
cancer_NN
since_OSUB
launch_NN
and_CC
in_PIN
2003_CD
,_,
showed_VBD [PRIV]
respectively_RB
,_,
grew_VBD
strongly_AMP
in_PIN
2003_CD
._.
Clinical_JJ
data_NN
confirmed_VBD [PUBV]
the_DT
efficacy_NN
and_CC
continued_VBD
strong_JJ
growth_NN
globally_RB
._.
Arimidex_NN
is_VPRT [SPAU]
rapidly_RB
moving_VBG [SUAV]
towards_PIN
safety_NN
of_PIN
Symbicort_NN
as_IN
an_DT
adjustable_JJ
Seroquel_NN
is_VPRT [SPAU] [PASS]
now_TIME
widely_RB
approved_VBN
in_PIN
replacing_VBG
tamoxifen_NN
as_IN
the_DT
standard_NN
of_PIN
maintenance_NN
treatment_NOMZ
for_PIN
asthma_NN
._.
Europe_NN
and_CC
the_DT
US_FPP1
,_,
for_PIN
the_DT
treatment_NOMZ
of_PIN
care_NN
in_PIN
breast_NN
cancer_NN
._.
During_PIN
the_DT
year_NN
,_,
we_FPP1
filed_VBD
for_PIN
approval_NN
in_PIN
bipolar_NN
mania_NN
which_WDT [WHSUB]
affects_VPRT
over_IN
17_CD
Europe_NN
of_PIN
Symbicort_NN
as_IN
a_DT
single_JJ
inhaler_NN
million_CD
people_NN
in_PIN
the_DT
major_JJ
markets_NN
._.
Good_JJ
sales_NN
for_PIN
Faslodex_NN
reflected_VBD [PRIV]
a_DT
treatment_NOMZ
for_PIN
asthma_NN
._.
Symbicort_NN
also_RB
steady_JJ
increase_NN
in_PIN
use_NN
for_PIN
the_DT
treatment_NOMZ
became_VBD
the_DT
first_JJ
fixed_VBN
combination_NOMZ
of_PIN
Zomig_NN
Nasal_NN
Spray_NN
,_,
a_DT
new_JJ
formulation_NOMZ
of_PIN
advanced_JJ
breast_NN
cancer_NN
in_PIN
the_DT
US_FPP1
._.
inhaled_JJ
corticosteroid_JJ
and_PHC
fast_JJ
onset_NN
,_,
of_PIN
our_FPP1
Zomig_NN
migraine_NN
therapy_NN
in_PIN
a_DT
Approval_NN
for_PIN
Faslodex_NN
in_PIN
Europe_NN
is_VPRT [BEMA]
long_PRED
acting_VBG
bronchodilator_NN
approved_VBD
for_PIN
convenient_JJ
device_NN
that_TSUB
delivers_VPRT
fast_RB
anticipated_VBN [PRIV]
early_TIME
in_PIN
2004_CD
following_VBG
a_DT
COPD_NN
in_PIN
Europe_NN
._.
pain_NN
relief_NN
,_,
was_VBD [SPAU] [PASS]
successfully_RB
launched_VBN
positive_JJ
opinion_NN
from_PIN
the_DT
Committee_NN
in_PIN
Europe_NN
and_CC
the_DT
US_FPP1
._.
for_PIN
Proprietary_NN
Medicinal_NN
Products_NN
in_PIN
In_PIN
the_DT
US_FPP1
,_,
growth_NN
of_PIN
32_CD
%_NN
in_PIN
total_NN
late_TIME
2003_CD
._.
prescriptions_NOMZ
for_PIN
Pulmicort_NN
Respules_NN
Our_FPP1
leading_VBG
range_NN
of_PIN
anaesthetics_NN
reflected_VBD [PRIV]
the_DT
products_NN
beneficial_JJ
continued_VBN
to_TO
perform_VB
well_RB
,_,
despite_PIN
the_DT
There_EX
has_VPRT [PEAS]
been_VBN
rapid_JJ
uptake_NN
of_PIN
our_FPP1
new_JJ
profile_NN
and_CC
strengthened_VBD
its_PIT
position_NOMZ
anticipated_VBD [PRIV]
slowing_VBG
in_PIN
sales_NN
growth_NN
for_PIN
lung_NN
cancer_NN
therapy_NN
,_,
Iressa_NN
over_IN
as_IN
the_DT
inhaled_JJ
corticosteroid_NN
of_PIN
choice_NN
Diprivan_NN
general_JJ
anesthetic_NN
following_VBG [WZPRES]
100,000_CD
patients_NN
have_VPRT [PEAS]
been_VBN [PASS]
treated_VBN
for_PIN
the_DT
treatment_NOMZ
of_PIN
children_NN
under_IN
five_CD
patent_NN
expiries_NN
._.
since_OSUB
its_PIT
first_JJ
launch_NN
in_PIN
Japan_NN
in_PIN
2002_CD
with_PIN
asthma_NN
._.
com_NN
Board_NN
of_PIN
Directors_NN
As_IN
at_PIN
31_CD
December_NN
2003_CD
Percy_NN
Barnevik_NN
Sir_NN
Tom_NN
McKillop_NN
Jonathan_NN
Symonds_NN
Non-Executive_NN
Chairman_NN
Executive_NN
Director_NN
Executive_NN
Director_NN
Chief_NN
Executive_NN
Chief_NN
Financial_NN
Officer_NN
Hkan_NN
Mogren_NN
Non-Executive_NN
Deputy_NN
Chairman_NN
Sir_NN
Peter_NN
Bonfield_NN
Dame_NN
Bridget_NN
Ogilvie_NN
Senior_NN
Non-Executive_NN
Director_NN
Non-Executive_NN
Director_NN
Jane_NN
Henney_NN
Non-Executive_NN
Director_NN
Marcus_NN
Wallenberg_NN
Michele_NN
Hooper_NN
Non-Executive_NN
Director_NN
Non-Executive_NN
Director_NN
Karl_NN
von_NN
der_NN
Heyden_NN
Non-Executive_NN
Director_NN
John_NN
Buchanan_NN
Joe_NN
Jimenez_NN
Non-Executive_NN
Director_NN
Non-Executive_NN
Director_NN
Erna_NN
Mller_NN
Non-Executive_NN
Director_NN
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
17_CD
Sir_NN
Tom_NN
McKillop_NN
60_CD
Jonathan_NN
Symonds_NN
44_CD
Percy_NN
Barnevik_NN
62_CD
Non-Executive_NN
Chairman_NN
Executive_NN
Director_NN
and_PHC
Chief_NN
Executive_NN
Executive_NN
Director_NN
and_PHC
Chief_NN
Financial_NN
Chairman_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
Appointed_VBD
as_IN
a_DT
Director_NN
1_CD
January_NN
1996_CD
._.
Officer_NN
Appointed_VBD
as_IN
a_DT
Director_NN
6_CD
April_NN
1999_CD
._.
Non-Executive_JJ
Director_NN
of_PIN
Lloyds_NN
TSB_NN
Group_NN
Appointed_VBD
as_IN
a_DT
Director_NN
1_CD
October_NN
1997_CD
._.
Honorary_NN
Chairman_NN
of_PIN
Sandvik_NN
AB_NN
._.
President_NN
of_PIN
the_DT
European_JJ
Federation_NOMZ
of_PIN
Also_RB
has_VPRT
overall_JJ
responsibility_NOMZ
for_PIN
Information_NOMZ
Executive_NN
Director_NN
of_PIN
General_NN
Motors_NN
Pharmaceutical_NN
Industries_NN
and_PHC
Associations_NOMZ
._.
Non-Executive_JJ
Director_NN
of_PIN
QinetiQ_NN
Corporation_NOMZ
._.
Member_NN
of_PIN
the_DT
Academies_NN
of_PIN
Pro-Chancellor_NN
of_PIN
the_DT
University_NOMZ
of_PIN
Leicester_NN
._.
Member_NN
of_PIN
the_DT
UK_NN
Accounting_GER
Engineering_GER
Sciences_NN
in_PIN
Sweden_NN
and_PHC
Finland_NN
Chairman_NN
of_PIN
the_DT
British_JJ
Pharma_NN
Group_NN
and_PHC
Standards_NN
Board_NN
._.
Chairman_NN
of_PIN
The_DT
Hundred_NN
and_PHC
Honorary_NN
Member_NN
of_PIN
the_DT
Royal_NN
Academy_NN
the_DT
North_NN
West_NN
Science_NN
Council_NN
._.
Group_NN
of_PIN
Finance_NN
Directors_NN
in_PIN
the_DT
UK_NN
._.
Member_NN
of_PIN
Advisory_NN
Councils_NN
in_PIN
Korea_NN
,_,
India_NN
and_CC
the_DT
Investment_NOMZ
Sir_NN
Peter_NN
Bonfield_NN
CBE_NN
,_,
FREng_NN
59_CD
Dame_NN
Bridget_NN
Ogilvie_NN
65_CD
Council_NN
advising_VBG [WZPRES]
the_DT
South_PLACE
African_JJ
Senior_JJ
Non-Executive_JJ
Director_NN
Non-Executive_NN
Director_NN
Government_NOMZ
._.
Member_NN
of_PIN
the_DT
Business_NOMZ
Chairman_NN
of_PIN
the_DT
Remuneration_NOMZ
Member_NN
of_PIN
the_DT
Audit_NN
Committee_NN
and_CC
the_DT
Council_NN
of_PIN
American_NN
CEOs_NN
._.
Member_NN
of_PIN
the_DT
Committee_NN
and_PHC
Member_NN
of_PIN
the_DT
Science_NN
Committee_NN
Advisory_NN
Board_NN
,_,
Centre_NN
for_PIN
European_JJ
Nomination_NOMZ
Committee_NN
Appointed_VBD
as_IN
a_DT
Director_NN
1_CD
January_NN
1997_CD
._.
Also_RB
has_VPRT
responsibility_NOMZ
for_PIN
overseeing_VBG
Fellow_NN
of_PIN
the_DT
Royal_NN
Academy_NN
of_PIN
Engineering_GER
._.
Non-Executive_JJ
Hkan_NN
Mogren_NN
59_CD
Non-Executive_NN
Director_NN
of_PIN
Director_NN
of_PIN
the_DT
Manchester_NN
Technology_NN
Non-Executive_NN
Deputy_NN
Chairman_NN
Telefonaktiebolaget_NN
LM_NN
Ericsson_NN
,_,
Mentor_NN
Fund_NN
Limited_NN
._.
Chairman_NN
of_PIN
the_DT
Medicines_NN
Member_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
Graphics_NN
Corporation_NOMZ
and_PHC
Taiwan_NN
for_PIN
Malaria_NN
Venture_NN
and_CC
the_DT
Association_NOMZ
of_PIN
Appointed_VBN
as_IN
a_DT
Director_NN
6_CD
April_NN
1999_CD
._.
Semiconductor_NN
Manufacturing_GER
Company_NN
,_,
Medical_NN
Research_NN
Charities_NOMZ
._.
Trustee_NN
of_PIN
Formerly_TIME
CEO_NN
and_CC
a_DT
Director_NN
of_PIN
Astra_NN
AB_NN
Ltd._NN
._.
Vice-President_NN
of_PIN
The_DT
British_JJ
Quality_NOMZ
Cancer_NN
Research_NN
UK_NN
._.
Chairman_NN
of_PIN
the_DT
appointed_VBN
18_CD
May_POMD
1988_CD
._.
Member_NN
of_PIN
Citigroup_NN
Trustees_NN
of_PIN
the_DT
AstraZeneca_NN
Science_NN
Affibody_NN
AB_NN
and_CC
the_DT
Sweden-America_NN
International_NN
Advisory_NN
Board_NN
._.
Member_NN
of_PIN
the_DT
Board_NN
of_PIN
Directors_NN
of_PIN
Investor_NN
Marcus_NN
Wallenberg_NN
47_CD
Michele_NN
Hooper_NN
52_CD
AB_NN
,_,
Rmy_NN
Cointreau_NN
S._NN
A._NN
Groupe_NN
Danone_NN
Non-Executive_NN
Director_NN
Non-Executive_NN
Director_NN
and_PHC
Norsk_NN
Hydro_NN
ASA_NN
._.
Director_NN
of_PIN
the_DT
Member_NN
of_PIN
the_DT
Audit_NN
Committee_NN
Appointed_VBD
as_IN
a_DT
Director_NN
1_CD
July_NN
2003_CD
._.
Marianne_NN
and_PHC
Marcus_NN
Wallenberg_NN
Appointed_VBD
as_IN
a_DT
Director_NN
6_CD
April_NN
1999_CD
._.
President_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
of_PIN
Foundation_NOMZ
._.
Formerly_TIME
a_DT
Director_NN
of_PIN
Astra_NN
AB_NN
appointed_VBD
Stadtlander_NN
Drug_NN
Company_NN
1998-1999_CD
._.
President_NN
and_PHC
Chief_NN
Executive_NN
Corporate_NN
Vice-President_NN
and_PHC
President_NN
,_,
Jane_NN
Henney_NN
56_CD
Officer_NN
of_PIN
Investor_NN
AB_NN
._.
Non-Executive_JJ
ViceInternational_NN
Businesses_NOMZ
of_PIN
Caremark_NN
Non-Executive_NN
Director_NN
Chairman_NN
of_PIN
Saab_NN
AB_NN
,_,
Skandinaviska_NN
International_NN
1992-1998_CD
._.
Non-Executive_JJ
Member_NN
of_PIN
the_DT
Audit_NN
Committee_NN
,_,
the_DT
Enskilda_NN
Banken_NN
AB_NN
and_PHC
Telefonaktiebolaget_NN
Director_NN
of_PIN
PPG_NN
Industries_NN
,_,
Inc._NN
._.
Target_NN
Nomination_NOMZ
Committee_NN
and_CC
the_DT
Science_NN
LM_NN
Ericsson_NN
._.
Non-Executive_JJ
Director_NN
of_PIN
Corporation_NOMZ
and_PHC
Davita_NN
Inc._NN
._.
Committee_NN
Scania_NN
AB_NN
,_,
Stora_NN
Enso_NN
Oyj_NN
and_CC
the_DT
Knut_NN
and_CC
Appointed_VBN
as_IN
a_DT
Director_NN
24_CD
September_NN
2001_CD
._.
Joe_NN
Jimenez_NN
44_CD
Senior_JJ
Vice-President_NN
&_CC
Provost_NN
for_PIN
Health_NN
Non-Executive_NN
Director_NN
Affairs_NN
,_,
University_NOMZ
of_PIN
Cincinnati_NN
Medical_NN
John_NN
Buchanan_NN
60_CD
Member_NN
of_PIN
the_DT
Nomination_NOMZ
Committee_NN
Center_NN
._.
Commissioner_NN
of_PIN
Food_NN
and_PHC
Drugs_NN
Non-Executive_NN
Director_NN
Appointed_VBD
as_IN
a_DT
Director_NN
1_CD
July_NN
2003_CD
._.
1998-2001_CD
and_CC
Deputy_NN
Commissioner_NN
for_PIN
Member_NN
of_PIN
the_DT
Audit_NN
Committee_NN
and_CC
the_DT
Executive_NN
Vice-President_NN
of_PIN
H_NN
J_NN
Heinz_NN
Operations_NOMZ
1992-1994_CD
,_,
US_FPP1
Food_NN
and_PHC
Drug_NN
Remuneration_NOMZ
Committee_NN
Company_NN
and_PHC
President_NN
and_PHC
Chief_NN
Executive_NN
Administration_NOMZ
._.
Deputy_NN
Director_NN
,_,
US_FPP1
National_NN
Appointed_VBD
as_IN
a_DT
Director_NN
25_CD
April_NN
2002_CD
._.
Officer_NN
of_PIN
Heinz_NN
Europe_NN
since_OSUB
2002_CD
._.
Non-Executive_JJ
Executive_NN
Director_NN
and_PHC
Group_NN
Chief_NN
Financial_NN
Corporate_NN
Vice-President_NN
then_RB
Senior_JJ
ViceDirector_NN
of_PIN
AmerisourceBergen_NN
Corporation_NOMZ
._.
Member_NN
of_PIN
President_NN
and_PHC
President_NN
of_PIN
Heinz_NN
North_NN
Member_NN
of_PIN
the_DT
Board_NN
of_PIN
Trustees_NN
of_PIN
the_DT
the_DT
UK_NN
Accounting_GER
Standards_NN
Board_NN
1997_CD
-_:
America_NN
1998-2002_CD
._.
Non-Executive_JJ
Director_NN
Commonwealth_NN
Fund_NN
and_CC
the_DT
Scripps_NN
2001_CD
._.
Senior_JJ
Independent_NN
Non-Executive_NN
of_PIN
Hain_NN
Celestial_NN
Group_NN
,_,
Inc._NN
._.
Research_NN
Institute_NN
._.
Member_NN
of_PIN
the_DT
Medical_NN
&_CC
Director_NN
of_PIN
BHP_NN
Billiton_NN
Plc_NN
and_PHC
NonScientific_NN
Advisory_NN
Board_NN
of_PIN
MPM_NN
Capital_NN
._.
Executive_NN
Director_NN
of_PIN
Vodafone_NN
Group_NN
Plc._NN
._.
Other_JJ
officers_NN
of_PIN
the_DT
Company_NN
at_PIN
31_CD
December_NN
2003_CD
included_VBD
members_NN
of_PIN
Karl_NN
von_NN
der_NN
Heyden_NN
67_CD
Erna_NN
Mller_NN
63_CD
the_DT
Senior_NN
Executive_NN
Team_NN
,_,
as_IN
set_VBN
out_PIN
on_PIN
Non-Executive_JJ
Director_NN
Non-Executive_NN
Director_NN
page_NN
19_CD
,_,
and_ANDC
:_:
Chairman_NN
of_PIN
the_DT
Audit_NN
Committee_NN
Member_NN
of_PIN
the_DT
Remuneration_NOMZ
Committee_NN
Appointed_VBD
as_IN
a_DT
Director_NN
1_CD
October_NN
1998_CD
._.
and_ANDC
the_DT
Science_NN
Committee_NN
Graeme_NN
Musker_NN
Executive_NN
Vice-President_NN
1989-1992_CD
and_CC
Appointed_VBN
as_IN
a_DT
Director_NN
6_CD
April_NN
1999_CD
._.
Group_NN
Secretary_NN
and_PHC
Solicitor_NN
Co-Chairman_NN
and_PHC
Chief_NN
Executive_NN
Officer_NN
Formerly_TIME
a_DT
Director_NN
of_PIN
Astra_NN
AB_NN
appointed_VBD
15_CD
Appointed_VBN
as_IN
Company_NN
Secretary_NN
1993_CD
of_PIN
RJR_NN
Nabisco_NN
._.
Executive_NN
Director_NN
of_PIN
the_DT
Knut_NN
6June_NN
1993_CD
._.
Executive_NN
Officer_NN
of_PIN
Metallgesellschaft_NN
Corp._NN
and_PHC
Alice_NN
Wallenberg_NN
Foundation_NOMZ
._.
Vice-Chairman_NN
of_PIN
PepsiCo_NN
,_,
Inc._NN
of_PIN
Clinical_NN
Immunology_NN
and_PHC
Member_NN
of_PIN
the_DT
1996-2001_CD
._.
Non-Executive_JJ
Director_NN
of_PIN
Nobel_NN
Assembly_NN
and_CC
of_PIN
the_DT
Nobel_NN
Federated_NN
Department_NOMZ
Stores_NN
Inc._NN
._.
Committee_NN
,_,
Karolinska_NN
Institutet_NN
._.
Member_NN
of_PIN
ARAMARK_NN
Inc._NN
and_PHC
Exult_NN
,_,
Inc._NN
the_DT
Royal_NN
Swedish_NN
Academy_NN
of_PIN
Engineering_GER
Sciences_NN
and_CC
the_DT
Royal_NN
Swedish_NN
Academy_NN
of_PIN
Science_NN
._.
com_NN
Summary_NN
Directors_NN
report_VPRT [PUBV]
subject_JJ
to_PIN
those_DEMO
provisions_NN
of_PIN
the_DT
Act_NN
Board_NN
of_PIN
Directors_NN
At_PIN
its_PIT
meeting_GER
in_PIN
December_NN
2003_CD
,_,
the_DT
Board_NN
Details_NN
of_PIN
the_DT
Board_NN
at_PIN
31_CD
December_NN
2003_CD
applicable_JJ
to_PIN
foreign_JJ
issuers_NN
._.
reviewed_VBN
and_PHC
assessed_VBN
how_RB
it_PIT
operates_VPRT
._.
This_DEMP
are_VPRT [PASS]
set_VBN
out_PIN
on_PIN
pages_NN
16_CD
and_CC
17_CD
._.
included_VBD
consideration_NOMZ
and_PHC
discussion_NN
of_PIN
the_DT
The_DT
Company_NN
either_CC
already_RB
complies_VPRT
with_PIN
or_CC
nature_NN
and_PHC
level_NN
of_PIN
its_PIT
interaction_NOMZ
with_PIN
the_DT
Board_NN
changes_NN
will_PRMD
comply_VB
with_PIN
those_DEMO
provisions_NN
of_PIN
the_DT
Act_NN
Companys_NN
management_NOMZ
:_:
the_DT
quality_NOMZ
,_,
ke_FW
Stavling_GER
,_,
Executive_NN
Director_NN
,_,
left_VBD
the_DT
applicable_JJ
to_PIN
foreign_JJ
issuers_NN
as_IN
and_ANDC
when_RB
quantity_NOMZ
and_PHC
coverage_NN
of_PIN
information_NOMZ
which_WDT [WHOBJ]
Company_NN
at_PIN
the_DT
end_NN
of_PIN
January_NN
2003_CD
._.
they_TPP3
become_VPRT
effective_JJ
._.
The_DT
Board_NN
believes_VPRT [PRIV]
flows_VPRT
to_PIN
the_DT
Board_NN
from_PIN
management_NOMZ
:_:
the_DT
that_DEMP
,_,
prior_RB
to_PIN
the_DT
Act_NN
coming_VBG [WZPRES]
into_PIN
force_NN
,_,
the_DT
balance_NN
of_PIN
the_DT
Boards_NN
time_NN
spent_VBD
In_PIN
July_NN
2003_CD
,_,
the_DT
Board_NN
appointed_VBN
Michele_NN
Company_NN
already_RB
had_VBD
a_DT
sound_JJ
corporate_JJ
considering_VBG [PRIV] [THATD]
strategic_JJ
issues_NN
compared_VBN [WZPAST]
to_PIN
Hooper_NN
and_PHC
Joe_NN
Jimenez_NN
as_IN
Non-Executive_JJ
governance_NN
framework_NN
,_,
good_JJ
processes_NN
for_PIN
other_JJ
matters_NN
:_:
the_DT
content_NN
of_PIN
Board_NN
meetings_GER
Directors_NN
._.
the_DT
accurate_JJ
and_PHC
timely_JJ
reporting_GER
of_PIN
its_PIT
and_CC
presentations_NOMZ
to_PIN
Board_NN
meetings_GER
:_:
the_DT
financial_JJ
position_NOMZ
and_PHC
results_NN
of_PIN
operations_NOMZ
composition_NOMZ
of_PIN
the_DT
Board_NN
:_:
the_DT
practical_JJ
At_PIN
the_DT
end_NN
of_PIN
August_NN
2003_CD
,_,
Hkan_NN
Mogren_NN
and_CC
an_DT
effective_JJ
and_PHC
robust_JJ
system_NN
of_PIN
internal_JJ
arrangements_NOMZ
for_PIN
the_DT
work_NN
of_PIN
the_DT
Board_NN
:_:
and_ANDC
ceased_VBD
to_TO
be_VB
Executive_NN
Deputy_NN
Chairman_NN
and_PHC
controls_NN
._.
Consequently_CONJ
,_,
the_DT
Companys_NN
the_DT
work_NN
and_PHC
operation_NOMZ
of_PIN
the_DT
Boards_NN
became_VBD
Non-Executive_JJ
Deputy_NN
Chairman_NN
._.
approach_NN
to_PIN
compliance_NN
with_PIN
the_DT
Act_NN
has_VPRT
committees_NN
._.
Overall_RB
,_,
Board_NN
members_NN
principally_RB
involved_VBD
the_DT
development_NOMZ
and_CC
concluded_VBD [PRIV]
that_THVC
the_DT
Board_NN
and_CC
its_PIT
committees_NN
Election_NOMZ
and_PHC
re-election_NOMZ
of_PIN
Directors_NN
adjustment_NOMZ
of_PIN
its_PIT
existing_VBG
corporate_JJ
were_VBD
operating_VBG
in_PIN
an_DT
effective_JJ
and_CC
All_QUAN
of_PIN
the_DT
Directors_NN
will_PRMD
retire_VB
under_IN
Article_NN
65_CD
governance_NN
framework_NN
and_CC
associated_VBN
constructive_JJ
manner_NN
._.
of_PIN
the_DT
Companys_NN
Articles_NN
of_PIN
Association_NOMZ
at_PIN
processes_NN
concerning_VBG [WZPRES]
reporting_GER
,_,
internal_JJ
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
AGM_NN
in_PIN
April_NN
controls_NN
and_CC
other_JJ
relevant_JJ
matters_NN
._.
At_PIN
the_DT
same_JJ
meeting_GER
,_,
the_DT
Chairman_NN
also_RB
2004_CD
._.
The_DT
Notice_NN
of_PIN
AGM_NN
will_PRMD
give_VB
details_NN
of_PIN
reported_VBN [PUBV]
to_PIN
the_DT
Board_NN
on_PIN
his_TPP3
conversations_NOMZ
those_DEMO
Directors_NN
presenting_VBG [WZPRES]
themselves_TPP3
for_PIN
Board_NN
structure_NN
and_CC
processes_VPRT
with_PIN
each_QUAN
Non-Executive_JJ
Director_NN
about_IN
their_TPP3
election_NOMZ
or_CC
re-election_NOMZ
at_PIN
the_DT
AGM_NN
._.
Board_NN
composition_NOMZ
,_,
responsibilities_NOMZ
and_CC
individual_JJ
performance_NN
and_CC
that_DEMO
of_PIN
the_DT
Board_NN
appointments_NOMZ
as_IN
a_DT
whole_NN
,_,
which_WDT [SERE]
took_VBD
place_NN
during_PIN
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
The_DT
Board_NN
comprises_VPRT
Executive_NN
and_PHC
Nonfourth_NN
quarter_NN
of_PIN
2003_CD
._.
The_DT
Chairman_NN
then_RB
The_DT
Companys_NN
AGM_NN
will_PRMD
be_VB [PASS]
held_VBN [PRIV]
on_PIN
29_CD
April_NN
Executive_NN
Directors_NN
._.
In_PIN
the_DT
view_NN
of_PIN
the_DT
Board_NN
,_,
left_VBD
the_DT
meeting_GER
while_OSUB
Sir_NN
Peter_NN
Bonfield_NN
,_,
2004_CD
._.
The_DT
principal_JJ
meeting_GER
place_NN
will_PRMD
be_VB [BEMA]
in_PIN
the_DT
majority_NOMZ
of_PIN
Board_NN
members_NN
excluding_VBG [WZPRES]
the_DT
senior_JJ
Non-Executive_NN
Director_NN
,_,
led_VBD
a_DT
review_NN
London_NN
._.
There_EX
will_PRMD
be_VB
a_DT
simultaneous_JJ
satellite_NN
Chairman_NN
are_VPRT [BEMA]
independent_JJ
Non-Executive_JJ
of_PIN
the_DT
Chairmans_NN
performance_NN
._.
On_PIN
the_DT
meeting_GER
in_PIN
Stockholm_NN
._.
The_DT
differing_VBG
roles_NN
of_PIN
Executive_NN
Chairmans_NN
return_NN
to_PIN
the_DT
meeting_GER
,_,
the_DT
Board_NN
Directors_NN
and_CC
Non-Executive_JJ
Directors_NN
are_VPRT [PASS]
reviewed_VBN
the_DT
performance_NN
of_PIN
the_DT
Chief_NN
Corporate_NN
governance_NN
clearly_RB
delineated_JJ
,_,
with_PIN
both_DT
having_VBG
fiduciary_JJ
Executive_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
UK_NN
Combined_NN
Code_NN
on_PIN
Corporate_NN
duties_NN
towards_PIN
shareholders_NN
and_CC
all_QUAN
being_VBG
who_WP
,_,
in_PIN
each_QUAN
case_NN
,_,
left_VBD
the_DT
meeting_GER
while_OSUB
Governance_NN
collectively_RB
responsible_JJ
for_PIN
the_DT
success_NN
of_PIN
the_DT
review_NN
took_VBD
place_NN
._.
In_PIN
July_NN
2003_CD
,_,
the_DT
Financial_NN
Reporting_GER
Council_NN
the_DT
Company_NN
._.
However_CONJ
,_,
Executive_NN
Directors_NN
in_PIN
the_DT
UK_NN
issued_VBD
the_DT
revised_VBN
Combined_NN
Code_NN
have_VPRT
direct_JJ
responsibility_NOMZ
for_PIN
business_NOMZ
Chief_NN
Executive_NN
and_CC
the_DT
Senior_JJ
on_PIN
Corporate_JJ
Governance_NN
which_WDT [WHOBJ]
operations_NOMZ
whereas_OSUB
the_DT
Non-Executive_NN
Executive_NN
Team_NN
superseded_VBD
and_PHC
replaced_VBD
the_DT
Combined_VBN
Directors_NN
have_VPRT
a_DT
responsibility_NOMZ
to_TO
bring_VB
The_DT
Chief_NN
Executive_NN
,_,
Sir_NN
Tom_NN
McKillop_NN
,_,
has_VPRT [PEAS]
Code_NN
published_VBN [WZPAST]
by_PIN
the_DT
Hampel_NN
Committee_NN
independent_JJ
,_,
objective_JJ
judgement_NOMZ
to_TO
bear_VB
on_PIN
delegated_JJ
authority_NOMZ
from_PIN [STPR]
,_,
and_ANDC
is_VPRT [BEMA]
responsible_PRED
on_PIN
Corporate_JJ
Governance_NN
in_PIN
1998_CD
._.
This_DEMP
includes_VPRT
constructively_RB
to_TO
,_,
the_DT
Board_NN
for_PIN
directing_VBG
and_PHC
promoting_VBG
the_DT
for_PIN
reporting_VBG [PUBV] [THATD]
years_NN
beginning_VBG [WZPRES]
on_PIN
or_CC
after_IN
1_CD
challenging_JJ
management_NOMZ
and_CC
helping_VBG
to_PIN
profitable_JJ
operation_NOMZ
and_PHC
development_NOMZ
of_PIN
the_DT
November_NN
2003_CD
._.
develop_VB
the_DT
Companys_NN
strategy_NN
._.
The_DT
NonCompany_NN
,_,
consistent_JJ
with_PIN
the_DT
primary_JJ
aim_NN
of_PIN
Executive_NN
Directors_NN
scrutinise_VPRT
the_DT
enhancing_VBG
long_JJ
term_NN
shareholder_NN
value_NN
._.
Although_CONC
the_DT
Company_NN
is_VPRT [PASS]
not_XX0
strictly_RB
required_VBN [SUAV]
performance_NN
of_PIN
management_NOMZ
and_CC
have_VPRT
to_TO
report_VB [PUBV]
against_PIN
the_DT
revised_VBN
Combined_NN
Code_NN
various_JJ
responsibilities_NOMZ
concerning_VBG [WZPRES]
the_DT
The_DT
Chief_NN
Executive_NN
is_VPRT [BEMA]
responsible_PRED
to_PIN
the_DT
until_IN
its_PIT
Directors_NN
Report_NN
for_PIN
2004_CD
,_,
the_DT
Board_NN
integrity_NOMZ
of_PIN
financial_JJ
information_NOMZ
,_,
internal_JJ
Board_NN
for_PIN
the_DT
management_NOMZ
and_PHC
performance_NN
did_EMPH
review_VB
the_DT
revised_VBN
Combined_NN
Code_NN
at_PIN
its_PIT
controls_NN
and_CC
risk_VB
management_NOMZ
._.
To_TO
help_VB
of_PIN
the_DT
Companys_NN
businesses_NOMZ
within_PIN
the_DT
meeting_GER
in_PIN
October_NN
2003_CD
and_CC
has_VPRT [PEAS]
prepared_VBN
maintain_VPRT [PUBV]
a_DT
strong_JJ
executive_NN
presence_NN
on_PIN
the_DT
framework_NN
of_PIN
Company_NN
policies_NN
,_,
reserved_VBN
this_DEMO
Directors_NN
Report_VPRT [PUBV]
with_PIN
reference_NN
to_PIN
the_DT
Board_NN
in_CONJ
addition_NULL
to_PIN
the_DT
two_CD
Executive_NN
powers_NN
and_CC
routine_JJ
reporting_GER
requirements_NOMZ
._.
Directors_NN
the_DT
Chief_NN
Executive_NN
and_CC
the_DT
Chief_NN
He_TPP3
is_VPRT [PASS]
obliged_VBN
to_TO
refer_VB
certain_JJ
major_JJ
matters_NN
Financial_JJ
Officer_NN
,_,
Board_NN
meetings_GER
are_VPRT [PASS]
defined_VBN
in_PIN
the_DT
formal_JJ
delegation_NOMZ
of_PIN
the_DT
The_DT
Company_NN
is_VPRT
applying_VBG
all_QUAN
of_PIN
the_DT
main_JJ
and_CC
attended_VBN
by_PIN
two_CD
members_NN
of_PIN
the_DT
Senior_JJ
Boards_NN
authority_NOMZ
back_RB
to_PIN
the_DT
Board_NN
._.
The_DT
supporting_VBG
principles_NN
of_PIN
good_JJ
governance_NN
in_PIN
Executive_NN
Team_NN
._.
roles_NN
of_PIN
the_DT
Board_NN
,_,
the_DT
Boards_NN
committees_NN
,_,
the_DT
revised_VBN
Combined_NN
Code_NN
._.
The_DT
way_NN
in_PIN
the_DT
Chairman_NN
,_,
the_DT
Chief_NN
Executive_NN
and_CC
the_DT
which_WDT
these_DEMO
principles_NN
are_VPRT
being_VBG [PASS]
applied_VBN
is_VPRT [BEMA]
The_DT
Board_NN
sets_VPRT
the_DT
Companys_NN
strategy_NN
Senior_NN
Executive_NN
Team_NN
are_VPRT [PASS]
documented_VBN
,_,
as_IN
described_VBN
below_PLACE
._.
and_ANDC
policies_NN
and_PHC
monitors_NN
progress_NN
towards_PIN
are_VPRT [BEMA]
the_DT
Companys_NN
delegated_VBD
authorities_NOMZ
and_CC
meeting_VBG
its_PIT
objectives_NN
._.
It_PIT
also_RB
assesses_VPRT
reserved_JJ
powers_NN
,_,
the_DT
means_NN
of_PIN
operation_NOMZ
of_PIN
The_DT
Company_NN
is_VPRT
complying_VBG
with_PIN
all_QUAN
of_PIN
the_DT
whether_IN
its_PIT
obligations_NOMZ
to_PIN
the_DT
Companys_NN
the_DT
business_NOMZ
and_CC
the_DT
roles_NN
of_PIN
corporate_JJ
provisions_NN
of_PIN
the_DT
revised_VBN
Combined_NN
Code_NN
._.
shareholders_NN
and_PHC
others_NN
are_VPRT [PASS]
understood_VBN [PRIV]
functions_NOMZ
._.
This_DEMP
includes_VPRT
regular_JJ
reviews_NN
of_PIN
The_DT
US_FPP1
Sarbanes-Oxley_NN
Act_NN
of_PIN
2002_CD
the_DT
Companys_NN
financial_JJ
performance_NN
and_CC
The_DT
Chief_NN
Executive_NN
has_VPRT [PEAS]
established_VBN [PRIV]
and_CC
AstraZeneca_NN
PLC_NN
American_NN
Depositary_NN
critical_JJ
business_NOMZ
issues_NN
._.
The_DT
Board_NN
met_VBD
six_CD
chairs_NN
the_DT
Senior_NN
Executive_NN
Team_NN
._.
While_OSUB
the_DT
Shares_NN
are_VPRT [PASS]
traded_VBN
on_PIN
the_DT
New_NN
York_NN
Stock_NN
times_NN
in_PIN
2003_CD
._.
Chief_NN
Executive_NN
retains_VPRT
full_JJ
responsibility_NOMZ
for_PIN
Exchange_NN
NYSE_NN
and_CC
the_DT
Company_NN
is_VPRT [BEMA]
the_DT
authority_NOMZ
delegated_VBD
to_PIN
him_TPP3
by_PIN
the_DT
Board_NN
,_,
subject_JJ
to_PIN
the_DT
reporting_GER
and_CC
other_JJ
There_EX
is_VPRT
an_DT
established_VBN [PRIV]
and_CC
transparent_JJ
the_DT
Senior_NN
Executive_NN
Team_NN
is_VPRT [BEMA]
the_DT
vehicle_NN
requirements_NOMZ
of_PIN
the_DT
US_FPP1
Securities_NOMZ
and_PHC
procedure_NN
for_PIN
appointments_NOMZ
of_PIN
new_JJ
directors_NN
through_PIN
which_WDT [PIRE]
he_TPP3
exercises_VPRT
that_DEMO
authority_NOMZ
in_PIN
Exchange_NN
Commission_NN
SEC_NN
applicable_JJ
to_TO
to_PIN
the_DT
Board_NN
which_WDT [WHSUB]
is_VPRT [BYPA]
operated_VBN
by_PIN
the_DT
respect_NN
of_PIN
the_DT
Companys_NN
business_NOMZ
including_VBG [WZPRES]
foreign_JJ
issuers_NN
._.
The_DT
US_FPP1
Sarbanes-Oxley_NN
Act_NN
Nomination_NOMZ
Committee_NN
._.
All_QUAN
of_PIN
the_DT
Directors_NN
Salick_NN
Health_NN
Care_NN
and_PHC
Astra_NN
Tech_NN
._.
came_VBD
into_PIN
force_NN
at_PIN
the_DT
end_NN
of_PIN
July_NN
2002_CD
._.
As_IN
a_DT
retire_VB
at_PIN
each_QUAN
AGM_NN
and_CC
may_POMD
offer_VB
themselves_TPP3
result_VB
of_PIN
its_PIT
NYSE_NN
listing_GER
,_,
the_DT
Company_NN
is_VPRT [BEMA]
for_PIN
re-election_NOMZ
by_PIN
shareholders_NN
._.
com_NN
19_CD
Remuneration_NOMZ
policy_NN
The_DT
members_NN
of_PIN
the_DT
Senior_NN
Executive_NN
Team_NN
During_PIN
the_DT
year_NN
,_,
the_DT
Code_NN
of_PIN
Conduct_NN
was_VBD [BEMA]
Overall_JJ
remuneration_NOMZ
policy_NN
and_PHC
purpose_NN
are_VPRT
Jonathan_NN
Symonds_NN
,_,
Chief_NN
Financial_NN
reviewed_VBD
and_PHC
revised_VBD
._.
The_DT
amended_VBN
version_NN
The_DT
Company_NN
is_VPRT [PASS]
committed_VBN
to_TO
maintaining_VBG [PUBV]
a_DT
Officer_NN
:_:
Bruno_NN
Angelici_NN
,_,
Executive_NN
Vicewas_NN
approved_VBN [WZPAST]
by_PIN
the_DT
Board_NN
in_PIN
July_NN
2003_CD
._.
To_PIN
dynamic_JJ
performance_NN
culture_NN
in_PIN
which_WDT [PIRE]
every_QUAN
President_NN
,_,
Europe_NN
,_,
Japan_NN
,_,
Asia_NN
Pacific_NN
and_CC
coincide_VB
with_PIN
the_DT
launch_NN
of_PIN
the_DT
new_JJ
Code_NN
of_PIN
employee_NN
champions_NN
the_DT
growth_NN
of_PIN
ROW_NN
:_:
David_NN
Brennan_NN
,_,
Executive_NN
ViceConduct_NN
,_,
the_DT
Company_NN
also_RB
updated_VBN
and_CC
shareholder_NN
value_NN
,_,
is_VPRT [BEMA]
clear_PRED
about_IN
the_DT
President_NN
,_,
North_NN
America_NN
:_:
Jan_NN
Lundberg_NN
,_,
extended_VBD
its_PIT
procedures_NN
for_PIN
raising_VBG
integrity_NOMZ
Companys_NN
objectives_NN
,_,
knows_VPRT [PRIV]
how_RB [WHCL]
their_TPP3
work_NN
Executive_NN
Vice-President_NN
,_,
Discovery_NN
concerns_NN
which_WDT [WHSUB]
include_VPRT
a_DT
confidential_JJ
impacts_NN
on_PIN
those_DEMO
objectives_NN
and_CC
that_THVC
they_TPP3
will_PRMD
Research_NN
:_:
John_NN
Patterson_NN
,_,
Executive_NN
Vicehelpline_NN
for_PIN
employees_NN
worldwide_VPRT
._.
benefit_NN
from_PIN
achieving_VBG
high_JJ
levels_NN
of_PIN
President_NN
,_,
Product_NN
Strategy_NN
&_CC
Licensing_GER
and_PHC
performance_NN
._.
Business_NOMZ
Development_NOMZ
:_:
Martin_NN
Nicklasson_NN
,_,
Purchase_NN
of_PIN
own_JJ
shares_NN
Executive_NN
Vice-President_NN
,_,
Development_NOMZ
:_:
The_DT
Companys_NN
stated_VBD [PUBV]
distribution_NOMZ
policy_NN
The_NN
Board_NN
has_VPRT [PEAS]
confirmed_VBN [PUBV]
that_THVC
the_DT
Barrie_NN
Thorpe_NN
,_,
Executive_NN
Vice-President_NN
,_,
contains_VPRT
both_PDT
a_DT
regular_JJ
dividend_NN
cash_NN
flow_NN
Companys_NN
overall_JJ
remuneration_NOMZ
policy_NN
and_PHC
Operations_NOMZ
:_:
and_ANDC
Tony_NN
Bloxham_NN
,_,
Executive_NN
and_CC
a_DT
share_NN
re-purchase_JJ
component_NN
to_TO
give_VB
purpose_NN
is_VPRT
:_:
Vice-President_NN
,_,
Human_NN
Resources_NN
._.
the_DT
Company_NN
more_EMPH
flexibility_NOMZ
in_PIN
managing_VBG
its_PIT
capital_NN
structure_NN
over_IN
time_NN
._.
In_PIN
August_NN
1999_CD
,_,
to_TO
attract_VB
and_PHC
retain_VB
people_NN
of_PIN
the_DT
quality_NOMZ
Internal_NN
controls_NN
and_PHC
management_NOMZ
of_PIN
risk_NN
the_DT
Company_NN
announced_VBD [PUBV]
a_DT
$_$
2_CD
billion_CD
share_NN
necessary_JJ
to_TO
sustain_VB
the_DT
Company_NN
as_IN
one_CD
of_PIN
The_NN
Board_NN
has_VPRT
overall_JJ
responsibility_NOMZ
for_PIN
the_DT
re-purchase_JJ
program_NN
to_TO
be_VB [PASS]
completed_VBN
the_DT
best_JJ
pharmaceutical_JJ
companies_NN
in_PIN
the_DT
Companys_NN
system_NN
of_PIN
internal_JJ
controls_NN
which_WDT [WHOBJ]
by_PIN
the_DT
end_NN
of_PIN
2002_CD
._.
This_DEMO
program_NN
was_VBD
world_NN
:_:
and_ANDC
aims_VPRT
to_TO
safeguard_VB
shareholders_NN
investments_NOMZ
completed_VBN [WZPAST]
ahead_PLACE
of_PIN
schedule_NN
in_PIN
the_DT
second_JJ
to_TO
motivate_VB
them_TPP3
to_TO
achieve_VB
the_DT
level_NN
of_PIN
and_CC
the_DT
Companys_NN
assets_NN
,_,
ensure_VB [SUAV] [PRIV]
that_THVC
quarter_NN
of_PIN
2002_CD
._.
In_PIN
January_NN
2002_CD
,_,
the_DT
performance_NN
necessary_JJ
to_TO
create_VB
sustained_VBN
proper_JJ
accounting_GER
records_NN
are_VPRT [PASS]
maintained_VBN [PUBV] [THATD]
Company_NN
announced_VBD [PUBV]
an_DT
additional_JJ
$_$
2_CD
billion_CD
growth_NN
in_PIN
shareholder_NN
value_NN
._.
and_ANDC
that_THVC
the_DT
financial_JJ
information_NOMZ
used_VBN [WZPAST]
within_PIN
re-purchase_JJ
program_NN
which_WDT [WHSUB]
was_VBD [BEMA]
the_DT
business_NOMZ
and_CC
for_PIN
publication_NOMZ
is_VPRT [BEMA]
accurate_PRED
,_,
completed_VBN [PASTP]
on_PIN
schedule_NN
by_PIN
the_DT
end_NN
of_PIN
2003_CD
._.
In_PIN
order_NN
to_TO
achieve_VB
this_DEMP
,_,
remuneration_NOMZ
policy_NN
reliable_JJ
and_CC
fairly_RB
presents_VPRT
the_DT
financial_JJ
and_CC
practice_NN
is_VPRT [PASS]
designed_VBN
:_:
position_NOMZ
of_PIN
the_DT
Company_NN
and_CC
the_DT
results_NN
of_PIN
its_PIT
During_PIN
2003_CD
,_,
the_DT
Company_NN
purchased_VBD
27.2_CD
business_NOMZ
operations_NOMZ
._.
The_DT
Board_NN
is_VPRT [BEMA]
also_RB
million_CD
of_PIN
its_PIT
own_JJ
Ordinary_NN
Shares_NN
with_PIN
a_DT
to_TO [SPIN]
closely_RB
align_VB
individual_JJ
and_CC
team_NN
responsible_JJ
for_PIN
reviewing_VBG
the_DT
effectiveness_NOMZ
of_PIN
nominal_JJ
value_NN
of_PIN
$_$
0.25_CD
each_QUAN
for_PIN
an_DT
aggregate_JJ
reward_NN
with_PIN
business_NOMZ
performance_NN
at_PIN
each_QUAN
the_DT
system_NN
of_PIN
internal_JJ
controls_NN
._.
The_DT
system_NN
is_VPRT
cost_NN
of_PIN
$_$
1,154_CD
million_CD
._.
Following_VBG [PRESP]
the_DT
level_NN
:_:
designed_VBN
to_TO
provide_VB
reasonable_JJ
assurance_NN
of_PIN
purchase_NN
of_PIN
these_DEMO
shares_NN
,_,
they_TPP3
were_VBD [BEMA]
all_QUAN
to_TO
encourage_VB
employees_NN
to_TO
perform_VB
to_PIN
effective_JJ
operations_NOMZ
and_PHC
compliance_NN
with_PIN
canceled_VBN
as_IN
required_VBN [SUAV]
by_PIN
applicable_JJ
English_NN
their_TPP3
fullest_JJ
capacity_NOMZ
:_:
laws_NN
and_PHC
regulations_NOMZ
,_,
although_CONC
any_QUAN
system_NN
of_PIN
law_NN
._.
This_DEMO
number_NN
of_PIN
shares_NN
represents_VPRT
1.6_CD
%_NN
to_TO
encourage_VB
employees_NN
to_TO
align_VB
their_TPP3
internal_JJ
controls_NN
can_POMD [SPAU]
only_DWNT
provide_VB
reasonable_JJ
,_,
of_PIN
the_DT
Companys_NN
total_VPRT
issued_VBN
share_NN
capital_NN
at_PIN
interests_NN
with_PIN
those_DEMO
of_PIN
shareholders_NN
:_:
not_XX0
absolute_JJ
,_,
assurance_NN
against_PIN
material_NN
31_CD
December_NN
2003_CD
._.
to_TO
support_VB
managers_NN
responsibility_NOMZ
to_PIN
misstatement_NOMZ
or_CC
loss_NN
._.
achieve_VB
business_NOMZ
performance_NN
through_PIN
Since_OSUB
the_DT
beginning_GER
of_PIN
the_DT
re-purchase_JJ
people_NN
and_CC
for_PIN
them_TPP3
to_TO
recognize_VB [PRIV]
superior_JJ
The_DT
Company_NN
views_VPRT
the_DT
careful_JJ
management_NOMZ
program_NN
in_PIN
1999_CD
,_,
the_DT
Company_NN
has_VPRT
performance_NN
,_,
in_PIN
the_DT
short_JJ
and_PHC
longer_JJ
term_NN
:_:
of_PIN
risk_NN
as_IN
a_DT
key_JJ
management_NOMZ
activity_NOMZ
._.
purchased_VBN [PASTP]
for_PIN
cancellation_NOMZ
in_PIN
total_JJ
92.8_CD
to_TO
be_VB
as_IN
locally_PLACE
focused_VBN
and_CC
flexible_JJ
as_IN
is_VPRT
Managing_VBG
business_NOMZ
risks_NN
to_TO
deliver_VB
million_CD
of_PIN
its_PIT
own_JJ
Ordinary_NN
Shares_NN
with_PIN
a_DT
practicable_JJ
and_PHC
beneficial_JJ
:_:
opportunities_NOMZ
is_VPRT [BEMA]
a_DT
key_JJ
element_NOMZ
of_PIN
all_QUAN
activities_NOMZ
._.
nominal_JJ
value_NN
of_PIN
$_$
0.25_CD
each_QUAN
for_PIN
an_DT
aggregate_NN
to_TO
be_VB [BEMA]
competitive_PRED
and_PHC
cost-effective_PRED
in_PIN
This_DEMP
is_VPRT [PASS]
done_EMPH
using_VBG
a_DT
simple_JJ
and_PHC
flexible_JJ
cost_NN
of_PIN
$_$
3,959_CD
million_CD
._.
This_DEMO
number_NN
of_PIN
shares_NN
each_QUAN
of_PIN
the_DT
relevant_JJ
employment_NOMZ
markets_NN
:_:
framework_NN
which_WDT [WHSUB]
provides_VPRT
a_DT
consistent_JJ
and_CC
represents_VPRT
5.5_CD
%_NN
of_PIN
the_DT
Companys_NN
total_NN
and_CC
sustained_VBD
way_NN
of_PIN
implementing_VBG
the_DT
issued_VBN
share_NN
capital_NN
at_PIN
31_CD
December_NN
2003_CD
._.
to_TO
be_VB
as_IN
internally_RB
consistent_JJ
as_IN
is_VPRT
Companys_NN
values_NN
._.
These_DEMO
business_NOMZ
risks_NN
,_,
practicable_JJ
and_PHC
beneficial_JJ
taking_VBG
due_JJ
account_NN
which_WDT [WHSUB]
may_POMD
be_VB [BEMA]
strategic_PRED
,_,
operational_JJ
,_,
The_DT
Company_NN
continues_VPRT
to_TO
maintain_VB [PUBV]
robust_JJ
of_PIN
market_NN
need_NN
._.
reputational_JJ
,_,
financial_JJ
or_CC
environmental_JJ
,_,
controls_NN
in_PIN
respect_NN
of_PIN
all_QUAN
aspects_NN
of_PIN
the_DT
share_NN
should_NEMD
be_VB [PASS]
understood_VBN [PRIV]
and_CC
visible_JJ
._.
The_DT
re-purchase_JJ
program_NN
to_TO
ensure_VB [SUAV] [PRIV]
The_DT
cost_NN
and_PHC
value_NN
of_PIN
the_DT
components_NN
of_PIN
the_DT
business_NOMZ
context_NN
determines_VPRT [SUAV] [PRIV]
in_PIN
each_QUAN
compliance_NN
with_PIN
English_JJ
law_NN
and_CC
the_DT
Listing_GER
remuneration_NOMZ
package_NN
are_VPRT [PASS]
considered_VBN [PRIV]
as_IN
a_DT
situation_NOMZ
the_DT
level_NN
of_PIN
acceptable_JJ
risk_NN
and_PHC
Rules_NN
of_PIN
the_DT
UK_NN
Listing_GER
Authority_NOMZ
._.
In_CONJ
particular_NULL
,_,
whole_JJ
and_CC
are_VPRT [PASS]
designed_VBN
:_:
controls_NN
._.
the_DT
Companys_NN
Disclosure_NN
Committee_NN
meets_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
Company_NN
does_VPRT
not_XX0
to_TO
ensure_VB [SUAV] [PRIV]
a_DT
proper_JJ
balance_NN
of_PIN
fixed_VBN
and_CC
Code_NN
of_PIN
Conduct_NN
purchase_NN
its_PIT
own_JJ
shares_NN
during_PIN
prohibited_VBN
variable_JJ
performance-related_JJ
components_NN
,_,
The_DT
policy_NN
of_PIN
the_DT
Company_NN
is_VPRT
to_TO
require_VB [SUAV]
all_QUAN
of_PIN
periods_NN
._.
At_PIN
the_DT
AGM_NN
on_PIN
29_CD
April_NN
2004_CD
,_,
the_DT
linked_VBN
to_PIN
short_JJ
and_PHC
longer_JJ
term_NN
objectives_NN
:_:
its_PIT
subsidiaries_NN
,_,
and_ANDC
their_TPP3
employees_NN
,_,
to_PIN
Company_NN
will_PRMD
seek_VB
a_DT
renewal_NN
of_PIN
its_PIT
current_JJ
and_CC
observe_VB [PRIV]
the_DT
highest_JJ
ethical_JJ
standards_NN
of_PIN
permission_NN
from_PIN
shareholders_NN
to_TO
purchase_VB
its_PIT
to_TO
reflect_VB [PRIV]
market_NN
competitiveness_NOMZ
taking_VBG [WZPRES]
integrity_NOMZ
and_PHC
honesty_NN
and_PHC
act_NN
with_PIN
due_JJ
skill_NN
,_,
own_JJ
shares_NN
._.
account_NN
of_PIN
the_DT
total_JJ
value_NN
of_PIN
all_QUAN
of_PIN
the_DT
benefit_NN
care_NN
,_,
diligence_NN
and_PHC
fairness_NOMZ
in_PIN
the_DT
conduct_NN
of_PIN
components_NN
._.
The_DT
Companys_NN
management_NOMZ
recognizes_VPRT [PRIV]
that_THVC
such_JJ
standards_NN
make_VB
a_DT
The_DT
principal_JJ
components_NN
contained_VBN [WZPAST]
in_PIN
the_DT
significant_JJ
contribution_NOMZ
to_PIN
the_DT
overall_JJ
control_NN
total_JJ
remuneration_NOMZ
package_NN
,_,
for_PIN
employees_NN
environment_NOMZ
and_CC
seeks_VPRT
,_,
by_PIN
its_PIT
words_NN
and_CC
as_IN
a_DT
whole_NN
,_,
are_VPRT
:_:
actions_NOMZ
,_,
to_TO
reinforce_VB
them_TPP3
throughout_PIN
the_DT
business_NOMZ
._.
In_CONJ
particular_NULL
,_,
all_QUAN
employees_NN
are_VPRT [BEMA]
annual_JJ
salary_NN
based_VBN [WZPAST]
on_PIN
conditions_NOMZ
in_PIN
required_VBN [SUAV]
to_TO
comply_VB
with_PIN
the_DT
letter_NN
and_PHC
spirit_NN
of_PIN
the_DT
relevant_JJ
geographic_JJ
market_NN
,_,
with_PIN
the_DT
the_DT
AstraZeneca_NN
Code_NN
of_PIN
Conduct_NN
and_CC
with_PIN
provision_NN
to_TO
recognize_VB [PRIV]
,_,
in_CONJ
addition_NULL
,_,
the_DT
value_NN
the_DT
high_JJ
ethical_JJ
standards_NN
detailed_VBN [WZPAST]
by_PIN
the_DT
of_PIN
individuals_NN
sustained_VBN
personal_JJ
Company_NN
in_PIN
support_NN
of_PIN
it_PIT
._.
performance_NN
,_,
resulting_VBG [PRESP]
from_PIN
their_TPP3
ability_NOMZ
and_PHC
experience_NN
:_:
annual_JJ
bonus_NN
a_DT
lump_NN
sum_NN
payment_NOMZ
related_VBN [WZPAST]
to_PIN
the_DT
targeted_JJ
achievement_NOMZ
of_PIN
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
20_CD
astrazeneca_NN
._.
com_NN
Remuneration_NOMZ
policy_NN
continued_VBD
of_PIN
responsibility_NOMZ
:_:
the_DT
bonus_NN
payable_JJ
is_VPRT [BEMA]
on_PIN
corporate_JJ
,_,
functional_JJ
and_PHC
individual_JJ
goals_NN
,_,
pension_NN
element_NOMZ
was_VBD
$_$
193,000_CD
:_:
measured_VBN
over_IN
a_DT
year_NN
within_PIN
a_DT
specific_JJ
plan_NN
:_:
a_DT
scale_NN
of_PIN
0-100_CD
%_NN
of_PIN
salary_NN
and_CC
50_CD
%_NN
of_PIN
the_DT
corporate_JJ
goals_NN
are_VPRT [PASS]
derived_VBN
from_PIN
the_DT
salary_NN
is_VPRT [BEMA]
payable_PRED
for_PIN
the_DT
achievement_NOMZ
of_PIN
Swedish_NN
Executive_NN
Directors_NN
pension_NN
annual_JJ
budget_NN
set_VBN [WZPAST]
by_PIN
the_DT
Board_NN
and_CC
take_VB
target_NN
business_NOMZ
performance_NN
:_:
80_CD
%_NN
of_PIN
the_DT
arrangements_NOMZ
normally_RB
,_,
Swedish_NN
into_PIN
account_NN
external_JJ
expectations_NOMZ
of_PIN
bonus_NN
relates_VPRT
to_PIN
the_DT
achievement_NOMZ
of_PIN
the_DT
Executive_NN
Directors_NN
participate_VB
in_PIN
the_DT
performance_NN
:_:
the_DT
functional_JJ
goals_NN
are_VPRT [PASS]
agreed_VBN [SUAV] [PUBV]
earnings_GER
per_PIN
share_NN
target_NN
and_CC
20_CD
%_NN
to_PIN
the_DT
collectively_RB
bargained_VBN
ITP_NN
pension_NN
plan_NN
,_,
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
at_PIN
the_DT
start_NN
other_JJ
performance_NN
measures_NN
:_:
which_WDT [SERE]
provides_VPRT
pensions_NN
,_,
dependents_NN
of_PIN [STPR]
,_,
and_ANDC
are_VPRT [PASS]
monitored_VBN
throughout_PIN [STPR]
,_,
the_DT
year_NN
:_:
pensions_NN
and_PHC
lump_NN
sums_NN
on_PIN
death_NN
in_PIN
longer_JJ
term_NN
incentive_NN
for_PIN
selected_VBN
longer_JJ
term_NN
incentive_NN
Executive_NN
service_NN
:_:
in_PIN
respect_NN
of_PIN
those_DEMO
Swedish_JJ
groups_NN
,_,
a_DT
longer_JJ
term_NN
incentive_NN
targeted_VBN [WZPAST]
at_PIN
Directors_NN
are_VPRT [SPAU] [PASS]
also_RB
rewarded_VBN
for_PIN
improvement_NOMZ
Directors_NN
or_CC
former_JJ
Directors_NN
,_,
namely_CONJ
the_DT
achievement_NOMZ
of_PIN
strategic_JJ
objectives_NN
with_PIN
in_PIN
the_DT
share_NN
price_NN
performance_NN
of_PIN
the_DT
Hkan_NN
Mogren_NN
and_PHC
ke_NN
Stavling_GER
,_,
whose_WPS
close_JJ
alignment_NOMZ
to_PIN
the_DT
interests_NN
of_PIN
Company_NN
over_IN
a_DT
period_NN
of_PIN
years_NN
by_PIN
the_DT
grant_NN
pensionable_JJ
earnings_GER
are_VPRT
or_CC
were_VBD [BEMA]
in_PIN
shareholders_NN
:_:
of_PIN
share_NN
options_NOMZ
:_:
the_DT
grant_NN
of_PIN
options_NOMZ
under_IN
excess_NN
of_PIN
the_DT
earnings_GER
limit_NN
imposed_VBN [WZPAST]
by_PIN
pension_NN
arrangements_NOMZ
which_WDT [WHSUB]
are_VPRT [BEMA]
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
is_VPRT [BEMA]
the_DT
Swedish_JJ
Communal_NN
Tax_NN
Law_NN
appropriate_JJ
to_PIN
the_DT
relevant_JJ
market_NN
:_:
determined_VBN [SUAV] [PRIV] [PASTP]
by_PIN
the_DT
Remuneration_NOMZ
Kommunalskattelagen_NN
,_,
supplementary_JJ
other_JJ
benefits_NN
such_JJ
as_IN
holidays_NN
and_PHC
Committee_NN
,_,
as_RB
are_VPRT [BEMA]
the_DT
performance_NN
targets_VPRT
pension_NN
commitments_NOMZ
are_VPRT [PASS]
made_VBN
:_:
the_DT
sickness_NOMZ
benefit_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
cost-effective_PRED
and_CC
that_DEMP
will_PRMD
apply_VB
and_ANDC
whether_IN
they_TPP3
will_PRMD
apply_VB
to_PIN
Company_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
pay_VB
70_CD
%_NN
of_PIN
compatible_JJ
with_PIN
the_DT
relevant_JJ
national_JJ
welfare_NN
the_DT
grant_NN
and_CC
or_CC
exercise_NN
of_PIN
options_NOMZ
:_:
and_ANDC
pensionable_JJ
salary_NN
from_PIN
age_NN
60_CD
to_PIN
age_NN
65_CD
arrangements_NOMZ
:_:
and_ANDC
and_CC
50_CD
%_NN
of_PIN
such_JJ
earnings_GER
from_PIN
age_NN
65_CD
:_:
share_NN
participation_NOMZ
various_JJ
plans_NN
pension_NN
arrangements_NOMZ
:_:
the_DT
ITP_NN
provisions_NN
are_VPRT [PASS]
included_VBN
in_PIN
this_DEMP
provide_VB
the_DT
opportunity_NOMZ
for_PIN
employees_NN
to_PIN
additional_JJ
commitment_NOMZ
:_:
paid_VBN [PASTP]
in_PIN
pension_NN
take_VPRT
a_DT
personal_JJ
stake_NN
in_PIN
the_DT
Companys_NN
UK_NN
Executive_NN
Directors_NN
pension_NN
capital_NN
may_POMD [SPAU]
also_RB
be_VB [PASS]
used_VBN
in_PIN
the_DT
event_NN
of_PIN
wealth_NN
as_IN
shareholders_NN
._.
arrangements_NOMZ
the_DT
Chief_NN
Executive_NN
is_VPRT
retirement_NOMZ
or_CC
termination_NOMZ
before_IN
the_DT
age_NN
a_DT
member_NN
of_PIN
the_DT
Companys_NN
main_JJ
UK_NN
of_PIN
60_CD
:_:
on_PIN
death_NN
in_PIN
retirement_NOMZ
the_DT
accrued_VBN
The_DT
way_NN
in_PIN
which_WDT [PIRE]
these_DEMO
elements_NOMZ
are_VPRT [PASS]
defined_VBN
benefit_NN
pension_NN
plan_NN
:_:
the_DT
normal_JJ
pension_NN
is_VPRT [BEMA]
payable_PRED
to_PIN
a_DT
surviving_VBG
spouse_NN
combined_VBN
and_PHC
applied_VBN
varies_VPRT
depending_VBG
,_,
pension_NN
age_NN
under_IN
this_DEMO
plan_NN
is_VPRT [BEMA]
62_CD
:_:
or_CC
other_JJ
dependent_JJ
._.
for_CONJ
example_NULL
,_,
on_PIN
market_NN
need_NN
and_PHC
practice_NN
however_CONJ
,_,
a_DT
members_NN
accrued_VBN
pension_NN
in_PIN
various_JJ
countries_NN
._.
is_VPRT [BEMA]
available_PRED
from_PIN
age_NN
60_CD
without_PIN
any_QUAN
Other_JJ
customary_JJ
benefits_NN
such_JJ
as_IN
a_DT
car_NN
and_CC
actuarial_JJ
reduction_NOMZ
:_:
in_CONJ
addition_NULL
the_DT
health_NN
benefits_NN
are_VPRT [SPAU] [PASS]
also_RB
made_VBN
available_JJ
._.
This_DEMO
For_PIN
each_QUAN
Executive_NN
Director_NN
,_,
the_DT
individual_JJ
accrued_VBN
pension_NN
is_VPRT [BEMA]
available_PRED
,_,
unreduced_JJ
,_,
happens_VPRT
by_PIN
way_NN
of_PIN
the_DT
Executive_NN
Directors_NN
components_NN
are_VPRT
:_:
from_PIN
age_NN
57_CD
if_COND
the_DT
Company_NN
consents_NN
participation_NOMZ
in_PIN
the_DT
Companys_NN
flexible_JJ
to_PIN
a_DT
request_NN
for_PIN
early_TIME
retirement_NOMZ
and_PHC
benefits_NN
arrangements_NOMZ
,_,
which_WDT [SERE]
apply_VPRT
to_PIN
the_DT
annual_JJ
salary_NN
the_DT
actual_JJ
salary_NN
for_PIN
each_QUAN
from_PIN
age_NN
50_CD
if_COND
the_DT
retirement_NOMZ
is_VPRT [BEMA]
at_PIN
the_DT
vast_JJ
majority_NOMZ
of_PIN
the_DT
Companys_NN
UK_NN
and_CC
of_PIN
the_DT
Executive_NN
Directors_NN
is_VPRT [BYPA]
determined_VBN [SUAV] [PRIV]
by_PIN
Companys_NN
request_NN
:_:
Swedish_NN
employees_NN
._.
the_DT
Remuneration_NOMZ
Committee_NN
on_PIN
behalf_NN
of_PIN
the_DT
Board_NN
:_:
these_DEMO
salaries_NN
reflect_VPRT [PRIV]
the_DT
On_PIN
death_NN
in_PIN
retirement_NOMZ
,_,
the_DT
accrued_VBN
Graph_NN
showing_VBG [PRIV] [WZPRES]
total_JJ
shareholder_NN
return_NN
experience_NN
and_CC
sustained_VBD
performance_NN
of_PIN
pension_NN
is_VPRT [PASS]
guaranteed_VBN [PUBV]
payable_JJ
for_PIN
the_DT
The_DT
UK_NN
Directors_NN
Remuneration_NOMZ
Report_NN
the_DT
individuals_NN
to_PIN
whom_WP [PIRE]
they_TPP3
apply_VPRT
,_,
as_IN
judged_VBN [PRIV]
first_RB
five_CD
years_NN
of_PIN
retirement_NOMZ
and_CC
then_RB
Regulations_NOMZ
2002_CD
require_VPRT [SUAV]
the_DT
inclusion_NN
in_PIN
the_DT
annually_RB
by_PIN
the_DT
Remuneration_NOMZ
Committee_NN
,_,
reduces_VPRT
to_PIN
two-thirds_NN
of_PIN
this_DEMO
amount_NN
Annual_JJ
Review_NN
of_PIN
a_DT
graph_NN
showing_VBG [PRIV] [WZPRES]
total_JJ
taking_VBG
account_NN
also_RB
of_PIN
market_NN
should_NEMD [SPAU]
there_RB
be_VB [BEMA]
a_DT
surviving_VBG
spouse_NN
or_CC
shareholder_NN
return_NN
TSR_NN
over_IN
a_DT
five_CD
year_NN
competitiveness_NOMZ
:_:
other_JJ
dependent_JJ
:_:
any_QUAN
member_NN
may_POMD
period_NN
in_PIN
respect_NN
of_PIN
a_DT
holding_GER
of_PIN
the_DT
choose_VB
higher_JJ
or_CC
lower_JJ
levels_NN
of_PIN
survivors_NN
Companys_NN
shares_NN
,_,
plotted_VBN [PASTP]
against_PIN
TSR_NN
in_PIN
short_JJ
term_NN
bonus_NN
:_:
pensions_NN
at_PIN
retirement_NOMZ
,_,
subject_JJ
to_PIN
respect_NN
of_PIN
a_DT
hypothetical_JJ
holding_GER
of_PIN
shares_NN
of_PIN
Inland_NN
Revenue_NN
limits_NN
,_,
in_PIN
return_NN
for_PIN
an_DT
a_DT
similar_JJ
kind_NN
and_PHC
number_NN
by_PIN
reference_NN
to_PIN
The_DT
Chief_NN
Executive_NN
is_VPRT [BEMA]
eligible_PRED
for_PIN
an_DT
adjustment_NOMZ
to_PIN
their_TPP3
own_JJ
pension_NN
of_PIN
which_WDT [PIRE]
a_DT
broad_JJ
equity_NOMZ
market_NN
index_NN
is_VPRT [BEMA]
annual_JJ
bonus_NN
related_VBN [WZPAST]
solely_RB
to_PIN
the_DT
equivalent_JJ
actuarial_JJ
value_NN
:_:
pensions_NN
calculated_VBN [PRIV]
._.
This_DEMP
illustrates_VPRT
the_DT
Companys_NN
achievement_NOMZ
of_PIN
the_DT
targeted_VBN
are_VPRT [BEMA]
also_RB
payable_PRED
to_PIN
dependent_JJ
children_NN
:_:
TSR_NN
performance_NN
against_PIN
the_DT
broad_JJ
equity_NOMZ
performance_NN
of_PIN
earnings_GER
per_PIN
share_NN
:_:
the_DT
pensions_NN
in_PIN
payment_NOMZ
are_VPRT [PASS]
increased_VBN
market_NN
index_NN
selected_VBN
._.
For_PIN
the_DT
purposes_NN
of_PIN
bonus_NN
payable_JJ
is_VPRT [BEMA]
on_PIN
a_DT
scale_NN
of_PIN
0-100_CD
%_NN
of_PIN
annually_RB
in_PIN
line_NN
with_PIN
inflation_NOMZ
,_,
as_IN
this_DEMO
graph_NN
,_,
set_VBN [PASTP]
out_PIN
below_PLACE
,_,
we_FPP1
have_VPRT [PEAS]
selected_VBN
salary_NN
and_CC
50_CD
%_NN
of_PIN
salary_NN
is_VPRT [BEMA]
payable_PRED
for_PIN
measured_VBN
by_PIN
the_DT
UK_NN
Retail_NN
Prices_NN
the_DT
FTSE_NN
100_CD
Index_NN
as_IN
the_DT
appropriate_JJ
index_NN
._.
the_DT
achievement_NOMZ
of_PIN
target_NN
performance_NN
:_:
Index_NN
,_,
up_RB
to_PIN
a_DT
maximum_NN
of_PIN
5_CD
%_NN
:_:
as_IN
referred_VBN
to_TO
above_PLACE
,_,
this_DEMP
is_VPRT [PASS]
derived_VBN
from_PIN
the_DT
budget_NN
set_VBN [WZPAST]
by_PIN
the_DT
Board_NN
and_CC
takes_VPRT
In_PIN
respect_NN
of_PIN
UK_NN
Executive_NN
Directors_NN
into_PIN
account_NN
external_JJ
expectations_NOMZ
of_PIN
whose_WPS [PIRE]
pensionable_JJ
earnings_GER
are_VPRT [BEMA]
capped_JJ
performance_NN
:_:
by_PIN
the_DT
earnings_GER
limit_NN
imposed_VBN [WZPAST]
by_PIN
the_DT
Finance_NN
Act_NN
1989_CD
,_,
unapproved_JJ
defined_VBN
The_DT
Deputy_NN
Chairman_NN
was_VBD [BEMA]
also_RB
eligible_JJ
contribution_NOMZ
schemes_NN
are_VPRT [PASS]
made_VBN
Graph_NN
showing_VBG [PRIV] [WZPRES]
total_JJ
shareholder_NN
return_NN
for_PIN
this_DEMO
annual_JJ
bonus_NN
related_VBN [WZPAST]
solely_RB
to_PIN
available_JJ
:_:
currently_RB
,_,
only_DWNT
the_DT
Chief_NN
1_CD
January_NN
1999_CD
31_CD
December_NN
2003_CD
earnings_GER
per_PIN
share_NN
for_PIN
that_DEMO
part_NN
of_PIN
2003_CD
Financial_NN
Officer_NN
is_VPRT [BYPA]
affected_VBN
by_PIN
this_DEMO
limit_NN
:_:
AstraZeneca_NN
during_PIN
which_WDT [PIRE]
he_TPP3
served_VBD
as_IN
an_DT
Executive_NN
the_DT
Company_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_TO
pay_VB
annually_RB
FTSE100_CD
Director_NN
1_CD
January_NN
2003_CD
until_IN
31_CD
August_NN
50_CD
%_NN
of_PIN
base_NN
salary_NN
in_PIN
excess_NN
of_PIN
the_DT
140_CD
2003_CD
:_:
statutory_JJ
earnings_GER
cap_NN
for_PIN
the_DT
pension_NN
120_CD
and_CC
associated_VBN
tax_NN
liability_NOMZ
,_,
with_PIN
the_DT
100_CD
The_DT
Chief_NN
Financial_NN
Officer_NN
is_VPRT [BEMA]
eligible_JJ
intention_NOMZ
of_PIN
providing_VBG
equivalence_NN
of_PIN
for_PIN
an_DT
annual_JJ
bonus_NN
related_VBN [WZPAST]
to_PIN
the_DT
benefits_NN
with_PIN
non-capped_JJ
UK_NN
Executive_NN
80_CD
achievement_NOMZ
of_PIN
both_DT
the_DT
targeted_VBN
Directors_NN
:_:
if_COND
this_DEMP
does_VPRT
not_XX0
provide_VB
60_CD
performance_NN
of_PIN
earnings_GER
per_PIN
share_NN
equivalence_NN
,_,
the_DT
Company_NN
has_VPRT [PEAS]
agreed_VBN [SUAV] [PUBV]
to_PIN
Jan_NN
99_CD
Jan_NN
00_CD
Jan_NN
01_CD
Jan_NN
02_CD
Jan_NN
03_CD
Dec_NN
03_CD
and_CC
the_DT
achievement_NOMZ
of_PIN
performance_NN
make_VPRT
up_RP
the_DT
difference_NN
:_:
the_DT
Company_NN
Source_NN
:_:
Thomson_NN
Financial_NN
Datastream_NN
measures_VPRT
relevant_JJ
to_PIN
his_TPP3
particular_JJ
area_NN
contribution_NOMZ
in_PIN
2003_CD
in_PIN
respect_NN
of_PIN
the_DT
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
21_CD
Summary_NN
financial_JJ
review_NN
as_IN
Nexium_NN
,_,
Crestor_NN
,_,
Symbicort_NN
and_PHC
Seroquel_NN
._.
The_DT
purpose_NN
of_PIN
the_DT
summary_NN
financial_JJ
review_NN
,_,
We_FPP1
continue_VPRT
to_TO
have_VB
operations_NOMZ
through_PIN
together_RB
with_PIN
the_DT
therapy_NN
area_NN
review_NN
is_VPRT
to_TO
However_CONJ
,_,
cost_NN
containment_NOMZ
initiatives_NN
have_VPRT
Astra_NN
Tech_NN
medical_JJ
equipment_NOMZ
and_CC
Salick_JJ
provide_VPRT
understanding_GER
and_PHC
analysis_NN
of_PIN
our_FPP1
restricted_VBN
underlying_VBG
cost_NN
growth_NN
in_PIN
these_DEMO
Health_NN
Care_NN
healthcare_NN
services_NN
and_PHC
results_NN
for_PIN
the_DT
year_NN
2003_CD
and_CC
of_PIN
the_DT
progress_NN
areas_NN
to_TO
just_EMPH
under_IN
6_CD
%_NN
._.
through_PIN
our_FPP1
non-core_JJ
joint_JJ
venture_NN
,_,
Advanta_NN
._.
In_PIN
the_DT
year_NN
we_FPP1
disposed_VBD
of_PIN
the_DT
Quorn_NN
Continued_VBD
good_JJ
performance_NN
from_PIN
newer_JJ
business_NOMZ
,_,
Marlow_NN
Foods_NN
._.
Our_FPP1
operations_NOMZ
are_VPRT [PASS]
focused_VBN
on_PIN
prescription_NOMZ
products_NN
should_NEMD
deliver_VB
strong_JJ
sales_NN
and_PHC
pharmaceuticals_NN
and_CC
more_EMPH
than_PIN
97_CD
%_NN
of_PIN
our_FPP1
profit_NN
growth_NN
over_IN
the_DT
next_JJ
several_QUAN
years_NN
as_IN
Geographic_JJ
analysis_NN
sales_NN
are_VPRT [PASS]
made_VBN
in_PIN
that_DEMO
sector_NN
._.
Sales_NN
of_PIN
the_DT
impact_NN
of_PIN
generic_JJ
erosion_NN
on_PIN
the_DT
business_NOMZ
In_PIN
the_DT
US_FPP1
,_,
sales_NN
declined_VBD
by_PIN
6_CD
%_NN
for_PIN
the_DT
full_JJ
pharmaceutical_JJ
products_NN
tend_VPRT
to_TO
be_VB [SPAU]
relatively_RB
diminishes_VPRT
._.
We_FPP1
believe_VPRT [PRIV]
that_THVC
our_FPP1
financial_JJ
year_NN
but_CC
,_,
excluding_VBG [PRESP]
the_DT
three_CD
products_NN
which_WDT [WHOBJ]
insensitive_JJ
to_PIN
general_JJ
economic_JJ
performance_NN
over_IN
this_DEMO
period_NN
is_VPRT [BEMA]
likely_PRED
to_TO
rank_VB
faced_VBN
generic_JJ
erosion_NN
Losec_NN
Prilosec_NN
,_,
circumstances_NN
in_PIN
the_DT
short_JJ
term_NN
._.
They_TPP3
are_VPRT [BEMA]
amongst_PIN
the_DT
best_JJ
in_PIN
the_DT
global_JJ
peer_VPRT
group_NN
of_PIN
Zestril_NN
and_PHC
Nolvadex_NN
increased_VBD
36_CD
%_NN
._.
more_EMPH
directly_RB
influenced_VBN
by_PIN
medical_JJ
needs_NN
large_JJ
pharmaceutical_JJ
companies_NN
._.
Growth_NN
products_NN
with_PIN
strong_JJ
performances_NN
and_CC
are_VPRT [SPAU] [BYPA]
generally_RB
financed_VBN
by_PIN
health_NN
included_VBD
Nexium_NN
up_IN
62_CD
%_NN
,_,
Seloken_NN
insurance_NN
schemes_NN
or_CC
national_JJ
healthcare_NN
Results_NN
of_PIN
operations_NOMZ
Toprol-XL_NN
up_IN
47_CD
%_NN
and_PHC
Seroquel_NN
up_IN
22_CD
%_NN
._.
Results_NN
described_VBD
in_PIN
this_DEMO
section_NOMZ
exclude_VPRT
the_DT
addition_NOMZ
,_,
Iressa_NN
and_PHC
Crestor_NN
were_VBD [PASS]
launched_VBN
in_PIN
effects_NN
of_PIN
exchange_NN
rate_NN
movements_NOMZ
unless_COND
the_DT
US_FPP1
in_PIN
2003_CD
._.
Our_FPP1
operating_GER
results_NN
in_PIN
the_DT
short_JJ
term_NN
and_ANDC
otherwise_CONJ
stated_VBN [PUBV]
to_TO
reflect_VB [PRIV]
underlying_VBG
long_JJ
term_NN
can_POMD
be_VB [BYPA]
affected_VBN
by_PIN
a_DT
number_NN
of_PIN
performance_NN
._.
Sales_NN
in_PIN
Europe_NN
increased_VBD
2_CD
%_NN
for_PIN
the_DT
full_JJ
year_NN
,_,
factors_NN
other_JJ
than_PIN
normal_JJ
competition_NOMZ
:_:
as_IN
strong_JJ
sales_NN
growth_NN
for_PIN
Nexium_NN
up_IN
55_CD
%_NN
,_,
Sales_NN
Symbicort_NN
up_IN
53_CD
%_NN
,_,
Seroquel_NN
up_IN
40_CD
%_NN
and_PHC
exposure_NN
to_PIN
currency_NN
fluctuations_NOMZ
:_:
After_IN
the_DT
effects_NN
of_PIN
changing_VBG
product_NN
mix_NN
,_,
the_DT
oncology_NN
products_NN
up_IN
18_CD
%_NN
more_EMPH
than_PIN
the_DT
risk_NN
of_PIN
loss_NN
or_CC
expiration_NOMZ
of_PIN
patents_NN
and_CC
excluding_VBG
the_DT
effects_NN
of_PIN
exchange_NN
,_,
our_FPP1
offset_VBN
declines_NN
in_PIN
Losec_NN
Prilosec_NN
,_,
Zestril_NN
and_CC
and_CC
the_DT
potential_JJ
adverse_JJ
affect_VB
on_PIN
sales_NN
underlying_VBG [WZPRES]
sales_NN
remained_VBD
virtually_RB
Pulmicort_NN
._.
Sales_NN
volumes_NN
increased_VBN [WZPAST]
by_PIN
5_CD
%_NN
volumes_NN
and_PHC
prices_NN
from_PIN
generic_JJ
unchanged_JJ
._.
Our_FPP1
sales_NN
performance_NN
was_VBD
but_CC
overall_JJ
prices_NN
were_VBD [BEMA]
lower_PRED
by_PIN
3_CD
%_NN
._.
competition_NOMZ
:_:
affected_VBN [PASTP]
by_PIN
the_DT
loss_NN
of_PIN
$_$
3.0_CD
billion_CD
underlying_VBG
Performance_NN
in_PIN
Europe_NN
was_VBD [SPAU] [PASS]
also_RB
affected_VBN
the_DT
rate_NN
of_PIN
growth_NN
and_PHC
costs_NN
associated_VBN
sales_NN
in_PIN
Losec_NN
Prilosec_NN
,_,
Zestril_NN
and_PHC
Nolvadex_NN
by_PIN
the_DT
significant_JJ
increase_NN
in_PIN
movements_NOMZ
of_PIN
with_PIN
new_JJ
product_NN
launches_NN
,_,
the_DT
timings_GER
which_WDT [WHSUB]
was_VBD [BYPA]
compensated_VBN
by_PIN
strong_JJ
products_NN
between_PIN
countries_NN
,_,
usually_RB
from_PIN
of_PIN
those_DEMO
launches_NN
and_CC
the_DT
risk_NN
that_TOBJ
such_JJ
performances_NN
elsewhere_RB
in_PIN
the_DT
portfolio_NN
._.
In_PIN
southern_JJ
Europe_NN
where_RB
prices_NN
tend_VPRT
to_TO
be_VB [BEMA]
new_JJ
products_NN
do_VPRT
not_XX0
succeed_VB
as_IN
particular_JJ
,_,
underlying_VBG
sales_NN
for_PIN
key_JJ
growth_NN
lower_JJ
than_PIN
in_PIN
northern_JJ
Europe_NN
._.
anticipated_VBN [PRIV]
:_:
and_ANDC
and_CC
launch_NN
products_NN
increased_VBN [WZPAST]
by_PIN
$_$
2.4_CD
billion_CD
the_DT
adverse_JJ
impact_NN
on_PIN
pharmaceutical_JJ
up_IN
45_CD
%_NN
to_TO
$_$
8.2_CD
billion_CD
._.
Sales_NN
in_PIN
Japan_NN
were_VBD [BEMA]
up_RB
14_CD
%_NN
for_PIN
the_DT
full_JJ
year_NN
,_,
prices_NN
as_CONJ
a_NULL
result_NULL
of_PIN
the_DT
regulatory_JJ
as_CONJ
a_NULL
result_NULL
of_PIN
increases_NN
in_PIN
Losec_NN
up_IN
39_CD
%_NN
,_,
environment_NOMZ
._.
Gastrointestinal_NN
is_VPRT [BEMA]
still_RB
our_FPP1
largest_JJ
therapy_NN
Seroquel_NN
up_IN
67_CD
%_NN
and_CC
a_DT
strong_JJ
oncology_JJ
area_NN
,_,
accounting_VBG [PRESP]
for_PIN
over_IN
31_CD
%_NN
of_PIN
total_JJ
sales_NN
portfolio_NN
up_RB
16_CD
%_NN
._.
Sales_NN
in_PIN
the_DT
rest_NN
of_PIN
the_DT
Over_IN
the_DT
longer_JJ
term_NN
,_,
the_DT
success_NN
of_PIN
our_FPP1
down_RP
from_PIN
over_IN
37_CD
%_NN
in_PIN
2002_CD
:_:
continued_JJ
world_NN
grew_VBD
by_PIN
16_CD
%_NN
._.
research_NN
and_PHC
development_NOMZ
is_VPRT [BEMA]
crucial_PRED
._.
In_PIN
strong_JJ
growth_NN
from_PIN
Nexium_NN
,_,
where_RB
sales_NN
common_JJ
with_PIN
other_JJ
pharmaceutical_JJ
grew_VBN
by_PIN
62_CD
%_NN
to_TO
$_$
3.3_CD
billion_CD
,_,
restricted_VBN
the_DT
Operating_GER
margin_NN
and_CC
retained_VBD
profit_NN
companies_NN
we_FPP1
devote_VPRT
substantial_JJ
resources_NN
declines_VPRT
seen_VBN [PRIV]
in_PIN
the_DT
Losec_NN
Prilosec_NN
area_NN
._.
Underlying_JJ
operating_GER
profit_NN
declined_VBD
by_PIN
11_CD
%_NN
to_PIN
R&D_NN
,_,
the_DT
benefit_NN
of_PIN
which_WDT [PIRE]
emerges_VPRT
over_IN
although_CONC
exchange_NN
effects_NN
reduced_VBD
the_DT
the_DT
long_JJ
term_NN
and_CC
carries_VPRT
considerable_JJ
In_PIN
Cardiovascular_NN
,_,
Crestor_NN
sales_NN
were_VBD
$_$
129_CD
reported_VBN [PUBV]
decline_NN
to_PIN
6_CD
%_NN
._.
Operating_VBG
margin_NN
uncertainty_NN
as_IN
to_PIN
whether_IN
it_PIT
will_PRMD
generate_VB
million_CD
for_PIN
the_DT
full_JJ
year_NN
and_PHC
Seloken_NN
Toprol-XL_NN
fell_VBD
from_PIN
24.4_CD
%_NN
to_PIN
21.8_CD
%_NN
._.
sales_NN
exceeded_VBD
the_DT
$_$
1_CD
billion_CD
mark_NN
for_PIN
the_DT
improved_VBN
primarily_RB
as_CONJ
a_NULL
result_NULL
of_PIN
lower_JJ
first_JJ
time_NN
up_RP
38_CD
%_NN
to_TO
$_$
1,280_CD
million_CD
:_:
these_DEMO
payments_NOMZ
to_PIN
Merck_NN
._.
Aggregate_JJ
R&D_NN
and_CC
In_PIN
the_DT
last_JJ
two_CD
years_NN
,_,
our_FPP1
key_JJ
challenge_NN
has_VPRT
performances_NN
more_EMPH
than_PIN
offset_VB
the_DT
50_CD
%_NN
SG&A_NN
grew_VBD
by_PIN
just_EMPH
under_IN
6_CD
%_NN
with_PIN
spending_GER
been_VBN
to_TO
effect_VB
a_DT
portfolio_NN
transformation_NOMZ
decline_NN
in_PIN
Zestril_NN
sales_NN
resulting_VBG [WZPRES]
in_PIN
an_DT
overall_JJ
including_VBG
several_QUAN
up-front_JJ
payments_NOMZ
for_PIN
whereby_OSUB
sales_NN
lost_VBD
to_PIN
patent_NN
expiries_NN
are_VPRT
underlying_VBG
performance_NN
up_IN
3_CD
%_NN
._.
collaboration_NOMZ
agreements_NOMZ
,_,
costs_NN
of_PIN
the_DT
replaced_VBN
by_PIN
new_JJ
products_NN
and_CC
a_DT
new_JJ
launches_NN
of_PIN
Crestor_NN
and_CC
some_QUAN
field_NN
force_NN
product_NN
portfolio_NN
created_VBN
._.
In_PIN
2003_CD
,_,
the_DT
effect_NN
Despite_PIN
the_DT
generic_JJ
erosion_NN
of_PIN
Nolvadex_NN
in_PIN
increases_NN
in_PIN
Europe_NN
and_PHC
Japan_NN
._.
of_PIN
this_DEMO
product_NN
portfolio_NN
transformation_NOMZ
and_CC
the_DT
US_FPP1
,_,
Oncology_NN
sales_NN
increased_VBN [WZPAST]
by_PIN
8_CD
%_NN
with_PIN
prioritisation_NOMZ
is_VPRT [SPAU] [BYPA]
clearly_RB
demonstrated_VBN [PRIV]
by_PIN
the_DT
Arimidex_NN
up_IN
46_CD
%_NN
to_TO
$_$
519_CD
million_CD
,_,
Iressa_NN
up_IN
Other_JJ
income_NN
was_VBD
$_$
43_CD
million_CD
lower_JJ
fact_NN
that_TOBJ
an_DT
underlying_VBG
$_$
3.0_CD
billion_CD
of_PIN
sales_NN
227_CD
%_NN
to_TO
$_$
228_CD
million_CD
and_CC
Casodex_NN
up_IN
22_CD
%_NN
principally_RB
due_JJ
to_PIN
the_DT
gain_NN
on_PIN
disposal_NN
lost_VBN [WZPAST]
to_PIN
generic_JJ
competition_NOMZ
Losec_NN
Prilosec_NN
,_,
to_TO
$_$
854_CD
million_CD
all_QUAN
mitigating_VBG
the_DT
fall_NN
in_PIN
of_PIN
Sular_NN
in_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2002_CD
._.
Zestril_NN
and_PHC
Nolvadex_NN
have_VPRT [PEAS]
been_VBN [BEMA]
Nolvadex_JJ
sales_NN
down_IN
66_CD
%_NN
to_TO
$_$
178_CD
million_CD
._.
Net_JJ
interest_NN
and_PHC
dividend_NN
income_NN
was_VBD [BYPA]
compensated_VBN
by_PIN
the_DT
performance_NN
of_PIN
our_FPP1
key_JJ
Neuroscience_NN
growth_NN
was_VBD [BEMA]
12_CD
%_NN
driven_VBN [WZPAST]
by_PIN
$_$
91_CD
million_CD
for_PIN
the_DT
year_NN
,_,
benefiting_VBG [PRESP]
in_PIN
growth_NN
and_PHC
launch_NN
products_NN
._.
Sales_NN
from_PIN
a_DT
27_CD
%_NN
increase_NN
in_PIN
Seroquel_NN
sales_NN
whilst_OSUB
comparison_NN
with_PIN
2002_CD
as_IN
several_QUAN
small_JJ
these_DEMO
growth_NN
and_PHC
launch_NN
products_NN
amounted_VBD
Respiratory_NN
and_PHC
Inflammation_NOMZ
improved_VBN [WZPAST]
by_PIN
exchange_NN
and_PHC
market_NN
revaluation_NOMZ
losses_NN
to_TO
$_$
8.2_CD
billion_CD
in_PIN
2003_CD
._.
15_CD
%_NN
,_,
with_PIN
the_DT
most_EMPH
significant_JJ
performance_NN
were_VBD [BEMA]
absent_PRED
in_PIN
2003_CD
._.
from_PIN
Symbicort_NN
up_IN
61_CD
%_NN
._.
Increased_VBN
investment_NOMZ
has_VPRT [PEAS]
continued_VBN
in_PIN
R&D_NN
The_NN
effective_JJ
tax_NN
rate_NN
for_PIN
the_DT
year_NN
was_VBD [BEMA]
27.2_CD
%_NN
and_CC
in_PIN
selling_GER
and_PHC
marketing_GER
activities_NOMZ
._.
In_PIN
both_DT
Although_CONC
wholesaler_NN
stocking_VBG [WZPRES]
patterns_NN
compared_VBN [WZPAST]
to_PIN
26.8_CD
%_NN
in_PIN
2002_CD
._.
In_PIN
the_DT
fourth_JJ
areas_NN
,_,
prioritisation_NOMZ
of_PIN
resources_NN
across_PLACE
the_DT
continue_VPRT
to_TO
have_VB
an_DT
impact_NN
on_PIN
the_DT
quarterly_JJ
quarter_NN
we_FPP1
concluded_VBD [PRIV]
a_DT
negotiated_VBN
portfolio_NN
is_VPRT [SPAU] [PASS]
actively_RB
managed_VBN
to_TO
avoid_VB
phasing_VBG
of_PIN
sales_NN
,_,
for_PIN
the_DT
year_NN
as_IN
a_DT
whole_NN
we_FPP1
settlement_NOMZ
with_PIN
the_DT
UK_NN
and_CC
the_DT
US_FPP1
committing_VBG [WZPRES]
resources_NN
before_IN
opportunities_NOMZ
estimate_VPRT [PRIV]
that_THVC
changes_NN
in_PIN
excess_JJ
wholesaler_NN
governments_NOMZ
in_PIN
respect_NN
of_PIN
ex-Zeneca_NN
are_VPRT [BEMA]
clear_PRED
._.
R&D_NN
spend_VPRT
was_VBD [SPAU] [PASS]
particularly_RB
focused_VBN
inventories_NN
had_VBD
little_JJ
or_CC
no_SYNE
effect_NN
on_PIN
sales_NN
products_NN
for_PIN
the_DT
years_NN
1987_CD
to_PIN
2001_CD
._.
on_PIN
completing_VBG
the_DT
development_NOMZ
programs_NN
growth_NN
._.
At_PIN
the_DT
year_NN
end_NN
,_,
we_FPP1
estimate_VPRT [PRIV]
that_THVC
for_PIN
Crestor_NN
,_,
Iressa_NN
and_PHC
Exanta_NN
._.
Selling_VBG
and_CC
excess_JJ
wholesaler_NN
inventories_NN
were_VBD
well_RB
Dividend_NN
and_PHC
share_NN
re-purchases_NN
marketing_VBG [WZPRES]
resources_NN
were_VBD [PASS]
prioritised_VBN
to_PIN
under_IN
$_$
100_CD
million_CD
._.
We_FPP1
paid_VBD
a_DT
first_JJ
interim_JJ
dividend_NN
for_PIN
2003_CD
on_PIN
recently_TIME
launched_VBN
and_CC
growth_NN
products_NN
such_JJ
6_CD
October_NN
2003_CD
of_PIN
$_$
0.255_CD
per_PIN
Ordinary_NN
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
22_CD
astrazeneca_NN
._.
com_NN
Summary_NN
financial_JJ
review_NN
continued_VBD
Share_NN
._.
A_DT
second_JJ
interim_JJ
dividend_NN
for_PIN
2003_CD
Sales_NN
$_$
m_CD
Cash_NN
flow_NN
of_PIN
$_$
0.540_CD
per_PIN
Ordinary_NN
Share_NN
has_VPRT [PEAS]
been_VBN [BEMA]
All_QUAN
data_NN
in_PIN
this_DEMO
section_NOMZ
is_VPRT [BEMA]
on_PIN
an_DT
actual_JJ
basis_NN
declared_VBD [PUBV]
,_,
which_WDT [SERE]
the_DT
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
unless_COND
noted_VBN [PRIV]
otherwise_CONJ
._.
will_PRMD
be_VB [PASS]
asked_VBN [SUAV]
to_TO
confirm_VB [PUBV]
as_IN
the_DT
final_JJ
dividend_NN
._.
This_DEMP
,_,
together_RB
with_PIN
the_DT
first_JJ
interim_JJ
dividend_NN
,_,
We_FPP1
continue_VPRT
to_TO
be_VB [BEMA]
a_DT
highly_AMP
cash_NN
generative_JJ
03_CD
18,849_CD
makes_VPRT
a_DT
total_JJ
dividend_NN
of_PIN
$_$
0.795_CD
for_PIN
the_DT
year_NN
._.
We_FPP1
believe_VPRT [PRIV]
our_FPP1
cash_NN
resources_NN
will_PRMD
It_PIT
is_VPRT [BEMA]
our_FPP1
intention_NOMZ
that_TOBJ
dividends_NN
will_PRMD
increase_VB
be_VB [BEMA]
sufficient_PRED
for_PIN
our_FPP1
present_JJ
requirements_NOMZ
and_CC
02_CD
17,841_CD
broadly_RB
in_PIN
line_NN
with_PIN
earnings_GER
growth_NN
whilst_OSUB
includes_VPRT
sufficient_JJ
cash_NN
for_PIN
our_FPP1
existing_VBG
01_CD
16,222_CD
bringing_VBG
dividend_NN
cover_NN
to_PIN
around_PLACE
the_DT
middle_JJ
capital_NN
program_NN
,_,
share_NN
re-purchases_NN
and_CC
of_PIN
the_DT
2-3_CD
times_NN
range_NN
._.
any_QUAN
costs_NN
of_PIN
launching_VBG
new_JJ
products_NN
._.
Profit_NN
$_$
m_CD [BEMA]
In_PIN
2003_CD
,_,
we_FPP1
re-purchased_VBD
27.2_CD
million_CD
Cash_NN
generated_VBD
from_PIN
operating_VBG
activities_NOMZ
Ordinary_NN
Shares_NN
for_PIN
cancellation_NOMZ
at_PIN
a_DT
total_NN
before_IN
exceptional_JJ
cash_NN
outflows_NN
was_VBD
$_$
4,617_CD
cost_NN
of_PIN
$_$
1,154_CD
million_CD
bringing_VBG
the_DT
total_JJ
million_CD
compared_VBN
with_PIN
$_$
5,686_CD
million_CD
in_PIN
2002_CD
._.
03_CD
number_NN
of_PIN
shares_NN
re-purchased_JJ
since_OSUB
the_DT
This_DEMO
decrease_NN
was_VBD [BEMA]
primarily_RB
a_DT
result_NN
of_PIN
a_DT
start_NN
of_PIN
the_DT
re-purchase_JJ
program_NN
in_PIN
1999_CD
$_$
1,101_CD
million_CD
outflow_NN
on_PIN
working_VBG
capital_NN
4,202_CD
to_PIN
92.8_CD
million_CD
at_PIN
a_DT
cumulative_JJ
cost_NN
of_PIN
$_$
3,959_CD
$_$
540_CD
million_CD
in_PIN
debtors_NN
,_,
$_$
430_CD
million_CD
in_PIN
4,202_CD
million_CD
._.
The_DT
Board_NN
has_VPRT [PEAS]
approved_VBN
a_DT
new_JJ
recreditors_NN
and_CC
$_$
131_CD
million_CD
in_PIN
stock_NN
._.
This_DEMP
was_VBD [BEMA]
02_CD
purchase_NN
program_NN
of_PIN
$_$
4_CD
billion_CD
to_TO
be_VB [BEMA]
principally_RB
a_DT
consequence_NN
of_PIN
factors_NN
set_VBN [WZPAST]
out_PIN
4,387_CD
completed_VBN
by_PIN
the_DT
end_NN
of_PIN
2005_CD
,_,
assuming_VBG [PRIV] [PRESP]
in_PIN
the_DT
discussions_NN
on_PIN
stocks_NN
and_PHC
debtors_NN
and_CC
4,037_CD
continued_JJ
market_NN
access_NN
and_CC
the_DT
absence_NN
of_PIN
creditors_NN
above_PLACE
._.
The_DT
stronger_JJ
European_JJ
and_PHC
strategic_JJ
needs_NN
for_PIN
cash_NN
._.
Japanese_JJ
currencies_NN
also_RB
increased_VBD
the_DT
cash_NN
01_CD
flow_NN
effect_NN
compared_VBN [WZPAST]
to_PIN
2002_CD
._.
Cash_NN
4,269_CD
Financial_NN
position_NOMZ
expenditure_NN
on_PIN
exceptional_JJ
items_NN
was_VBD
$_$
391_CD
4,077_CD
All_QUAN
data_NN
in_PIN
this_DEMO
section_NOMZ
is_VPRT [BEMA]
on_PIN
an_DT
actual_JJ
basis_NN
million_CD
compared_VBN
with_PIN
$_$
93_CD
million_CD
in_PIN
2002_CD
,_,
unless_COND
noted_VBN [PRIV]
otherwise_CONJ
._.
following_VBG [PRESP]
the_DT
payment_NOMZ
of_PIN
$_$
355_CD
million_CD
in_PIN
Key_NN
settlement_NOMZ
of_PIN
the_DT
Zoladex_NN
investigation_NOMZ
._.
Tax_NN
Profit_NN
before_IN
exceptional_JJ
items_NN
The_DT
net_JJ
book_NN
value_NN
of_PIN
our_FPP1
assets_NN
increased_VBD
paid_VBN
was_VBD
$_$
886_CD
million_CD
and_CC
includes_VPRT
the_DT
Profit_NN
before_IN
tax_NN
from_PIN
$_$
11,226_CD
million_CD
at_PIN
31_CD
December_NN
2002_CD
transfer_NN
pricing_GER
settlement_NOMZ
._.
R&D_NN
investment_NOMZ
$_$
m_CD
Capital_NN
expenditure_NN
on_PIN
tangible_JJ
fixed_JJ
assets_NN
Capital_NN
expenditure_NN
,_,
including_VBG
new_JJ
fixed_VBN
asset_NN
totalled_VBD
$_$
1,239_CD
million_CD
,_,
with_PIN
major_JJ
investments_NOMZ
and_CC
intangible_JJ
assets_NN
,_,
totalled_VBD
investments_NOMZ
in_PIN
Nexium_NN
manufacturing_GER
and_CC
$_$
1,597_CD
million_CD
._.
Although_CONC
this_DEMP
is_VPRT [BEMA]
similar_PRED
to_TO
cash_VB
Investment_NOMZ
as_IN
%_NN
R&D_NN
facilities_NOMZ
._.
Additions_NOMZ
to_PIN
goodwill_NN
and_PHC
expenditure_NN
in_PIN
2002_CD
,_,
it_PIT
reflects_VPRT [PRIV]
slightly_DWNT
lower_JJ
of_PIN
sales_NN
intangible_JJ
assets_NN
amounted_VBD
to_TO
$_$
113_CD
million_CD
expenditure_NN
on_PIN
tangible_JJ
fixed_JJ
assets_NN
,_,
offset_VBN [PASTP]
by_PIN
03_CD
3,451_CD
18.3_CD
and_CC
fixed_VBN
asset_NN
investment_NOMZ
expenditure_NN
exchange_NN
and_CC
higher_JJ
fixed_JJ
asset_NN
investments_NOMZ
._.
included_VBD
a_DT
$_$
100_CD
million_CD
investment_NOMZ
in_PIN
The_DT
cash_NN
inflow_NN
in_PIN
respect_NN
of_PIN
the_DT
disposal_NN
of_PIN
02_CD
3,069_CD
17.2_CD
Abgenix_NN
Inc._NN
as_IN
part_NN
of_PIN
an_DT
oncology_NN
Marlow_NN
Foods_NN
contributed_VBD
$_$
80_CD
million_CD
in_PIN
the_DT
collaboration_NOMZ
agreement_NOMZ
._.
01_CD
2,687_CD
16.6_CD
exchange_NN
effects_NN
and_CC
underlying_VBG
increases_NN
support_NN
of_PIN
newly_RB
launched_VBN
and_CC
rapidly_RB
After_IN
accounting_VBG
for_PIN
dividends_NN
paid_VBN [WZPAST]
of_PIN
$_$
1,222_CD
growing_VBG
products_NN
offset_VBN [WZPAST]
by_PIN
reductions_NOMZ
in_PIN
million_CD
,_,
net_JJ
share_NN
re-purchases_NN
of_PIN
$_$
1,107_CD
Earnings_GER
per_PIN
Ordinary_NN
Share_NN
$_$
holdings_GER
of_PIN
mature_JJ
products_NN
._.
Underlying_JJ
million_CD
and_CC
exchange_NN
of_PIN
$_$
82_CD
million_CD
,_,
there_EX
is_VPRT
a_DT
debtor_NN
balances_NN
increased_VBD
through_PIN
higher_JJ
$_$
348_CD
million_CD
decrease_NN
in_PIN
net_JJ
cash_NN
funds_NN
,_,
invoice_NN
sales_NN
in_PIN
the_DT
US_FPP1
in_PIN
December_NN
,_,
a_DT
higher_JJ
which_WDT
totalled_VBD
$_$
3,496_CD
million_CD
at_PIN
31_CD
December_NN
03_CD
proportion_NOMZ
of_PIN
sales_NN
from_PIN
Europe_NN
where_RB
2003_CD
._.
1.78_CD
average_JJ
credit_NN
terms_NN
are_VPRT [BEMA]
longer_RB
than_PIN
in_PIN
the_DT
1.78_CD
US_FPP1
and_CC
increased_VBD
pension_NN
prepayments_NOMZ
._.
Creditors_NN
fell_VBD
due_JJ
to_PIN
the_DT
settlement_NOMZ
of_PIN
the_DT
US_FPP1
02_CD
Department_NOMZ
of_PIN
Justice_NN
Zoladex_NN
investigation_NOMZ
1.84_CD
provided_VBN
for_PIN
in_PIN
2002_CD
,_,
the_DT
payment_NOMZ
of_PIN
certain_JJ
1.64_CD
pension_NN
commitments_NOMZ
and_CC
lower_JJ
trade_NN
creditors_NN
offset_VBN [WZPAST]
by_PIN
currency_NN
impacts_NN
._.
01_CD
1.73_CD
1.65_CD
Key_NN
Earnings_GER
per_PIN
share_NN
before_IN
exceptional_JJ
items_NN
Group_NN
earnings_GER
per_PIN
share_NN
statutory_JJ
FRS_NN
3_CD
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
23_CD
Summary_NN
financial_JJ
Auditors_NN
statement_NOMZ
statements_NOMZ
Auditors_NN
statement_NOMZ
to_PIN
the_DT
members_NN
of_PIN
These_DEMO
summary_NN
Financial_NN
Statements_NOMZ
are_VPRT
Basis_NN
of_PIN
opinion_NN
a_DT
summary_NN
of_PIN
information_NOMZ
in_PIN
the_DT
Groups_NN
AstraZeneca_NN
PLC_NN
,_,
pursuant_JJ
to_PIN
section_NOMZ
251_CD
We_FPP1
conducted_VBD
our_FPP1
work_NN
in_PIN
accordance_NN
with_PIN
annual_JJ
Financial_NN
Statements_NOMZ
,_,
Directors_NN
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
Bulletin_NN
1999_CD
6_CD
The_DT
auditors_NN
statement_NOMZ
on_PIN
Report_NN
and_PHC
Directors_NN
Remuneration_NOMZ
Report_NN
We_FPP1
have_VPRT [PEAS]
examined_VBN
the_DT
summary_NN
Financial_NN
the_DT
summary_NN
financial_JJ
statement_NOMZ
issued_VBN [WZPAST]
by_PIN
and_CC
do_VB
not_XX0
contain_VB
sufficient_JJ
information_NOMZ
to_PIN
Statements_NOMZ
set_VBD
out_PIN
on_PIN
pages_NN
24_CD
to_PIN
29_CD
._.
This_DEMO
the_DT
Auditing_GER
Practices_NN
Board_NN
for_PIN
use_NN
in_PIN
the_DT
allow_VB [SUAV]
for_PIN
as_RB
full_JJ
an_DT
understanding_GER
of_PIN
the_DT
statement_NOMZ
is_VPRT [PASS]
made_VBN
solely_RB
to_PIN
the_DT
Companys_NN
UK_NN
._.
Our_FPP1
report_NN
on_PIN
the_DT
Groups_NN
full_JJ
annual_JJ
results_NN
and_PHC
state_NN
of_PIN
affairs_NN
of_PIN
the_DT
Group_NN
members_NN
,_,
as_IN
a_DT
body_NN
,_,
in_PIN
accordance_NN
with_PIN
Financial_NN
Statements_NOMZ
describes_VPRT
the_DT
basis_NN
of_PIN
as_RB
would_PRMD
be_VB [BYPA]
provided_VBN
by_PIN
the_DT
full_JJ
annual_JJ
section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Our_FPP1
our_FPP1
audit_NN
opinion_NN
on_PIN
those_DEMO
Financial_NN
Financial_NN
Statements_NOMZ
,_,
Directors_NN
Report_NN
work_NN
has_VPRT [PEAS]
been_VBN [PASS]
undertaken_VBN
so_OSUB
that_NULL
we_FPP1
might_POMD
Statements_NOMZ
._.
state_NN
to_PIN
the_DT
Companys_NN
members_NN
those_DEMO
Shareholders_NN
requiring_VBG [SUAV] [WZPRES]
more_EMPH
detailed_JJ
matters_NN
we_FPP1
are_VPRT [PASS]
required_VBN [SUAV]
to_PIN
state_NN
to_PIN
them_TPP3
in_PIN
Opinion_NN
information_NOMZ
have_VPRT
the_DT
right_NN
to_TO
obtain_VB
,_,
free_JJ
of_PIN
such_EMPH
a_NULL
statement_NOMZ
and_CC
for_PIN
no_SYNE
other_JJ
purpose_NN
._.
In_PIN
our_FPP1
opinion_NN
the_DT
summary_NN
Financial_NN
charge_NN
,_,
a_DT
copy_NN
of_PIN
the_DT
Groups_NN
last_JJ
full_JJ
Annual_JJ
To_PIN
the_DT
fullest_JJ
extent_NN
permitted_VBN [WZPAST]
by_PIN
law_NN
,_,
we_FPP1
do_VPRT
Statements_NOMZ
are_VPRT [BEMA]
consistent_PRED
with_PIN
the_DT
full_JJ
annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
Information_NOMZ
,_,
available_JJ
not_XX0
accept_VB [PRIV]
or_CC
assume_VB [PRIV]
responsibility_NOMZ
to_PIN
Financial_NN
Statements_NOMZ
,_,
the_DT
Directors_NN
Report_VPRT [PUBV]
from_PIN
the_DT
Secretary_NN
at_PIN
the_DT
registered_JJ
office_NN
of_PIN
anyone_QUPR
other_JJ
than_PIN
the_DT
Company_NN
and_CC
the_DT
and_CC
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
the_DT
Company_NN
._.
Companys_NN
members_NN
as_IN
a_DT
body_NN
,_,
for_PIN
our_FPP1
of_PIN
AstraZeneca_NN
PLC_NN
for_PIN
the_DT
year_NN
ended_VBD
work_NN
,_,
for_PIN
this_DEMO
statement_NOMZ
,_,
or_CC
for_PIN
the_DT
opinions_NN
31_CD
December_NN
2003_CD
and_CC
comply_VB
with_PIN
the_DT
The_DT
summary_NN
Financial_NN
Statements_NOMZ
on_PIN
we_FPP1
have_VPRT [PEAS]
formed_VBN
._.
applicable_JJ
requirements_NOMZ
of_PIN
section_NOMZ
251_CD
of_PIN
pages_NN
24_CD
to_PIN
29_CD
were_VBD [BYPA]
approved_VBN
by_PIN
the_DT
the_DT
Companies_NN
Act_NN
1985_CD
,_,
and_ANDC
the_DT
regulations_NOMZ
Board_NN
of_PIN
Directors_NN
on_PIN
29_CD
January_NN
2004_CD
Respective_NN
responsibilities_NOMZ
of_PIN
Directors_NN
made_VBN [WZPAST]
thereunder_RB
._.
and_ANDC
were_VBD [PASS]
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
:_:
and_ANDC
Auditor_NN
The_DT
Directors_NN
are_VPRT [BEMA]
responsible_PRED
for_PIN
preparing_VBG
29_CD
January_NN
2004_CD
the_DT
Annual_JJ
Review_NN
2003_CD
in_PIN
accordance_NN
with_PIN
applicable_JJ
UK_NN
law_NN
._.
Our_FPP1
responsibility_NOMZ
is_VPRT
KPMG_NN
Audit_NN
Plc_NN
to_TO
report_VB [PUBV]
to_PIN
you_SPP2
our_FPP1
opinion_NN
on_PIN
the_DT
Chartered_NN
Accountants_NN
consistency_NN
of_PIN
the_DT
summary_NN
Financial_NN
Registered_NN
Auditor_NN
Statements_NOMZ
within_PIN
the_DT
Annual_JJ
Review_NN
2003_CD
8_CD
Salisbury_NN
Square_NN
Sir_NN
Tom_NN
McKillop_NN
,_,
Director_NN
with_PIN
the_DT
full_JJ
annual_JJ
Financial_NN
Statements_NOMZ
,_,
the_DT
London_NN
EC4Y_NN
8BB_NN
Directors_NN
Report_NN
and_CC
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
,_,
and_ANDC
its_PIT
compliance_NN
with_PIN
the_DT
relevant_JJ
requirements_NOMZ
of_PIN
section_NOMZ
251_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
the_DT
regulations_NOMZ
made_VBD
thereunder_RB
._.
We_FPP1
also_RB
read_VBD
the_DT
other_JJ
information_NOMZ
contained_VBN [WZPAST]
in_PIN
the_DT
Jonathan_NN
Symonds_NN
,_,
Director_NN
summary_NN
Annual_JJ
Review_NN
and_CC
consider_VB [PRIV]
the_DT
implications_NOMZ
for_PIN
our_FPP1
report_NN
if_COND
we_FPP1
become_VPRT
aware_JJ
of_PIN
any_QUAN
apparent_JJ
misstatements_NOMZ
or_CC
material_NN
inconsistencies_NN
with_PIN
the_DT
summary_NN
Financial_NN
Statements_NOMZ
._.
com_NN
24_CD
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
Before_IN
exceptional_JJ
Exceptional_JJ
2003_CD
items_NN
items_NN
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
Group_NN
turnover_NN
18,849_CD
18,849_CD
Operating_GER
costs_NN
14,938_CD
14,938_CD
Other_JJ
operating_GER
income_NN
200_CD
200_CD
Group_NN
operating_GER
profit_NN
4,111_CD
4,111_CD
Share_NN
of_PIN
operating_VBG
profits_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
Profits_NN
on_PIN
sale_NN
of_PIN
fixed_JJ
assets_NN
Dividend_NN
income_NN
2_CD
2_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
interest_NN
4,113_CD
4,113_CD
Net_JJ
interest_NN
89_CD
89_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
4,202_CD
4,202_CD
Taxation_NOMZ
1,143_CD
1,143_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
after_IN
taxation_NOMZ
3,059_CD
3,059_CD
Attributable_JJ
to_PIN
minorities_NOMZ
23_CD
23_CD
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
3,036_CD
3,036_CD
Dividends_NN
to_PIN
shareholders_NN
1,350_CD
Profit_NN
retained_VBN [WZPAST]
for_PIN
the_DT
financial_JJ
year_NN
1,686_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
$_$
1.78_CD
$_$
1.78_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
basic_JJ
$_$
1.78_CD
$_$
1.78_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
diluted_VBD
$_$
1.78_CD
$_$
1.78_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
1,709_CD
All_QUAN
activities_NOMZ
were_VBD [BEMA]
in_PIN
respect_NN
of_PIN
continuing_VBG
operations_NOMZ
._.
There_EX
were_VBD
no_SYNE
material_NN
differences_NN
between_PIN
reported_VBN [PUBV]
profits_NN
and_PHC
losses_NN
and_CC
historical_JJ
cost_NN
profits_NN
and_PHC
losses_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
._.
Group_NN
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
$_$
m_CD [BEMA]
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
3,036_CD
Foreign_NN
exchange_NN
adjustments_NOMZ
on_PIN
consolidation_NOMZ
1,361_CD
Tax_NN
on_PIN
foreign_JJ
exchange_NN
adjustments_NOMZ
on_PIN
consolidation_NOMZ
66_CD
Translation_NOMZ
differences_NN
on_PIN
foreign_JJ
currency_NN
borrowings_GER
Tax_NN
on_PIN
translation_NOMZ
differences_NN
on_PIN
foreign_JJ
currency_NN
borrowings_GER
Total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
relating_VBG [WZPRES]
to_PIN
the_DT
financial_JJ
year_NN
4,463_CD
$_$
m_JJ
means_NN
millions_NN
of_PIN
US_FPP1
dollars_NN
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
26_CD
Group_NN
balance_NN
sheet_NN
at_PIN
31_CD
December_NN
2003_CD
2002_CD
$_$
m_CD
$_$
m_CD [PASS]
Fixed_VBN
assets_NN
Tangible_JJ
fixed_VBN
assets_NN
7,536_CD
6,597_CD
Goodwill_NN
and_CC
intangible_JJ
assets_NN
2,884_CD
2,807_CD
Fixed_VBN
asset_NN
investments_NOMZ
220_CD
46_CD
10,640_CD
9,450_CD
Current_JJ
assets_NN
Stocks_NN
3,022_CD
2,593_CD
Debtors_NN
5,960_CD
4,845_CD
Short_JJ
term_NN
investments_NOMZ
3,218_CD
3,962_CD
Cash_NN
733_CD
726_CD
12,933_CD
12,126_CD
Total_JJ
assets_NN
23,573_CD
21,576_CD
Creditors_NN
due_JJ
within_PIN
one_CD
year_NN
Short_JJ
term_NN
borrowings_GER
and_PHC
overdrafts_NN
152_CD
202_CD
Current_JJ
instalments_NOMZ
of_PIN
loans_NN
314_CD
Other_JJ
creditors_NN
7,543_CD
7,699_CD
7,695_CD
8,215_CD
Net_JJ
current_JJ
assets_NN
5,238_CD
3,911_CD
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
15,878_CD
13,361_CD
Creditors_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Loans_NN
303_CD
328_CD
Other_JJ
creditors_NN
52 34 355 362_CD
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
2,266_CD
1,773_CD
Net_JJ
assets_NN
13,257_CD
11,226_CD
Capital_NN
and_PHC
reserves_NN
Called-up_JJ
share_NN
capital_NN
423_CD
429_CD
Share_NN
premium_NN
account_NN
449_CD
403_CD
Capital_NN
redemption_NOMZ
reserve_NN
23_CD
16_CD
Merger_NN
reserve_NN
433_CD
433_CD
Other_JJ
reserves_NN
1,401_CD
1,440_CD
Profit_NN
and_PHC
loss_NN
account_NN
10,449_CD
8,451_CD
Shareholders_NN
funds_NN
equity_NOMZ
interests_NN
13,178_CD
11,172_CD
Minority_NOMZ
equity_NOMZ
interests_NN
79_CD
54_CD
Shareholders_NN
funds_NN
and_PHC
minority_NOMZ
interests_NN
13,257_CD
11,226_CD
The_DT
summary_NN
Financial_NN
Statements_NOMZ
on_PIN
pages_NN
24_CD
to_PIN
29_CD
were_VBD [BYPA]
approved_VBN
by_PIN
the_DT
Board_NN
of_PIN
Directors_NN
on_PIN
29_CD
January_NN
2004_CD
and_CC
were_VBD [PASS]
signed_VBN
on_PIN
its_PIT
behalf_NN
by_PIN
:_:
Sir_NN
Tom_NN
McKillop_NN
Jonathan_NN
Symonds_NN
Director_NN
Director_NN
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
27_CD
Statement_NOMZ
of_PIN
Group_NN
cash_NN
flow_NN
for_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003 2002 2001_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cash_NN
flow_NN
from_PIN
operating_VBG
activities_NOMZ
Net_JJ
cash_NN
inflow_NN
from_PIN
trading_GER
operations_NOMZ
4,617_CD
5,686_CD
4,130_CD
Outflow_NN
related_VBN [WZPAST]
to_PIN
exceptional_JJ
items_NN
391_CD
93_CD
368_CD
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
4,226_CD
5,593_CD
3,762_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
Interest_NN
received_VBD
117 142 232_CD
Interest_NN
paid_VBN
32_CD
96_CD
84_CD
Dividends_NN
received_VBD
2_CD
8_CD
Dividends_NN
paid_VBN [WZPAST]
by_PIN
subsidiaries_NN
to_PIN
minority_NOMZ
interests_NN
11_CD
11_CD
76_CD
35_CD
156_CD
Tax_NN
paid_VBD
886 795 792_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
Cash_NN
expenditure_NN
on_PIN
tangible_JJ
fixed_JJ
assets_NN
1,282_CD
1,340_CD
1,385_CD
Cash_NN
expenditure_NN
on_PIN
intangible_JJ
assets_NN
233 268 197_CD
Cash_NN
expenditure_NN
on_PIN
fixed_JJ
asset_NN
investments_NOMZ
120_CD
1_CD
5_CD
Disposals_NN
of_PIN
fixed_JJ
assets_NN
38_CD
66_CD
44_CD
1,597_CD
1,543_CD
1,543_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
Acquisitions_NOMZ
of_PIN
subsidiaries_NN
and_PHC
purchases_NN
of_PIN
minority_NOMZ
interests_NN
44_CD
Disposals_NN
of_PIN
business_NOMZ
operations_NOMZ
80_CD
80_CD
44_CD
Equity_NOMZ
dividends_NN
paid_VBD
to_PIN
shareholders_NN
1,222_CD
1,234_CD
1,236_CD
Net_JJ
cash_NN
inflow_NN
before_IN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
677_CD
2,056_CD
303_CD
Management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
Movement_NOMZ
in_PIN
short_JJ
term_NN
investments_NOMZ
and_CC
fixed_VBN
deposits_NN
net_JJ
771 806 260_CD
Financing_GER
345_CD
118_CD
35_CD
Net_JJ
share_NN
re-purchases_VPRT
1,107_CD
1,154_CD
994_CD
Decrease_NN
in_PIN
cash_NN
in_PIN
the_DT
year_NN
4_CD
22_CD
396_CD
Cash_NN
outflow_NN
inflow_NN
from_PIN
decrease_NN
increase_NN
in_PIN
loans_NN
and_CC
short_JJ
term_NN
borrowings_GER
345_CD
118_CD
35_CD
Cash_NN
outflow_NN
inflow_NN
from_PIN
increase_NN
decrease_NN
in_PIN
short_JJ
term_NN
investments_NOMZ
771 806 260_CD
Change_NN
in_PIN
net_JJ
funds_NN
resulting_VBG [WZPRES]
from_PIN
cash_NN
flows_NN
430 902 691_CD
Exchange_NN
movements_NOMZ
82_CD
75_CD
47_CD
Movement_NOMZ
in_PIN
net_JJ
funds_NN
348 977 738_CD
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
28_CD
Dividends_NN
2003 2002 2001 2003_CD
2002_CD
2001_CD
Per_PIN
Per_PIN
Per_PIN
Share_NN
Share_NN
Share_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
Interim_NN
,_,
paid_VBN [PASTP]
on_PIN
6_CD
October_NN
2003_CD
$_$
0.255_CD
$_$
0.23_CD
$_$
0.23_CD
436 398 405_CD
Second_JJ
interim_NN
,_,
to_TO
be_VB [PASS]
confirmed_VBN [PUBV]
as_IN
final_JJ
,_,
payable_JJ
6_CD
April_NN
2004_CD
$_$
0.540_CD
$_$
0.47_CD
$_$
0.47_CD
914 808 820_CD
$_$
0.795_CD
$_$
0.70_CD
$_$
0.70_CD
1,350_CD
1,206_CD
1,225_CD
Earnings_GER
per_PIN
share_NN
2003 2002 2001_CD
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
before_IN
exceptional_JJ
items_NN
$_$
m_CD [BEMA]
3,036_CD
3,186_CD
3,044_CD
Exceptional_JJ
items_NN
after_IN
tax_NN
$_$
m_CD [BEMA]
350_CD
138_CD
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
$_$
m_CD [BEMA]
3,036_CD
2,836_CD
2,906_CD
Earnings_GER
per_PIN
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
$_$
1.78_CD
$_$
1.84_CD
$_$
1.73_CD
Loss_NN
per_PIN
Ordinary_NN
Share_NN
on_PIN
exceptional_JJ
items_NN
$_$
0.20_CD
$_$
0.08_CD
Earnings_GER
per_PIN
Ordinary_NN
Share_NN
$_$
1.78_CD
$_$
1.64_CD
$_$
1.65_CD
Diluted_VBN
earnings_GER
per_PIN
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
$_$
1.78_CD
$_$
1.84_CD
$_$
1.73_CD
Diluted_VBN
loss_NN
per_PIN
Ordinary_NN
Share_NN
on_PIN
exceptional_JJ
items_NN
$_$
0.20_CD
$_$
0.08_CD
Diluted_VBN
earnings_GER
per_PIN
Ordinary_NN
Share_NN
$_$
1.78_CD
$_$
1.64_CD
$_$
1.65_CD
Weighted_VBN
average_JJ
number_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
issue_NN
for_PIN
basic_JJ
earnings_GER
millions_NN
1,709_CD
1,733_CD
1,758_CD
Dilutive_JJ
impact_NN
of_PIN
share_NN
options_NOMZ
outstanding_JJ
millions_NN
3_CD
23_CD
Diluted_VBN
average_JJ
number_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
1,712_CD
1,735_CD
1,761_CD
There_EX
are_VPRT
no_SYNE
options_NOMZ
,_,
warrants_NN
or_CC
rights_NN
outstanding_JJ
in_PIN
respect_NN
of_PIN
unissued_JJ
shares_NN
except_PIN
for_PIN
employee_NN
share_NN
option_NOMZ
schemes_NN
._.
The_DT
earnings_GER
figures_NN
used_VBN [WZPAST]
in_PIN
the_DT
calculations_NOMZ
above_PLACE
are_VPRT [BEMA]
unchanged_PRED
for_PIN
diluted_JJ
earnings_GER
per_PIN
Ordinary_NN
Share_NN
._.
Earnings_GER
per_PIN
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
have_VPRT [PEAS]
been_VBN [PASS]
calculated_VBN [PRIV]
to_TO
eliminate_VB
the_DT
impact_NN
of_PIN
exceptional_JJ
items_NN
on_PIN
the_DT
results_NN
of_PIN
the_DT
business_NOMZ
._.
com_NN
29_CD
Emoluments_NOMZ
of_PIN
Directors_NN
The_DT
aggregate_JJ
remuneration_NOMZ
,_,
excluding_VBG
pension_NN
contributions_NOMZ
,_,
paid_VBN
to_TO
or_CC
accrued_VBN
for_PIN
all_QUAN
Directors_NN
and_PHC
officers_NN
of_PIN
the_DT
Company_NN
for_PIN
services_NN
in_PIN
all_QUAN
capacities_NOMZ
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2003_CD
was_VBD [BEMA]
11_CD
million_CD
$_$
18_CD
million_CD
including_VBG
250,000_CD
$_$
403,000_CD
to_PIN
the_DT
Chairman_NN
._.
Remuneration_NOMZ
of_PIN
individual_JJ
Directors_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
in_PIN
sterling_GER
and_PHC
US_FPP1
dollars_NN
._.
Among_PIN
those_DEMO
Directors_NN
who_WP [WHSUB]
receive_VPRT
their_TPP3
remuneration_NOMZ
in_PIN
sterling_GER
are_VPRT [BEMA]
the_DT
Chairman_NN
,_,
the_DT
Non-Executive_NN
Deputy_NN
Chairman_NN
,_,
the_DT
senior_JJ
Non-Executive_NN
Director_NN
,_,
the_DT
Chief_NN
Executive_NN
and_CC
the_DT
Chief_NN
Financial_NN
Officer_NN
._.
Salary_NN
Taxable_NN
Total_NN
Total_NN
Total_NN
and_PHC
fees_NN
Bonuses_NN
benefits_NN
Other_JJ
2003 2002 2001_CD
Sterling_GER
000 000 000 000_CD
000 000 000_CD
Percy_NN
Barnevik_NN
250 250 250 250_CD
Hkan_NN
Mogren_NN
461_CD
450_CD
51_CD
284_CD
1,246_CD
1,347_CD
1,104_CD
Sir_NN
Tom_NN
McKillop_NN
885_CD
860_CD
1_CD
44_CD
1,790_CD
1,479_CD
1,304_CD
Jonathan_NN
Symonds_NN
534_CD
451_CD
6_CD
80_CD
1,071_CD
909_CD
815_CD
Sir_NN
Peter_NN
Bonfield_NN
74_CD
74_CD
46_CD
38_CD
John_NN
Buchanan_NN
53_CD
53_CD
33_CD
Jane_NN
Henney_NN
49_CD
49_CD
60_CD
9_CD
Karl_NN
von_NN
der_NN
Heyden_NN
55_CD
55_CD
47_CD
41_CD
Michele_NN
Hooper_NN
19_CD
19_CD
Joe_NN
Jimenez_NN
19_CD
19_CD
Erna_NN
Mller49_NN
49_CD
62_CD
55_CD
Dame_NN
Bridget_NN
Ogilvie_NN
49_CD
49_CD
62_CD
55_CD
Marcus_NN
Wallenberg_NN
46_CD
46_CD
42_CD
38_CD
Former_JJ
Directors_NN
ke_VPRT
Stavling_VBG
81_CD
6_CD
402 489 835 712_CD
Others_NN
621_CD
702_CD
Total_JJ
2,624_CD
1,761_CD
64_CD
810_CD
5,259_CD
5,793_CD
5,123_CD
Relates_VPRT
to_PIN
relocation_NOMZ
allowances_NN
:_:
Payment_NOMZ
for_PIN
pension_NN
related_VBN
tax_NN
liabilities_NOMZ
:_:
Includes_VPRT
settlement_NOMZ
on_PIN
retirement_NOMZ
of_PIN
accrued_VBN
holiday_NN
entitlement_NOMZ
:_:
Includes_VPRT
provision_NN
for_PIN
accommodation_NOMZ
in_PIN
the_DT
UK_NN
:_:
Compensation_NOMZ
payment_NOMZ
and_CC
for_PIN
accommodation_NOMZ
related_VBN
tax_NN
liabilities_NOMZ
:_:
Part_NN
year_NN
only_DWNT
._.
Salary_NN
Taxable_NN
Total_NN
Total_NN
Total_NN
and_PHC
fees_NN
Bonuses_NN
benefits_NN
Other_JJ
2003 2002 2001_CD
US_FPP1
dollars_NN
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
$_$
000_CD
Percy_NN
Barnevik_NN
403 403 373 368_CD
Hkan_NN
Mogren_NN
743_CD
725_CD
82_CD
458_CD
2,008_CD
2,010_CD
1,623_CD
Sir_NN
Tom_NN
McKillop_NN
1,427_CD
1,387_CD
1_CD
71_CD
2,886_CD
2,208_CD
1,918_CD
Jonathan_NN
Symonds_NN
861_CD
727_CD
9_CD
129_CD
1,726_CD
1,357_CD
1,199_CD
Sir_NN
Peter_NN
Bonfield_NN
119_CD
119_CD
68_CD
56_CD
John_NN
Buchanan_NN
86_CD
86_CD
49_CD
Jane_NN
Henney_NN
79_CD
79_CD
90_CD
13_CD
Karl_NN
von_NN
der_NN
Heyden_NN
89_CD
89_CD
70_CD
60_CD
Michele_NN
Hooper_NN
31_CD
31_CD
Joe_NN
Jimenez_NN
31_CD
31_CD
Erna_NN
Mller79_NN
79_CD
93_CD
81_CD
Dame_NN
Bridget_NN
Ogilvie_NN
79_CD
79_CD
93_CD
81_CD
Marcus_NN
Wallenberg_NN
74_CD
74_CD
63_CD
56_CD
Former_JJ
Directors_NN
ke_VPRT
Stavling_VBG
131_CD
9_CD
648_CD
788_CD
1,246_CD
1,047_CD
Others_NN
927_CD
1,032_CD
Total_JJ
4,232_CD
2,839_CD
101_CD
1,306_CD
8,478_CD
8,647_CD
7,534_CD
Relates_VPRT
to_PIN
relocation_NOMZ
allowances_NN
:_:
Payment_NOMZ
for_PIN
pension_NN
related_VBN
tax_NN
liabilities_NOMZ
:_:
Includes_VPRT
settlement_NOMZ
on_PIN
retirement_NOMZ
of_PIN
accrued_VBN
holiday_NN
entitlement_NOMZ
:_:
Includes_VPRT
provision_NN
for_PIN
accommodation_NOMZ
in_PIN
the_DT
UK_NN
:_:
Compensation_NOMZ
payment_NOMZ
and_CC
for_PIN
accommodation_NOMZ
related_VBN
tax_NN
liabilities_NOMZ
:_:
Part_NN
year_NN
only_DWNT
._.
Compensation_NOMZ
payments_NOMZ
to_PIN
Hkan_NN
Mogren_NN
and_PHC
ke_NN
Stavling_GER
were_VBD [BEMA]
225,000_CD
$_$
363,000_CD
and_CC
399,000_CD
$_$
643,000_CD
respectively_RB
and_CC
are_VPRT [PASS]
included_VBN
within_PIN
Other_JJ
in_PIN
the_DT
above_PLACE
tables_NN
._.
com_NN
30_CD
Group_NN
financial_JJ
record_NN
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
1999 2000 2001 2002_CD
2003_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Turnover_NN
and_PHC
profits_NN
Group_NN
turnover_NN
18,257_CD
17,882_CD
16,222_CD
17,841_CD
18,849_CD
Cost_NN
of_PIN
sales_NN
5,849_CD
5,270_CD
4,232_CD
4,520_CD
4,469_CD
Distribution_NOMZ
costs_NN
343 286 122 141_CD
162_CD
Research_NN
and_PHC
development_NOMZ
2,923_CD
2,893_CD
2,773_CD
3,069_CD
3,451_CD
Selling_GER
,_,
general_JJ
and_PHC
administrative_JJ
expenses_NN
6,585_CD
5,691_CD
5,509_CD
6,348_CD
6,856_CD
Other_JJ
income_NN
189 266 368 243_CD
200_CD
Group_NN
operating_GER
profit_NN
2,746_CD
4,008_CD
3,954_CD
4,006_CD
4,111_CD
Group_NN
operating_GER
profit_NN
before_IN
exceptional_JJ
items_NN
3,908_CD
4,330_CD
4,156_CD
4,356_CD
4,111_CD
Exceptional_JJ
items_NN
charged_VBN
to_TO
operating_VBG
profit_NN
1,162_CD
322 202 350_CD
Share_NN
of_PIN
operating_GER
profit_NN
of_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
7_CD
149_CD
Exceptional_JJ
items_NN
776_CD
150_CD
Profits_NN
on_PIN
sale_NN
of_PIN
fixed_JJ
assets_NN
10_CD
Dividend_NN
income_NN
3_CD
8_CD
1_CD
2_CD
Net_JJ
interest_NN
4_CD
135_CD
105_CD
30_CD
89_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
1,959_CD
3,847_CD
4,077_CD
4,037_CD
4,202_CD
Taxation_NOMZ
661_CD
1,560_CD
1,160_CD
1,177_CD
1,143_CD
Profit_NN
on_PIN
ordinary_JJ
activities_NOMZ
after_IN
taxation_NOMZ
1,298_CD
2,287_CD
2,917_CD
2,860_CD
3,059_CD
Attributable_JJ
to_PIN
minorities_NOMZ
1_CD
10_CD
11_CD
24_CD
23_CD
Net_JJ
profit_NN
for_PIN
the_DT
financial_JJ
year_NN
1,297_CD
2,277_CD
2,906_CD
2,836_CD
3,036_CD
Return_NN
on_PIN
sales_NN
Group_NN
operating_GER
profit_NN
before_IN
exceptional_JJ
items_NN
as_IN
a_DT
percentage_NN
of_PIN
sales_NN
21.4_CD
%_NN
24.2_CD
%_NN
25.6_CD
%_NN
24.4_CD
%_NN
21.8_CD
%_NN
Ratio_NN
of_PIN
earnings_GER
to_PIN
fixed_JJ
charges_NN
UK_NN
GAAP_NN
10.1_CD
25.2_CD
42.8_CD
45.6_CD
103.5_CD
At_PIN
31_CD
December_NN
1999 2000 2001 2002_CD
2003_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Balance_NN
sheet_NN
Fixed_VBN
assets_NN
tangible_JJ
and_PHC
intangible_JJ
and_CC
goodwill_NN
9,717_CD
7,908_CD
8,109_CD
9,404_CD
10,420_CD
Fixed_VBN
asset_NN
investments_NOMZ
185_CD
11_CD
23_CD
46_CD
220_CD
Current_JJ
assets_NN
10,393_CD
10,938_CD
10,364_CD
12,126_CD
12,933_CD
Total_JJ
assets_NN
20,295_CD
18,857_CD
18,496_CD
21,576_CD
23,573_CD
Creditors_NN
due_JJ
within_PIN
one_CD
year_NN
7,019_CD
6,897_CD
6,480_CD
8,215_CD
7,695_CD
Total_JJ
assets_NN
less_RB
current_JJ
liabilities_NOMZ
13,276_CD
11,960_CD
12,016_CD
13,361_CD
15,878_CD
Creditors_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
1,202_CD
927 787 362 355_CD
Provisions_NN
for_PIN
liabilities_NOMZ
and_PHC
charges_NN
1,765_CD
1,617_CD
1,600_CD
1,773_CD
2,266_CD
Minority_NOMZ
equity_NOMZ
interests_NN
46_CD
27_CD
43_CD
54_CD
79_CD
Shareholders_NN
funds_NN
equity_NOMZ
interests_NN
10,263_CD
9,389_CD
9,586_CD
11,172_CD
13,178_CD
Shareholders_NN
funds_NN
and_PHC
minority_NOMZ
interests_NN
10,309_CD
9,416_CD
9,629_CD
11,226_CD
13,257_CD
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
1999 2000 2001 2002_CD
2003_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Cash_NN
flow_NN
Net_JJ
cash_NN
inflow_NN
from_PIN
operating_VBG
activities_NOMZ
3,113_CD
4,183_CD
3,762_CD
5,593_CD
4,226_CD
Dividends_NN
received_VBN [WZPAST]
from_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
3_CD
Returns_NN
on_PIN
investments_NOMZ
and_PHC
servicing_GER
of_PIN
finance_NN
29_CD
19_CD
156_CD
35_CD
76_CD
Tax_NN
paid_VBD
1,020_CD
648 792 795 886_CD
Capital_NN
expenditure_NN
and_CC
financial_JJ
investment_NOMZ
2,731_CD
1,426_CD
1,543_CD
1,543_CD
1,597_CD
Acquisitions_NOMZ
and_PHC
disposals_NN
1,978_CD
740_CD
44_CD
80_CD
Equity_NOMZ
dividends_NN
paid_VBD
to_PIN
shareholders_NN
1,216_CD
1,220_CD
1,236_CD
1,234_CD
1,222_CD
Net_JJ
cash_NN
inflow_NN
before_IN
management_NOMZ
of_PIN
liquid_JJ
resources_NN
and_PHC
financing_GER
156_CD
1,648_CD
303_CD
2,056_CD
677_CD
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
In_CONJ
addition_NULL
,_,
shareholders_NN
received_VBD
a_DT
distribution_NOMZ
of_PIN
shares_NN
in_PIN
Syngenta_NN
AG_NN
as_IN
a_DT
dividend_NN
in_PIN
specie_NN
in_PIN
respect_NN
of_PIN
the_DT
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
._.
Zeneca_NN
1999_CD
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
At_PIN
period_NN
end_NN
953_CD
Weighted_JJ
average_NN
for_PIN
period_NN
951_CD
Stock_NN
market_NN
price_NN
per_PIN
25_CD
pence_NN
Ordinary_NN
Share_NN
Highest_NN
pence_NN
3037_CD
Lowest_NN
pence_NN
2406_CD
At_PIN
period_NN
end_NN
pence_NN
3037_CD
For_PIN
the_DT
period_NN
from_PIN
1_CD
January_NN
1999_CD
to_PIN
6_CD
April_NN
1999_CD
Astra_NN
1999_CD
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
At_PIN
period_NN
end_NN
1,643_CD
Weighted_VBN
average_NN
for_PIN
period_NN
1,643_CD
Stock_NN
market_NN
price_NN
per_PIN
Astra_NN
A_NN
Share_NN
Highest_NN
SEK_NN
190_CD
Lowest_NN
SEK_NN
154_CD
At_PIN
period_NN
end_NN
SEK_NN
190_CD
Stock_NN
market_NN
price_NN
per_PIN
Astra_NN
B_NN
Share_NN
Highest_NN
SEK_NN
190_CD
Lowest_NN
SEK_NN
154_CD
At_PIN
period_NN
end_NN
SEK_NN
190_CD
For_PIN
the_DT
period_NN
from_PIN
1_CD
January_NN
1999_CD
to_PIN
6_CD
April_NN
1999_CD
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
32_CD
Shareholder_NN
information_NOMZ
Percentage_NN
analysis_NN
at_PIN
31_CD
December_NN
2003_CD
of_PIN
issued_VBN
share_NN
capital_NN
By_PIN
size_NN
of_PIN
account_NN
2003_CD
No._NN
._.
In_CONJ
addition_NULL
,_,
there_EX
were_VBD
approximately_RB
41,000_CD
holders_NN
of_PIN
American_JJ
Depositary_NN
Receipts_NN
ADRs_NN
representing_VBG [WZPRES]
7.53_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
and_CC
161,000_CD
holders_NN
of_PIN
shares_NN
held_VBN [PRIV]
under_IN
the_DT
VPC_NN
Services_NN
Agreement_NOMZ
representing_VBG [WZPRES]
22.13_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
._.
The_DT
ADRs_NN
,_,
each_QUAN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
equivalent_PRED
to_PIN
one_CD
Ordinary_NN
Share_NN
,_,
are_VPRT [BYPA]
issued_VBN
by_PIN
JPMorgan_NN
Chase_NN
Bank_NN
._.
AstraZenecas_RB
largest_JJ
shareholders_NN
Percentage_NN
of_PIN
issued_VBN
Shareholder_NN
Number_NN
of_PIN
shares_NN
share_VPRT
capital_NN
The_DT
Capital_NN
Group_NN
Companies_NN
,_,
Inc._NN
254,143,676_CD
15.01_CD
%_NN
Investor_NN
AB_NN
91,545,308_CD
5.41_CD
%_NN
Putnam_NN
Investment_NOMZ
Management_NOMZ
,_,
LLC_NN
and_CC
The_DT
Putnam_NN
Advisory_NN
Company_NN
,_,
LLC_NN
52,643,485_CD
3.11_CD
%_NN
Legal_NN
&_CC
General_NN
Investment_NOMZ
Management_NOMZ
Limited_NN
52,518,020_CD
3.10_CD
%_NN
Financial_JJ
calendar_NN
2004_CD
29_CD
April_NN
2004_CD
Annual_JJ
General_NN
Meeting_VBG [WZPRES]
and_CC
announcement_NOMZ
of_PIN
first_JJ
quarter_NN
2004_CD
results_NN
22_CD
July_NN
2004_CD
Announcement_NOMZ
of_PIN
second_JJ
quarter_NN
and_CC
half_DT
year_NN
2004_CD
results_NN
13_CD
August_NN
2004_CD
Record_NN
date_NN
for_PIN
first_JJ
interim_JJ
dividend_NN
2004_CD
20_CD
September_NN
2004_CD
First_NN
interim_JJ
dividend_NN
payment_NOMZ
date_NN
Dividend_NN
payments_NOMZ
The_DT
record_NN
date_NN
for_PIN
the_DT
second_JJ
interim_JJ
dividend_NN
for_PIN
2003_CD
payable_JJ
on_PIN
6_CD
April_NN
2004_CD
in_PIN
the_DT
UK_NN
,_,
the_DT
US_FPP1
and_PHC
Sweden_NN
is_VPRT [BEMA]
20_CD
February_NN
2004_CD
._.
Shares_NN
trade_NN
ex-dividend_NN
on_PIN
the_DT
London_NN
and_PHC
Stockholm_NN
Stock_NN
Exchanges_NN
from_PIN
18_CD
February_NN
2004_CD
and_CC
ADRs_NN
trade_NN
ex-dividend_NN
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
from_PIN
the_DT
same_JJ
date_NN
._.
From_PIN
2004_CD
,_,
dividends_NN
will_PRMD [SPAU]
normally_RB
be_VB [PASS]
paid_VBN
as_IN
follows_VPRT
:_:
First_NN
interim_JJ
:_:
Announced_JJ
end_NN
of_PIN
July_NN
and_CC
paid_VBN
in_PIN
September_NN
Second_NN
interim_NN
:_:
Announced_JJ
end_NN
of_PIN
January_NN
and_CC
paid_VBN
in_PIN
March_NN
The_NN
record_NN
date_NN
for_PIN
the_DT
first_JJ
interim_JJ
dividend_NN
for_PIN
2004_CD
payable_JJ
on_PIN
20_CD
September_NN
2004_CD
in_PIN
the_DT
UK_NN
,_,
the_DT
US_FPP1
and_PHC
Sweden_NN
is_VPRT [BEMA]
13_CD
August_NN
2004_CD
._.
2003_CD
dividend_NN
$_$
pence_NN
SEK_NN
Payment_NOMZ
date_NN
First_NN
interim_JJ
dividend_NN
0.255_CD
15.9_CD
2.07_CD
6_CD
October_NN
2003_CD
Second_JJ
interim_JJ
dividend_NN
0.540_CD
29.4_CD
3.91_CD
6_CD
April_NN
2004_CD
Total_JJ
dividend_NN
0.795_CD
45.3_CD
5.98_CD
AstraZeneca_NN
Annual_JJ
Review_NN
2003_CD
astrazeneca_NN
._.
com_NN
Shareview_NN
The_NN
contents_NN
of_PIN
this_DEMO
AstraZeneca_NN
Annual_JJ
Review_NN
are_VPRT [PASS]
derived_VBN
wholly_RB
and_PHC
exclusively_RB
from_PIN
the_DT
AstraZenecas_NN
shareholders_NN
with_PIN
internet_NN
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
access_NN
may_POMD
visit_VB
www_NN
._.
co._JJ
uk_NN
and_PHC
Information_NOMZ
for_PIN
the_DT
financial_JJ
year_NN
ended_VBD
register_VB
their_TPP3
details_NN
to_TO
create_VB
a_DT
portfolio_NN
._.
31_CD
December_NN
2003_CD
,_,
to_PIN
which_WDT [PIRE]
the_DT
reader_NN
is_VPRT [PASS]
referred_VBN
for_PIN
additional_JJ
analytical_JJ
information_NOMZ
._.
Shareview_NN
is_VPRT [BEMA]
a_DT
free_JJ
and_PHC
secure_JJ
on-line_JJ
service_NN
from_PIN
Lloyds_NN
TSB_NN
Registrars_NN
that_TOBJ
Trade_NN
marks_NN
gives_VPRT
access_NN
to_PIN
shareholdings_GER
including_VBG [WZPRES]
Trade_NN
marks_NN
of_PIN
the_DT
AstraZeneca_NN
group_NN
of_PIN
companies_NN
appear_VPRT [SMP]
throughout_PIN
this_DEMO
document_NOMZ
in_PIN
balance_NN
movements_NOMZ
,_,
indicative_JJ
share_NN
prices_NN
italics_NN
._.
AstraZeneca_NN
,_,
the_DT
AstraZeneca_NN
logotype_NN
and_PHC
information_NOMZ
about_IN
recent_JJ
dividends_NN
._.
and_ANDC
the_DT
AstraZeneca_NN
symbol_NN
are_VPRT [BEMA]
all_QUAN
trade_NN
marks_NN
of_PIN
the_DT
AstraZeneca_NN
group_NN
of_PIN
companies_NN
._.
ShareGift_NN
Use_NN
of_PIN
terms_NN
AstraZeneca_NN
welcomes_VPRT
and_PHC
values_VPRT
all_QUAN
its_PIT
In_PIN
this_DEMO
Annual_JJ
Review_NN
2003_CD
,_,
unless_COND
the_DT
context_NN
shareholders_NN
,_,
no_SYNE
matter_NN
how_RB
many_QUAN
or_CC
how_RB
otherwise_CONJ
requires_VPRT [SUAV]
,_,
AstraZeneca_NN
,_,
the_DT
Group_NN
,_,
the_DT
Company_NN
,_,
we_FPP1
,_,
us_FPP1
and_CC
our_FPP1
refer_VPRT
to_PIN
few_QUAN
shares_NN
they_TPP3
own_VPRT
._.
However_CONJ
,_,
AstraZeneca_NN
PLC_NN
and_CC
its_PIT
consolidated_JJ
entities_NOMZ
._.
shareholders_NN
who_WP [WHSUB]
have_VPRT
only_DWNT
a_DT
small_JJ
number_NN
of_PIN
shares_NN
whose_WPS [WHOBJ]
value_NN
makes_VPRT
it_PIT
Cautionary_JJ
statement_NOMZ
regarding_VBG [WZPRES]
forwardlooking_VBG
statements_NOMZ
uneconomic_JJ
to_TO
sell_VB
them_TPP3
,_,
either_RB
now_TIME
or_CC
at_PIN
In_PIN
order_NN
to_TO
utilise_VB
the_DT
safe_JJ
harbor_NN
provisions_NN
of_PIN
some_QUAN
stage_NN
in_PIN
the_DT
future_NN
,_,
may_POMD
wish_VB
to_PIN
the_DT
US_FPP1
Private_NN
Securities_NOMZ
Litigation_NOMZ
Reform_NN
Act_NN
consider_VPRT [PRIV]
donating_VBG
them_TPP3
to_PIN
charity_NOMZ
through_PIN
1995_CD
,_,
we_FPP1
are_VPRT
providing_VBG
the_DT
following_VBG
cautionary_JJ
statement_NOMZ
:_:
This_DEMO
Annual_JJ
Review_NN
2003_CD
contains_VPRT
ShareGift_NN
,_,
an_DT
independent_JJ
charity_NOMZ
share_NN
certain_JJ
forward-looking_JJ
statements_NOMZ
about_IN
donation_NOMZ
scheme_NN
._.
One_CD
of_PIN
the_DT
advantages_NN
of_PIN
AstraZeneca_NN
._.
Although_CONC
we_FPP1
believe_VPRT [PRIV]
our_FPP1
expectations_NOMZ
the_DT
scheme_NN
is_VPRT
that_DEMO
there_EX
is_VPRT
no_SYNE
gain_NN
or_CC
loss_NN
are_VPRT [PASS]
based_VBN
on_PIN
reasonable_JJ
assumptions_NOMZ
,_,
any_QUAN
forward-looking_JJ
statements_NOMZ
may_POMD
be_VB [BYPA]
influenced_VBN
by_PIN
for_PIN
capital_NN
gains_NN
tax_NN
purposes_NN
on_PIN
gifts_NN
of_PIN
factors_NN
that_TSUB
could_POMD
cause_VB
actual_JJ
outcomes_NN
and_PHC
shares_NN
through_PIN
ShareGift_NN
and_CC
it_PIT
may_POMD [SPAU]
now_TIME
results_VPRT
to_TO
be_VB [BEMA]
materially_RB
different_PRED
from_PIN
those_DEMO
also_RB
be_VB [BEMA]
possible_PRED
to_TO
obtain_VB
income_NN
tax_NN
relief_NN
predicted_VBD [PUBV]
._.
We_FPP1
identify_VPRT
the_DT
forward-looking_JJ
statements_NOMZ
by_PIN
using_VBG
the_DT
words_NN
anticipates_VPRT [PRIV]
,_,
on_PIN
the_DT
donation_NOMZ
._.
Further_JJ
information_NOMZ
about_IN
believes_VPRT [PRIV]
,_,
expects_VPRT [PRIV]
,_,
intends_VPRT [SUAV]
and_CC
similar_JJ
ShareGift_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
on_PIN
its_PIT
website_NN
,_,
expressions_NN
in_PIN
such_JJ
statements_NOMZ
._.
org_NN
,_,
or_CC
by_PIN
contacting_VBG
looking_VBG
statements_NOMZ
are_VPRT [BEMA]
subject_PRED
to_PIN
numerous_JJ
risks_NN
and_PHC
uncertainties_NN
._.
Important_JJ
factors_NN
that_TSUB
could_POMD
ShareGift_VB
on_PIN
020 7337 0501_CD
or_CC
at_PIN
46_CD
cause_NN
actual_JJ
results_NN
to_TO
differ_VB
materially_RB
from_PIN
those_DEMO
Grosvenor_NN
Street_NN
,_,
London_NN
W1K_NN
3HN_NN
._.
More_EMPH
contained_VBN
in_PIN
forward-looking_JJ
statements_NOMZ
,_,
certain_JJ
information_NOMZ
about_IN
the_DT
tax_NN
position_NOMZ
on_PIN
gifts_NN
of_PIN
of_PIN
which_WDT [PIRE]
are_VPRT
beyond_IN
our_FPP1
control_NN
,_,
include_VPRT
,_,
among_PIN
other_JJ
things_NN
:_:
the_DT
loss_NN
or_CC
expiration_NOMZ
of_PIN
patents_NN
,_,
shares_NN
to_PIN
ShareGift_NN
can_POMD
be_VB [PASS]
obtained_VBN
from_PIN
marketing_GER
exclusivity_NOMZ
or_CC
trade_NN
marks_NN
:_:
exchange_NN
the_DT
Inland_NN
Revenue_NN
whose_WPS [WHOBJ]
website_JJ
address_NN
rate_NN
fluctuations_NOMZ
:_:
the_DT
risk_NN
that_TOBJ
R&D_NN
will_PRMD
not_XX0
yield_VB
is_VPRT
www_VB
._.
The_DT
share_NN
new_JJ
products_NN
that_TSUB
achieve_VPRT
commercial_JJ
success_NN
:_:
the_DT
impact_NN
of_PIN
competition_NOMZ
,_,
price_NN
controls_NN
and_CC
transfer_VB
form_NN
needed_VBN
to_TO
make_VB
a_DT
donation_NOMZ
price_NN
reductions_NOMZ
:_:
taxation_NOMZ
risks_NN
:_:
the_DT
risk_NN
of_PIN
may_POMD
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
AstraZeneca_NN
substantial_JJ
product_NN
liability_NOMZ
claims_NN
:_:
the_DT
impact_NN
of_PIN
Registrar_NN
,_,
Lloyds_NN
TSB_NN
Registrars_NN
whose_WPS [WHOBJ]
any_QUAN
failure_NN
by_PIN
third_JJ
parties_NN
to_TO
supply_VB
materials_NN
or_CC
services_NN
:_:
the_DT
risk_NN
of_PIN
delay_NN
to_PIN
new_JJ
product_NN
address_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
on_PIN
the_DT
back_JJ
cover_NN
of_PIN
launches_NN
:_:
the_DT
difficulties_NN
of_PIN
obtaining_VBG
and_CC
this_DEMO
document_NOMZ
._.
ShareGift_NN
is_VPRT [BYPA]
administered_VBN
by_PIN
maintaining_VBG [PUBV]
governmental_JJ
approvals_NN
for_PIN
The_DT
Orr_NN
Mackintosh_NN
Foundation_NOMZ
,_,
registered_VBD
products_NN
:_:
and_ANDC
the_DT
risk_NN
of_PIN
environmental_JJ
liabilities_NOMZ
._.
Statements_NOMZ
of_PIN
competitive_JJ
position_NOMZ
Except_PIN
as_IN
otherwise_CONJ
stated_VBN [PUBV]
,_,
market_NN
information_NOMZ
in_PIN
The_DT
Unclaimed_NN
Assets_NN
Register_NN
this_DEMO
Annual_JJ
Review_NN
2003_CD
regarding_VBG
the_DT
position_NOMZ
of_PIN
our_FPP1
business_NOMZ
or_CC
products_NN
relative_JJ
to_PIN
its_PIT
or_CC
their_TPP3
AstraZeneca_NN
supplies_NN
unclaimed_JJ
dividend_NN
competition_NOMZ
is_VPRT [PASS]
based_VBN
upon_PIN
published_VBN
statistical_JJ
data_NN
to_PIN
the_DT
Unclaimed_NN
Assets_NN
Register_NN
data_NN
for_PIN
the_DT
12_CD
months_NN
ended_VBD
30_CD
September_NN
UAR_NN
which_WDT [WHSUB]
provides_VPRT
investors_NN
who_WP [WHSUB]
have_VPRT
2003_CD
,_,
or_CC
the_DT
month_NN
of_PIN
November_NN
2003_CD
,_,
obtained_VBN [PASTP]
from_PIN
IMS_NN
Health_NN
,_,
a_DT
leading_VBG
supplier_NN
of_PIN
statistical_JJ
lost_VBN
track_NN
of_PIN
shareholdings_GER
with_PIN
an_DT
data_NN
to_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
Except_PIN
as_IN
opportunity_NOMZ
to_TO
search_VB
the_DT
UARs_NN
database_NN
otherwise_CONJ
stated_VBD [PUBV]
,_,
this_DEMO
market_NN
share_NN
and_PHC
industry_NN
of_PIN
unclaimed_JJ
financial_JJ
assets_NN
on_PIN
payment_NOMZ
of_PIN
data_NN
from_PIN
IMS_NN
Health_NN
has_VPRT [PEAS]
been_VBN [BYPA]
derived_VBN
by_PIN
comparing_VBG
our_FPP1
sales_NN
revenue_NN
to_PIN
competitors_NN
and_CC
a_DT
small_JJ
,_,
fixed_JJ
fee_NN
._.
The_DT
UAR_NN
donates_VPRT
part_NN
of_PIN
total_JJ
market_NN
sales_NN
revenues_NN
for_PIN
that_DEMO
period_NN
._.
the_DT
search_NN
fee_NN
to_PIN
charity_NOMZ
._.
The_DT
UAR_NN
can_POMD
be_VB [PASS]
contacted_VBN
at_PIN
Leconfield_NN
House_NN
,_,
Curzon_NN
Statements_NOMZ
of_PIN
growth_NN
rates_NN
Except_PIN
as_IN
otherwise_CONJ
stated_VBN [PUBV]
,_,
growth_NN
rates_NN
in_PIN
this_DEMO
Street_NN
,_,
London_NN
W1J_NN
5JA_NN
and_CC
at_PIN
Annual_JJ
Review_NN
2003_CD
are_VPRT [PASS]
given_VBN
at_PIN
constant_JJ
www_NN
._.
AstraZeneca_NN
website_JJ
Information_NOMZ
on_PIN
our_FPP1
website_NN
,_,
astrazeneca_NN
._.
com_NN
,_,
does_VPRT
not_XX0
form_VB
part_NN
of_PIN
this_DEMO
document_NOMZ
._.
AstraZeneca_NN
PLC_NN
2004_CD
Designed_VBN
by_PIN
Addison_NN
Corporate_NN
Marketing_GER
Ltd_NN
astrazeneca_NN
._.
com_NN
Contact_NN
information_NOMZ
Registered_NN
office_NN
Registrar_NN
and_CC
transfer_VB
office_NN
:_:
and_ANDC
corporate_JJ
headquarters_NN
address_NN
:_:
Lloyds_NN
TSB_NN
Registrars_NN
AstraZeneca_NN
PLC_NN
The_NN
Causeway_NN
15_CD
Stanhope_NN
Gate_NN
Worthing_GER
London_NN
W1K_NN
1LN_NN
West_NN
Sussex_NN
UK_NN
BN99_NN
6DA_NN
Tel_NN
:_:
44_CD
0_CD
20 7304 5000_CD
UK_NN
Fax_NN
:_:
44_CD
0_CD
20 7304 5183_CD
Tel_NN
in_PIN
the_DT
UK_NN
:_:
0870 600 3956_CD
Tel_NN
outside_PLACE
the_DT
UK_NN
:_:
44_CD
0_CD
121 415 7033_CD
R&D_NN
headquarters_NN
address_NN
:_:
AstraZeneca_NN
AB_NN
Swedish_NN
securities_NOMZ
registration_NOMZ
center_NN
:_:
R&D_NN
Headquarters_NN
VPC_NN
AB_NN
SE-151_NN
85_CD
Sdertlje_NN
PO_NN
Box_NN
7822_CD
Sweden_NN
SE-103_NN
97_CD
Stockholm_NN
Tel_NN
:_:
46_CD
0_CD
8_CD
553_CD
260_CD
00_CD
Sweden_NN
Fax_NN
:_:
46_CD
0_CD
8_CD
553_CD
290_CD
00_CD
Tel_NN
:_:
46_CD
0_CD
8_CD
402_CD
9000_CD
Investor_NN
relations_NOMZ
contacts_NN
:_:
US_FPP1
depositary_NN
:_:
UK_NN
and_PHC
Sweden_NN
:_:
As_IN
above_PLACE
or_CC
e-mail_VB
:_:
JPMorgan_NN
Chase_NN
Bank_NN
IR@astrazeneca_NN
._.
com_NN
PO_NN
Box_NN
43013_CD
US_FPP1
:_:
Providence_NN
Investor_NN
Relations_NOMZ
RI_NN
02940-3013_CD
AstraZeneca_NN
Pharmaceuticals_NN
LP_NN
US_FPP1
1800_CD
Concord_NN
Pike_NN
Tel_NN
toll_NN
free_JJ
in_PIN
the_DT
US_FPP1
:_:
888 697 8018_CD
PO_NN
Box_NN
15438_CD
Tel_NN
:_:
1_CD
781 575 4328_CD
Wilmington_NN
fide_NN
19850-5438_CD
US_FPP1
Tel_NN
:_:
1_CD
302 886 3000_CD
Fax_NN
:_:
1_CD
302 886 2972_CD
Delivering_VBG
our_FPP1
values_NN
Corporate_JJ
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
At_PIN
the_DT
heart_NN
of_PIN
our_FPP1
commitment_NOMZ
to_PIN
corporate_JJ
responsibility_NOMZ
are_VPRT
AstraZenecas_NN
core_NN
values_NN
._.
Our_FPP1
continuing_VBG
challenge_NN
is_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
these_DEMO
high_JJ
level_NN
values_NN
are_VPRT [PASS]
translated_VBN
into_PIN
consistent_JJ
and_PHC
appropriate_JJ
actions_NOMZ
and_PHC
behavior_NN
worldwide_NN
._.
This_DEMO
Summary_NN
Report_NN
is_VPRT [PASS]
designed_VBN
to_TO
capture_VB
the_DT
main_JJ
points_NN
of_PIN
our_FPP1
approach_NN
to_TO
managing_VBG
this_DEMO
challenge_NN
and_CC
to_TO
present_VB
a_DT
brief_JJ
overview_NN
of_PIN
our_FPP1
2003_CD
performance_NN
in_PIN
the_DT
three_CD
areas_NN
of_PIN
sustainable_JJ
development_NOMZ
:_:
economic_JJ
,_,
environmental_JJ
and_PHC
social_JJ
responsibility_NOMZ
._.
Detailed_JJ
statistics_NN
and_CC
further_JJ
information_NOMZ
about_IN
our_FPP1
policies_NN
,_,
principles_NN
and_PHC
commitment_NOMZ
are_VPRT [PASS]
provided_VBN
on_PIN
our_FPP1
website_NN
,_,
astrazeneca_NN
._.
com_NN
,_,
which_WDT [SERE]
also_RB
provides_VPRT
a_DT
feedback_NN
facility_NOMZ
._.
AstraZeneca_NN
core_NN
values_NN
:_:
Integrity_NOMZ
and_CC
high_JJ
ethical_JJ
standards_NN
Respect_NN
for_PIN
the_DT
individual_JJ
and_CC
diversity_NOMZ
Openness_NOMZ
,_,
honesty_NN
,_,
trust_NN
and_PHC
support_NN
for_PIN
each_QUAN
other_JJ
Leadership_NN
by_PIN
example_NN
at_PIN
all_QUAN
levels_NN
Chief_NN
Executives_NN
message_NN
01_CD
AstraZeneca_NN
in_PIN
brief_JJ
One_CD
of_PIN
the_DT
worlds_NN
leading_VBG [WZPRES]
pharmaceutical_JJ
companies_NN
Our_FPP1
commitment_NOMZ
02_CD
Turns_VPRT
ideas_NN
into_PIN
innovative_JJ
,_,
effective_JJ
medicines_NN
for_PIN
Our_FPP1
goals_NN
04_CD
important_JJ
areas_NN
of_PIN
healthcare_NN
Economic_NN
performance_NN
06_CD
Powerful_JJ
product_NN
range_NN
including_VBG [WZPRES]
many_QUAN
world_NN
leaders_NN
Environmental_JJ
performance_NN
08_CD
Spends_VPRT
over_IN
$_$
14_CD
million_CD
each_QUAN
working_VBG
day_NN
on_PIN
research_NN
and_PHC
development_NOMZ
Social_NN
performance_NN
10_CD
Corporate_JJ
HQ_NN
London_NN
,_,
UK_NN
:_:
R&D_NN
HQ_NN
Sdertlje_NN
,_,
Performance_NN
summary_NN
16_CD
Sweden_NN
:_:
strong_JJ
presence_NN
in_PIN
key_JJ
US_FPP1
market_NN
Sales_NN
in_PIN
over_IN
100_CD
countries_NN
Manufacturing_GER
in_PIN
20_CD
countries_NN
Research_NN
in_PIN
7_CD
countries_NN
Over_IN
60,000_CD
employees_NN
worldwide_JJ
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
01_CD
Chief_NN
Executives_NN
message_NN
Respect_NN
for_PIN
the_DT
individual_JJ
and_CC
diversity_NOMZ
of_PIN
appropriate_JJ
programs_NN
in_PIN
their_TPP3
areas_NN
We_FPP1
value_VPRT
the_DT
different_JJ
backgrounds_NN
and_CC
of_PIN
responsibility_NOMZ
._.
An_DT
important_JJ
step_NN
in_PIN
skills_NN
that_TOBJ
our_FPP1
global_JJ
workforce_NN
brings_VPRT
to_PIN
2003_CD
was_VBD [BEMA]
the_DT
inclusion_NN
in_PIN
our_FPP1
annual_JJ
our_FPP1
business_NOMZ
and_CC
are_VPRT [PASS]
committed_VBN
to_PIN
compliance_NN
report_NN
by_PIN
senior_JJ
management_NOMZ
ensuring_VBG [SUAV] [PRIV] [WZPRES]
that_THVC
diversity_NOMZ
is_VPRT [BEMA]
appropriately_RB
to_PIN
the_DT
AstraZeneca_NN
Board_NN
the_DT
letter_NN
of_PIN
supported_VBN
in_PIN
the_DT
workplace_NN
at_PIN
all_QUAN
levels_NN
._.
assurance_NN
of_PIN
a_DT
requirement_NOMZ
to_TO
develop_VB
At_PIN
the_DT
end_NN
of_PIN
2003_CD
,_,
we_FPP1
had_VBD
around_PLACE
28_CD
local_JJ
CR_NN
implementation_NOMZ
plans_NN
._.
diversity_NOMZ
programs_NN
in_PIN
place_NN
within_PIN
the_DT
Group_NN
and_CC
a_DT
number_NN
of_PIN
awareness_NOMZ
Our_FPP1
business_NOMZ
is_VPRT [PASS]
focused_VBN
on_PIN
the_DT
discovery_NN
raising_VBG [WZPRES]
initiatives_NN
took_VBD
place_NN
during_PIN
the_DT
and_CC
development_NOMZ
of_PIN
life-saving_NN
and_PHC
year_NN
,_,
mainly_RB
within_PIN
R&D_NN
and_CC
our_FPP1
US_FPP1
life-enhancing_GER
medicines_NN
._.
Historically_NN
,_,
Our_FPP1
reputation_NOMZ
is_VPRT [PASS]
built_VBN
on_PIN
the_DT
trust_NN
and_PHC
business_NOMZ
._.
Further_JJ
work_NN
is_VPRT [PASS]
needed_VBN
to_PIN
the_DT
markets_NN
for_PIN
these_DEMO
therapies_NN
have_VPRT
confidence_NN
of_PIN
all_QUAN
our_FPP1
stakeholders_NN
and_CC
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
benefits_NN
of_PIN
diversity_NOMZ
are_VPRT [PASS]
been_VBN [BEMA]
in_PIN
developed_JJ
countries_NN
but_CC
as_IN
the_DT
is_VPRT [BEMA]
one_CD
of_PIN
AstraZenecas_NN
most_EMPH
valuable_JJ
fully_AMP
recognized_VBN [PRIV]
across_PLACE
the_DT
Group_NN
._.
economies_NN
of_PIN
developing_VBG
countries_NN
assets_NN
._.
Along_IN
with_PIN
our_FPP1
commitment_NOMZ
grow_VB
,_,
new_JJ
markets_NN
for_PIN
our_FPP1
prescription_NOMZ
to_PIN
competitiveness_NOMZ
and_PHC
performance_NN
,_,
Openness_NOMZ
,_,
honesty_NN
,_,
trust_NN
and_PHC
support_NN
medicines_NN
emerge_VPRT
._.
Our_FPP1
strategy_NN
for_PIN
we_FPP1
will_PRMD
continue_VB
to_TO
be_VB [BYPA]
led_VBN
by_PIN
our_FPP1
core_NN
for_PIN
each_QUAN
other_JJ
expansion_NN
in_PIN
these_DEMP
emerging_VBG
markets_NN
is_VPRT
values_NN
to_TO
achieve_VB
sustainable_JJ
success_NN
._.
Our_FPP1
Code_NN
of_PIN
Conduct_NN
has_VPRT [PEAS]
been_VBN [PASS]
revised_VBN
designed_VBN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
through_PIN
timely_JJ
and_PHC
re-published_JJ
during_PIN
the_DT
year_NN
and_CC
a_DT
investment_NOMZ
,_,
we_FPP1
are_VPRT [SPAU] [PASS]
well_RB
placed_VBN
to_TO
meet_VB
Stakeholder_NN
expectations_NOMZ
are_VPRT [BEMA]
constantly_RB
formal_PRED
,_,
confidential_JJ
helpline_NN
procedure_NN
the_DT
needs_NN
of_PIN
patients_NN
in_PIN
these_DEMO
countries_NN
._.
evolving_VBG
and_CC
we_FPP1
continuously_RB
monitor_VPRT
our_FPP1
is_VPRT [BEMA]
now_TIME
in_PIN
place_NN
for_PIN
employees_NN
wishing_VBG [WZPRES]
As_IN
part_NN
of_PIN
this_DEMP
,_,
we_FPP1
are_VPRT [PASS]
committed_VBN
to_PIN
internal_JJ
and_PHC
external_JJ
environment_NOMZ
for_PIN
to_TO
raise_VB
concerns_NN
on_PIN
integrity_NOMZ
issues_NN
or_CC
playing_VBG
a_DT
role_NN
in_PIN
targeting_VBG
improved_JJ
issues_NN
relating_VBG [WZPRES]
to_PIN
our_FPP1
business_NOMZ
that_TSUB
affect_VB
report_NN
inappropriate_JJ
behavior_NN
._.
We_FPP1
also_RB
treatment_NOMZ
of_PIN
the_DT
highest_JJ
priority_NOMZ
or_CC
concern_NN
society_NN
today_TIME
._.
We_FPP1
use_VPRT
a_DT
formal_JJ
concentrated_JJ
on_PIN
reviewing_VBG
and_PHC
refining_VBG
diseases_NN
._.
In_PIN
June_NN
2003_CD
,_,
we_FPP1
opened_VBD
risk_NN
assessment_NOMZ
process_NN
to_TO
identify_VB
both_DT
our_FPP1
corporate_JJ
governance_NN
controls_NN
and_CC
our_FPP1
new_JJ
state_NN
of_PIN
the_DT
art_NN
laboratories_NN
the_DT
opportunities_NOMZ
and_CC
the_DT
challenges_NN
that_TSUB
reporting_VBG [PUBV]
procedures_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
we_FPP1
in_PIN
Bangalore_NN
,_,
India_NN
._.
Work_NN
there_EX
is_VPRT
these_DEMO
issues_NN
present_RB
,_,
and_ANDC
to_TO
plan_VB
the_DT
are_VPRT
meeting_VBG
new_JJ
laws_NN
and_CC
regulatory_JJ
dedicated_VBN
to_TO
finding_VBG [PRIV]
the_DT
first_JJ
new_JJ
actions_NOMZ
needed_VBN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
our_FPP1
response_NN
is_VPRT
requirements_NOMZ
._.
This_DEMP
includes_VPRT
the_DT
ability_NOMZ
treatment_NOMZ
in_PIN
40_CD
years_NN
for_PIN
tuberculosis_NN
,_,
appropriate_JJ
and_PHC
consistent_JJ
._.
Our_FPP1
current_JJ
to_TO
meet_VB
the_DT
appropriate_JJ
executive_NN
one_CD
of_PIN
the_DT
worlds_NN
greatest_JJ
causes_NN
of_PIN
Priority_NOMZ
Action_NOMZ
Plan_NN
is_VPRT [PASS]
shown_VBN [PRIV]
on_PIN
page_NN
4_CD
._.
certification_NOMZ
requirements_NOMZ
of_PIN
the_DT
death_NN
from_PIN
infectious_JJ
disease_NN
._.
Sarbanes-Oxley_NN
legislation_NOMZ
in_PIN
the_DT
US_FPP1
AstraZeneca_NN
will_PRMD
make_VB
any_QUAN
treatment_NOMZ
Corporate_JJ
responsibility_NOMZ
CR_NN
is_VPRT [BEMA]
not_XX0
an_DT
and_CC
the_DT
changes_NN
introduced_VBN [WZPAST]
in_PIN
2003_CD
invented_VBD
in_PIN
these_DEMO
laboratories_NN
available_JJ
optional_JJ
extra_JJ
it_PIT
must_NEMD
be_VB [BEMA]
integral_PRED
by_PIN
the_DT
revised_VBN
Combined_NN
Code_NN
on_PIN
for_PIN
clinical_JJ
development_NOMZ
and_PHC
supply_NN
to_TO
to_PIN
all_QUAN
that_DEMO
we_FPP1
do_VPRT [PROD]
._.
Our_FPP1
strategy_NN
to_PIN
Corporate_JJ
Governance_NN
of_PIN
the_DT
UK_NN
the_DT
worlds_NN
poorest_JJ
countries_NN
at_PIN
low_JJ
include_VB
considerations_NOMZ
of_PIN
corporate_JJ
Financial_NN
Reporting_GER
Council_NN
._.
prices_NN
in_PIN
partnership_NN
with_PIN
governments_NOMZ
,_,
responsibility_NOMZ
across_PLACE
all_QUAN
our_FPP1
activities_NOMZ
is_VPRT
healthcare_NN
systems_NN
,_,
international_JJ
beginning_GER
to_TO
take_VB
effect_NN
._.
In_CONJ
particular_NULL
,_,
Integrity_NOMZ
and_CC
high_JJ
ethical_JJ
standards_NN
agencies_NN
and_PHC
others_NN
all_QUAN
of_PIN
whom_WP [PIRE]
have_VPRT
a_DT
relevant_JJ
aspects_NN
are_VPRT
being_VBG [BEMA]
increasingly_RB
During_PIN
the_DT
year_NN
,_,
we_FPP1
added_VBD [PUBV]
sales_NN
and_PHC
part_NN
to_TO
play_VB
in_PIN
bringing_VBG
essential_JJ
medicines_NN
integrated_VBN [WZPAST]
into_PIN
our_FPP1
risk_NN
assessments_NOMZ
,_,
marketing_GER
practices_NN
to_PIN
the_DT
Priority_NOMZ
Action_NOMZ
to_PIN
the_DT
patients_NN
who_WP [WHSUB]
need_VPRT
them_TPP3
._.
scenario_NN
planning_GER
,_,
training_GER
,_,
purchasing_VBG
Plan_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
they_TPP3
continue_VPRT
to_TO
get_VB
the_DT
practices_NN
and_PHC
market_NN
access_NN
strategy_NN
._.
In_PIN
appropriate_JJ
high_JJ
level_NN
of_PIN
attention_NOMZ
and_CC
Good_JJ
corporate_JJ
responsibility_NOMZ
enhances_VPRT
2003_CD
,_,
we_FPP1
made_VBD
some_QUAN
good_JJ
progress_NN
,_,
that_THVC
we_FPP1
develop_VPRT
ways_NN
of_PIN
improving_VBG
our_FPP1
the_DT
benefits_NN
of_PIN
our_FPP1
medicines_NN
,_,
the_DT
quality_NOMZ
but_CC
recognize_VPRT [PRIV]
that_THVC
there_EX
is_VPRT
more_EMPH
work_NN
to_PIN
global_JJ
reporting_GER
in_PIN
this_DEMO
area_NN
._.
The_DT
of_PIN
our_FPP1
financial_JJ
performance_NN
and_CC
the_DT
do_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
a_DT
sense_NN
of_PIN
corporate_JJ
settlement_NOMZ
of_PIN
the_DT
Zoladex_NN
investigation_NOMZ
significance_NN
of_PIN
our_FPP1
contributions_NOMZ
to_PIN
our_FPP1
responsibility_NOMZ
is_VPRT [SPAU] [PASS]
consistently_RB
embedded_VBN
in_PIN
the_DT
US_FPP1
see_VB [PRIV]
page_NN
13_CD
strengthened_VBD
local_JJ
communities_NOMZ
._.
I_FPP1
am_VPRT [PASS]
committed_VBN
to_PIN
throughout_PIN
the_DT
Group_NN
and_CC
actively_RB
our_FPP1
commitment_NOMZ
to_TO
deliver_VB
high_JJ
the_DT
high_JJ
standards_NN
necessary_JJ
for_PIN
our_FPP1
interpreted_VBN
and_PHC
managed_VBN
at_PIN
a_DT
local_JJ
level_NN
._.
standards_NN
of_PIN
ethical_JJ
behavior_NN
in_PIN
the_DT
continued_JJ
business_NOMZ
success_NN
and_CC
for_PIN
marketing_GER
of_PIN
our_FPP1
medicines_NN
worldwide_VPRT
._.
maintaining_VBG [PUBV] [PRESP]
the_DT
value_NN
of_PIN
our_FPP1
contribution_NOMZ
Because_CAUS
corporate_JJ
responsibility_NOMZ
spans_NN
to_PIN
society_NN
._.
a_DT
wide_JJ
range_NN
of_PIN
issues_NN
,_,
they_TPP3
can_POMD
not_XX0
Leadership_VB
by_PIN
example_NN
at_PIN
all_QUAN
levels_NN
all_QUAN
be_VB [PASS]
covered_VBN
in_PIN
this_DEMO
brief_JJ
introduction_NOMZ
._.
Good_JJ
corporate_JJ
responsibility_NOMZ
depends_VPRT
However_CONJ
,_,
I_FPP1
will_PRMD
highlight_VB
under_IN
each_QUAN
on_PIN
the_DT
right_JJ
level_NN
of_PIN
commitment_NOMZ
from_PIN
of_PIN
our_FPP1
core_NN
values_VPRT
some_QUAN
areas_NN
of_PIN
all_QUAN
employees_NN
,_,
led_VBN [PASTP]
by_PIN
the_DT
AstraZeneca_NN
progress_NN
and_CC
some_QUAN
where_RB
further_JJ
work_NN
Board_NN
,_,
who_WP
approve_VPRT
the_DT
strategic_JJ
is_VPRT [PASS]
needed_VBN
._.
More_EMPH
information_NOMZ
is_VPRT [BEMA]
available_JJ
direction_NOMZ
,_,
and_ANDC
our_FPP1
Senior_NN
Executive_NN
Team_NN
in_PIN
this_DEMO
Summary_NN
Report_NN
and_CC
on_PIN
our_FPP1
and_CC
management_NOMZ
,_,
who_WP
are_VPRT [BEMA]
accountable_JJ
Sir_NN
Tom_NN
McKillop_NN
website_NN
,_,
astrazeneca_NN
._.
for_PIN
the_DT
development_NOMZ
and_PHC
implementation_NOMZ
Chief_NN
Executive_NN
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
02_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
Our_FPP1
commitment_NOMZ
Making_VBG [WZPRES]
it_PIT
happen_VB
We_FPP1
believe_VB [PRIV]
that_THVC
good_JJ
corporate_JJ
We_FPP1
plan_VPRT
to_TO
build_VB
and_PHC
extend_VB
these_DEMO
responsibility_NOMZ
CR_NN
performance_NN
During_PIN
2003_CD
,_,
we_FPP1
continued_VBD
to_TO
drive_VB
activities_NOMZ
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
CR_NN
is_VPRT
depends_VPRT
on_PIN
the_DT
effective_JJ
managethe_NN
integration_NOMZ
of_PIN
CR_NN
into_PIN
business_NOMZ
consistently_RB
embedded_VBN
at_PIN
a_DT
local_JJ
ment_NOMZ
of_PIN
the_DT
economic_JJ
,_,
environmental_JJ
processes_NN
and_CC
consolidate_VB
the_DT
level_NN
throughout_PIN
the_DT
Group_NN
._.
and_ANDC
social_JJ
priorities_NOMZ
of_PIN
sustainable_JJ
framework_NN
for_PIN
local_JJ
implementation_NOMZ
development_NOMZ
._.
This_DEMP
can_POMD [SPAU]
only_DWNT
be_VB [BEMA]
of_PIN
our_FPP1
global_JJ
standards_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
Improving_GER
understanding_VBG [PRIV] [WZPRES]
achieved_VBN
through_PIN
the_DT
successful_JJ
consistent_JJ
and_PHC
appropriate_JJ
behavior_NN
Communication_NOMZ
is_VPRT [BEMA]
essential_PRED
to_PIN
integration_NOMZ
of_PIN
CR_NN
considerations_NOMZ
worldwide_VPRT
._.
We_FPP1
continue_VPRT
into_PIN
all_QUAN
of_PIN
our_FPP1
business_NOMZ
activities_NOMZ
._.
to_TO
communicate_VB
our_FPP1
CR_NN
objectives_NN
to_PIN
Senior_JJ
managers_NN
throughout_PIN
the_DT
build_VB
awareness_NOMZ
and_PHC
commitment_NOMZ
._.
We_FPP1
Our_FPP1
Global_JJ
CR_NN
Committee_NN
leads_VPRT
the_DT
Company_NN
are_VPRT [BEMA]
accountable_PRED
for_PIN
the_DT
have_VPRT [PEAS]
made_VBN
progress_NN
but_CC
more_EMPH
work_NN
development_NOMZ
of_PIN
CR_NN
management_NOMZ
development_NOMZ
and_PHC
implementation_NOMZ
needs_VPRT
to_TO
be_VB [PASS]
done_VBN [PROD]
._.
The_DT
Committee_NN
reports_NN
to_PIN
of_PIN
CR_NN
programs_NN
in_PIN
their_TPP3
areas_NN
of_PIN
communications_NOMZ
focused_VBN [WZPAST]
on_PIN
improving_VBG
Dame_NN
Bridget_NN
Ogilvie_NN
,_,
Non-Executive_JJ
responsibility_NOMZ
._.
Based_VBN [PASTP]
on_PIN
the_DT
global_JJ
CR_NN
the_DT
understanding_GER
of_PIN
what_WP
corporate_JJ
Director_NN
with_PIN
responsibility_NOMZ
for_PIN
policy_NN
,_,
these_DEMO
programs_NN
are_VPRT [PASS]
required_VBN [SUAV] [THATD]
responsibility_NOMZ
means_VPRT [PRIV]
in_PIN
practice_NN
for_PIN
all_QUAN
overseeing_VBG
CR_NN
in_PIN
AstraZeneca_NN
._.
to_TO
take_VB
account_NN
of_PIN
regional_JJ
,_,
site_NN
or_CC
levels_NN
of_PIN
the_DT
organization_NOMZ
._.
In_CONJ
particular_NULL
,_,
in_PIN
functional_JJ
priorities_NOMZ
and_PHC
objectives_NN
._.
todays_NN
demanding_VBG [SUAV] [WZPRES]
world_NN
,_,
we_FPP1
need_VPRT
to_TO
Identifying_VBG
the_DT
priorities_NOMZ
Our_FPP1
CR_NN
Management_NOMZ
Standards_NN
help_VPRT
continue_VB
to_TO
promote_VB
an_DT
understanding_GER
We_FPP1
use_VPRT
a_DT
risk_NN
assessment_NOMZ
process_NN
to_PIN
managers_NN
to_TO
understand_VB [PRIV]
the_DT
issues_NN
,_,
that_THVC
CR_NN
implementation_NOMZ
does_VPRT
not_XX0
help_VB
us_FPP1
identify_VB
the_DT
opportunities_NOMZ
and_CC
outline_VB
the_DT
framework_NN
for_PIN
managing_VBG
necessarily_RB
depend_VB
on_PIN
extra_JJ
resource_NN
challenges_NN
associated_VBN [WZPAST]
with_PIN
our_FPP1
our_FPP1
commitments_NOMZ
and_CC
provide_VB
advice_NN
but_CC
on_PIN
the_DT
consistent_JJ
adoption_NOMZ
and_CC
corporate_JJ
responsibility_NOMZ
._.
Our_FPP1
Corporate_JJ
on_PIN
putting_VBG
the_DT
standards_NN
into_PIN
practice_NN
._.
integration_NOMZ
of_PIN
CR_NN
considerations_NOMZ
into_PIN
Responsibility_NOMZ
Priority_NOMZ
Action_NOMZ
Plan_NN
set_VBD
everyday_JJ
business_NOMZ
thinking_GER
._.
out_PIN
on_PIN
page_NN
4_CD
provides_VPRT
a_DT
framework_NN
The_DT
size_NN
and_PHC
scale_NN
of_PIN
AstraZeneca_NN
and_CC
for_PIN
managing_VBG
these_DEMO
in_PIN
line_NN
with_PIN
our_FPP1
core_NN
its_PIT
business_NOMZ
mean_VB [PRIV]
that_THVC
developments_NOMZ
To_TO
help_VB
build_VB
corporate_JJ
skills_NN
in_PIN
CR_NN
values_NN
,_,
including_VBG
defined_VBN
objectives_NN
and_CC
,_,
such_JJ
as_IN
these_DEMP
take_VB
time_NN
to_TO
embed_VBN
._.
Local_JJ
management_NOMZ
,_,
we_FPP1
are_VPRT [BEMA]
in_PIN
the_DT
process_NN
of_PIN
where_RB
possible_JJ
,_,
appropriate_JJ
key_JJ
CR_NN
committees_NN
in_PIN
the_DT
US_FPP1
and_PHC
Sweden_NN
integrating_VBG [WZPRES]
CR_NN
into_PIN
our_FPP1
Leadership_NN
performance_NN
indicators_NN
KPIs_NN
._.
have_VPRT [PEAS]
been_VBN [PASS]
established_VBN [PRIV]
and_CC
one_CD
is_VPRT
Development_NOMZ
programs_NN
._.
This_DEMP
planned_VBN
for_PIN
2004_CD
in_PIN
the_DT
UK_NN
,_,
representing_VBG
includes_VPRT
using_VBG
case_NN
studies_NN
to_PIN
This_DEMO
year_NN
,_,
we_FPP1
have_VPRT [PEAS]
added_VBN [PUBV]
sales_NN
and_CC
three_CD
cornerstones_NN
of_PIN
our_FPP1
global_JJ
demonstrate_VPRT [PRIV]
the_DT
importance_NN
of_PIN
good_JJ
marketing_GER
practices_NN
and_PHC
access_NN
to_PIN
presence_NN
._.
These_DEMO
cross-functional_JJ
CR_NN
performance_NN
,_,
to_TO
raise_VB
awareness_NOMZ
medicines_NN
to_PIN
the_DT
Plan_NN
and_CC
we_FPP1
continue_VPRT
committees_NN
have_VPRT
an_DT
ongoing_JJ
role_NN
for_PIN
and_CC
to_TO
stimulate_VB
discussion_NN
of_PIN
how_RB
to_TO
monitor_VB
our_FPP1
internal_JJ
and_PHC
external_JJ
setting_GER
,_,
monitoring_GER
and_CC
reviewing_VBG
CR_NN
we_FPP1
can_POMD
all_QUAN
contribute_VPRT
to_TO
delivering_VBG
environment_NOMZ
for_PIN
emerging_VBG
issues_NN
that_TOBJ
programs_NN
that_TSUB
are_VPRT [BEMA]
relevant_PRED
and_CC
our_FPP1
values_NN
._.
may_POMD
require_VB [SUAV]
attention_NOMZ
and_PHC
inclusion_NN
in_PIN
appropriate_JJ
for_PIN
their_TPP3
areas_NN
._.
work_NN
closely_RB
with_PIN
the_DT
Global_JJ
CR_NN
Committee_NN
to_TO
share_VB
best_JJ
practice_NN
and_CC
ensure_VB [SUAV] [PRIV]
that_THVC
local_JJ
and_PHC
global_JJ
objectives_NN
are_VPRT [PASS]
aligned_VBN
._.
AstraZeneca_NN
Corporate_NN
AstraZeneca_NN
safety_NN
,_,
health_NN
and_CC
the_DT
individuality_NOMZ
,_,
ethical_JJ
issues_NN
are_VPRT
Responsibility_NOMZ
Policy_NN
aims_VPRT
to_TO
set_VB
,_,
promote_VB
environmental_JJ
diverse_JJ
talent_NN
and_CC
dealt_VBD
with_PIN
in_PIN
an_DT
Through_PIN
the_DT
provision_NN
of_PIN
innovative_JJ
new_JJ
and_CC
maintain_VB [PUBV]
considerations_NOMZ
creative_JJ
potential_JJ
effective_JJ
and_CC
medicines_NN
,_,
AstraZeneca_NN
improves_VPRT
human_JJ
high_JJ
standards_NN
continue_VPRT
to_TO
be_VB
that_DEMO
every_QUAN
transparent_JJ
way_NN
health_NN
and_CC
enhances_VPRT
peoples_NN
lives_NN
._.
Our_FPP1
of_PIN
corporate_JJ
a_DT
fundamental_JJ
employee_NN
brings_VPRT
activities_NOMZ
impact_NN
not_XX0
just_EMPH
on_PIN
the_DT
patients_NN
responsibility_NOMZ
company_NN
to_PIN
the_DT
business_NOMZ
our_FPP1
CR_NN
we_FPP1
serve_VPRT
and_CC
our_FPP1
investors_NN
but_CC
also_RB
on_PIN
worldwide_NN
which_WDT [WHOBJ]
consideration_NOMZ
are_VPRT [SPAU] [PASS]
fully_AMP
valued_VBN
commitments_NOMZ
our_FPP1
employees_NN
and_CC
on_PIN
society_NN
as_IN
a_DT
whole_NN
._.
will_PRMD
ensure_VB [SUAV] [PRIV] [THATD]
that_DEMP
:_:
and_ANDC
respected_VBN
are_VPRT [PASS]
expanded_VBN
Our_FPP1
continued_VBN
long_JJ
term_NN
success_NN
depends_VPRT
we_FPP1
make_VPRT
a_DT
positive_JJ
by_PIN
encouraging_VBG
on_PIN
our_FPP1
ability_NOMZ
to_TO
integrate_VB
successfully_RB
our_FPP1
as_IN
a_DT
minimum_NN
,_,
contribution_NOMZ
to_PIN
the_DT
sales_NN
and_PHC
suppliers_NN
financial_JJ
obligations_NOMZ
with_PIN
our_FPP1
social_JJ
and_CC
we_FPP1
meet_VPRT
national_JJ
communities_NOMZ
in_PIN
marketing_GER
to_TO
embrace_VB
environmental_JJ
responsibilities_NOMZ
._.
and_ANDC
international_JJ
which_WDT
we_FPP1
operate_VPRT
practices_NN
are_VPRT
standards_NN
similar_JJ
regulations_NOMZ
reputable_JJ
to_PIN
our_FPP1
own_JJ
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
03_CD
We_FPP1
also_RB
plan_VPRT
to_TO
publish_VB
our_FPP1
first_JJ
US_FPP1
CR_NN
Our_FPP1
rolling_VBG
program_NN
of_PIN
AstraZeneca_NN
Stakeholder_NN
dialogue_NN
We_FPP1
encourage_VPRT
constructive_JJ
dialogue_NN
Report_NN
in_PIN
2004_CD
which_WDT
will_PRMD
outline_VB
the_DT
site_NN
audits_NN
included_VBD
14_CD
in_PIN
2003_CD
,_,
11_CD
of_PIN
with_PIN
all_QUAN
our_FPP1
stakeholders_NN
and_PHC
others_NN
who_WP [WHOBJ]
commitment_NOMZ
and_PHC
progress_NN
to_PIN
date_NN
in_PIN
which_WDT [PIRE]
covered_VBD
CR_NN
,_,
helping_VBG [PRESP]
us_FPP1
to_TO
have_VB
an_DT
interest_NN
in_PIN
our_FPP1
activities_NOMZ
._.
monitor_NN
progress_NN
and_CC
identify_VB
areas_NN
Feedback_NN
opportunities_NOMZ
are_VPRT [PASS]
integrated_VBN
for_PIN
improvement_NOMZ
in_PIN
the_DT
consistent_JJ
into_PIN
our_FPP1
employee_NN
communication_NOMZ
Measuring_VBG [WZPRES]
progress_NN
adoption_NOMZ
of_PIN
our_FPP1
standards_NN
._.
Of_PIN
the_DT
11_CD
programs_NN
to_TO
help_VB
us_FPP1
identify_VB
areas_NN
of_PIN
Measuring_VBG
our_FPP1
performance_NN
is_VPRT [BEMA]
essential_JJ
sites_NN
audited_VBD
,_,
five_CD
were_VBD
marketing_VBG
both_DT
satisfaction_NOMZ
and_PHC
concern_NN
._.
We_FPP1
hold_VPRT [PRIV]
to_TO
understanding_VBG [PRIV]
the_DT
progress_NN
we_FPP1
are_VPRT
companies_NN
,_,
four_CD
were_VBD
manufacturing_VBG
face-to-face_JJ
meetings_GER
with_PIN
investors_NN
making_VBG [WZPRES]
and_PHC
identifying_VBG
potential_JJ
areas_NN
sites_NN
and_CC
two_CD
were_VBD
research_NN
facilities_NOMZ
._.
mainstream_NN
and_CC
ethical_JJ
investor_NN
for_PIN
improvement_NOMZ
._.
We_FPP1
have_VPRT
for_PIN
some_QUAN
time_NN
In_CONJ
particular_NULL
,_,
the_DT
audits_NN
highlighted_VBD
the_DT
groups_NN
._.
Our_FPP1
site-based_JJ
community_NOMZ
had_VBD
processes_NN
in_PIN
place_NN
for_PIN
monitoring_VBG
need_NN
to_TO
continue_VB
to_TO
support_VB
managers_NN
liaison_NN
staff_NN
ensure_VB [SUAV] [PRIV]
that_THVC
our_FPP1
local_JJ
our_FPP1
economic_JJ
,_,
environmental_JJ
,_,
safety_NN
with_PIN
clear_JJ
guidance_NN
on_PIN
what_WP
is_VPRT [PASS]
required_VBN [SUAV] [THATD]
communities_NOMZ
including_VBG [WZPRES]
local_JJ
and_CC
health_NN
performance_NN
._.
More_EMPH
recently_TIME
,_,
of_PIN
them_TPP3
in_PIN
these_DEMO
early_TIME
days_NN
of_PIN
local_JJ
CR_NN
committees_NN
and_PHC
politicians_NN
are_VPRT [PASS]
kept_VBN
we_FPP1
have_VPRT [PEAS]
been_VBN
focusing_VBG
on_PIN
developing_VBG
implementation_NOMZ
._.
informed_VBN [PASTP]
of_PIN
our_FPP1
business_NOMZ
activities_NOMZ
and_PHC
KPIs_NN
in_PIN
other_JJ
areas_NN
of_PIN
social_JJ
plans_NN
and_CC
given_VBN
the_DT
opportunity_NOMZ
to_TO
raise_VB
performance_NN
._.
These_DEMP
are_VPRT [PASS]
listed_VBN
in_PIN
the_DT
A_DT
new_JJ
CR_NN
Audit_NN
Handbook_NN
that_TSUB
provides_VPRT
any_QUAN
concerns_NN
._.
The_DT
regular_JJ
contact_NN
we_FPP1
Priority_NOMZ
Action_NOMZ
Plan_NN
and_CC
discussed_VBN
guidance_NN
and_PHC
support_NN
in_PIN
the_DT
new_JJ
areas_NN
have_VPRT
with_PIN
customers_NN
in_PIN
our_FPP1
day-to-day_TIME
further_JJ
in_PIN
the_DT
narrative_NN
of_PIN
this_DEMO
report_NN
for_PIN
our_FPP1
internal_JJ
auditors_NN
was_VBD [PASS]
published_VBN
business_NOMZ
activities_NOMZ
provides_VPRT
them_TPP3
with_PIN
and_CC
on_PIN
our_FPP1
website_NN
._.
Establishing_VBG [PRIV]
KPIs_NN
during_PIN
the_DT
year_NN
and_CC
we_FPP1
are_VPRT [SPAU]
now_TIME
working_VBG
opportunities_NOMZ
to_TO
comment_VB [PUBV]
on_PIN
CR_NN
issues_NN
._.
in_PIN
some_QUAN
areas_NN
of_PIN
social_JJ
responsibility_NOMZ
to_TO
build_VB
on_PIN
this_DEMO
with_PIN
further_JJ
guidelines_NN
is_VPRT
proving_VBG [PRIV]
to_TO
be_VB [BEMA]
a_DT
challenge_NN
for_PIN
industry_NN
and_PHC
training_GER
to_TO
ensure_VB [SUAV] [PRIV]
an_DT
appropriate_JJ
During_PIN
2003_CD
,_,
our_FPP1
CR_NN
Committee_NN
in_PIN
in_PIN
general_JJ
and_CC
AstraZeneca_NN
is_VPRT [BEMA]
no_SYNE
focus_NN
on_PIN
CR_NN
in_PIN
all_QUAN
of_PIN
our_FPP1
audits_NN
._.
Sweden_NN
held_VBD [PRIV]
dialogue_NN
sessions_NN
with_PIN
exception_NOMZ
._.
We_FPP1
are_VPRT [SPAU]
continually_RB
exploring_VBG
internal_JJ
and_PHC
external_JJ
stakeholders_NN
in_PIN
the_DT
ways_NN
in_PIN
which_WDT [PIRE]
we_FPP1
can_POMD
meaningfully_RB
Additionally_RB
,_,
AstraZenecas_NN
Group_NN
their_TPP3
country_NN
to_TO
help_VB
them_TPP3
understand_VB [PRIV]
benchmark_JJ
our_FPP1
performance_NN
._.
Internal_NN
Audit_NN
function_NOMZ
works_VPRT
to_TO
review_VB
,_,
better_JJ
the_DT
challenges_NN
of_PIN
their_TPP3
local_JJ
CR_NN
among_PIN
other_JJ
things_NN
,_,
compliance_NN
with_PIN
implementation_NOMZ
programs_NN
._.
Issues_NN
Auditing_VBG [WZPRES]
compliance_NN
laws_NN
,_,
regulations_NOMZ
and_PHC
Group_NN
policies_NN
._.
raised_VBN [PASTP]
by_PIN
stakeholders_NN
included_VBD
supply_NN
An_DT
important_JJ
step_NN
in_PIN
2003_CD
was_VBD [BEMA]
the_DT
During_PIN
2003_CD
,_,
a_DT
number_NN
of_PIN
reviews_NN
were_VBD
chain_NN
management_NOMZ
,_,
pharmaceuticals_NN
inclusion_NN
of_PIN
a_DT
requirement_NOMZ
to_TO
develop_VB
conducted_VBN
and_PHC
reported_VBN [PUBV]
to_PIN
the_DT
Audit_NN
in_PIN
the_DT
environment_NOMZ
and_CC
the_DT
extent_NN
to_PIN
local_JJ
CR_NN
implementation_NOMZ
plans_NN
in_PIN
our_FPP1
Committee_NN
of_PIN
the_DT
Board_NN
._.
Areas_NN
covered_VBD
which_WDT
our_FPP1
core_NN
values_NN
are_VPRT [PASS]
reflected_VBN [PRIV]
in_PIN
annual_JJ
compliance_NN
report_NN
by_PIN
senior_JJ
included_VBN
our_FPP1
Code_NN
of_PIN
Conduct_NN
and_CC
our_FPP1
our_FPP1
behavior_NN
and_CC
strategic_JJ
decisionmanagement_NOMZ
to_PIN
the_DT
AstraZeneca_NN
Code_NN
of_PIN
Sales_NN
and_PHC
Marketing_GER
Practices_NN
._.
The_DT
Swedish_NN
CR_NN
Committee_NN
Board_NN
the_DT
letter_NN
of_PIN
assurance_NN
._.
is_VPRT [SPAU]
currently_RB
updating_VBG
the_DT
Swedish_JJ
CR_NN
Action_NOMZ
Plan_NN
in_PIN
the_DT
light_NN
of_PIN
these_DEMO
Alongside_PLACE
this_DEMP
,_,
we_FPP1
are_VPRT
building_VBG
on_PIN
the_DT
discussions_NN
._.
experience_NN
of_PIN
our_FPP1
long_JJ
standing_GER
safety_NN
,_,
health_NN
and_PHC
environment_NOMZ
audit_NN
In_PIN
the_DT
US_FPP1
,_,
the_DT
CR_NN
Committee_NN
has_VPRT
program_NN
to_TO
include_VB
additional_JJ
areas_NN
interviews_NN
with_PIN
key_JJ
stakeholders_NN
of_PIN
CR_NN
,_,
such_JJ
as_IN
purchasing_VBG
principles_NN
,_,
scheduled_VBN [PASTP]
for_PIN
the_DT
first_JJ
quarter_NN
of_PIN
2004_CD
,_,
labor_NN
practices_NN
and_PHC
community_NOMZ
the_DT
outcomes_NN
of_PIN
which_WDT [PIRE]
will_PRMD
help_VB
shape_VB
support_NN
._.
the_DT
US_FPP1
Priority_NOMZ
Action_NOMZ
Plan_NN
._.
Dame_NN
Bridget_NN
Ogilvie_NN
Non-Executive_NN
Director_NN
with_PIN
responsibility_NOMZ
for_PIN
overseeing_VBG
CR_NN
in_PIN
AstraZeneca_NN
AstraZeneca_NN
continues_VPRT
to_TO
make_VB
progress_NN
in_PIN
the_DT
integration_NOMZ
of_PIN
CR_NN
into_PIN
all_QUAN
its_PIT
activities_NOMZ
._.
Staying_VBG [PRESP]
in_PIN
tune_NN
with_PIN
the_DT
changing_VBG
expectations_NOMZ
of_PIN
its_PIT
stakeholders_NN
is_VPRT [BEMA]
an_DT
ever_RB
present_JJ
challenge_NN
._.
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
04_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
Our_FPP1
goals_NN
Corporate_JJ
Responsibility_NOMZ
Priority_NOMZ
Action_NOMZ
Plan_NN
Issue_NN
Objective_NN
Action_NOMZ
plan_NN
Integration_NOMZ
of_PIN
CR_NN
into_PIN
all_QUAN
activities_NOMZ
CR_NN
considerations_NOMZ
are_VPRT [PASS]
included_VBN
in_PIN
all_QUAN
relevant_JJ
strategies_NN
Continued_VBN
internal_JJ
communication_NOMZ
of_PIN
policies_NN
,_,
framework_NN
,_,
and_ANDC
decisions_NN
management_NOMZ
standards_NN
and_PHC
guidelines_NN
Continued_VBN
local_JJ
implementation_NOMZ
and_CC
global_JJ
auditing_GER
Integration_NOMZ
of_PIN
CR_NN
into_PIN
learning_VBG [PRIV]
and_CC
development_NOMZ
programs_NN
Sampling_VBG [WZPRES]
employee_NN
understanding_GER
and_PHC
opinion_NN
Corporate_JJ
governance_NN
Deal_NN
with_PIN
all_QUAN
stakeholders_NN
with_PIN
the_DT
highest_JJ
ethical_JJ
standards_NN
Internal_NN
communication_NOMZ
and_PHC
training_GER
in_PIN
our_FPP1
revised_VBN
Code_NN
of_PIN
Conduct_NN
for_PIN
all_QUAN
employees_NN
Improve_VPRT
systems_NN
for_PIN
reporting_VBG [PUBV]
concerns_NN
To_TO
consider_VB [PRIV]
access_NN
to_PIN
medicines_NN
when_RB
defining_VBG
pricing_GER
and_PHC
Communication_NOMZ
of_PIN
our_FPP1
framework_NN
for_PIN
considering_VBG [PRIV]
access_NN
Access_NN
to_PIN
medicines_NN
market_NN
access_NN
strategies_NN
for_PIN
new_JJ
brands_NN
to_PIN
medicines_NN
early_TIME
in_PIN
product_NN
development_NOMZ
Monitor_NN
local_JJ
alignment_NOMZ
with_PIN
global_JJ
principles_NN
Share_NN
good_JJ
practice_NN
High_NN
ethical_JJ
standards_NN
of_PIN
sales_NN
and_PHC
marketing_GER
in_PIN
all_QUAN
countries_NN
Further_JJ
develop_VB
mechanisms_NN
for_PIN
monitoring_GER
and_CC
reporting_VBG [PUBV]
Sales_NN
and_PHC
marketing_GER
practices_NN
of_PIN
operation_NOMZ
compliance_NN
Establish_VB [PRIV]
KPIs_NN
Compliance_NN
Global_NN
consistency_NN
of_PIN
implementation_NOMZ
of_PIN
CR_NN
standards_NN
Continued_VBN
development_NOMZ
of_PIN
audit_NN
processes_NN
to_TO
include_VB
CR_NN
including_VBG [WZPRES]
new_JJ
governance_NN
laws_NN
and_PHC
regulations_NOMZ
Human_JJ
rights_NN
Ensure_VPRT [SUAV] [PRIV]
that_THVC
we_FPP1
consistently_RB
live_VPRT
up_RP
to_PIN
our_FPP1
core_NN
values_NN
and_CC
our_FPP1
Establish_VB [PRIV]
a_DT
means_NN
of_PIN
collecting_VBG
Human_NN
Resources_NN
data_NN
commitment_NOMZ
to_PIN
the_DT
principles_NN
of_PIN
the_DT
UN_NN
Declaration_NOMZ
of_PIN
Human_NN
on_PIN
a_DT
consistent_JJ
global_JJ
basis_NN
Rights_NN
worldwide_VPRT
Establish_JJ
KPIs_NN
based_VBN [WZPAST]
on_PIN
the_DT
planned_VBN
areas_NN
of_PIN
data_NN
collection_NOMZ
Diversity_NOMZ
equal_JJ
opportunity_NOMZ
Ensure_VB [SUAV] [PRIV] [THATD]
diversity_NOMZ
is_VPRT [SPAU] [PASS]
appropriately_RB
supported_VBN
in_PIN
our_FPP1
global_JJ
Creation_NOMZ
of_PIN
diversity_NOMZ
programs_NN
workforce_NN
and_CC
reflected_VBN [PRIV]
in_PIN
our_FPP1
leadership_NN
Ensure_VB [SUAV] [PRIV]
recruitment_NOMZ
processes_NN
are_VPRT [BEMA]
appropriate_PRED
Establish_VB [PRIV]
a_DT
means_NN
of_PIN
collecting_VBG
Human_NN
Resources_NN
data_NN
on_PIN
a_DT
consistent_JJ
global_JJ
basis_NN
Use_NN
of_PIN
laboratory_NN
animals_NN
Minimise_VPRT
the_DT
number_NN
of_PIN
animals_NN
used_VBN
Continued_VBN
adoption_NOMZ
of_PIN
alternative_NN
techniques_NN
where_RB
possible_JJ
Animal_NN
welfare_NN
Ensure_NN
high_JJ
standards_NN
of_PIN
care_NN
for_PIN
those_DEMO
that_DEMP
are_VPRT [PASS]
used_VBN
Continued_VBN
monitoring_VBG
using_VBG
established_VBN [PRIV]
procedures_NN
Suppliers_NN
Encourage_VPRT
our_FPP1
suppliers_NN
to_TO
embrace_VB
CR_NN
standards_NN
similar_JJ
to_TO
Build_VB
CR_NN
into_PIN
the_DT
external_JJ
spend_VPRT
and_CC
supplier_NN
our_FPP1
own_JJ
and_CC
working_VBG
with_PIN
them_TPP3
to_TO
share_VB
best_JJ
practice_NN
and_PHC
management_NOMZ
processes_NN
that_TOBJ
we_FPP1
are_VPRT
developing_VBG
help_VB
them_TPP3
improve_VB
,_,
if_COND
appropriate_JJ
Community_NOMZ
support_NN
Ensure_VB [SUAV] [PRIV]
optimum_JJ
effectiveness_NOMZ
of_PIN
our_FPP1
commitment_NOMZ
to_TO
Continued_VBN
communication_NOMZ
of_PIN
our_FPP1
Community_NOMZ
Support_NN
community_NOMZ
support_NN
,_,
which_WDT [SERE]
focuses_VPRT
on_PIN
health_NN
,_,
science_NN
Policy_NN
worldwide_NN
and_PHC
education_NOMZ
Monitoring_GER
activity_NOMZ
and_CC
sharing_VBG
best_JJ
practice_NN
through_PIN
Enable_NN
the_DT
sharing_GER
of_PIN
best_JJ
practice_NN
the_DT
global_JJ
community_NOMZ
support_NN
database_NN
Compliance_NN
with_PIN
the_DT
SHE_TPP3
Policy_NN
Aim_NN
to_TO
eliminate_VB
all_QUAN
injuries_NN
and_PHC
accidents_NN
Safety_NN
,_,
health_NN
and_PHC
environment_NOMZ
SHE_TPP3
No_SYNE
hurt_NN
,_,
harm_NN
or_CC
alarm_NN
Economise_NN
on_PIN
the_DT
use_NN
of_PIN
natural_JJ
resources_NN
and_PHC
work_NN
to_TO
minimize_VB
our_FPP1
impact_NN
on_PIN
the_DT
environment_NOMZ
Be_VB [BEMA]
among_PIN
the_DT
industry_NN
leaders_NN
in_PIN
SHE_TPP3
performance_NN
As_IN
part_NN
of_PIN
the_DT
overall_JJ
CR_NN
integration_NOMZ
objective_NN
,_,
ensure_VB [SUAV] [PRIV]
that_THVC
SHE_TPP3
considerations_NOMZ
continue_VPRT
to_TO
be_VB [PASS]
integrated_VBN
into_PIN
all_QUAN
activities_NOMZ
across_PLACE
the_DT
Group_NN
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
05_CD
KPI_NN
where_RB
appropriate_JJ
Progress_NN
in_PIN
2003_CD
2_CD
yearly_JJ
global_JJ
employee_NN
survey_NN
plus_PIN
ad_NN
hoc_FW
pulse_NN
surveys_NN
CR_NN
implementation_NOMZ
included_VBD
in_PIN
letter_NN
of_PIN
assurance_NN
process_NN
CR_NN
included_VBD
in_PIN
global_JJ
risk_NN
assessment_NOMZ
Local_JJ
CR_NN
committees_NN
established_VBN [PRIV] [WZPAST]
in_PIN
the_DT
US_FPP1
and_PHC
Sweden_NN
CR_NN
module_NN
approved_VBD
for_PIN
inclusion_NN
in_PIN
leadership_NN
development_NOMZ
program_NN
See_VB [PRIV]
page_NN
2_CD
2_CD
yearly_JJ
global_JJ
employee_NN
survey_NN
Code_NN
of_PIN
Conduct_NN
revised_VBD
and_PHC
re-published_VBD
International_NN
,_,
confidential_JJ
employee_NN
telephone_NN
helpline_NN
established_VBN [PRIV]
See_VB [PRIV]
page_NN
7_CD
Candidate_NN
drug_NN
identified_VBD
for_PIN
development_NOMZ
as_IN
a_DT
new_JJ
tuberculosis_NN
Collective_NN
global_JJ
approach_NN
agreed_VBD [SUAV] [PUBV]
treatment_NOMZ
Appointment_NOMZ
of_PIN
Access_NN
to_PIN
Medicines_NN
Director_NN
Oncology_NN
and_PHC
Infection_NOMZ
See_VB [PRIV]
page_NN
14_CD
Under_IN
discussion_NN
Network_NN
of_PIN
promotional_JJ
standards_NN
experts_NN
established_VBN [PRIV]
See_VB [PRIV]
page_NN
13_CD
Number_NN
of_PIN
audits_NN
conducted_VBN
11_CD
CR_NN
audits_NN
carried_VBD
out_PIN
by_PIN
SHE_TPP3
auditors_NN
,_,
complemented_VBN [PASTP]
by_PIN
Group_NN
Internal_NN
Audit_NN
reviews_VPRT
See_VB [PRIV]
page_NN
3_CD
Under_IN
discussion_NN
Human_NN
Resources_NN
global_JJ
database_NN
project_NN
on_PIN
track_NN
See_VB [PRIV]
page_NN
11_CD
Number_NN
of_PIN
diversity_NOMZ
programs_NN
Around_PLACE
28_CD
diversity_NOMZ
programs_NN
in_PIN
place_NN
Percent_NN
of_PIN
women_NN
at_PIN
senior_JJ
levels_NN
13_CD
%_NN
of_PIN
our_FPP1
200_CD
most_EMPH
senior_JJ
managers_NN
are_VPRT
women_NN
Human_NN
Resources_NN
global_JJ
database_NN
project_NN
on_PIN
track_NN
See_VB [PRIV]
page_NN
12_CD
Number_NN
of_PIN
animals_NN
used_VBN
242,000_CD
animals_NN
used_VBN [WZPAST]
in_PIN
2002_CD
2003_CD
figure_NN
not_XX0
yet_RB
available_JJ
See_VB [PRIV]
page_NN
14_CD
Number_NN
of_PIN
business_NOMZ
control_NN
meetings_GER
including_VBG [WZPRES]
CR_NN
150_CD
business_NOMZ
control_NN
meetings_GER
included_VBD
CR_NN
considerations_NOMZ
CR_NN
built_VBD
into_PIN
contracts_NN
and_PHC
master_NN
agreements_NOMZ
See_VB [PRIV]
page_NN
11_CD
Percent_NN
of_PIN
community_NOMZ
programs_NN
focused_VBD
on_PIN
our_FPP1
priorities_NOMZ
of_PIN
90_CD
%_NN
of_PIN
community_NOMZ
programs_NN
focused_VBD
on_PIN
our_FPP1
priorities_NOMZ
health_NN
,_,
science_NN
and_PHC
education_NOMZ
Inclusion_NN
in_PIN
the_DT
UKs_NN
Business_NOMZ
in_PIN
the_DT
Community_NOMZ
One_CD
Per_PIN
Cent_NN
Club_NN
See_VB [PRIV]
page_NN
15_CD
Accidents_NN
with_PIN
injury_NN
Target_NN
:_:
30_CD
%_NN
reduction_NOMZ
by_PIN
2005_CD
14_CD
%_NN
reduction_NOMZ
in_PIN
accidents_NN
with_PIN
injury_NN
,_,
relative_JJ
to_PIN
hours_NN
worked_VBD
New_NN
cases_NN
of_PIN
occupational_JJ
illness_NOMZ
Target_NN
:_:
30_CD
%_NN
reduction_NOMZ
by_PIN
2005_CD
52_CD
%_NN
reduction_NOMZ
in_PIN
new_JJ
cases_NN
of_PIN
occupational_JJ
illness_NOMZ
,_,
relative_JJ
to_PIN
hours_NN
worked_VBD
Unplanned_JJ
releases_NN
to_PIN
the_DT
environment_NOMZ
not_XX0
contained_VBD
within_PIN
site_NN
18_CD
%_NN
reduction_NOMZ
in_PIN
unplanned_JJ
releases_NN
boundary_NN
Target_NN
:_:
50_CD
%_NN
reduction_NOMZ
by_PIN
2005_CD
15_CD
%_NN
reduction_NOMZ
in_PIN
waste_NN
,_,
relative_JJ
to_PIN
sales_NN
Total_JJ
waste_NN
produced_VBD
Target_NN
:_:
10_CD
%_NN
reduction_NOMZ
by_PIN
2005_CD
3_CD
%_NN
reduction_NOMZ
in_PIN
greenhouse_NN
gas_NN
emissions_NN
Global_JJ
warming_VBG
potential_JJ
Target_NN
:_:
10_CD
%_NN
reduction_NOMZ
by_PIN
2005_CD
18_CD
%_NN
reduction_NOMZ
in_PIN
ODP_NN
emissions_NN
Ozone_NN
depletion_NOMZ
potential_JJ
ODP_NN
Target_NN
:_:
30_CD
%_NN
reduction_NOMZ
by_PIN
2005_CD
See_VB [PRIV]
pages_NN
9_CD
,_,
12_CD
and_CC
16_CD
Against_PIN
2001_CD
2002_CD
reference_NN
point_NN
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
06_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
Economic_NN
performance_NN
Our_FPP1
business_NOMZ
is_VPRT [PASS]
focused_VBN
on_PIN
delivering_VBG
value_NN
for_PIN
our_FPP1
shareholders_NN
and_CC
for_PIN
society_NN
by_PIN
maintaining_VBG [PUBV]
a_DT
flow_NN
of_PIN
new_JJ
medicines_NN
designed_VBN
to_TO
meet_VB
the_DT
needs_NN
of_PIN
patients_NN
and_CC
the_DT
healthcare_NN
professionals_NN
who_WP [WHSUB]
treat_VPRT
them_TPP3
._.
Jonathan_NN
Symonds_NN
AstraZeneca_NN
is_VPRT [PASS]
listed_VBN
Chief_NN
Financial_NN
Officer_NN
in_PIN
the_DT
2004_CD
Dow_NN
You_SPP2
can_POMD
read_VB
regularly_RB
in_PIN
the_DT
newspapers_NN
Jones_NN
Sustainability_NOMZ
about_IN
companies_NN
that_TSUB
have_VPRT [PEAS]
lost_VBN
value_NN
Indexes_NN
World_NN
through_PIN
failing_VBG
to_TO
manage_VB
some_QUAN
aspects_NN
and_CC
European_JJ
._.
These_DEMO
aspects_NN
Participation_NOMZ
in_PIN
this_DEMP
can_POMD
be_VB
far_PLACE
more_EMPH
important_JJ
to_PIN
the_DT
market_NN
type_NN
of_PIN
survey_NN
is_VPRT [BEMA]
than_PIN
decisions_NN
that_TSUB
directly_RB
affect_VPRT
a_DT
an_DT
important_JJ
means_NN
companys_NN
profits_NN
._.
of_PIN
evaluating_VBG
our_FPP1
performance_NN
and_PHC
understanding_GER
better_RB
the_DT
demands_NN
of_PIN
sustainable_JJ
development_NOMZ
._.
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
07_CD
Shareholders_NN
naturally_RB
look_VPRT
for_PIN
a_DT
We_FPP1
also_RB
reviewed_VBD
and_PHC
re-published_VBD
our_FPP1
good_JJ
return_NN
on_PIN
their_TPP3
investment_NOMZ
but_CC
Code_NN
of_PIN
Conduct_NN
to_TO
make_VB
sure_JJ
that_THAC
it_PIT
increasingly_RB
people_NN
want_VPRT
assurance_NN
continues_VPRT
to_TO
be_VB [BEMA]
appropriate_PRED
._.
Compliance_NN
that_TOBJ
they_TPP3
are_VPRT
investing_VBG
in_PIN
a_DT
company_NN
with_PIN
the_DT
Code_NN
is_VPRT [BEMA]
mandatory_PRED
and_CC
is_VPRT [BEMA]
that_DEMP
delivers_VPRT
a_DT
return_NN
in_PIN
a_DT
responsible_JJ
monitored_VBN
through_PIN
the_DT
annual_JJ
letter_NN
way_NN
._.
The_DT
establishment_NOMZ
of_PIN
ethical_JJ
of_PIN
assurance_NN
process_NN
and_PHC
Group_NN
investment_NOMZ
indices_NN
such_JJ
as_IN
Dow_NN
Internal_NN
Audit_NN
reviews_VPRT
._.
The_DT
revised_VBN
Jones_NN
Sustainability_NOMZ
reflects_VPRT [PRIV]
these_DEMO
version_NN
is_VPRT
being_VBG [SPAU] [PASS]
widely_RB
circulated_VBN
to_TO
rising_VBG
expectations_NOMZ
._.
employees_NN
and_PHC
communication_NOMZ
tools_NN
provided_VBN [WZPAST]
to_PIN
managers_NN
to_TO
support_VB
Failure_NN
to_TO
deliver_VB
our_FPP1
core_NN
values_NN
could_POMD
discussions_NN
with_PIN
their_TPP3
teams_NN
about_IN
seriously_RB
impact_NN
our_FPP1
reputation_NOMZ
,_,
which_WDT [SERE]
what_WP
is_VPRT [PASS]
expected_VBN [PRIV]
of_PIN
them_TPP3
._.
we_FPP1
recognize_VPRT [PRIV]
is_VPRT [BEMA]
an_DT
important_JJ
driver_NN
of_PIN
the_DT
Companys_NN
worth_NN
._.
The_DT
Code_NN
of_PIN
Conduct_NN
includes_VPRT
procedures_NN
for_PIN
employees_NN
to_TO
raise_VB
Managing_VBG
risk_NN
integrity_NOMZ
concerns_NN
,_,
including_VBG [PRESP]
a_DT
AstraZenecas_NN
Risk_NN
Advisory_NN
Group_NN
,_,
confidential_JJ
telephone_NN
helpline_NN
number_NN
._.
led_VBN [PASTP]
by_PIN
our_FPP1
Chief_NN
Financial_NN
Officer_NN
,_,
Jonathan_NN
Symonds_NN
,_,
looks_VPRT
at_PIN
the_DT
risks_NN
Contributing_VBG [WZPRES]
to_PIN
economic_JJ
the_DT
Company_NN
faces_VPRT
and_ANDC
how_RB
they_TPP3
are_VPRT
development_NOMZ
being_VBG [WZPRES] [PASS]
addressed_VBN
._.
Increasingly_RB
we_FPP1
are_VPRT [BEMA]
Our_FPP1
medicines_NN
are_VPRT [PASS]
designed_VBN
to_TO
improve_VB
integrating_VBG
reputational_JJ
risk_NN
,_,
including_VBG
health_NN
and_PHC
quality_NOMZ
of_PIN
life_NN
._.
They_TPP3
also_RB
bring_VPRT
CR_NN
,_,
into_PIN
our_FPP1
risk_NN
management_NOMZ
processes_VPRT
other_JJ
benefits_NN
to_PIN
society_NN
._.
Reducing_VBG [PRESP]
the_DT
and_CC
aim_NN
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
managers_NN
build_VPRT
it_PIT
incidence_NN
of_PIN
disease_NN
or_CC
the_DT
time_NN
needed_VBN [WZPAST]
into_PIN
their_TPP3
everyday_JJ
thinking_GER
._.
Appropriate_JJ
for_PIN
treatment_NOMZ
relieves_VPRT
pressure_NN
on_PIN
tools_NN
are_VPRT [BEMA]
available_PRED
in_PIN
the_DT
form_NN
of_PIN
a_DT
shared_VBN
healthcare_NN
systems_NN
and_CC
helps_VPRT
to_TO
risk_VB
management_NOMZ
philosophy_NN
,_,
principles_NN
improve_VPRT
productivity_NOMZ
._.
and_ANDC
a_DT
framework_NN
that_TOBJ
all_QUAN
managers_NN
can_POMD
use_VB
to_TO
reflect_VB [PRIV]
on_PIN
behaviors_NN
,_,
assess_VPRT
As_IN
the_DT
economic_JJ
burden_NN
of_PIN
funding_VBG
risks_NN
and_CC
positively_RB
shape_VB
their_TPP3
decision_NN
therapies_NN
grows_VPRT
,_,
we_FPP1
are_VPRT [SPAU]
increasingly_RB
making_VBG
._.
including_VBG
explanation_NOMZ
of_PIN
the_DT
economic_JJ
,_,
as_RB
well_RB
as_IN
the_DT
therapeutic_JJ
,_,
advantages_NN
Corporate_JJ
governance_NN
of_PIN
our_FPP1
medicines_NN
to_TO
help_VB
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
An_DT
essential_JJ
part_NN
of_PIN
our_FPP1
corporate_JJ
full_JJ
benefit_NN
to_PIN
healthcare_NN
providers_NN
and_PHC
responsibility_NOMZ
is_VPRT
to_TO
continue_VB
to_TO
operate_VB
to_PIN
society_NN
is_VPRT [PASS]
understood_VBN [PRIV]
._.
high_JJ
standards_NN
of_PIN
corporate_JJ
governance_NN
._.
Our_FPP1
business_NOMZ
activities_NOMZ
also_RB
benefit_VPRT
the_DT
During_PIN
the_DT
year_NN
,_,
we_FPP1
reviewed_VBD
and_CC
communities_NOMZ
around_PLACE
us_FPP1
through_PIN
local_JJ
refined_VBN
our_FPP1
corporate_JJ
governance_NN
employment_NOMZ
and_PHC
wages_NN
,_,
taxes_NN
,_,
controls_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
we_FPP1
are_VPRT
meeting_VBG
community_NOMZ
support_NN
and_CC
local_JJ
and_PHC
new_JJ
laws_NN
and_CC
regulatory_JJ
requirements_NOMZ
._.
national_JJ
sourcing_VBG
of_PIN
materials_NN
and_CC
This_DEMP
includes_VPRT
the_DT
ability_NOMZ
to_TO
meet_VB
the_DT
services_NN
._.
appropriate_JJ
executive_NN
certification_NOMZ
requirements_NOMZ
of_PIN
the_DT
Sarbanes-Oxley_NN
Investing_VBG [WZPRES]
in_PIN
innovation_NOMZ
legislation_NOMZ
in_PIN
the_DT
US_FPP1
and_CC
the_DT
changes_NN
AstraZeneca_NN
spends_VPRT
around_PLACE
$_$
14_CD
million_CD
introduced_VBN
in_PIN
2003_CD
by_PIN
the_DT
revised_VBN
each_QUAN
working_VBG
day_NN
on_PIN
research_NN
and_PHC
Combined_NN
Code_NN
on_PIN
Corporate_JJ
development_NOMZ
which_WDT [WHSUB]
is_VPRT [BEMA]
an_DT
important_JJ
Governance_NN
of_PIN
the_DT
UK_NN
Financial_NN
contribution_NOMZ
to_PIN
the_DT
combined_VBN
commitReporting_GER
Council_NN
._.
ment_NOMZ
of_PIN
the_DT
pharmaceutical_JJ
industry_NN
,_,
which_WDT [SERE]
is_VPRT [BEMA]
the_DT
source_NN
of_PIN
the_DT
vast_JJ
majority_NOMZ
AstraZenecas_NN
senior_JJ
Non-Executive_NN
of_PIN
medical_JJ
innovation_NOMZ
,_,
researching_VBG
and_CC
Director_NN
,_,
Sir_NN
Peter_NN
Bonfield_NN
,_,
was_VBD
developing_VBG
over_IN
90_CD
%_NN
of_PIN
new_JJ
medicines_NN
._.
nominated_VBN [PASTP]
in_PIN
2002_CD
as_IN
the_DT
contact_NN
for_PIN
investors_NN
wishing_VBG [WZPRES]
to_TO
raise_VB
high_JJ
level_NN
concerns_NN
about_IN
any_QUAN
potential_JJ
corporate_JJ
governance_NN
issues_NN
._.
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
08_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
Environmental_NN
performance_NN
We_FPP1
continue_VPRT
to_TO
pursue_VB
sustained_JJ
improvement_NOMZ
in_PIN
areas_NN
where_RB
we_FPP1
believe_VPRT [PRIV] [THATD]
our_FPP1
global_JJ
business_NOMZ
has_VPRT
the_DT
greatest_JJ
potential_JJ
impact_NN
on_PIN
the_DT
environment_NOMZ
:_:
climate_NN
change_NN
,_,
ozone_NN
depletion_NOMZ
and_PHC
waste_NN
production_NOMZ
._.
The_DT
installation_NOMZ
Leading_VBG [WZPRES]
by_PIN
In_PIN
Sweden_NN
,_,
as_IN
part_NN
An_DT
energy_NN
efficient_JJ
At_PIN
our_FPP1
US_FPP1
headquarters_NN
in_PIN
Wilmington_NN
,_,
of_PIN
two_CD
new_JJ
large_JJ
example_NN
in_PIN
the_DT
of_PIN
our_FPP1
commitment_NOMZ
HVAC_NN
heating_GER
,_,
Delaware_NN
,_,
our_FPP1
employees_NN
have_VPRT [PEAS]
formed_VBN
energy_NN
efficient_JJ
use_NN
of_PIN
alternatives_NN
to_TO
ensuring_VBG [SUAV] [PRIV]
correct_JJ
ventilation_NOMZ
and_CC
an_DT
environmental_JJ
awareness_NOMZ
team_NN
,_,
which_WDT [SERE]
combined_VBN
heat_NN
and_CC
to_PIN
business_NOMZ
disposal_NN
of_PIN
preair_NN
conditioning_GER
participated_VBD
in_PIN
a_DT
range_NN
of_PIN
projects_NN
during_PIN
power_NN
CHP_NN
plants_NN
in_PIN
travel_NN
,_,
our_FPP1
2003_CD
scribed_VBD
treatments_NOMZ
,_,
system_NN
has_VPRT [PEAS]
been_VBN [BEMA]
the_DT
year_NN
including_VBG [WZPRES]
the_DT
re-forestation_NOMZ
of_PIN
the_DT
UK_NN
and_PHC
Puerto_NN
Senior_NN
Managers_NN
we_FPP1
supported_VBD
installed_VBN
at_PIN
our_FPP1
10,000_CD
acres_NN
of_PIN
biologically_RB
critical_JJ
habitat_NN
Rico_NN
will_PRMD
reduce_VB
our_FPP1
Conference_NN
,_,
a_DT
major_JJ
campaign_NN
,_,
new_JJ
research_NN
in_PIN
the_DT
state_NN
of_PIN
Delaware_NN
._.
CO2_CD
emissions_NN
by_PIN
an_DT
involving_VBG
over_RP
in_PIN
partnership_NN
with_PIN
laboratories_NN
in_PIN
estimated_VBN [PRIV]
50,000_CD
200_CD
AstraZeneca_NN
other_JJ
interested_JJ
Bangalore_NN
,_,
India_NN
,_,
tonnes_VPRT
each_QUAN
year_NN
._.
leaders_NN
from_PIN
parties_NN
,_,
to_TO
encourage_VB
opened_VBN
in_PIN
2003_CD
._.
CHP_NN
is_VPRT [BEMA]
the_DT
simularound_JJ
the_DT
world_NN
,_,
patients_NN
to_TO
return_VB
taneous_JJ
generation_NOMZ
took_VBD
place_NN
as_IN
a_DT
surplus_NN
medicines_NN
of_PIN
heat_NN
and_PHC
power_NN
video-conference_NN
._.
com_NN
09_CD
A_DT
detailed_JJ
analysis_NN
in_PIN
2001_CD
of_PIN
the_DT
potential_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
maintained_VBN [PUBV]
,_,
we_FPP1
are_VPRT [BEMA]
Unplanned_JJ
releases_NN
environmental_JJ
impacts_NN
of_PIN
our_FPP1
business_NOMZ
,_,
committed_VBN
to_TO
maximizing_VBG
other_JJ
ways_NN
of_PIN
Unplanned_JJ
releases_NN
can_POMD
cause_VB
damage_NN
combined_VBN [WZPAST]
with_PIN
stakeholder_NN
discussions_NN
,_,
reducing_VBG [PRESP]
our_FPP1
reliance_NN
on_PIN
air_NN
and_PHC
road_NN
both_DT
to_PIN
the_DT
environment_NOMZ
and_CC
to_PIN
our_FPP1
helped_VBD
us_FPP1
to_TO
identify_VB
our_FPP1
priority_NOMZ
action_NOMZ
transport_NN
,_,
including_VBG
rationalising_VBG
our_FPP1
relationships_NN
with_PIN
our_FPP1
local_JJ
communities_NOMZ
areas_NN
._.
We_FPP1
have_VPRT
clear_JJ
targets_NN
for_PIN
reducing_VBG
product_NN
distribution_NOMZ
networks_NN
and_CC
using_VBG
and_CC
regulators_NN
._.
We_FPP1
aim_VPRT
to_TO
eliminate_VB
such_JJ
our_FPP1
impact_NN
,_,
as_IN
set_VBN
out_PIN
on_PIN
page_NN
5_CD
,_,
and_ANDC
alternatives_NN
to_PIN
business_NOMZ
travel_NN
,_,
such_JJ
as_IN
incidents_NN
by_PIN
ensuring_VBG [SUAV] [PRIV]
that_THVC
our_FPP1
processes_NN
here_RB
we_FPP1
summarise_VPRT
our_FPP1
progress_NN
._.
In_PIN
2003_CD
,_,
we_FPP1
had_VBD
information_NOMZ
and_CC
detailed_JJ
statistics_NN
are_VPRT [BEMA]
nine_CD
unplanned_JJ
releases_NN
that_TSUB
were_VBD [BEMA]
not_XX0
available_PRED
on_PIN
our_FPP1
website_NN
._.
Ozone_NN
depletion_NOMZ
contained_VBD
within_PIN
the_DT
site_NN
boundary_NN
Some_QUAN
of_PIN
our_FPP1
products_NN
,_,
such_JJ
as_IN
asthma_NN
compared_VBN [WZPAST]
to_PIN
10_CD
in_PIN
2002_CD
._.
Our_FPP1
challenge_NN
is_VPRT
to_TO
sustain_VB
improvement_NOMZ
therapies_NN
,_,
are_VPRT [PASS]
presented_VBN
in_PIN
a_DT
pressurized_VBN
,_,
as_IN
we_FPP1
grow_VPRT
our_FPP1
business_NOMZ
._.
There_EX
is_VPRT
no_SYNE
metered_JJ
dose_NN
inhaler_NN
that_TSUB
uses_VPRT
non-toxic_JJ
,_,
Pharmaceuticals_NN
in_PIN
the_DT
environment_NOMZ
completely_AMP
satisfactory_JJ
measure_NN
that_TSUB
can_POMD
stable_JJ
gases_NN
to_TO
propel_VB
the_DT
treatment_NOMZ
Traces_NN
of_PIN
pharmaceuticals_NN
can_POMD
somebe_VB
used_VBN
to_TO
relate_VB
resource_NN
consumption_NOMZ
safely_RB
and_PHC
effectively_RB
to_PIN
a_DT
patients_NN
times_NN
be_VB [PASS]
found_VBN [PRIV]
in_PIN
the_DT
environment_NOMZ
._.
to_PIN
the_DT
size_NN
of_PIN
a_DT
complex_JJ
global_JJ
business_NOMZ
airways_NN
._.
The_DT
most_EMPH
commonly_RB
used_VBN
Studies_NN
in_PIN
recent_JJ
years_NN
by_PIN
industry_NN
,_,
such_JJ
as_IN
ours_JJ
._.
In_PIN
common_JJ
with_PIN
other_JJ
propellants_NN
have_VPRT [PEAS]
been_VBN
CFCs_NN
,_,
which_WDT [SERE]
academic_JJ
and_PHC
regulatory_JJ
bodies_NN
suggest_VPRT [SUAV] [PUBV]
similar_JJ
companies_NN
and_CC
in_PIN
line_NN
with_PIN
the_DT
contribute_VPRT
to_PIN
ozone_NN
depletion_NOMZ
as_RB
well_RB
as_IN
that_DEMO
the_DT
concentrations_NOMZ
being_VBG [WZPRES] [PASS]
found_VBN [PRIV]
in_PIN
Global_JJ
Reporting_GER
Initiative_NN
,_,
we_FPP1
use_VPRT
being_VBG
greenhouse_NN
gases_NN
._.
watercourses_NN
are_VPRT [BEMA]
many_QUAN
times_NN
less_RB
than_PIN
reported_VBN [PUBV]
sales_NN
to_TO
calculate_VB [PRIV]
our_FPP1
resource_NN
those_DEMO
that_DEMP
would_PRMD
pose_VB
significant_JJ
risk_NN
to_PIN
efficiency_NN
._.
This_DEMP
is_VPRT
because_CAUS
reported_VBN [PUBV]
sales_NN
AstraZeneca_NN
has_VPRT [PEAS]
been_VBN [BEMA]
very_AMP
active_PRED
in_PIN
humans_NN
and_CC
are_VPRT [BEMA]
not_XX0
high_JJ
enough_RB
to_TO
is_VPRT [BEMA]
a_DT
transparent_JJ
,_,
audited_JJ
number_NN
that_TOBJ
the_DT
development_NOMZ
of_PIN
alternatives_NN
to_TO
cause_VB
immediate_JJ
or_CC
short_JJ
term_NN
harm_NN
to_TO
enables_VPRT
comparison_NN
over_IN
time_NN
,_,
as_IN
shown_VBN [PRIV]
CFC-driven_JJ
inhalers_NN
such_JJ
as_IN
dry_JJ
powder_NN
aquatic_JJ
life_NN
._.
Nevertheless_CONJ
,_,
we_FPP1
recognize_VPRT [PRIV]
on_PIN
page_NN
16_CD
but_CC
it_PIT
should_NEMD
be_VB [PASS]
noted_VBN [PRIV]
that_THVC
inhalers_NN
and_CC
pump_VB
sprays_NN
._.
We_FPP1
have_VPRT
that_DEMO
stakeholders_NN
may_POMD
be_VB [BEMA]
concerned_JJ
exchange_NN
rate_NN
fluctuations_NOMZ
can_POMD
have_VB
an_DT
also_RB
now_TIME
begun_VBN
the_DT
regulatory_JJ
approval_NN
about_RB
longer_JJ
term_NN
effects_NN
and_CC
this_DEMP
is_VPRT [BEMA]
one_CD
effect_NN
on_PIN
reported_VBN [PUBV]
sales_NN
._.
process_NN
for_PIN
a_DT
new_JJ
generation_NOMZ
of_PIN
of_PIN
our_FPP1
priority_NOMZ
areas_NN
of_PIN
study_NN
._.
We_FPP1
continue_VPRT
respiratory_JJ
HFC_NN
inhalers_NN
that_TSUB
do_VPRT
not_XX0
to_TO
work_VB
alongside_PLACE
other_JJ
pharmaceutical_JJ
Climate_NN
change_NN
damage_NN
the_DT
ozone_NN
layer_NN
._.
However_CONJ
,_,
companies_NN
and_CC
regulatory_JJ
bodies_NN
to_PIN
Our_FPP1
global_JJ
warming_GER
emissions_NN
arise_VPRT
CFC-driven_JJ
inhalers_NN
continue_VPRT
to_TO
be_VB [PASS]
used_VBN
provide_VB
further_JJ
improvement_NOMZ
to_PIN
the_DT
primarily_RB
from_PIN
the_DT
use_NN
of_PIN
energy_NN
at_PIN
our_FPP1
by_PIN
patients_NN
who_WP [WHSUB]
can_POMD
not_XX0
tolerate_VB
,_,
or_CC
do_EMPH
existing_VBG
techniques_NN
used_VBN
to_TO
assess_VB
the_DT
facilities_NOMZ
,_,
transport_NN
and_CC
the_DT
propellant_NN
gas_NN
not_XX0
have_VB
the_DT
choice_NN
of_PIN [STPR]
,_,
alternatives_NN
._.
In_PIN
environmental_JJ
risk_NN
associated_VBN [WZPAST]
with_PIN
used_VBN
in_PIN
some_QUAN
of_PIN
our_FPP1
inhalation_NOMZ
products_NN
._.
2003_CD
,_,
decreased_VBD
sales_NN
of_PIN
our_FPP1
CFC-driven_JJ
pharmaceuticals_NN
._.
inhalers_NN
resulted_VBD
in_PIN
an_DT
11_CD
%_NN
decrease_NN
in_PIN
During_PIN
the_DT
year_NN
,_,
we_FPP1
completed_VBD
a_DT
strategic_JJ
our_FPP1
overall_JJ
release_NN
of_PIN
ozone_NN
depleting_GER
Consistent_NN
with_PIN
our_FPP1
commitment_NOMZ
to_TO
strengthening_VBG
of_PIN
our_FPP1
product_NN
portfolio_NN
substances_NN
._.
We_FPP1
are_VPRT [SPAU]
still_RB
planning_VBG
to_TO
reach_VB
product_NN
stewardship_NN
,_,
we_FPP1
also_RB
aim_VPRT
to_PIN
with_PIN
a_DT
range_NN
of_PIN
new_JJ
high_JJ
quality_NOMZ
medicines_NN
our_FPP1
target_NN
of_PIN
reducing_VBG
CFC_NN
emissions_NN
by_PIN
minimize_VPRT
the_DT
amounts_NN
of_PIN
any_QUAN
of_PIN
our_FPP1
that_DEMP
will_PRMD
drive_VB
AstraZenecas_NN
future_JJ
30_CD
%_NN
against_PIN
the_DT
2001_CD
2002_CD
reference_NN
products_NN
being_VBG [WZPRES] [PASS]
released_VBN
into_PIN
the_DT
success_NN
._.
Planning_GER
for_PIN
the_DT
new_JJ
products_NN
point_NN
by_PIN
2005_CD
._.
Exact_JJ
timing_NN
will_PRMD
depend_VB
environment_NOMZ
from_PIN
our_FPP1
facilities_NOMZ
._.
We_FPP1
are_VPRT
has_VPRT [PEAS]
included_VBN
making_VBG
necessary_JJ
changes_NN
on_PIN
gaining_VBG
regulatory_JJ
approvals_NN
for_PIN
the_DT
improving_VBG
our_FPP1
effluent_JJ
treatment_NOMZ
processes_VPRT
to_PIN
our_FPP1
manufacturing_GER
processes_NN
and_CC
new_JJ
inhalation_NOMZ
devices_NN
._.
globally_RB
including_VBG
the_DT
installation_NOMZ
of_PIN
a_DT
$_$
36_CD
increasing_VBG
the_DT
size_NN
of_PIN
our_FPP1
sales_NN
forces_NN
million_CD
state_NN
of_PIN
the_DT
art_NN
biological_JJ
treatment_NOMZ
and_ANDC
consequently_CONJ
the_DT
distance_NN
traveled_VBD
Our_FPP1
use_NN
of_PIN
ozone_NN
depleting_GER
substances_NN
facility_NOMZ
at_PIN
our_FPP1
plant_NN
in_PIN
Bristol_NN
,_,
UK_NN
._.
Despite_PIN
these_DEMO
changes_NN
,_,
for_PIN
refrigeration_NOMZ
and_PHC
fire_NN
suppression_NN
has_VPRT
improvements_NOMZ
in_PIN
efficiency_NN
and_CC
lower_JJ
been_VBN [SPAU] [PASS]
substantially_RB
reduced_VBN
and_PHC
is_VPRT
being_VBG [PASS]
Proposed_VBN [SUAV]
EU_NN
chemicals_NN
policy_NN
carbon_NN
intensity_NOMZ
of_PIN
our_FPP1
fuel_NN
sources_NN
,_,
phased_VBD
out_PIN
completely_AMP
._.
In_PIN
October_NN
2003_CD
,_,
the_DT
EU_NN
Commission_NN
coupled_VBN [WZPAST]
with_PIN
a_DT
reduced_VBN
use_NN
of_PIN
our_FPP1
CFCpublished_JJ
draft_NN
legislation_NOMZ
regarding_VBG [WZPRES]
the_DT
driven_VBN
inhalers_NN
,_,
led_VBD
to_TO
total_VB
emissions_NN
from_PIN
Minimising_VBG
waste_NN
approval_NN
of_PIN
chemicals_NN
in_PIN
Europe_NN
,_,
a_DT
key_NN
all_QUAN
sources_NN
decreasing_VBG [WZPRES]
by_PIN
2_CD
%_NN
in_PIN
2003_CD
._.
We_FPP1
aim_VPRT
to_TO
use_VB
materials_NN
efficiently_RB
and_CC
component_NN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
the_DT
introduction_NOMZ
of_PIN
We_FPP1
are_VPRT [SPAU]
still_RB
working_VBG
hard_RB
to_TO
meet_VB
our_FPP1
maximize_VB
re-use_NN
and_PHC
re-cycling_GER
._.
Where_RB
a_DT
new_JJ
regulatory_JJ
system_NN
called_VBN
REACH_NN
target_NN
of_PIN
a_DT
10_CD
%_NN
reduction_NOMZ
in_PIN
our_FPP1
global_JJ
possible_JJ
,_,
we_FPP1
avoid_VPRT
the_DT
use_NN
of_PIN
the_DT
most_EMPH
Registration_NOMZ
,_,
Evaluation_NOMZ
and_PHC
Authorisation_NOMZ
warming_VBG [WZPRES]
potential_JJ
over_IN
the_DT
2001_CD
2002_CD
hazardous_JJ
substances_NN
and_CC
are_VPRT [BEMA]
of_PIN
Chemicals_NN
._.
AstraZeneca_NN
supports_VPRT
the_DT
reference_NN
point_NN
by_PIN
the_DT
end_NN
of_PIN
2005_CD
._.
developing_VBG
avoidance_NN
and_PHC
substitution_NOMZ
Commissions_NN
efforts_NN
to_TO
overhaul_VB
the_DT
strategies_NN
to_TO
assist_VB
this_DEMO
process_NN
._.
regulatory_JJ
framework_NN
for_PIN
approval_NN
of_PIN
We_FPP1
continue_VPRT
to_TO
implement_VB
programs_NN
Approaches_NN
to_TO
reducing_VBG
the_DT
amount_NN
of_PIN
chemicals_NN
in_PIN
Europe_NN
and_CC
through_PIN
EFPIA_NN
,_,
to_TO
maximize_VB
energy_NN
efficiency_NN
._.
We_FPP1
are_VPRT
waste_NN
we_FPP1
generate_VPRT
include_VPRT
the_DT
improved_VBN
the_DT
pharmaceutical_JJ
industrys_NN
trade_NN
also_RB
working_VBG
to_TO
increase_VB
the_DT
amount_NN
of_PIN
operation_NOMZ
of_PIN
existing_VBG
production_NOMZ
association_NOMZ
in_PIN
Europe_NN
,_,
we_FPP1
are_VPRT
actively_RB
energy_NN
purchased_VBN [WZPAST]
from_PIN
renewable_JJ
processes_NN
and_CC
the_DT
better_JJ
design_NN
of_PIN
new_JJ
contributing_VBG
to_PIN
the_DT
dialogue_NN
on_PIN
this_DEMO
issue_NN
._.
resources_NN
and_CC
most_EMPH
of_PIN
our_FPP1
sites_NN
around_PLACE
ones_NN
,_,
improved_VBD
purchasing_VBG
processes_NN
We_FPP1
agree_VPRT [SUAV] [PUBV]
with_PIN
the_DT
principles_NN
of_PIN
the_DT
the_DT
world_NN
have_VPRT
local_JJ
programs_NN
in_PIN
place_NN
and_CC
internal_JJ
waste_NN
awareness_NOMZ
proposal_NN
but_CC
,_,
working_VBG [PRESP]
with_PIN
EFPIA_NN
and_CC
to_TO
improve_VB
energy_NN
efficiency_NN
._.
In_PIN
2003_CD
,_,
we_FPP1
reduced_VBD
our_FPP1
other_JJ
industry_NN
trade_NN
associations_NOMZ
,_,
we_FPP1
total_VPRT
waste_NN
by_PIN
3_CD
%_NN
including_VBG [WZPRES]
a_DT
9_CD
%_NN
seek_VPRT
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
eventual_JJ
Whilst_OSUB
the_DT
current_JJ
level_NN
of_PIN
travel_NN
activity_NOMZ
reduction_NOMZ
in_PIN
hazardous_JJ
waste_NN
._.
regulation_NOMZ
is_VPRT
not_XX0
only_DWNT
effective_PRED
but_CC
also_RB
of_PIN
our_FPP1
sales_NN
forces_NN
up_IN
10_CD
%_NN
in_PIN
2003_CD
is_VPRT [BEMA]
workable_PRED
and_CC
avoids_VPRT
obstacles_NN
that_TSUB
may_POMD [SPAU]
unnecessarily_RB
harm_VB
our_FPP1
competitiveness_NOMZ
._.
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
10_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
Social_NN
performance_NN
Managing_VBG [WZPRES]
our_FPP1
business_NOMZ
in_PIN
a_DT
constructive_JJ
and_PHC
responsible_JJ
way_NN
means_VPRT [PRIV]
understanding_GER
and_CC
responding_VBG
appropriately_RB
to_PIN
the_DT
issues_NN
relating_VBG [WZPRES]
to_PIN
our_FPP1
activities_NOMZ
that_TSUB
affect_VPRT
or_CC
concern_NN
society_NN
._.
During_PIN
2003_CD
,_,
we_FPP1
Our_FPP1
overall_JJ
We_FPP1
continue_VPRT
to_PIN
As_IN
part_NN
of_PIN
our_FPP1
We_FPP1
strengthened_VBD
developed_VBN
a_DT
new_JJ
contribution_NOMZ
to_PIN
our_FPP1
make_VB
progress_NN
,_,
commitment_NOMZ
our_FPP1
commitment_NOMZ
automated_VBN
system_NN
local_JJ
communities_NOMZ
but_CC
recognize_VPRT [PRIV]
to_PIN
employee_NN
to_PIN
high_JJ
ethical_JJ
for_PIN
collecting_VBG
through_PIN
charitable_JJ
there_EX
is_VPRT [SPAU]
still_RB
work_VB
wellbeing_JJ
,_,
at_PIN
least_JJ
standards_NN
in_PIN
Human_NN
Resources_NN
donations_NOMZ
and_CC
to_TO
do_VB
in_PIN
ensuring_VBG [SUAV] [PRIV]
60_CD
%_NN
of_PIN
our_FPP1
staff_NN
the_DT
sales_NN
and_PHC
data_NN
globally_RB
._.
sponsorships_NN
that_DEMO
diversity_NOMZ
worldwide_NN
now_TIME
marketing_VBG
of_PIN
our_FPP1
totalled_JJ
$_$
22_CD
million_CD
is_VPRT [SPAU]
appropriately_RB
have_VPRT
access_NN
medicines_NN
globally_RB
._.
in_PIN
2003_CD
._.
supported_VBN [PASTP]
in_PIN
to_PIN
confidential_JJ
our_FPP1
workforce_NN
._.
com_NN
11_CD
Here_RB
we_FPP1
describe_VPRT
our_FPP1
approach_NN
to_PIN
some_QUAN
We_FPP1
have_VPRT [PEAS]
been_VBN
working_VBG
to_TO
improve_VB
our_FPP1
of_PIN
the_DT
social_JJ
issues_NN
relating_VBG [WZPRES]
to_PIN
our_FPP1
global_JJ
reporting_GER
processes_NN
,_,
building_GER
business_NOMZ
._.
You_SPP2
can_POMD
read_VB
more_EMPH
about_IN
on_PIN
our_FPP1
long_JJ
standing_GER
systems_NN
for_PIN
these_DEMP
and_CC
other_JJ
areas_NN
of_PIN
our_FPP1
social_JJ
monitoring_GER
compliance_NN
wherever_RB
we_FPP1
performance_NN
on_PIN
our_FPP1
website_NN
._.
During_PIN
2003_CD
,_,
we_FPP1
developed_VBD
a_DT
new_JJ
automated_VBN
information_NOMZ
system_NN
for_PIN
Human_JJ
rights_NN
collating_VBG [WZPRES]
,_,
reporting_VBG [PUBV]
and_PHC
analyzing_VBG
With_PIN
over_IN
60,000_CD
people_NN
working_VBG [WZPRES]
in_PIN
employee_NN
demographics_NN
globally_RB
._.
By_PIN
45_CD
countries_NN
,_,
AstraZeneca_NN
is_VPRT [BEMA]
a_DT
major_JJ
the_DT
end_NN
of_PIN
the_DT
year_NN
,_,
this_DEMP
was_VBD [BEMA]
operational_JJ
employer_NN
worldwide_NN
._.
Our_FPP1
core_NN
values_NN
across_PLACE
the_DT
UK_NN
,_,
the_DT
US_FPP1
and_PHC
Sweden_NN
reflect_VPRT [PRIV]
our_FPP1
commitment_NOMZ
to_TO
ensuring_VBG [SUAV] [PRIV]
that_THVC
where_RB
more_EMPH
than_PIN
60_CD
%_NN
of_PIN
our_FPP1
employees_NN
all_QUAN
of_PIN
our_FPP1
people_NN
are_VPRT [PASS]
treated_VBN
with_PIN
integrity_NOMZ
are_VPRT [PASS]
located_VBN
and_CC
the_DT
rest_NN
of_PIN
the_DT
world_NN
is_VPRT
and_CC
respect_NN
within_PIN
a_DT
working_VBG
environexpected_VBN
to_TO
be_VB [PASS]
brought_VBN
into_PIN
the_DT
system_NN
ment_NOMZ
that_TSUB
recognizes_VPRT [PRIV]
the_DT
freedom_NN
of_PIN
the_DT
during_PIN
2004_CD
._.
individual_NN
._.
Working_VBG [PRESP]
with_PIN
suppliers_NN
AstraZeneca_NN
supports_VPRT
the_DT
principles_NN
set_VBN [WZPAST]
In_PIN
2003_CD
,_,
we_FPP1
published_VBD
a_DT
revised_VBN
CR_NN
out_PIN
in_PIN
the_DT
UN_NN
Declaration_NOMZ
of_PIN
Human_NN
Principles_NN
in_PIN
Purchasing_GER
guide_NN
which_WDT [WHOBJ]
Rights_NN
._.
Our_FPP1
Code_NN
of_PIN
Conduct_NN
and_CC
our_FPP1
included_VBN
further_JJ
guidance_NN
for_PIN
our_FPP1
Global_JJ
Human_NN
Resources_NN
policies_NN
detail_NN
purchasing_VBG [WZPRES]
community_NOMZ
in_PIN
working_VBG
with_PIN
the_DT
high_JJ
standards_NN
of_PIN
ethical_JJ
behavior_NN
suppliers_NN
to_TO
encourage_VB
similar_JJ
standards_NN
with_PIN
which_WDT [PIRE]
everyone_QUPR
in_PIN
AstraZeneca_NN
is_VPRT [BEMA]
to_PIN
our_FPP1
own_JJ
,_,
share_NN
best_JJ
practice_NN
and_CC
expected_VBN [PRIV]
to_TO
comply_VB
,_,
both_DT
in_PIN
spirit_NN
and_CC
stimulate_VB
improved_VBN
CR_NN
performance_NN
._.
Time_NN
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
to_TO [SPIN]
fully_AMP
implement_VB
these_DEMO
guidelines_NN
._.
This_DEMP
includes_VPRT
only_DWNT
employing_VBG
adults_NN
,_,
as_IN
defined_VBN
by_PIN
the_DT
labor_NN
laws_NN
in_PIN
the_DT
During_PIN
the_DT
year_NN
,_,
we_FPP1
continued_VBD
our_FPP1
countries_NN
in_PIN
which_WDT [PIRE]
we_FPP1
operate_VPRT
and_CC
,_,
program_NN
of_PIN
priority_NOMZ
audit_NN
of_PIN
main_JJ
as_IN
a_DT
minimum_NN
,_,
compliance_NN
with_PIN
national_JJ
suppliers_NN
._.
In_PIN
total_JJ
,_,
14_CD
sites_NN
were_VBD [BEMA]
audited_JJ
legal_JJ
requirements_NOMZ
regarding_VBG [WZPRES]
wages_NN
and_CC
at_PIN
our_FPP1
major_JJ
chemical_NN
suppliers_NN
._.
All_QUAN
our_FPP1
employees_NN
have_VPRT
potential_JJ
new_JJ
chemical_NN
suppliers_NN
were_VBD [BEMA]
the_DT
right_NN
to_TO
be_VB [BEMA]
a_DT
member_NN
of_PIN
a_DT
trade_NN
also_RB
audited_VBD
and_CC
at_PIN
one_CD
of_PIN
these_DEMP
,_,
we_FPP1
union_NN
._.
We_FPP1
have_VPRT
agreements_NOMZ
with_PIN
trade_NN
identified_VBD
the_DT
need_NN
for_PIN
an_DT
improvement_NOMZ
unions_NN
in_PIN
a_DT
number_NN
of_PIN
countries_NN
where_RB
in_PIN
standards_NN
before_IN
any_QUAN
work_NN
could_POMD
be_VB [BEMA]
collective_JJ
bargaining_GER
is_VPRT [BEMA]
customary_PRED
commissioned_VBN
by_PIN
AstraZeneca_NN
._.
practice_NN
within_PIN
a_DT
countrys_NN
legal_JJ
framework_NN
and_ANDC
where_RB
employees_NN
CR_NN
is_VPRT [SPAU]
also_RB
being_VBG [PASS]
integrated_VBN
into_PIN
the_DT
support_NN
it_PIT
._.
regular_JJ
business_NOMZ
control_NN
meetings_GER
that_TSUB
are_VPRT
being_VBG [PASS]
introduced_VBN
into_PIN
our_FPP1
purchasing_VBG
We_FPP1
also_RB
work_VPRT
closely_RB
with_PIN
our_FPP1
major_JJ
practice_NN
._.
In_PIN
2003_CD
,_,
approximately_RB
150_CD
suppliers_NN
and_CC
use_VB
purchasing_VBG
practices_NN
meetings_GER
that_TSUB
took_VBD
place_NN
included_VBD
CR_NN
to_TO
encourage_VB
similar_JJ
standards_NN
to_PIN
our_FPP1
considerations_NOMZ
._.
We_FPP1
do_VPRT
not_XX0
think_VB [PRIV] [THATD]
it_PIT
is_VPRT [BEMA]
appropriate_PRED
for_PIN
AstraZeneca_NN
to_TO
promote_VB
individual_JJ
rights_NN
and_PHC
freedoms_NN
more_EMPH
widely_RB
in_PIN
society_NN
,_,
but_CC
we_FPP1
believe_VPRT [PRIV]
that_THVC
we_FPP1
can_POMD
and_CC
do_EMPH
influence_VB
others_NN
through_PIN
leading_VBG
by_PIN
example_NN
._.
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
12_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
Social_NN
performance_NN
continued_VBD
To_PIN
that_DEMO
end_NN
,_,
we_FPP1
are_VPRT
increasing_VBG
the_DT
Employee_NN
safety_NN
,_,
health_NN
and_CC
particularly_RB
encouraging_JJ
decrease_NN
in_PIN
the_DT
wellbeing_JJ
emphasis_NN
on_PIN
the_DT
management_NOMZ
of_PIN
driving_VBG
two_CD
major_JJ
areas_NN
of_PIN
work-related_JJ
upper_JJ
We_FPP1
believe_VPRT [PRIV]
that_THVC
if_COND
we_FPP1
are_VPRT
to_TO
expect_VB [PRIV]
activities_NOMZ
in_PIN
our_FPP1
marketing_GER
companies_NN
limb_NN
disorder_NN
and_CC
work-related_JJ
stress_NN
peoples_NN
continued_VBD
energy_NN
and_CC
around_PLACE
the_DT
world_NN
._.
commitment_NOMZ
at_PIN
work_NN
,_,
we_FPP1
must_NEMD
provide_VB
a_DT
common_JJ
cause_NN
for_PIN
concern_NN
for_PIN
many_QUAN
the_DT
right_JJ
environment_NOMZ
in_PIN
which_WDT [PIRE]
they_TPP3
feel_VPRT [PRIV]
companies_NN
and_CC
we_FPP1
are_VPRT
working_VBG
together_RB
Diversity_NOMZ
safe_JJ
and_CC
well_RB
and_CC
positive_JJ
and_CC
with_PIN
other_JJ
organizations_NOMZ
to_TO
share_VB
Our_FPP1
approach_NN
to_PIN
diversity_NOMZ
takes_VPRT
account_NN
enthusiastic_JJ
about_IN
what_WP
they_TPP3
are_VPRT
doing_VBG [PROD]
._.
of_PIN
all_QUAN
the_DT
ways_NN
in_PIN
which_WDT [PIRE]
our_FPP1
employees_NN
Our_FPP1
broad_JJ
range_NN
of_PIN
occupational_JJ
safety_NN
are_VPRT [BEMA]
different_PRED
not_XX0
just_EMPH
in_PIN
terms_NN
of_PIN
gender_NN
and_PHC
health_NN
programs_NN
is_VPRT [PASS]
focused_VBN
on_PIN
In_PIN
2003_CD
,_,
our_FPP1
overall_JJ
frequency_NN
rate_NN
for_PIN
and_CC
race_NN
,_,
but_CC
also_RB
culture_NN
,_,
age_NN
,_,
ability_NOMZ
continuous_JJ
improvement_NOMZ
in_PIN
the_DT
accidents_NN
with_PIN
fatal_JJ
and_PHC
serious_JJ
injuries_NN
to_TO
and_CC
family_NN
situation_NOMZ
._.
We_FPP1
value_VPRT
the_DT
frequency_NN
rates_NN
for_PIN
accidents_NN
with_PIN
injury_NN
AstraZeneca_NN
employees_NN
and_PHC
contractors_NN
creative_JJ
energy_NN
that_TOBJ
these_DEMO
differences_NN
and_CC
for_PIN
new_JJ
cases_NN
of_PIN
occupational_NN
fell_VBD
by_PIN
13_CD
%_NN
._.
This_DEMP
is_VPRT [BEMA]
largely_RB
due_PRED
to_PIN
an_DT
bring_VB
to_PIN
our_FPP1
business_NOMZ
._.
illness_NOMZ
,_,
with_PIN
a_DT
target_NN
for_PIN
achieving_VBG
a_DT
30_CD
%_NN
improvement_NOMZ
in_PIN
contractor_NN
performance_NN
._.
reduction_NOMZ
against_PIN
the_DT
2001_CD
2002_CD
In_PIN
2002_CD
,_,
we_FPP1
identified_VBD
that_DEMO
we_FPP1
had_VBD
reference_NN
point_NN
by_PIN
the_DT
end_NN
of_PIN
2005_CD
._.
To_PIN
Our_FPP1
wellbeing_JJ
programs_NN
are_VPRT [PASS]
designed_VBN
work_NN
to_TO
do_VB
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
diversity_NOMZ
is_VPRT
help_VB
us_FPP1
meet_VB
this_DEMO
target_NN
,_,
we_FPP1
continue_VPRT
to_TO
to_TO
promote_VB
physical_JJ
and_PHC
psychological_JJ
appropriately_RB
supported_VBN
in_PIN
our_FPP1
workdevelop_NN
behaviour-based_JJ
safety_NN
and_PHC
welfare_NN
and_CC
include_VPRT
physical_JJ
fitness_NOMZ
force_NN
and_CC
reflected_VBN [PRIV]
in_PIN
our_FPP1
leadership_NN
._.
health_NN
programs_NN
and_CC
make_VB
them_TPP3
activities_NOMZ
,_,
nutrition_NOMZ
advice_NN
and_PHC
stress_NN
We_FPP1
made_VBD
some_QUAN
progress_NN
during_PIN
2003_CD
._.
widely_RB
available_JJ
._.
When_RB
accidents_NN
occur_VPRT
,_,
management_NOMZ
courses_NN
._.
Examples_NN
of_PIN
good_JJ
Our_FPP1
R&D_NN
community_NOMZ
,_,
which_WDT [SERE]
has_VPRT [PEAS]
been_VBN [BEMA]
we_FPP1
investigate_VPRT
thoroughly_AMP
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
we_FPP1
practice_VB
from_PIN
Europe_NN
,_,
Asia_NN
,_,
North_NN
and_CC
active_JJ
for_PIN
some_QUAN
time_NN
in_PIN
this_DEMO
area_NN
,_,
understand_VPRT [PRIV] [THATD]
the_DT
root_NN
causes_VPRT
,_,
take_VB
steps_NN
South_NN
America_NN
feature_NN
prominently_RB
in_PIN
our_FPP1
introduced_VBN
an_DT
innovative_JJ
,_,
interactive_JJ
to_TO
avoid_VB
repetition_NOMZ
in_PIN
the_DT
future_NN
and_PHC
improvement_NOMZ
plans_NN
and_CC
are_VPRT [PASS]
shared_VBN
diversity_NOMZ
program_NN
which_WDT [WHSUB]
is_VPRT
being_VBG
communicate_VPRT
to_TO
build_VB
awareness_NOMZ
and_PHC
worldwide_NN
through_PIN
our_FPP1
Wellbeing_VBG
in_PIN
rolled_VBN
out_PIN
to_PIN
the_DT
R&D_NN
workforce_NN
._.
Programmes_NN
vary_VPRT
depending_VBG
on_PIN
country_NN
,_,
In_CONJ
addition_NULL
,_,
diversity_NOMZ
improvement_NOMZ
plans_VPRT
Although_CONC
our_FPP1
overall_JJ
accident_NN
frequency_NN
culture_NN
and_PHC
need_NN
._.
They_TPP3
include_VPRT
flexible_JJ
were_VBD [PASS]
created_VBN
and_PHC
implemented_VBN
for_PIN
the_DT
rate_NN
for_PIN
employees_NN
improved_VBN [WZPAST]
by_PIN
5_CD
%_NN
in_PIN
working_VBG
arrangements_NOMZ
,_,
access_NN
to_PIN
fitness_NOMZ
six_CD
major_JJ
areas_NN
of_PIN
R&D_NN
._.
Our_FPP1
Operations_NOMZ
2003_CD
,_,
we_FPP1
are_VPRT [PASS]
disappointed_VBN
that_DEMO
we_FPP1
and_CC
social_JJ
activities_NOMZ
and_PHC
support_NN
for_PIN
staff_NN
group_NN
included_VBD
as_IN
one_CD
of_PIN
their_TPP3
three_CD
showed_VBD [PRIV]
little_JJ
improvement_NOMZ
in_PIN
our_FPP1
vehicle_NN
experiencing_VBG [WZPRES]
stress_NN
._.
Communications_NOMZ
to_PIN
global_JJ
people_NN
targets_VPRT
the_DT
requirement_NOMZ
accident_NN
record_NN
._.
Around_PLACE
a_DT
third_JJ
of_PIN
the_DT
help_NN
ensure_VB [SUAV] [PRIV]
that_THVC
employee_NN
wellbeing_VBG [WZPRES]
that_DEMO
each_QUAN
of_PIN
our_FPP1
20_CD
manufacturing_GER
sites_NN
total_VPRT
accidents_NN
reported_VBD [PUBV]
including_VBG
one_CD
remains_VPRT
high_JJ
on_PIN
the_DT
agenda_NN
include_VPRT
faceshould_JJ
prepare_VPRT
priority_NOMZ
action_NOMZ
plans_VPRT
fatal_JJ
accident_NN
in_PIN
Germany_NN
were_VBD [PASS]
related_VBN
to-face_JJ
discussions_NN
with_PIN
the_DT
top_JJ
200_CD
addressing_VBG
their_TPP3
diversity_NOMZ
needs_VPRT
._.
This_DEMP
remains_VPRT
the_DT
greatest_JJ
managers_NN
in_PIN
the_DT
Company_NN
,_,
addressing_VBG [PRESP]
the_DT
year_NN
,_,
around_PLACE
15_CD
plans_NN
were_VBD
cause_NN
of_PIN
accidents_NN
with_PIN
injury_NN
to_PIN
their_TPP3
personal_JJ
wellbeing_GER
and_CC
that_DEMO
of_PIN
their_TPP3
completed_VBN
._.
With_PIN
seven_CD
diversity_NOMZ
plans_NN
in_PIN
AstraZeneca_NN
employees_NN
._.
place_NN
in_PIN
the_DT
US_FPP1
,_,
our_FPP1
total_NN
is_VPRT [SPAU]
now_TIME
around_PLACE
has_VPRT [SPAU] [PEAS]
always_RB
been_VBN [BEMA]
a_DT
core_NN
feature_NN
of_PIN
our_FPP1
28_CD
programs_NN
._.
safety_NN
education_NOMZ
programs_NN
,_,
but_CC
we_FPP1
In_PIN
2003_CD
,_,
our_FPP1
overall_JJ
frequency_NN
rate_NN
of_PIN
recognize_VB [PRIV]
,_,
and_ANDC
take_VB
seriously_RB
,_,
the_DT
need_NN
occupational_JJ
illnesses_NOMZ
per_PIN
million_CD
hours_NN
Our_FPP1
challenge_NN
is_VPRT
to_TO
build_VB
on_PIN
this_DEMO
work_NN
and_CC
to_TO
improve_VB
our_FPP1
performance_NN
in_PIN
this_DEMO
area_NN
._.
worked_VBD
improved_VBN
by_PIN
47_CD
%_NN
,_,
with_PIN
a_DT
continue_VPRT
to_TO
drive_VB
improvement_NOMZ
in_PIN
other_JJ
Pilot_NN
projects_NN
that_TSUB
aim_VPRT
In_PIN
the_DT
US_FPP1
,_,
our_FPP1
to_TO
build_VB
understanding_GER
senior_JJ
managers_NN
of_PIN
the_DT
causes_NN
of_PIN
minor_JJ
and_CC
their_TPP3
direct_JJ
vehicle_NN
accidents_NN
to_PIN
reports_NN
all_QUAN
reduce_VPRT
the_DT
likelihood_NN
attended_VBD
diversity_NOMZ
of_PIN
more_EMPH
serious_JJ
ones_NN
training_GER
and_CC
occurring_VBG
will_PRMD
be_VB [PASS]
started_VBN
work_NN
implemented_VBN [WZPAST]
in_PIN
on_PIN
developing_VBG
Europe_NN
,_,
Asia_NN
Pacific_NN
diversity_NOMZ
action_NOMZ
and_CC
the_DT
Americas_NN
._.
plans_NN
for_PIN
their_TPP3
This_DEMP
is_VPRT [BEMA]
in_CONJ
addition_NULL
to_PIN
functional_JJ
areas_NN
._.
the_DT
defensive_JJ
driver_NN
Seven_CD
plans_NN
were_VBD
training_GER
programs_NN
completed_VBN [WZPAST]
by_PIN
the_DT
that_DEMP
are_VPRT
already_RB
end_NN
of_PIN
the_DT
year_NN
._.
com_NN
13_CD
we_FPP1
added_VBD [PUBV]
sales_NN
and_PHC
marketing_GER
practices_NN
areas_NN
of_PIN
our_FPP1
organization_NOMZ
,_,
at_PIN
all_QUAN
levels_NN
._.
For_CONJ
example_NULL
,_,
direct_JJ
to_PIN
Senior_NN
Executive_NN
Team_NN
has_VPRT
responsibility_NOMZ
to_PIN
the_DT
Corporate_JJ
Responsibility_NOMZ
Priority_NOMZ
consumer_NN
advertising_GER
of_PIN
prescription_NOMZ
for_PIN
reviewing_VBG
the_DT
diversity_NOMZ
among_PIN
the_DT
top_JJ
Action_NOMZ
Plan_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
they_TPP3
continue_VPRT
to_PIN
medicines_NN
is_VPRT [BEMA]
illegal_PRED
in_PIN
many_QUAN
countries_NN
,_,
management_NOMZ
of_PIN
the_DT
Company_NN
,_,
including_VBG
get_VB
the_DT
appropriate_JJ
high_JJ
level_NN
of_PIN
attention_NOMZ
yet_CC
it_PIT
is_VPRT [BEMA]
not_XX0
only_DWNT
legal_JJ
in_PIN
the_DT
US_FPP1
but_CC
also_RB
the_DT
percentage_NN
of_PIN
women_NN
at_PIN
a_DT
senior_JJ
globally_RB
._.
Our_FPP1
AstraZeneca_NN
Code_NN
of_PIN
Sales_NN
considered_VBN [PRIV] [WZPAST]
by_PIN
many_QUAN
to_TO
have_VB
a_DT
positive_JJ
level_NN
._.
In_PIN
2003_CD
,_,
13_CD
%_NN
of_PIN
our_FPP1
200_CD
most_EMPH
and_CC
Marketing_GER
Practices_NN
outlines_VPRT
the_DT
influence_NN
on_PIN
patient_JJ
welfare_NN
._.
During_PIN
senior_JJ
managers_NN
were_VBD
women_NN
._.
high_JJ
standards_NN
of_PIN
ethical_JJ
behavior_NN
we_FPP1
2003_CD
,_,
we_FPP1
tested_VBD
draft_NN
reporting_VBG [PUBV] [WZPRES]
criteria_NN
demand_NN
in_PIN
the_DT
marketing_GER
of_PIN
our_FPP1
which_WDT
we_FPP1
hope_VPRT [PRIV]
will_PRMD
lay_VB
a_DT
basis_NN
for_PIN
a_DT
Sales_NN
and_PHC
marketing_GER
practices_NN
medicines_NN
._.
It_PIT
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
global_JJ
meaningful_JJ
global_JJ
promotional_JJ
During_PIN
2003_CD
,_,
AstraZeneca_NN
settled_VBD
an_DT
industry_NN
code_NN
of_PIN
conduct_NN
the_DT
IFPMA_NN
regulatory_JJ
monitoring_GER
system_NN
which_WDT [WHOBJ]
investigation_NOMZ
into_PIN
US_FPP1
sales_NN
and_PHC
Code_NN
of_PIN
Pharmaceutical_NN
Marketing_GER
takes_VPRT
account_NN
of_PIN
the_DT
different_JJ
national_JJ
marketing_GER
practices_NN
for_PIN
Zoladex_NN
prostate_NN
Practice_NN
,_,
as_RB
well_RB
as_IN
the_DT
codes_NN
of_PIN
environments_NOMZ
._.
We_FPP1
have_VPRT [PEAS]
established_VBN [PRIV]
a_DT
cancer_NN
treatment_NOMZ
,_,
admitting_VBG [PUBV]
violation_NOMZ
of_PIN
marketing_GER
practice_NN
,_,
laws_NN
and_PHC
regulations_NOMZ
global_JJ
network_NN
of_PIN
promotional_JJ
standards_NN
the_DT
Prescription_NOMZ
Drug_NN
Marketing_GER
Act_NN
by_PIN
applicable_JJ
in_PIN
each_QUAN
of_PIN
the_DT
countries_NN
in_PIN
contacts_NN
in_PIN
our_FPP1
marketing_GER
companies_NN
providing_VBG [WZPRES]
free_JJ
samples_NN
of_PIN
the_DT
product_NN
to_PIN
which_WDT [PIRE]
we_FPP1
operate_VPRT
._.
The_DT
IFPMA_NN
Code_NN
and_CC
known_VBN [PRIV]
as_IN
Nominated_VBN
Signatories_NN
and_PHC
physicians_NN
between_PIN
1993_CD
and_CC
1996_CD
,_,
our_FPP1
own_JJ
Code_NN
of_PIN
Practice_NN
embody_VPRT
the_DT
have_VPRT [PEAS]
begun_VBN
to_TO
share_VB
experience_NN
and_CC
with_PIN
the_DT
understanding_GER
that_TOBJ
these_DEMO
principles_NN
proposed_VBN [SUAV] [WZPAST]
in_PIN
the_DT
World_NN
Health_NN
best_JJ
practice_NN
amongst_PIN
this_DEMO
group_NN
._.
physicians_NN
would_PRMD
bill_VB
Medicare_NN
for_PIN
Organisations_NOMZ
Ethical_NN
Criteria_NN
for_PIN
reimbursement_NOMZ
._.
AstraZeneca_NN
also_RB
Medicinal_NN
Drug_NN
Promotion_NOMZ
,_,
although_CONC
the_DT
Clinical_JJ
trials_NN
settled_VBD
civil_JJ
claims_NN
,_,
without_PIN
admitting_VBG [PUBV]
WHO_WP [WHCL]
suggestion_NOMZ
that_DEMO
advertising_GER
of_PIN
A_DT
potential_JJ
new_JJ
medicine_NN
enters_VPRT
clinical_JJ
liability_NOMZ
,_,
involving_VBG
allegations_NOMZ
that_TOBJ
the_DT
prescription_NOMZ
medicines_NN
to_PIN
the_DT
public_JJ
studies_NN
only_DWNT
after_IN
its_PIT
potential_JJ
efficacy_NN
Company_NN
provided_VBD
inducements_NOMZ
to_TO
should_NEMD
not_XX0
generally_RB
be_VB [PASS]
permitted_VBN
is_VPRT
not_XX0
and_CC
adequate_JJ
safety_NN
has_VPRT [PEAS]
been_VBN [PASS]
confirmed_VBN [PUBV]
physicians_NN
to_TO
purchase_VB
Zoladex_NN
and_CC
for_PIN
consistent_JJ
with_PIN
the_DT
law_NN
or_CC
self-regulatory_JJ
in_PIN
pre-clinical_JJ
trials_NN
,_,
which_WDT [SERE]
include_VPRT
animal_JJ
improperly_RB
setting_VBG
and_PHC
reporting_VBG [PUBV]
its_PIT
standards_NN
in_PIN
certain_JJ
countries_NN
notably_RB
testing_VBG
._.
All_QUAN
proposed_VBN [SUAV] [THATD]
clinical_JJ
trials_NN
are_VPRT
price_NN
._.
The_DT
settlement_NOMZ
provides_VPRT
for_PIN
a_DT
five_CD
the_DT
US_FPP1
._.
reviewed_VBN
and_PHC
approved_VBN
including_VBG
year_NN
Corporate_JJ
Integrity_NOMZ
Agreement_NOMZ
with_PIN
consideration_NOMZ
of_PIN
the_DT
pre-clinical_JJ
data_NN
,_,
the_DT
Office_NN
of_PIN
the_DT
Inspector_NN
General_NN
OIG_NN
Compliance_NN
with_PIN
our_FPP1
Code_NN
is_VPRT [BEMA]
the_DT
safety_NN
of_PIN
the_DT
trial_NN
and_CC
the_DT
nature_NN
and_CC
for_PIN
the_DT
Department_NOMZ
of_PIN
Health_NN
and_CC
mandatory_JJ
._.
Whilst_OSUB
we_FPP1
have_VPRT
local_JJ
amount_NN
of_PIN
information_NOMZ
given_VBN [WZPAST]
to_PIN
trial_NN
Human_NN
Services_NN
under_IN
which_WDT
monitoring_GER
systems_NN
in_PIN
place_NN
,_,
including_VBG
volunteers_NN
._.
We_FPP1
have_VPRT
strict_JJ
guidelines_NN
to_PIN
AstraZeneca_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
keep_VB
in_PIN
place_NN
auditing_GER
of_PIN
our_FPP1
marketing_GER
companies_NN
ensure_VB [SUAV] [PRIV]
that_THVC
volunteers_NN
and_PHC
patients_NN
taking_VBG [WZPRES]
its_PIT
current_JJ
compliance_NN
program_NN
and_CC
by_PIN
Group_NN
Internal_NN
Audit_NN
,_,
we_FPP1
are_VPRT
now_TIME
part_NN
in_PIN
trials_NN
understand_VPRT [PRIV] [THATD]
their_TPP3
purpose_NN
provide_VB
periodic_JJ
reports_NN
to_PIN
the_DT
OIG_NN
on_PIN
looking_VBG
to_TO
establish_VB [PRIV]
KPIs_NN
in_PIN
this_DEMO
area_NN
and_CC
are_VPRT [PASS]
not_XX0
exposed_VBN
to_PIN
unnecessary_JJ
risks_NN
the_DT
status_NN
of_PIN
compliance_NN
activities_NOMZ
._.
The_DT
that_DEMP
will_PRMD
enable_VB
improved_VBN
reporting_GER
of_PIN
and_CC
that_THVC
the_DT
privacy_NN
of_PIN
health_NN
information_NOMZ
total_JJ
payment_NOMZ
associated_VBN [WZPAST]
with_PIN
the_DT
our_FPP1
global_JJ
performance_NN
._.
A_DT
variety_NN
of_PIN
of_PIN
individuals_NN
taking_VBG [WZPRES]
part_NN
is_VPRT [PASS]
protected_VBN
._.
legal_JJ
,_,
regulatory_JJ
and_PHC
self-regulatory_JJ
mechanisms_NN
are_VPRT [PASS]
applied_VBN
to_TO
pharmaWe_VB
continue_VB
to_TO
monitor_VB
the_DT
safety_NN
of_PIN
our_FPP1
We_FPP1
are_VPRT [PASS]
committed_VBN
to_TO
ensuring_VBG [SUAV] [PRIV]
that_THVC
ceutical_JJ
marketing_GER
activities_NOMZ
around_PLACE
products_NN
after_IN
they_TPP3
have_VPRT [PEAS]
been_VBN [PASS]
approved_VBN
improper_JJ
practice_NN
such_JJ
as_IN
this_DEMP
is_VPRT [BEMA]
not_XX0
the_DT
world_NN
and_CC
different_JJ
interpretations_NOMZ
as_IN
new_JJ
medicines_NN
,_,
including_VBG
collection_NOMZ
repeated_VBN [PUBV]
._.
In_CONJ
addition_NULL
to_PIN
the_DT
strong_JJ
US_FPP1
of_PIN
what_WP
constitutes_VPRT
acceptable_JJ
practice_NN
of_PIN
data_NN
on_PIN
any_QUAN
adverse_JJ
reactions_NOMZ
to_PIN
a_DT
compliance_NN
program_NN
,_,
during_PIN
the_DT
year_NN
exist_VPRT
according_VBG
to_PIN
national_JJ
cultures_NN
and_PHC
treatment_NOMZ
._.
Within_PIN
the_DT
UK_NN
During_PIN
2003_CD
,_,
FTSE100_CD
,_,
an_DT
employee_NN
AstraZeneca_NN
is_VPRT [BEMA]
one_CD
assistance_NN
of_PIN
two_CD
companies_NN
program_NN
,_,
CALM_NN
with_PIN
the_DT
highest_JJ
Counselling_GER
and_PHC
representation_NOMZ
of_PIN
Life_NN
Management_NOMZ
women_NN
on_PIN
the_DT
was_VBD [PASS]
made_VBN
available_JJ
Board_NN
four_CD
out_PIN
to_PIN
staff_NN
in_PIN
Japan_NN
._.
of_PIN
13_CD
Board_NN
members_NN
are_VPRT
women_NN
._.
Jane_NN
Henney_NN
Dame_NN
Bridget_NN
Ogilvie_NN
Erna_NN
Mller_NN
Michele_NN
Hooper_NN
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
14_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
Social_NN
performance_NN
continued_VBD
reduction_NOMZ
include_VPRT
our_FPP1
commitment_NOMZ
to_PIN
Animal_NN
welfare_NN
our_FPP1
products_NN
whilst_OSUB
continuing_VBG
our_FPP1
Laboratory_NN
animals_NN
continue_VPRT
to_TO
play_VB
a_DT
adopting_VBG
alternative_NN
techniques_NN
._.
investment_NOMZ
in_PIN
research_NN
and_CC
ensuring_VBG [SUAV] [PRIV]
vital_JJ
and_PHC
necessary_JJ
role_NN
in_PIN
the_DT
research_NN
that_DEMO
wherever_RB
possible_JJ
medicines_NN
are_VPRT
and_CC
development_NOMZ
of_PIN
new_JJ
medicines_NN
for_PIN
The_DT
welfare_NN
of_PIN
the_DT
animals_NN
we_FPP1
use_VPRT
is_VPRT [BEMA]
available_PRED
to_PIN
those_DEMO
that_DEMP
need_VPRT
them_TPP3
._.
important_JJ
areas_NN
of_PIN
human_JJ
healthcare_NN
._.
Our_FPP1
research_NN
sites_NN
are_VPRT [BEMA]
This_DEMP
includes_VPRT
early_TIME
testing_GER
of_PIN
the_DT
effects_NN
of_PIN
subject_JJ
to_PIN
formal_JJ
inspections_NOMZ
by_PIN
our_FPP1
Although_CONC
essential_JJ
medicines_NN
are_VPRT [BEMA]
new_JJ
compounds_NN
and_CC
the_DT
requirement_NOMZ
by_PIN
own_JJ
staff_NN
every_QUAN
two_CD
years_NN
in_CONJ
addition_NULL
to_TO
becoming_VBG
increasingly_RB
available_JJ
to_PIN
those_DEMO
regulatory_JJ
authorities_NOMZ
for_PIN
the_DT
submission_NN
the_DT
mandatory_JJ
visits_NN
by_PIN
government_NOMZ
that_TSUB
need_VPRT
them_TPP3
in_PIN
developing_VBG
countries_NN
,_,
of_PIN
safety_NN
data_NN
from_PIN
animal_JJ
studies_NN
before_IN
authorities_NOMZ
around_PLACE
the_DT
world_NN
._.
Meeting_VBG
there_EX
are_VPRT
still_RB
many_QUAN
other_JJ
factors_NN
such_EMPH
a_NULL
new_JJ
medicine_NN
can_POMD
be_VB [PASS]
tested_VBN
in_PIN
healthy_JJ
local_JJ
regulatory_JJ
requirements_NOMZ
is_VPRT [BEMA]
a_DT
as_RB
basic_JJ
hygiene_NN
,_,
healthcare_NN
infravolunteers_NN
and_CC
then_RB
patients_NN
._.
minimum_JJ
baseline_NN
and_CC
we_FPP1
have_VPRT
our_FPP1
structure_NN
and_PHC
training_GER
and_PHC
education_NOMZ
own_JJ
strict_JJ
guidelines_NN
on_PIN
animal_NN
welfare_NN
that_TSUB
are_VPRT
also_RB
pre-requisites_NN
before_IN
As_IN
we_FPP1
continue_VPRT
to_TO
expand_VB
our_FPP1
R&D_NN
as_IN
outlined_VBN
in_PIN
our_FPP1
Bioethics_NN
Policy_NN
and_CC
significant_JJ
progress_NN
can_POMD
be_VB [PASS]
made_VBN
in_PIN
activity_NOMZ
,_,
we_FPP1
aim_VPRT
to_TO
manage_VB
the_DT
potential_JJ
supported_VBN
by_PIN
programs_NN
such_JJ
as_IN
delivering_VBG
medicines_NN
to_PIN
patients_NN
in_PIN
increase_NN
in_PIN
use_NN
of_PIN
animals_NN
by_PIN
adopting_VBG
animal_NN
care_NN
training_GER
for_PIN
our_FPP1
laboratory_NN
these_DEMO
countries_NN
._.
alternative_NN
techniques_NN
such_JJ
as_IN
technicians_NN
._.
computer_NN
simulations_NOMZ
,_,
informatics_NN
and_CC
Each_QUAN
of_PIN
our_FPP1
development_NOMZ
products_NN
is_VPRT [BEMA]
high_JJ
throughput_NN
screening_GER
,_,
which_WDT [SERE]
Where_RB
we_FPP1
outsource_VPRT
animal_JJ
studies_NN
to_TO
reviewed_VBN
independently_RB
in_PIN
relation_NOMZ
to_TO
eliminate_VB
the_DT
use_NN
of_PIN
animals_NN
or_CC
reduce_VB
give_VB
us_FPP1
access_NN
to_PIN
additional_JJ
expertise_NN
pricing_GER
and_PHC
access_NN
in_PIN
all_QUAN
markets_NN
,_,
so_IN
the_DT
number_NN
needed_VBN
._.
As_RB
well_RB
as_IN
or_CC
capacity_NOMZ
,_,
inspections_NOMZ
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
plans_NN
can_POMD
be_VB [PASS]
put_VBN
in_PIN
place_NN
early_TIME
for_PIN
developing_VBG
our_FPP1
own_JJ
alternatives_NN
,_,
we_FPP1
also_RB
compliance_NN
with_PIN
our_FPP1
own_JJ
standards_NN
those_DEMP
which_WDT
may_POMD
be_VB [PASS]
regarded_VBN
as_IN
adopt_VB
those_DEMO
successfully_RB
developed_VBN
by_PIN
are_VPRT [BEMA]
a_DT
significant_JJ
part_NN
of_PIN
our_FPP1
animal_NN
essential_JJ
medicines_NN
either_CC
because_CAUS
others_NN
and_CC
we_FPP1
continue_VPRT
to_TO
work_VB
,_,
welfare_NN
program_NN
._.
they_TPP3
address_VPRT
diseases_NN
prevalent_JJ
in_PIN
alongside_PLACE
the_DT
rest_NN
of_PIN
the_DT
pharmaceutical_JJ
developing_VBG
countries_NN
or_CC
because_CAUS
they_TPP3
industry_NN
,_,
with_PIN
regulatory_JJ
authorities_NOMZ
to_PIN
Access_NN
to_PIN
medicines_NN
are_VPRT [BEMA]
potentially_RB
a_DT
leading_VBG
or_CC
unique_JJ
agree_VPRT [SUAV] [PUBV]
reductions_NOMZ
wherever_RB
possible_JJ
in_PIN
The_DT
increasing_VBG
demand_NN
for_PIN
new_JJ
product_NN
in_PIN
their_TPP3
class_NN
,_,
offering_VBG [PRESP]
the_DT
animals_NN
required_VBN [SUAV] [WZPAST]
by_PIN
their_TPP3
protocols_NN
._.
medicines_NN
that_TSUB
improve_VPRT
and_PHC
extend_VPRT
lives_NN
significant_JJ
patient_NN
benefit_NN
in_PIN
a_DT
serious_JJ
is_VPRT [PASS]
driven_VBN
both_DT
by_PIN
the_DT
ageing_JJ
population_NOMZ
or_CC
life_NN
threatening_JJ
condition_NOMZ
._.
In_PIN
these_DEMO
In_PIN
2002_CD
,_,
we_FPP1
used_VBD
around_PLACE
242,000_CD
and_CC
advances_NN
in_PIN
technology_NN
._.
At_PIN
the_DT
circumstances_NN
,_,
we_FPP1
aim_VPRT
to_TO
make_VB
animals_NN
,_,
a_DT
small_JJ
reduction_NOMZ
on_PIN
2001_CD
same_JJ
time_NN
infectious_JJ
diseases_NN
such_JJ
as_IN
arrangements_NOMZ
to_TO
ensure_VB [SUAV] [PRIV]
patient_JJ
access_NN
248,000_CD
._.
Some_QUAN
98_CD
%_NN
of_PIN
these_DEMP
were_VBD
HIV_NN
AIDS_NN
are_VPRT
threatening_VBG
to_TO
overwhelm_VB
to_PIN
these_DEMO
medicines_NN
through_PIN
charitable_JJ
rodents_NN
and_PHC
fish_NN
._.
Approximately_RB
4_CD
%_NN
were_VBD [BEMA]
the_DT
populations_NOMZ
of_PIN
some_QUAN
of_PIN
the_DT
least_JJ
donation_NOMZ
,_,
expanded_VBD
access_NN
used_VBN [WZPAST]
by_PIN
external_JJ
contractors_NN
._.
Governments_NOMZ
are_VPRT
programs_NN
or_CC
differential_JJ
pricing_GER
._.
number_NN
of_PIN
animals_NN
we_FPP1
use_VPRT
each_QUAN
year_NN
will_PRMD
responding_VBG
in_PIN
different_JJ
ways_NN
to_TO
balance_VB
continue_VB
to_TO
fluctuate_VB
._.
Increases_NN
can_POMD
result_VB
healthcare_NN
budgets_NN
against_PIN
the_DT
ever_RB
The_DT
appointment_NOMZ
in_PIN
January_NN
2004_CD
of_PIN
from_PIN
a_DT
rise_NN
in_PIN
the_DT
number_NN
of_PIN
compounds_NN
increasing_VBG [WZPRES]
demand_NN
for_PIN
wider_JJ
access_NN
an_DT
Access_NN
to_PIN
Medicines_NN
Director_NN
,_,
a_DT
new_JJ
in_PIN
development_NOMZ
and_CC
from_PIN
our_FPP1
further_JJ
to_PIN
medicines_NN
._.
The_DT
challenge_NN
for_PIN
position_NOMZ
in_PIN
the_DT
Company_NN
,_,
strengthens_VPRT
adoption_NOMZ
of_PIN
tests_NN
using_VBG [WZPRES]
genetically_RB
AstraZeneca_NN
is_VPRT
to_TO
address_VB
the_DT
continued_VBN
our_FPP1
commitment_NOMZ
._.
Working_VBG [PRESP]
in_PIN
the_DT
modified_VBN
animals_NN
._.
Factors_NN
influencing_VBG [WZPRES]
a_DT
downward_JJ
pressure_NN
on_PIN
the_DT
costs_NN
of_PIN
Oncology_NN
and_PHC
Infection_NOMZ
therapy_NN
areas_NN
,_,
In_PIN
the_DT
UK_NN
,_,
AstraZeneca_NN
supports_VPRT
the_DT
Prior_RB
to_PIN
its_PIT
launch_NN
,_,
we_FPP1
implemented_VBD
an_DT
Brightside_NN
Trust_NN
,_,
a_DT
charity_NOMZ
that_TSUB
aims_VPRT
to_TO
help_VB
expanded_JJ
access_NN
program_NN
for_PIN
Iressa_NN
,_,
underprivileged_JJ
young_JJ
people_NN
enter_VPRT
the_DT
our_FPP1
new_JJ
treatment_NOMZ
for_PIN
lung_NN
cancer_NN
,_,
which_WDT [SERE]
medical_JJ
and_CC
healthcare_NN
professions_NN
._.
This_DEMP
made_VBD
the_DT
therapy_NN
available_JJ
to_PIN
patients_NN
with_PIN
addresses_NN
a_DT
particular_JJ
issue_NN
for_PIN
modern_JJ
lung_NN
cancer_NN
for_PIN
whom_WP [PIRE]
no_SYNE
other_JJ
treatment_NOMZ
medical_JJ
practice_NN
that_TOBJ
most_EMPH
disadvantaged_JJ
had_VBD [PEAS]
been_VBN [BEMA]
successful_PRED
._.
During_PIN
2002_CD
and_CC
communities_NOMZ
do_VPRT
not_XX0
have_VB
access_NN
to_PIN
2003_CD
,_,
over_IN
42,000_CD
patients_NN
in_PIN
70_CD
countries_NN
doctors_NN
with_PIN
a_DT
similar_JJ
background_NN
._.
Our_FPP1
received_VBN
Iressa_NN
through_PIN
this_DEMO
route_NN
._.
support_NN
includes_VPRT
a_DT
one_CD
year_NN
secondment_NOMZ
to_PIN
the_DT
charity_NOMZ
as_RB
well_RB
as_IN
a_DT
$_$
160,000_CD
financial_JJ
contribution_NOMZ
over_IN
three_CD
years_NN
._.
com_NN
15_CD
In_PIN
all_QUAN
cases_NN
of_PIN
facilitating_VBG
access_NN
to_PIN
our_FPP1
the_DT
role_NN
will_PRMD [SPAU]
initially_TIME
focus_VB
on_PIN
Iressa_NN
,_,
our_FPP1
In_PIN
2003_CD
,_,
our_FPP1
spend_VPRT
on_PIN
community_NOMZ
new_JJ
lung_NN
cancer_NN
treatment_NOMZ
,_,
and_ANDC
other_JJ
medicines_NN
,_,
we_FPP1
can_POMD [SPAU]
only_DWNT
be_VB [BEMA]
successful_JJ
sponsorships_NN
and_CC
charitable_JJ
donations_NOMZ
emerging_VBG [WZPRES]
treatments_NOMZ
for_PIN
cancer_NN
._.
if_COND
we_FPP1
can_POMD
ensure_VB [SUAV] [PRIV]
that_THVC
the_DT
product_NN
is_VPRT [PASS]
not_XX0
totalled_VBN
$_$
22_CD
million_CD
._.
diverted_VBN [PASTP]
away_PLACE
from_PIN
those_DEMP
who_WP
need_VPRT
it_PIT
Whilst_OSUB
we_FPP1
support_VPRT
the_DT
concept_NN
of_PIN
and_CC
that_THVC
we_FPP1
retain_VPRT
intellectual_JJ
property_NN
Improving_GER
data_NN
collection_NOMZ
differential_JJ
pricing_GER
in_PIN
this_DEMO
context_NN
,_,
we_FPP1
rights_NN
which_WDT [WHSUB]
enable_VPRT
us_FPP1
to_TO
protect_VB
our_FPP1
In_PIN
2002_CD
,_,
we_FPP1
introduced_VBD
a_DT
central_JJ
continue_VPRT
to_TO
seek_VB
safeguards_NN
that_DEMO
core_NN
business_NOMZ
and_CC
provide_VB
for_PIN
future_JJ
database_NN
to_TO
improve_VB
our_FPP1
processes_NN
differentially_RB
priced_VBN
products_NN
are_VPRT
not_XX0
investment_NOMZ
in_PIN
the_DT
discovery_NN
and_CC
for_PIN
capturing_VBG
the_DT
full_JJ
extent_NN
of_PIN
our_FPP1
diverted_VBN
from_PIN
the_DT
patients_NN
who_WP [WHSUB]
need_VPRT
development_NOMZ
of_PIN
new_JJ
medicines_NN
for_PIN
community_NOMZ
support_NN
initiatives_NN
,_,
product_NN
them_TPP3
,_,
to_TO
be_VB [PASS]
sold_VBN
and_PHC
used_VBN
in_PIN
more_EMPH
a_DT
wide_JJ
range_NN
of_PIN
diseases_NN
._.
donations_NOMZ
and_CC
patient_JJ
access_NN
affluent_JJ
markets_NN
._.
Differential_NN
pricing_GER
can_POMD
programs_NN
around_PLACE
the_DT
world_NN
and_CC
only_DWNT
be_VB [BEMA]
of_PIN
benefit_NN
in_PIN
countries_NN
where_RB
Product_NN
donations_NOMZ
and_PHC
patient_NN
to_TO
ensure_VB [SUAV] [PRIV] [THATD]
the_DT
information_NOMZ
can_POMD
be_VB
healthcare_NN
systems_NN
can_POMD
deliver_VB
assistance_NN
programs_NN
shared_VBN [WZPAST]
internally_RB
to_TO
promote_VB
best_JJ
medicines_NN
to_PIN
the_DT
patients_NN
that_TSUB
need_VPRT
Our_FPP1
product_NN
donations_NOMZ
and_CC
patient_JJ
practice_NN
._.
In_PIN
2003_CD
,_,
over_IN
1,000_CD
projects_NN
them_TPP3
and_CC
ensure_VB [SUAV] [PRIV]
that_THVC
they_TPP3
are_VPRT [PASS]
used_VBN
assistance_NN
programs_NN
make_VPRT
products_NN
were_VBD [PASS]
entered_VBN
into_PIN
the_DT
database_NN
,_,
appropriately_RB
._.
available_JJ
free_JJ
of_PIN
charge_NN
or_CC
at_PIN
reduced_JJ
covering_VBG
activities_NOMZ
in_PIN
34_CD
countries_NN
._.
In_PIN
2003_CD
,_,
our_FPP1
expanded_VBN
patient_NN
Research_NN
into_PIN
neglected_VBN
diseases_NN
of_PIN
the_DT
assistance_NN
programs_NN
in_PIN
the_DT
US_FPP1
For_PIN
the_DT
first_JJ
time_NN
,_,
in_PIN
2003_CD
AstraZeneca_NN
developing_VBG [WZPRES]
world_NN
is_VPRT [BEMA]
essential_PRED
to_PIN
the_DT
contributed_VBN
to_PIN
a_DT
total_JJ
spend_VPRT
of_PIN
was_VBD [PASS]
included_VBN
in_PIN
the_DT
UK_NN
Business_NOMZ
in_PIN
the_DT
effective_JJ
treatment_NOMZ
of_PIN
these_DEMO
diseases_NN
in_PIN
$_$
724_CD
million_CD
in_PIN
this_DEMO
area_NN
,_,
at_PIN
average_JJ
Communitys_NN
One_CD
Per_PIN
Cent_NN
Club_NN
,_,
an_DT
the_DT
future_NN
._.
AstraZeneca_NN
has_VPRT
recently_TIME
wholesale_JJ
price_NN
._.
index_NN
of_PIN
companies_NN
that_TSUB
contribute_VPRT
1_CD
%_NN
made_VBD
a_DT
substantial_JJ
investment_NOMZ
in_PIN
new_JJ
or_CC
more_EMPH
of_PIN
their_TPP3
annual_JJ
operating_GER
profit_NN
research_NN
facilities_NOMZ
in_PIN
Bangalore_NN
,_,
India_NN
,_,
that_THVC
Community_NOMZ
support_NN
to_PIN
community_NOMZ
support_NN
._.
are_VPRT [PASS]
focused_VBN
on_PIN
finding_VBG [PRIV]
a_DT
new_JJ
treatment_NOMZ
Wherever_NN
AstraZeneca_NN
is_VPRT [PASS]
located_VBN
for_PIN
tuberculosis_NN
a_DT
major_JJ
and_CC
increasing_VBG
worldwide_NN
,_,
we_FPP1
aim_VPRT
to_TO
make_VB
a_DT
positive_JJ
threat_NN
to_PIN
life_NN
in_PIN
developing_VBG
countries_NN
._.
contribution_NOMZ
to_PIN
our_FPP1
local_JJ
communities_NOMZ
through_PIN
charitable_JJ
donations_NOMZ
,_,
sponsorShould_NN
we_FPP1
be_VB [BEMA]
successful_PRED
in_PIN
identifying_VBG
ships_NN
and_CC
other_JJ
initiatives_NN
that_TSUB
help_VPRT
to_PIN
a_DT
potential_JJ
new_JJ
medicine_NN
,_,
a_DT
key_JJ
priority_NOMZ
make_VB
a_DT
difference_NN
._.
In_CONJ
particular_NULL
,_,
we_FPP1
will_PRMD
be_VB
to_TO
develop_VB
it_PIT
in_PIN
partnership_NN
with_PIN
focus_NN
on_PIN
bringing_VBG
benefits_NN
in_PIN
ways_NN
that_TOBJ
governments_NOMZ
,_,
local_JJ
organizations_NOMZ
and_CC
are_VPRT [BEMA]
consistent_PRED
with_PIN
our_FPP1
business_NOMZ
of_PIN
international_JJ
bodies_NN
in_PIN
order_NN
to_TO
achieve_VB
improving_VBG
health_NN
and_PHC
quality_NOMZ
of_PIN
life_NN
the_DT
earliest_JJ
possible_JJ
approval_NN
according_VBG [WZPRES]
and_CC
on_PIN
promoting_VBG
the_DT
value_NN
of_PIN
science_NN
to_PIN
global_JJ
standards_NN
._.
We_FPP1
hope_VPRT [PRIV]
that_THVC
we_FPP1
among_PIN
young_JJ
people_NN
._.
can_POMD [SPAU]
then_RB
again_TIME
work_VB
in_PIN
partnership_NN
with_PIN
the_DT
relevant_JJ
global_JJ
and_PHC
local_JJ
organizations_NOMZ
to_TO
ensure_VB [SUAV] [PRIV]
that_THVC
any_QUAN
new_JJ
treatment_NOMZ
reaches_VPRT
the_DT
patients_NN
who_WP [WHSUB]
need_VPRT
it_PIT
._.
The_DT
Together_RB
Rx_JJ
program_NN
in_PIN
the_DT
US_FPP1
,_,
run_VPRT
In_PIN
December_NN
2003_CD
,_,
AstraZeneca_NN
announced_VBD [PUBV]
by_PIN
AstraZeneca_NN
and_CC
six_CD
other_JJ
pharmaa_JJ
$_$
360,000_CD
three-year_JJ
partnership_NN
with_PIN
ceutical_JJ
companies_NN
,_,
provides_VPRT
eligible_JJ
Peking_GER
Universitys_NN
Guanghua_NN
School_NN
Medicare_NN
patients_NN
with_PIN
up_RB
to_PIN
40_CD
%_NN
savings_GER
of_PIN
Management_NOMZ
to_TO
fund_VB
the_DT
China_NN
Center_NN
on_PIN
medicines_NN
used_VBN
to_TO
treat_VB
a_DT
range_NN
of_PIN
for_PIN
Pharmacoeconomics_NN
and_PHC
Outcomes_NN
common_JJ
conditions_NOMZ
that_TSUB
affect_VPRT
older_JJ
people_NN
._.
Research_NN
in_PIN
a_DT
series_NN
of_PIN
research_NN
and_CC
educational_JJ
programs_NN
aimed_VBN [WZPAST]
at_PIN
supporting_VBG
Chinas_NN
continued_VBD
reform_NN
of_PIN
its_PIT
healthcare_NN
system_NN
._.
In_CONJ
particular_NULL
,_,
the_DT
programs_NN
will_PRMD
focus_VB
on_PIN
building_GER
research_NN
skills_NN
and_PHC
expertise_NN
in_PIN
health_NN
economics_NN
._.
Sir_NN
Tom_NN
McKillop_NN
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
16_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
2003_CD
performance_NN
summary_NN
2001 2002 2003 2005_CD
target_NN
Economic_JJ
$_$
m_CD
where_RB
relevant_JJ
Sales_NN
16,222_CD
17,841_CD
18,849_CD
Operating_GER
profit_NN
4,156_CD
4,356_CD
4,111_CD
Dividends_NN
1,225_CD
1,206_CD
1,350_CD
Ratio_NN
of_PIN
market_NN
capitalization_NOMZ
to_PIN
book_NN
value_NN
of_PIN
net_JJ
assets_NN
8.0_CD
5.5_CD
6.1_CD
R&D_NN
investment_NOMZ
2,687_CD
3,069_CD
3,451_CD
Total_JJ
wages_NN
3,542_CD
3,993_CD
4,745_CD
Taxation_NOMZ
1,214_CD
1,177_CD
1,143_CD
Environmental_NN
1_CD
Greenhouse_NN
gases_NN
CO2-equivalents_NN
million_CD
tonnes_NN
1.87_CD
1.77_CD
1.72_CD
1.59_CD
Index_NN
tonnes_VPRT
$_$
m_JJ
sales_NN
115_CD
99_CD
92_CD
Energy_NN
GWh_NN
2,170_CD
2,240_CD
2,440_CD
Index_NN
MWh_NN
$_$
m_JJ
sales_NN
134 126 129_CD
CFCs_NN
Total_NN
ozone_NN
depletion_NOMZ
potential_JJ
CFC11_NN
equivalent_NN
tonnes_VPRT
110_CD
99_CD
88_CD
75_CD
Index_NN
kg_FW
$_$
m_JJ
sales_NN
7.0_CD
5.6_CD
4.7_CD
Waste_NN
Hazardous_NN
waste_NN
kte_NN
36.7_CD
31.1_CD
28.3_CD
Total_JJ
waste_NN
kte_NN
65.5_CD
60.3_CD
58.4_CD
Index_NN
total_JJ
waste_NN
tonnes_VPRT
$_$
m_JJ
sales_NN
4.04_CD
3.38_CD
3.10_CD
3.26_CD
Unplanned_JJ
releases_NN
Contained_VBN [WZPAST]
within_PIN
site_NN
boundary_NN
24_CD
17_CD
8_CD
Not_XX0
contained_VBN
within_PIN
site_NN
boundary_NN
12_CD
10_CD
9_CD
6_CD
Social_NN
Safety_NN
and_PHC
health_NN
:_:
AstraZeneca_NN
employees_NN
Number_NN
of_PIN
accidents_NN
with_PIN
injury_NN
per_PIN
million_CD
hours_NN
4.16_CD
3.84_CD
3.64_CD
Number_NN
of_PIN
accidents_NN
with_PIN
injury_NN
and_PHC
days_NN
lost_VBD
per_PIN
million_CD
hours_NN
2.86_CD
2.84_CD
2.66_CD
Cases_NN
of_PIN
occupational_JJ
illnesses_NOMZ
per_PIN
million_CD
hours_NN
3.83_CD
3.15_CD
1.67_CD
2.44_CD
Safety_NN
and_PHC
health_NN
:_:
AstraZeneca_NN
employees_NN
and_PHC
contractors_NN
Number_NN
of_PIN
accidents_NN
with_PIN
injury_NN
per_PIN
million_CD
hours_NN
4.18_CD
4.11_CD
3.57_CD
2.90_CD
2_CD
Number_NN
of_PIN
animals_NN
used_VBN [WZPAST]
in_PIN
research_NN
248,000_CD
242,000_CD
Site_NN
audits_NN
that_TSUB
included_VBD
CR_NN
11_NN
Community_NOMZ
support_NN
$_$
m_CD [PASS]
Sponsorships_NN
n_VBD
a_DT
9.7_CD
16.4_CD
Charitable_JJ
contributions_NOMZ
n_VPRT
a_DT
3.3_CD
5.6_CD
Total_JJ
n_NN
a_DT
13.0_CD
22.0_CD
Product_NN
donations_NOMZ
and_CC
patient_JJ
assistance_NN
programs_NN
at_PIN
average_JJ
wholesale_JJ
price_NN
$_$
m_CD
n_NN
a_DT
303.0_CD
724.0_CD
Regulatory_NN
infringements_NOMZ
safety_NN
,_,
health_NN
and_PHC
environment_NOMZ
Prosecutions_NOMZ
1_CD
1_CD
1_CD
Legal_NN
sanctions_NOMZ
4_CD
7_CD
4_CD
Failures_NN
to_TO
obtain_VB
correct_JJ
permits_NN
1_CD
0_CD
0_CD
Infringements_NOMZ
of_PIN
operating_VBG
permits_NN
7_CD
6_CD
12_CD
Total_JJ
13_CD
14_CD
17_CD
1_CD
2_CD
Figures_NN
are_VPRT [PASS]
calculated_VBN [PRIV]
in_PIN
line_NN
with_PIN
the_DT
Greenhouse_NN
Gas_NN
GhG_NN
Protocol_NN
guidance_NN
ghgprotocol_NN
._.
org_NN
2003_CD
figure_NN
not_XX0
yet_RB
available_JJ
n_IN
a_DT
Not_XX0
applicable_JJ
AstraZeneca_NN
Corporate_NN
Responsibility_NOMZ
Summary_NN
Report_NN
2003_CD
For_PIN
more_EMPH
information_NOMZ
visit_NN
astrazeneca_NN
._.
com_NN
During_PIN
2003_CD
,_,
AstraZeneca_NN
sold_VBD
its_PIT
Marlow_NN
Foods_NN
operation_NOMZ
._.
Although_CONC
no_SYNE
changes_NN
have_VPRT [PEAS]
been_VBN [PASS]
made_VBN
to_PIN
the_DT
absolute_JJ
performance_NN
figures_NN
,_,
the_DT
SHE_TPP3
improvement_NOMZ
targets_NN
and_CC
their_TPP3
reference_NN
points_NN
have_VPRT [PEAS]
been_VBN [PASS]
modified_VBN
in_PIN
line_NN
with_PIN
the_DT
WRI_NN
WBCSD_NN
protocol_NN
._.
This_DEMP
avoids_VPRT
incorporating_VBG
the_DT
reduction_NOMZ
in_PIN
emissions_NN
resulting_VBG [WZPRES]
from_PIN
the_DT
divestment_NOMZ
as_IN
part_NN
of_PIN
our_FPP1
improvement_NOMZ
process_NN
._.
With_PIN
the_DT
exception_NOMZ
of_PIN
the_DT
economic_JJ
data_NN
,_,
the_DT
above_PLACE
represents_VPRT
preliminary_JJ
figures_NN
only_DWNT
._.
Final_JJ
statistics_NN
will_PRMD
be_VB [PASS]
published_VBN
on_PIN
our_FPP1
website_NN
,_,
astrazeneca_NN
._.
com_NN
Designed_VBN [WZPAST]
by_PIN
Addison_NN
Corporate_NN
Marketing_GER
Ltd_NN
astrazeneca_NN
._.
